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Bacteria produce a vast array of low-molecular-weight compounds endowed with 
a multitude of biological effects. As these compounds have developed in a 
biological context, it is hypothesized that bacteria exploit them to gain a 
competitive advantage for example through antagonistic interactions. It is 
speculated that these compounds can be used as antibiotics against biomedically 
important pathogens. The oceans, covering over 70% of the Earth’s surface, 
constitute a unique ecosystem that promotes bacterial adaptations to the marine 
environment and provides a driving force for chemical diversity. Thus, marine 
bacteria represent a promising source of new chemical classes with antibiotic 
properties to counter the evolution of drug-resistant pathogens.  
The aim of this PhD study was to explore a global collection of over 
500 marine bacteria for their ability to produce bioactive natural products. This 
included both compounds with antibacterial activities and compounds interfering 
with virulent phenotypes of pathogens such as Staphyloccocus aureus and 
Pseudomonas aeruginosa. A primary goal was to provide a robust setup for 
chemical evaluation of the collected bacteria and develop methods that facilitate 
rapid dereplication of the associated extracts.  
In order to efficiently evaluate the large collection of bacteria in 
terms of their biosynthetic potential and their ability to produce novel compounds, 
a combination of chemical profiling and dereplication techniques was applied. 
Profiling of the metabolites produced by members of Pseudoalteromonas and 
Vibrionaceae by LC-UV/MS was successful in differentiating strains at species 
and sub-species level. Within our collection, production of secondary metabolites 
was found to be independent of sample location, with ‘strain siblings’ from distant 
geographical locations producing the same combination of metabolites. However, 
significant intraspecies differences were still observed. In Pseudoalteromonas 
luteoviolacea and Vibrio coralliilyticus some of these differences were related to 
the production of antibacterial compounds. In this thesis, it is speculated that this 
contributes to specific niche-adaptation. The potential ecological role of 
antibiotics in V. coralliilyticus was further corroborated by studies showing that 
the antibiotic, andrimid, was produced under conditions mimicking the natural 
environment of this bacterium.  
During the course of this PhD, three known antibacterial compounds 
were isolated: Indolmycin (Pseudoalteromonas luteoviolacea), andrimid (Vibrio 
coralliilyticus), and holomycin (Photobacterium halotolerans). All three are 
 examples of cosmopolitan antibiotics found in distantly related taxa. Genomic 
promiscuity among bacteria stresses the need for efficient and dynamic 
dereplication methods to avoid redundancy in isolation of bioactives. To extend 
our means of dereplication, an explorative solid-phase extraction (E-SPE) method 
based on three different ion-exchangers and a size-exclusion column was 
developed. E-SPE exploits the sensitivity of the biological assays to obtain 
information about the charge, polarity, and size of active components in a crude 
extract. This can be used to discriminate between possible candidates during 
dereplication and allows detailed mapping of bioactives.  
This thesis provides a complete overview of known bioactive 
metabolites produced by members of the Vibrionaceae family, which constitutes 
an under-explored source of chemistry. Among the compounds reported so far, 
there is a prevalence of non-ribosomal peptides or hybrids hereof, with examples 
of N-containing compounds produced by NRPS-independent pathways. 
Compounds isolated from Vibrio and Photobacterium during this PhD 
corroborated this general trend. From Photobacterium halotolerans, we isolated 
two new cyclic tetradepsipeptides, designated solonamides A and B, as potent 
inhibitors of the agr QS system involved in virulence expression in 
Staphyloccocus aureus. Of special interest was a pronounced effect against a 
highly virulent, community-acquired, methicillin-resistant S. aureus strain 
(USA300).  
In conclusion, this PhD study adds to the knowledge of marine 
bacteria as competent producers of secondary metabolites, some of which possess 
biological activities attractive for alternative strategies in antibacterial therapy.  
 
 
 
 
Bakterier er i stand til at producere en bred vifte af små molekyler beriget med 
biologisk aktivitet. Da disse stoffer er udviklet i en naturlig kontekst, er 
forventningen, at bakterierne bruger stofferne som en del af konkurrencen mod 
andre bakterier. Derfor kan nogle af disse stoffer måske bruges som antibiotika 
mod sygdomsfremkaldende bakterier. Havet, der udgør over 70% af jordens 
overflade, er et unikt økosystem, der fordrer særlige tilpasninger hos bakterier, 
herunder kemisk diversitet. Havbakterier udgør således en lovende kilde til nye 
typer af kemiske strukturer med antibakterielle egenskaber, der kan bruges i 
kampen mod den stigende antibiotikaresistens.  
Formålet med dette PhD studie var at udforske en global samling af 
over 500 havbakterier for deres evne til at producere naturstoffer med biologisk 
aktivitet. Dette gælder både stoffer med antibakteriel effekt og stoffer, der kan 
hæmme virulensen i vigtige sygdomsfremkaldende bakterier, såsom 
Staphylococcus aureus og Pseudomonas aeruginosa. Et af hovedmålene var at 
finde en konsistent fremgangsmåde til kemisk at evaluere de indsamlede bakterier 
og at udvikle metoder til at fremme dereplikeringen.  
For effektivt at kunne bedømme det biosyntetiske potentiale i vores 
store samling af bakterier og deres evne til at lave nye stoffer, er der brugt en 
kombination af kemisk profilering og forskellige dereplikeringsteknikker. Kemisk 
profilering af stoffer produceret af bakterier tilhørende slægten 
Pseudoalteromonas og Vibrionaceae familien gjorde det muligt at skelne stammer 
på artsniveau samt at lave underinddelinger til disse. Produktionen af sekundære 
metabolitter i vores samling viste sig at være uafhængig af, hvor prøven var 
indsamlet, og nærtbeslægtede stammer indsamlet fra indbyrdes fjerntliggende dele 
af verden viste sig at producere de samme stoffer. Inden for samme art var der dog 
stadig signifikante forskelle. Blandt stammer tilhørende Pseudoalteromonas 
luteoviolacea og Vibrio coralliilyticus viste denne forskel sig at ligge i 
produktionen af antibakterielle stoffer. I denne afhandling foreslås det, at denne 
forskel er en del af bakteriernes tilpasning til forskellige økologiske nicher. Den 
potentielle økologiske betydning af antibakterielle stoffer for V. coralliilyticus 
blev underbygget af studier, der viste, at antibiotikummet andrimid blev 
produceret under betingelser, der mindede om de naturlige vækstbetingelser for 
bakterien.  
Tre kendte antibakterielle stoffer blev isoleret under dette PhD 
studie, nemlig indolmycin (Pseudoalteromonas luteoviolacea), andrimid (Vibrio 
coralliilyticus) og holomycin (Photobacterium halotolerans). Alle tre stoffer er 
 eksempler på almindeligt udbredte antibiotika, der produceres af fjernt beslægtede 
bakterier. Det faktum, at nogle typer af antibiotika findes udbredt blandt bakterier, 
strammer kravet om mere effektive og dynamiske dereplikeringsmetoder, hvis 
man skal undgå at genopdage kendte typer af antibiotika. For at udvide vores 
arsenal af dereplikeringsmetoder, udviklede vi en ’explorative solid-phase 
extraction’ (E-SPE) metode baseret på fastfase ekstraktionskolonner, herunder tre 
ionbyttere og en kolonne til størrelseskromatografi. E-SPE gav os muligheden for 
at udnytte den indbyggede følsomhed i vores biologiske test til at udvinde kemisk 
information omkring ladning, opløselighed og størrelse på de aktive stoffer i vores 
ekstrakter. Dette kan således bruges til at skelne mellem flere mulige kandidater 
under dereplikering og bruges til at give et klart overblik over aktive stoffer i 
samme ekstrakt.  
I denne afhandling findes en komplet oversigt over kendte, biologisk 
aktive stoffer produceret af bakterier tilhørende Vibrionaceae familien, der i høj 
grad stadig repræsenterer en gruppe af uudforskede bakterier. Blandt de stoffer, 
der er fundet hidtil, stammer en overvejende del fra non-ribosomal petidsyntese 
samt andre typer af peptider. Stoffer isoleret i løbet af dette PhD studie tilhører 
ligeledes denne stofgruppe. Fra Photobacterium halotolerans isolerede vi to nye 
cykliske tetradepsipeptider, kaldet solonamide A og B. Disse stoffer hæmmede 
kraftigt quorum sensing systemet agr, der involveret i at regulere virulensen i 
Staphylococcus aureus. Solonamiderne viste sig at have en kraftigt hæmmende 
effekt på en særligt aggressiv, multiresistent S. aureus stamme (USA300).  
Dette PhD studie bidrager til vores viden omkring havbakterier som 
kompetente producenter af naturstoffer, hvoraf nogle udviser biologiske 
aktiviteter, der er interessante i forbindelse med alternative behandlingsstategier af 
bakterieinfektioner. 
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The ability of nature to create unexpected chemistry has made natural products an 
unparalleled reservoir of chemical diversity, attractive for drug discovery and 
development. Although heavily studied over the past half-century, 
microorganisms continue to prove themselves to be reliable sources of novel 
bioactive compounds.  
Today, many natural product-based antibiotics from the ‘Golden 
Age of Antibiotics’ in the 1950s and 1960s are rendered ineffective due to 
evolving resistance.
1
 Motivated by this increasing need for new antibiotics, Center 
for Microbial Biotechnology and the National Food Institute participated in the 
global scientific expedition, Galathea 3, in order to mine the oceans for marine 
bacteria with antibacterial activity and potential biotechnological use. Throughout 
the nine month cruise, bacterial samples were collected from the seawater as well 
as various surfaces. This resulted in a unique collection of more than 900 different 
bacterial samples with the ability to inhibit the fish pathogen Vibrio anguillarum.
2
 
After re-culturing and re-testing, 519 strains were selected as representatives for 
all samples and geographical locations. Partial 16S rRNA gene sequence 
similarities revealed that the collection consisted of three major groups (Figure 1): 
Vibrionaceae (309 strains), Pseudoalteromonas spp. (128 strains), and the 
Roseobacter clade (29 strains).
2
 All of these bacteria are Gram-negative bacteria, 
a group known to be less prolific in their production of secondary metabolites 
compared to e.g. actinomycetes.
3,4
 For that reason, many species belonging to 
these taxa have never been investigated for their chemistry and therefore represent 
an under-explored source of new natural products.  
  
 
To evaluate the collected bacteria, we set up a two-pronged screening approach, 
which was (i) to find new chemical classes with antibacterial properties, and (ii) to 
aim at new targets for antibacterial therapy.  
In order to identify new chemical scaffolds, we sought to enhance 
the diversity of secondary metabolites by sourcing for new microbiological 
material. The marine environment, covering over 70% of the Earth’s surface, is 
still largely unexplored and thus a major resource for the isolation of less 
exploited repertoires of microorganisms. By assessment of the global chemistry of 
a given bacterium, we aimed at selecting the strains representing the highest 
chemical diversity, at the same time avoiding redundant chemistry. In addition, 
we sought to develop a chemical screening strategy that allows efficient and 
accurate identification of interesting new compounds for purification. This would 
help us to identify compounds that have been overlooked previously.   
In the last 10 years, there has been a shift from traditional growth 
inhibition towards new avenues in antibacterial control. With regard to the second 
component area, we aimed at discovery of compounds that do not necessarily kill 
pathogenic bacteria but rather inhibit virulence or biofilm formation, with the 
hypothesis that these compounds are not subject to resistance mechanisms.
5
 
Therefore, the screening array of the Galathea project included screening for 
 
 
 
compounds that inhibit the quorum sensing response in pathogens like 
Pseudomonas aeruginosa
6
 and Staphylococcus aureus.
7
 Also, the screening setup 
included an immunoassay based on dendritic cells that identify compounds that 
can modulate an immune response.
8
 This combination of assays provided a broad 
spectrum for screening our extracts.  
The aim of this PhD study was to evaluate the chemical potential of 
the collected bacteria (paper 3 and 4), prioritize strains for chemical analysis by 
assessing their global chemistry and production of bioactive compounds (paper 3, 
4, and 5), establishing suitable extraction, dereplication, and purification 
procedures (paper 1 and 2), and to purify active components for evaluation in the 
assays and structural elucidation (paper 1, 4, and 6). In this thesis, the results are 
presented and discussed in five different chapters. The first chapter introduces the 
potential and some challenges when dealing with marine microbial natural 
products. Chapter 2 outlines the experimental setup for the thesis. Chapter 3 
describes and compares different dereplication strategies used through this study. 
Examples from both Pseudoalteromonas and Vibrio will be included in this 
chapter. Chapter 4 focuses on the chemistry of the Vibrionaceae, reviewing 
reported metabolites and discussing the biosynthetic potential of this under-
explored group of bacteria. This chapter is intended as a mini-review for 
publication in a peer-reviewed journal; however, the version included in this 
thesis holds also unpublished results. Finally, chapter 5 is the overall discussion 
and conclusions.  
  
  
 
 
 
Historically, the most important sources of natural products (or secondary 
metabolites) have been plants and terrestrial microorganisms. However, within the 
last 35 years,
1
 the quest for novel chemistry has been extended into a world of 
fascinating marine biodiversity.
2,3
 Some of the first marine organisms to be 
investigated for their production of secondary metabolites were plants and 
invertebrates. In 1951, the first marine-derived natural products were isolated 
from the sponge, Tethya crypta, that is the two nucleosides spongosine and 
spongothymidine.
4,5
 Since then, natural products (NP) have been isolated from 
several marine invertebrates such as sponges, tunicates, molluscs, and bryozoans 
(Figure 1.1),
6
 yielding a plethora of interesting bioactive molecules and covering 
new structural classes and functional groups.
7
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Many marine structures have served as leads for drug development.
9
 Today, three 
marine-derived drugs are approved by the Food and Drug Administration 
(FDA).
10
 That includes ziconotide (Prialt
®
, Elan Corporation) for chronic pain 
relief, the anticancer drug, cytarabine (Cytosar-U
®
, Bedford Laboratories/-
Depocyt
®
, Enzon Pharmaceuticals), and the antiviral, vidarabine (Vira-A
®
, King 
Pharmaceuticals) (Figure 1.2). In addition, the anticancer drug, trabectedin 
(Yondelis
®
, PharmaMar) is approved by the European Agency for the Evaluation 
of Medicinal Products (EMEA) and is awaiting final approval by FDA.
11
  
 „The supply problem‟ has been a major obstacle for the use of drugs 
isolated from marine invertebrates,
6,12,13
 as many of these organisms produce very 
low yields of their metabolites. In the case of trabectedin, the yield obtained from 
the source tunicate, Ecteinascidia turbinata, was less than 1 μg g-1.11 Owe to the 
structural complexity of many marine natural products, total synthesis of the 
compounds is not valuable. Striking structural similarities between metabolites 
from marine invertebrates and microorganisms raised questions about the true 
biosynthetic origin of these molecules.
14,15
 Faulkner and coworkers (1993) were 
the first to show that sponge-derived metabolites were actually localized in the 
cells of a bacterial symbiont.
16
 Demonstrating the correct origin of marine natural 
 
 
 
products can be a quite comprehensive task that includes complete sequence 
analysis of the biosynthetic genes and heterologous expression to confirm their 
function.
17,18
 Even so, today it is a well-acknowledged fact that many natural 
products of marine invertebrates are produced by associated microorganisms.
15,17
 
As production of complex molecules by microorganisms is a way to obtain a 
sustainable supply for marine drug development,
12
 this has fueled the study of 
microbial natural products in the recent years. Within the last five years the 
number of metabolites from marine microorganisms has increased markedly,
8
 and 
almost one fifth of new entries in AntiBase 2010 arise from marine bacteria.
19
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 The marine environment, covering over 70% of the Earth‟s surface, is a vast and 
complex source of bacteria, especially considering that one milliliter of sea water 
contains more than 10
5
 bacterial cells.
20,21
 Notwithstanding, the undisputed and 
vital roles of bacteria in marine ecosystems like decomposition of organic matter 
and fixation of nitrogen, marine bacteria are still under-explored for their 
production of bioactive secondary metabolites.  
Marine bacteria encompass many different phyla, including 
actinobacteria, proteobacteria, and cyanobacteria.
22
 Divergence between terrestrial 
and marine bacteria is often defined as a sodium-specific requirement for growth;
7
 
however, the definition of a truly marine bacterium is difficult and many phyla 
contain both terrestrial and marine species.
23
 Nonetheless, certain species and 
even genera, for example within the Roseobacter clade
24
 and Pseudoalteromonas, 
have not yet been found in terrestrial environments.
25
 Also, actinobacteria found 
in deep-ocean sediments seem to be autochthonous marine bacteria.
26,27
 Even 
though bacteria do not keep to a strict definition of „marine‟ and „terrestrial‟ 
organisms, the oceans constitute a unique ecosystem that promotes bacterial 
adaptations to the marine environment.
23,28
 Extreme variations in pressure, 
salinity, temperature, and nutrients create diverse micro-niches that can select for 
unique biosynthetic pathways leading to new types of molecules.
23
 The best 
example of marine structural features is probably the bacterial production of 
halogenated, especially brominated, metabolites, due to the availability of these 
elements in seawater.
7,29
  
The vast majority of marine bacterial species have unknown growth 
requirements and have not yet been cultured.
23,30
 It is estimated that less than 1% 
of marine bacteria can be isolated using traditional culturing techniques,
20,21
 in 
consequence leaving many natural products and their biosynthetic pathways 
inaccessible. So the full wealth of microbial diversity in the sea is yet to be 
revealed, and with it presumably an equally high chemical diversity.
31
  
 
 
 
 
The ability of marine bacteria to produce antibiotics was first documented in 1947 
by Rosenfeld and ZoBell;
32
 however, no compounds were isolated until 20 years 
later where Burkholder
33
 and Lovell
34
 purified and reported the structure of 
pentabromopseudilin (structure page 12) from Pseudomonas bromoutilis (later 
identified as Pseudoalteromonas). Since then, an increasing number of unusual 
secondary metabolites have been isolated from marine bacteria. Most reported 
metabolites originate from marine actinobacteria (Figure 1.3), mainly due to the 
proven success in their terrestrial counterparts.
35
 However, members of 
Alteromonas/Pseudoalteromonas (genus revised in 1995 by Gauthier)
36
 have also 
yielded a substantial number of metabolites with interesting biological activities.
37
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Figure 1.3 displays the number of metabolites reported from marine bacteria in 
AntiBase 2010. Though the list of represented taxa might not be exhaustive, it 
gives a fair representation of the organisms of main interest to the natural product 
chemists so far. Aside from the groups highlighted in the figure, representing the 
highest number of compounds, there are examples of isolated compounds from 
other genera such as Halomonas and Flavobacterium (Appendix A). Hence, it is 
clear that many marine bacterial taxa have not yet been studied in detail for their 
production of secondary metabolites.  
 Actinobacteria have long been cultivated from marine samples;
38
 however, these 
common soil bacteria were considered terrestrial contaminants, washed or blown 
into the sea. Improved sampling and cultivation techniques
39
 revealed that 
actinobacteria can be found in abundance in ocean sediments 
40
 and on the surface 
of various marine macroorganisms.
41
 Using culture-dependent analyses of 225 
marine sediment samples, Jensen and Fenical (2007) found the actinobacterial 
diversity to span more than 22 different families.
42
  Also, Schneemann et al. 
(2010) found more than 46 unique strains of actinobacteria, spanning five 
different genera, on the surface of a single sponge Halicondria panacea.
43
 
Although most species are not restricted to the sea, new species of indigenous 
marine actinobacteria have been described.
44
 That includes Salinibacterium 
amurskyense
45
 and Serinicoccus marinus
46
 isolated from seawater, and 
Salinispora arenicola and Salinispora tropica from deep-sea sediment.
27
 
Actinobacteria boast some of the richest structural and biosynthetic diversity in 
the marine environment.
26,47
 Compounds like the ammosamides
48
 and 
marinopyrroles
49
 produced by Streptomyces sp. derived from deep sea sediment 
samples have unique carbon skeletons and extraordinary biological activities. The 
ammosamides (A-B) are highly unsaturated aza-aromatic heterocycles with strong 
in vitro cytotoxicity against HCT-116 colon carcinoma (IC50 at 320 nM).
50
 The 
marinopyrroles (A-F) feature an unusual N,C-linked bipyrrole decorated with 
several chlorine and bromine substituents.
51
 The major analogues A and B 
displayed pronounced antibacterial activity against methicillin-resistant S. aureus 
(MRSA), with minimum inhibitory concentrations (MIC90) of less than 2 μM.
49
  
 
 
The genus Salinispora, described by Jensen and Fenical in 2003,
52
 was found to 
have great potential for the production of interesting bioactive metabolites.
53
 
Exploration of this new genus led to the isolation of the potent anticancer 
compound, salinosporamide A from Salinispora tropica.
54
 The compound targets 
the 20S proteasome that induce apoptosis, and it has entered human clinical trials 
(NPI-0052, Nereus Pharmaceuticals) against solid tumors and lymphomas just 
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three years after its first discovery.
55
 A strain of S. arenicola isolated from the 
tunicate Ecteinascidia turbinata was found to produce the benzo[α]naphthacene 
quinone antibiotic, arenimycin with marked activity against rifampin and 
methicillin-resistant S. aureus strains.
56
 
 
 
 
 
Most of the bacteria studied in this thesis belong to the γ-proteobacteria. Despite 
being the most represented bacteria in the culturable microbiota of many marine 
environments,
57-59
 the number of compounds isolated is far smaller than that of 
marine actinobacteria. Most compounds isolated from γ-proteobacteria have been 
found in species belonging to the genera, Alteromonas/Pseudoalteromonas and 
Vibrio.
57
 Like with actinobacteria, some unique structures with strong marine 
features have been isolated. Recently, a series of unusual nitro-substituted 
compounds called aqabamycins with antibacterial and cytotoxic effects were 
isolated from an unidentified Vibrio by the Laatsch group.
60
  
 
 
 
The chemistry of Vibrio will be more extensively reviewed in chapter 4. 
Several members of Pseudoalteromonas are known to be producers 
of bioactive substances, many of which have been covered in reviews by Bowman 
(2007)
37
 and Holmström et al. (1999).
61
 As mentioned, the first antibiotic 
discovered from a marine bacterial source was pentabromopseudilin.
33,34
 This 
highly brominated compound was found to possess strong antibacterial activity 
against a variety of human pathogens
62
 including methicillin-resistant S. aureus.
63
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 Since its first isolation in P. bromoutilis, it has been found in P. luteoviolacea
64,65
 
and terrestrial Chromobacterium sp.
62
 Similarly, the purple pigment, violacein has 
been isolated from P. luteoviolacea,
66,67
 P. tunicata,
68,69
 P. ulvae,
70
 and C. 
violaceum,
71
 to name a few. Violacein presents diverse biological activities, 
including antimicrobial, antiprotozoan, antiviral, and anticancer.
72
 Kjelleberg and 
co-workers (2008) posit that violacein plays a role in the grazing resistance of 
Pseudoalteromonas in the natural environment through induction of an apoptosis-
like cell death mechanism in protozoan predators.
70
 Other noteworthy compounds 
isolated from Pseudoalteromonas include korormicin.
73
 This compound 
selectively inhibits the Na
+
-translocating NADH:quinone involved in sodium 
transport in marine, halophilic Gram-negative bacteria, thus displaying a very 
narrow spectrum of activity.
74
 P. maricaloris isolated from the sponge 
Fascaplysinopsis reticulata yielded a series of remarkable brominated penta-
depsipeptides called bromoalterochromides.
75
 Bromoalterochromide A was found 
to exhibit cytotoxic effects
76
 but showed no antibiotic activity.
77
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Some of the more interesting sources of secondary metabolites among the α-
proteobacteria are members of the Roseobacter clade, including Ruegeria and 
Phaeobacter.
78
 These bacteria appear to be strictly marine and represent a 
significant fraction of marine bacterioplankton communities.
79,80
 Roseobacters are 
often associated with different types of surfaces, especially marine algae, and the 
production of active secondary metabolites has been linked to the formation of 
biofilm.
81
 Selected members of this group produce the antibacterial compound 
tropodithietic acid (TDA)
82
 with an active four-membered sulfur-containing ring. 
TDA show broad but moderate antibacterial activity against both Gram-positive 
and Gram-negative bacteria. During the Galathea 3 expedition, strains belonging 
to the Roseobacter clade were collected from almost all geographical locations 
except those in Arctic and Antarctic waters. The majority of these strains were 
found to be Ruegeria mobilis,
21
 which all were found to produce TDA.
83
 
 
 
 
 
Myxobacteria are gliding bacteria belonging to the δ-proteobacteria. Marine 
myxobacteria have been found in coastal sand or sediments,
84
 biofilms in 
intertidal habitats,
85
 and on surfaces of marine invertebrates and algae.
86,87
 Marine 
members are differentiated from terrestrial myxobacteria mainly on the basis of 
halotolerance
88
 and genera of true marine, halophilic myxobacteria include 
Haliangium,
89
 Plesiocystis,
90
 and Enhygromyxa.
87
 There are only few reports of 
secondary metabolite from marine myxobacteria,
91
 which is partly due to the only 
recent acknowledgement of these bacteria as true marine species and partly to 
their unculturable nature.
92
 Haliangicin was the first compound reported from a 
marine myxobacterium, Haloangium ochraceum.
93,94
 This compound displays 
potent antifungal activity but no effect against bacteria. 
Within the Firmicutes, strains of the genus Bacillus represent the 
highest number of compounds reported from the marine environment. A large 
number of Bacillus species found in marine samples are also found in terrestrial 
environments; however, examples of halotolerant bacilli have been described 
including the genus Halobacillus.
95
 Strains of B. marinus, B. cereus, B. 
S
S
OO
OH
O
O
O
O
O
 licheniformis, B. subtilis, and B. pumilus have been isolated frequently from 
marine invertebrates,
96-98
 algae,
99
 and sea water.
100
 Marine bacilli have provided 
several peptide antibiotics. Two potent thiopeptide antibiotics, YM-266183 and 
YM-266184 were isolated from B. cereus from the sponge Halochondria 
japonica.
101,102
 The compounds displayed activity against Staphylococci and 
Enterococci sp., including multiple-drug resistant strains.  
 
 
Cyanobacteria, or blue-green algae, are a group of filamentous bacteria. As these 
bacteria rely on photosynthesis, they are found only in the euphotic zone of the 
oceans.
103
 Cyanobacteria represent a shallow clade of bacteria (taxonomy of 
cyanobacteria is currently under revision), even so with clear phenotypical 
differences. The cyanobacteria account for a substantial fraction of the reported 
metabolites from marine sources,
104,105
 though it is difficult to completely separate 
freshwater and marine cyanobacteria.
104
 A noteworthy example is curacin A,
106,107
 
an antitubulin agent that has been in preclinical trials
108
 and served as lead 
structure for development of more potent synthetic analogues.
105,109
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Long have the central questions for natural product chemists been: what are the 
chances that we will find new and interesting compounds? What is the 
biosynthetic potential of a given organism? With the rise of the genomic era, the 
answers to these questions are now within reach. The cost of a full-genome 
sequence has drastically decreased and can be obtained quickly.
110
 A high number 
of microbial genomes have been sequenced and even more are pending (Figure 
1.4). That includes the genomes of many marine bacteria. Access to a full genome 
enables bioinformatic search for genes related to the biosynthesis of secondary 
metabolites, including clusters of polyketide synthases (PKSs), non-ribosomal 
synthases (NRPSs), and hybrids hereof, potentially linking them to production of 
specific compounds.  
 
 
 
 
The metabolic capacity of the different bacterial genera varies greatly (Table 1). 
Statistical analysis of a subset of completed genomes revealed a strong positive 
correlation between genome size and secondary metabolite biosynthesis.
112
 By 
studying functionally annotated genomes of some terrestrial and marine 
actinobacteria it becomes evident why these organisms have supplied such an 
extraordinary number of metabolites. The important producer of streptomycin and 
 other industrial antibiotics, Streptomyces griseus IFO13350 has no less than 34 
gene clusters devoted to secondary metabolites in the 8.5 Mb genome, including 
19 PKS/NPRS related clusters.
113
 Despite having significantly smaller genomes, 
marine actinobacteria were found to match that capacity with 19 PKS/NRPS 
clusters in Salinospora arenicola, corresponding to an impressive 10.9% of the 
5.8 Mb genome allocated to secondary metabolite production.
114,115
 
Genomes of many marine bacteria have been investigated in order to 
understand their role in an ecological context, for example their role in CO2 and 
N2 fixation,
116,117
 iron acquisition,
118,119
 and environmental adaptations.
69,115,120,121
 
Whilst several members of Pseudoalteromonas
122,123
 and Vibrio
121
 have been 
sequenced, few have looked into the number of genes dedicated to production of 
secondary metabolites.
124
 Thomas et al. (2008) investigated the genome of 
Pseudoalteromonas tunicata strain D2, and found only 2% of the genome 
allocated to production of secondary metabolites.
69
 They were able to identify the 
genes responsible for the production of the known metabolites, violacein and 
tambjamine, and a single unidentified NRPS cluster. This scant evidence of 
PKS/NRPS related secondary metabolism was in accordance with the genomes of 
other sequenced Alteromonas/Pseudoalteromonas species, including P. 
haloplanktis TAC 125, P. atlantica T6c, and Alteromonas macleodii which all had 
less than 2% of their total genome allocated to secondary metabolism.
69
  Whether 
this relatively low biosynthetic capacity is a common feature of γ-proteobacteria is 
yet to be revealed. However, the recent annotation of the genome of the marine 
shipworm symbiont, Teredinibacter turnerae, showed that this γ-proteobacterium 
might be able to “keep up with the Joneses” with at least nine biosynthetic clusters 
predicted to encode secondary metabolite pathways,
125
 This bacterium has not 
been investigated for its ability to produce NPs and thus no compounds have been 
isolated so far. This underlines the pending potential for exploitation of marine 
bacteria for NP production.  
The advances within genomics have revealed that bacteria rarely 
fulfill their potential for secondary metabolism under laboratory conditions.
126
  In 
the wake of the availability of full bacterial genomes, mining for new chemical 
diversity has become widespread.
126-130
 Before the sequencing of Streptomyces 
avermitilis in 2001, only three compounds were known, which was a number far 
smaller than the actual number of biosynthetic clusters.
47
 Even today, only 13 of 
the total 37 secondary metabolite gene clusters in S. avermitilis are linked to 
production of a specific compound.
131
 Thus, two thirds of the potential 
compounds produced by this organism is either not expressed or overlooked in 
chemical analyses. By exploring the genomes of other actinomycetes, for example 
Salinispora, it was found that their biosynthetic potential was underestimated with 
 
 
 
up to 80-90% in some cases. Due to the modular, sequential design of some 
bacterial polyketides and non-ribosomal peptides,
132
 it is possible to predict a 
putative structure in silico based on gene sequences with quite high accuracy. This 
can help unlock the nature of these cryptic pathways and identify their associated 
compounds.
126,133
  
 
 
Silent or „cryptic‟ pathways may be expressed in the natural setting, e.g. in a more 
competitive environment;
141
 however, turning these genes on in the laboratory can 
require the presence of different elicitors.
30,140,141
 This be either stress factors, 
signal molecules, or culture conditions. Attempts to mimic the natural habitat can 
include cultivation in media based on natural seawater from the sample location, 
addition of sponge
142
 or algal host extracts,
143,144
 or marine-derived nutrients like 
chitin or alginate.
145
 Okazaki et al. (1975) found that a marine actinomycete, 
Chania sp. only produced the antibiotic SS-228 Y
146
 on media containing the 
seaweed, Laminaria.
144
 A more random variation of culture conditions for 
metabolic „talented‟ strains is the „OSMAC‟ (One Strain MAny Compounds) 
approach that has the purpose of diversifying or maximizing the spectrum of 
 secondary metabolites from a given strain
147
. Attempts to trigger natural product 
biosynthesis also include biofilm formation.
148,149
 Bruhn et al. (2007) found that 
production of the antibiotic TDA by members of the Roseobacter clade was 
closely linked to biofilm formation.
81
 Production of antibacterial compounds has 
been linked to the production quorum sensing regulated homoserine lactones in 
several terrestrial bacteria,
150-154
 and a similar connection have been suggested for 
production of TDA in Roseobacter
155
 and violacein in Pseudoalteromonas.
156
 
Mixed fermentations or co-culture experiments can elicit secondary metabolite 
production in marine bacteria.
157
 Mearns-Spragg et al. (1998) found that the 
production of antibiotics by surface-associated marine bacteria was conditional to 
the presence of competitors.
158
 Angell et al. (2006) found two marine bacteria, a 
Pseudomonas aeruginosa and an Enterobacter sp., collected from the same 
sediment sample to have synergistic production of a blue pigment, pyocyanin, a 
compound not present in any of the pure cultures.
159
  
Establishment of a meaningful link between secondary metabolite 
production and the true ecological setting of a bacterium will enable the 
identification of new targets for the NP chemists. Based on the number of isolated 
compounds, current marine hot spots for bioactive metabolite production are the 
actinobacteria
26
 and cyanobacteria;
105,160
 however, the chemical potential of many 
marine bacteria is yet to be unraveled and only by a combination of optimized NP 
discovery, genomics, and molecular biology will we find a way to isolate these 
compounds.
3
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
The figure is intended as an overview of the main experiments performed during 
the course of this thesis. The results obtained will be discussed as an integrated 
part of the following chapters. The experimental details can be found in the 
denoted papers.  
 
 Extracts from biological samples including microbial fermentates often represent 
a complex mixture of secondary metabolites covering a high structural diversity. 
A given extract usually attracts attention when an interesting biological activity, 
either from a drug discovery or an ecological perspective, is detected. To begin 
with, the chemical composition of a given extract is often completely unknown; 
including which compound(s) is responsible for the observed bioactivity. In order 
to identify the bioactive compounds, it is necessary to isolate and structure 
elucidate the individual components. In most cases, this poses a considerable 
challenge, requiring a great amount of time, labor, and cost. Thus, a primary goal 
for the natural product chemist is to reduce the time from the detection of 
biological activity to the identification a specific chemical structure.  
The initial steps of this process will be described in the following sections. 
 
In order to efficiently evaluate the many bacterial strains collected during the 
Galathea 3 expedition while accelerating the discovery process, we have 
established a three-step chemical screening approach (Figure 3.1).  
Our primary screen is based on raw extracts from less than 30 mL of 
bacterial culture, which is sufficient for screening in multiple bioassays and to 
obtain chemical profiles by LC-UV/MS, yet has the necessary scale to allow 
many samples to be processed per day. This allows us to quickly determine the 
spectrum of activity and biosynthetic potential of a given strain. The best 
candidates often display activity in more than one bioassay. In our collection, we 
have many strains that belong to the same species collected from distant 
geographical locations. Consequently, there is a high possibility of redundancy. 
To select the strains that will cover the broadest chemical diversity, thorough 
assessment of the global chemistry is necessary both in terms of quantity and 
novelty. Thus, careful dereplication by LC-UV/MS is performed at this level.  
 
 
 
 
 
 
 
The most promising candidates from the primary screen are forwarded for a 
second level of screening and chemical evaluation prior to the investment in 
preparative-scale isolation. The bacteria are cultured in larger containers (200-
1000 mL) in order to ensure that growth characteristics and metabolite production 
is reproducible. This indicates the yield that can be expected from a given 
organism when scaled-up. From these cultivations, the obtained biomass is 
sufficient for various pre-fractionations, including explorative solid-phase 
extraction (E-SPE) (paper 1). Fractions are evaluated in the various bioassays, 
which enables detailed mapping of the bioactive compounds. Quorum sensing 
inhibition assays are often less suitable for testing of crude extracts since the more 
subtle QSI effects are easily camouflaged by the presence of antibacterial 
compounds. Therefore, fractions are forwarded for QSI assays despite a negative 
response in the primary screen. The reduced complexity of the fractions compared 
 to the crude extract also facilitates a more detailed dereplication. On this scale, a 
purification strategy can be planned and tested in order to ensure maximum 
recovery and stability of active components.  
Lastly, the best producers are selected for large-scale cultivation. We 
found that 10-20 L of culture was sufficient for most strains. For compounds 
excreted into the broth Diaion HP20 or XAD-7 was used for extraction and 
desalting. Compounds associated with the cells were extracted after harvesting the 
cells by centrifugation. As the typical yield of pure compounds obtained from the 
bacteria studied in this thesis was less than 0.5 mg L
-1
, the majority of NMR data 
for structure elucidation has been obtained on either 800 MHz spectrometer with 3 
mm cryo-probe (Carlsberg) or 600 MHz with a capillary flow-probe for enhanced 
sensitivity and improved resolution (for details on NMR refer to papers 1, 4, and 
6).  
 
Detailed chemical analysis of the small molecule composition (the metabolome) 
of an organism
1
 can contribute to the understanding of phenotypic changes in an 
organism as response to its environment. Metabolite profiling (or chemical 
profiling) refers to the qualitative analysis of all metabolites produced with the 
objective to identify a specific metabolite profile that characterizes a given sample 
(Figure 3.2).
1
 This can concern a group of metabolites related to a specific 
biosynthetic pathway or compound class (targeted metabolite profiling),
2
 or 
completely unknown metabolites.
4
 Even though primary metabolites are of great 
importance to the producing organisms, they are less useful for profiling purposes 
as they have a more general distribution and thus no differentiation power.
3
 
Therefore, within the scope of this thesis, metabolite profiling refers only to the 
analysis of the secondary metabolome. 
Metabolite profiling involves peak/compound analysis, i.e. 
establishment of molecular formulas or other spectral features (Figure 3.2). Thus, 
metabolite profiling and dereplication are tightly coupled (section 3.3.1). A 
complementary approach is metabolite fingerprinting where ‘patterns of 
metabolites’ are investigated rather than the individual metabolites.2 This can be 
used to cluster groups of extracts that represent different species or chemotypes in 
an unbiased way and to identify chemical markers responsible for the 
differentiation.
2
 
  
 
 
 
In filamentous fungi, chemical profiling of secondary metabolites has been used 
with success, greatly improving fungal classifications and taxonomy.
3,5
 Owe to a 
high degree of horizontal gene transfer, phylogenetically unrelated bacteria often 
produce the same secondary metabolites (paper 1, 3, 4). Concomitantly, bacteria 
within the same species tend to show a low degree of chemo-consistency, with 
very few metabolites, if any, consistently expressed in all members (paper 3, 5). 
Therefore, secondary metabolite profiling or fingerprinting is less suited for 
taxonomic purposes in bacteria. In a drug discovery or ecological context 
however, chemical profiling of bacteria very 
much has its justification as part of an 
intelligent screening strategy (paper 4).
5,6
  
Assessment of metabolite profiles 
or fingerprints can help select representatives 
of a species by recognizing redundant strains 
(strain dereplication) or strains of the same 
species that might produce different 
metabolites as a result of different niche-
specificity (ecotype identification).
5,7
 Such 
analyses are imperative to uncover the full 
biosynthetic potential of a bacterium (paper 
3). Chemical profiling can also be used to 
prioritize compounds for further investigation.
8
 
Principal component analysis (PCA) of 
metabolite fingerprints can help identify peaks or compounds that are 
characteristic of specific chemotypes, and therefore likely to be of ecological 
importance. Also, profiles of secondary metabolites under different culture 
conditions
9
 will help identify compounds that are involved in a particular 
phenotypic response (paper 5).  
 
  
 
 
In many cases, the number of secondary metabolites produced by a single 
organism can exceed several hundred compounds with different physiochemical 
properties. This specifies the need for a versatile method that allows the detection 
of most compounds. At CMB, we use liquid-chromatography coupled with 
ultraviolet diode-array (UV/DAD) and electrospray ionization (ESI) mass 
spectrometry detection for the profiling of secondary metabolites. ESI has the 
ability to ionize a broad range of metabolites with minimal fragmentation which 
helps the interpretation of the spectral data.
9,10
 Other interfaces suitable for 
metabolite analysis include atmospheric pressure chemical ionization (APCI)
11
 
and more recently, atmospheric pressure photoionization (APPI).
11-13
 To obtain 
the best metabolite coverage, ionization is performed in both positive and negative 
mode (paper 2)., and complementary detection by UV and MS reduces the risk of 
overlooking metabolites that lack a chromophore or ionize poorly. Coupled to a 
LC system, the number of metabolites detected is maximized due to reduced 
signal suppression.
14
 Reversed-phase (RP) chromatography is a versatile method 
for the separation of secondary metabolites, but also aqueous normal phase 
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systems such as hydrophilic interaction chromatography (HILIC) gain a foothold 
in metabolite profiling.
15,16
 However, the latter is less suited for marine bacteria 
due to high levels of salt in the extracts which impairs binding to the column. The 
introduction of ultra-high pressure liquid chromatography (UHPLC) using sub-2-
μm particles has greatly improved performance in terms of analysis time, allowing 
sample runs with chromatographic separation in less than 5 minutes.
17,18
  
For metabolite fingerprinting of bacteria, the method of choice has 
been matrix assisted laser desorption ionization (MALDI) time-of-flight (TOF) 
MS.
19
 Bacterial fingerprints have been compared for taxonomic and diagnostic 
purposes,
20
 for example to identify pathogenic strains of Bacillus and Yersinia.
21,22
 
Dieckmann et al. (2005 and 2009)  successfully applied whole-cell MALDI-TOF 
MS fingerprinting on strains of Vibrio
23
 and other sponge-associated marine 
bacteria.
24
 Most examples of bacterial fingerprinting are based on small protein 
analysis (m/z 2,000-15,000 Da) rather than secondary metabolites; however, 
Esquenazi et al. (2008) demonstrated how whole-cell MALDI-TOF MS can be 
used to detect jamaicamide (m/z 589), curacin (m/z 374), and other low-molecular 
weight compounds in cyanobacteria.
25
 This suggests that the method can be 
extended to cover secondary metabolites,
26-28
 even though the matrix will cause 
interference in the small mass area (m/z <300, dependent on the type of matrix). 
Covering a lower mass range, direct infusion mass spectrometry (DIMS) has been 
identified as a very useful method for detailed metabolite fingerprinting of 
filamentous fungi.
29
 There are only few examples of the application of DIMS to 
bacterial extracts or suspensions.
30
 Vaidyanathan et al. (2001) were able to 
discriminate various Bacillus strains at species and sub-species level using ESI-
DIMS analysis of whole-cell suspensions.
31
 Also, cell-free supernatants of 
Halomonas sp. were clustered for preliminary phenotypic characterization using 
ESI-DIMS.
32
 However, DIMS analysis suffers from a number of disadvantages 
compared to LC coupled MS analysis, the major issue being signal suppression 
due to co-injection of extract components.
2,14
 Also, in our experience DIMS 
analysis is less suitable for marine-derived extracts due to the high levels of salt 
that block the cone even for organic extracts.  
For marine extracts, an attractive alternative to DIMS is desorption 
electrospray ionization (DESI) MS. Like whole-cell MALDI, DESI-MS is able to 
record mass spectra of intact cells without sample preparation
33
 but will cover a 
mass range as low as m/z 50-500.
34
 As DESI is a soft ionization technique like 
ESI,
33
 it will cause minimum fragmentation and studies have demonstrated that 
DESI provides comparable results to that of ESI-DIMS,
35
 however with a much 
higher salt tolerance.
36
 DESI-MS analysis has successfully been applied to intact 
bacteria for species and sub-species differentiation.
34,37,38
 
 A supplement to MS-based fingerprinting is nuclear magnetic resonance (NMR). 
One-dimensional proton (1D-
1
H) NMR has been used extensively for 
fingerprinting of plant extracts,
39
 where chemical shift values and coupling 
patterns are used for clustering. Unlike mass spectrometric methods, NMR 
fingerprinting provides structural information on functional groups and 
compounds classes. Kim et al. (2006) used 
1
H NMR to discriminate whole-cell 
extracts of cyanobacteria,
40
 and recently the approach was applied by Boroujerdi 
et al. (2009) to characterize temperature-dependent metabolite fingerprints of V. 
coralliilyticus.
41
 One of the major drawbacks of 
1
H-NMR fingerprinting is high 
signal congestion. The enhanced sensitivity of many NMR probes
42
 has enabled 
the use of two-dimensional (2D) experiments for fingerprinting,
43
 increasing the 
dispersion of resonances and thus information content of the spectrum. Often 
13
C 
isotope labeling is used to increase sensitivity in heterologous experiments like 
HSQC,
44
 However, NMR-based methods still suffer from intrinsically poor 
sensitivity, which means that the metabolome analysis is restricted to the subset of 
secondary metabolites that exceeds a concentration threshold.
39
  
 
Metabolite profiling of marine bacteria has only been employed in a few cases so 
far. To the best of my knowledge, the first example of metabolite profiling of a 
large collection of marine bacteria is the investigation of Salinispora by Jensen 
and Fenical (2007).
45
 They found a clear link between phylotype and secondary 
metabolite production irrespective of geographical location in members of the 
genus Salinispora. Widely distributed strains of S. arenicola had consistent 
production of three core metabolites, rifamycin, staurosporine, and saliniketal, 
joined by a number of accessory metabolites potentially acquired by horizontal 
gene transfer.
45
 The study confirms that secondary metabolite profiles in bacteria 
represent more than a strain-specific phenotype despite intra-species differences. 
In line with these results, Gram et al. (2011) found production of the antibiotic 
TDA in members belonging to the Roseobacter clade to be a conserved feature 
independent of sample location.
46
  
We have extended the use of LC-UV/MS metabolite profiling to 
members of Vibrionaceae (paper 4-6) and Pseudoalteromonas (paper 3). In our 
Galathea collection of 101 Pseudoalteromonas strains, we were able to resolve 
distinct chemotypes at species and subspecies level (paper 3). Several compounds 
were exclusively produced by strains belonging to the same cluster defining core 
metabolites, whereas other compounds were produced across more than one 
 
 
cluster. The antibiotic pigments violacein and prodigiosin (Figure 3.4) were found 
to be restricted to members of P. luteoviolaceae and P. rubra, respectively. 
Interestingly, while violacein seemed to be a core metabolite defining the species, 
prodigiosin production was only detected in five of nine P. rubra strains. We 
assume that this may be due to loss of the ability to produce the pigment or strain 
variations in growth requirements for production of prodigiosin, as we did not 
observe prodigiosin in the type strain where it was originally reported.
47,48
 Some 
species were found to be very homogenous in their metabolite production despite 
geographically distant sample locations, for example P. flavipulchra and P. 
piscicida (Figure 3.3) where all but one produced large amounts of 
bromoalterochromides
49
 and other brominated metabolites.  
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In contrast, four P. luteoviolacea strains collected during the expedition showed 
both local and global variations in their secondary metabolite profile and 
antibiotic production. Chemotype PL1 (strains S2607/S4060) showed coordinated 
production of the antibiotics violacein and pentabromopseudillin (paper 3), while 
chemotype PL2 (S4047/S4054) produced violacein and indolmycin (paper 1) (see 
section 3.3.2). The grouping was supported by analysis of seven additional strains 
of P. luteoviolacea from culture collections (Månsson and Vynne, unpublished 
results, Table 1), adding at least one other chemotype, PL3, that produced 
violacein but neither indolmycin nor pentabromopseudilin (Figure 3.5). We 
hypothesize that the production of different antibiotic cocktails by P. 
luteoviolacea is a reflection of its adaptation to specific niches, for example as a 
successful colonizer of marine surfaces such as sponges or corals.
50,51 
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A putative connection between chemotype and phenotype was also found among 
Vibrionaceae. Two strains of V. coralliilyticus (S2052/S4053) from distant 
sample locations displayed almost identical metabolite profiles, with the 
production of the antibiotic andrimid as a dominant feature (paper 4). Yet, 
andrimid was not observed in two closely related strains of V. coralliilyticus, 
including the type strain (paper 5). In addition, we found a temperature-
dependent variation in the metabolic capabilities of S2052 and its relatives (paper 
5). V. coralliilyticus S2052 had metabolic optimum at 25 
ο
C, whereas the type 
 
 
strain and its relative showed optimum at 30 
ο
C. Interestingly, these two strains 
also show increased pathogenicity against corals at increased temperatures.
52
 
Thus, there might be a link between pathogenicity and metabolic capabilities.  
When grown on the natural substrate chitin, V. coralliilyticus S2052 
solely produced andrimid (paper 5) (Figure 3.6), indicating that andrimid serves a 
function while growing on chitin-containing surfaces such as zooplankton. In 
contrast, P. halotolerans S2753 sustained production of all metabolites including 
the antibiotic holomycin (paper 4).  Furthermore, chitin stimulated the production 
of two potentially novel metabolites (RT 10.24 min, MW 618 and RT 11.15 min, 
MW 269) not observed on glucose. The different phenotypic responses to a 
natural growth substrate may reflect different niche-adaptations or different 
ecological functions of the compounds produced.  
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 In practice, many isolated fractions of natural product extracts contain compounds 
that have been characterized previously. Due to the cosmopolitan occurrence of a 
lot of antibiotics and other bioactives, many compounds will be rediscovered even 
by intelligent selection of new types of organisms (paper 4).
53,54
 Therefore, there 
is a continual need for dereplication in natural product discovery, i.e. the ability to 
exclude previously discovered compounds or classes of compounds.
55
 Through 
rapid chemical and biological screening, dereplication provides fast, tentative 
identification of compounds in an extract, which makes it possible to rank natural 
product extracts according to the probability that the active constituent will be 
new.
56
 By making dereplication an integral part of the early stages of the 
discovery process, it is possible to minimize the potential risk of replicating 
previous results, and thereby ensure that the time invested in isolation of 
compounds and ensuing structure elucidation is time well spent.
54,56
   
Several approaches to the dereplication process exist, typically based 
on a combination of chromatographic and spectroscopic methods and database 
searching.
57
 Traditional dereplication methods relied on thin layer 
chromatography (TLC) bioautography combined with numerous staining reagents 
for the identification of specific compound classes or functional groups.
55,58
 
Eventually, this approach was complemented by the use of HPLC-UV
59,60
 for 
dereplication based on retention time and characteristic UV spectra. With on-line 
diode array detection (DAD) as standard equipment on most HPLC systems 
today, the UV spectrum of a compound still is one of the most readily accessible 
pieces of structural information.
5
 Modern dereplication methods include various 
combinations of LC-UV, LC-MS, LC-MS/MS, and LC-NMR,
17
 each with their 
set of advantages and limitations. Also, with the increasing availability of 
genomic data, dereplication performed on the basis of sequence information is 
emerging.
61
 The dereplication methods applied during the course of this PhD at 
CMB and University of Canterbury will be discussed in the following sections.  
For each analytical method, the data need to be translated into a 
searchable query for a database. A number of commercial databases are currently 
available for the marine natural products chemist:  
 Encyclopedia of Marine Natural Products (8,700 compounds; J.-M. 
Kornprobst)  
 Dictionary of Natural Products (230,000 compounds; J. Buckingham) 
 Dictionary of Marine Natural Products (30,000 compounds; J. Blunt and 
M. Munro) 
 
 
 AntiBase (37,000 compounds; H. Laatsch) 
 MarinLit (22,000 compounds; J. Blunt and M. Munro) 
 AntiMarin (50,000 compounds; J. Blunt, H. Laatsch, and M. Munro) 
 
AntiMarin, being compiled from AntiBase and MarinLit, is currently the largest 
and most specialized resource for the dereplication of marine microbial natural 
products. The database contains the structures of all known compounds from 
marine macroorganisms and marine and terrestrial microorganisms. Besides 
accurate masses and UV characteristics, all compounds are coded for 
1
H NMR-
recognizable features, which make it possible to extend the query to include 
characteristic functional groups. The work at CMB is only concerned with 
investigation of marine microorganisms; therefore our database facilities are 
restricted to AntiBase.    
Dereplication can be an laborious task, as each probable candidate 
from a database hit list need to be evaluated. In 1994, Corley and Durley 
estimated that it takes $50,000 and three months to isolate and characterize an 
active compound from a natural source.
62
 For every known compound isolated, 
these resources are squandered. Even though this number might not be completely 
valid today due to improved equipment and techniques, it greatly exceeds the cost 
of subscribing to any commercial database. Thus, the time and effort spent on 
early dereplication is worthwhile.  
 
The method of choice for front line dereplication of extracts at CMB is LC-
UV/MS (paper 2).
5,63
 LC-MS is a simple and rapid dereplication method that can 
be controlled automatically to obtain a high throughput and reproducibility. 
Dereplication by this approach is based on determination of the accurate mass of 
the [M+H]
+
, [M-H]
-
, or other identified ions. Today, it is the most widely used 
dereplication method as accurate mass can be used as query in nearly all natural 
product databases.
54
 LC-MS is a generally sensitive method, providing reliable 
results within the 10
-15
-10
-9
 g range for most compounds, although some classes 
of especially very small molecules and non-oxygen and non-nitrogen containing 
compound often do not ionize (paper 2). The signals obtained can be easily 
deconvoluted, which makes LC-MS very suitable for the dereplication of complex 
mixtures.  
 Correct interpretation of LC-MS data is essential for correct assignment of the 
molecular mass and the subsequent database searching.  ESI ionization is the most 
common ionization technique for LC-MS, and in most cases interpretation is 
relative simple (Figure 3.7). Other ions than the molecular ion can be quite 
abundant depending on the nature of the target compound, the ion source 
parameters (e.g. the applied skimmer voltage), and the solvents and additives used 
(paper 2). These ions can validate the assignment of the molecular ion, especially 
for compounds undergoing both fragmentation and adduct formation.
63
 However, 
this part of the process is prone to error. Strong adduct ions such as [M+Na]
+
, 
[M+NH4]
+
, [M-H+HCOOH]
-
 etc. or fragment ions can easily be misinterpreted as 
[M+H]
+
 or [M-H]
-
, leading to false compound identification.
64,65
 Interpretation of 
the data can be hampered by the presence of interfering ions from minor 
components more prone to ionization than the target compound. On the basis of 
statistical analysis of our in-house metabolite database, we found that ESI
+
 alone 
was able to unambiguously assign the correct molecular mass for 56% of the 
compounds (paper 2). Extended with ESI
-
, this fraction was increased to 93%, 
demonstrating the power of LC-ESI-MS.  
The accuracy of the data is fundamental for the success of MS-based 
dereplication.
66
 The American Chemical Society has defined ‘accurate mass’ as a 
mass measurement error of maximum 5 ppm. On most state-of-the-art mass 
analyzers operated under ‘high-resolution’ (HRMS) conditions, the mass accuracy 
is typically 1-5 ppm (depending on internal mass calibration), with some 
analyzers (FT-ICR) providing ultra-high resolution with sub ppm mass accuracy. 
However, few natural products laboratories currently have access to equipment of 
that accuracy. Therefore, it is common that several molecular formulas are 
compatible with the observed molecular mass.
66
 This necessitates a relatively high 
tolerance in database queries, resulting in a lot of candidates of which most are 
false positives. Statistical analysis of all molecular formulas in AntiBase 2008 
(paper 2) revealed at 5 ppm mass difference, 195 compounds with different 
elementary composition could not be differentiated from each other in the mass 
range 400-99 Da. The number of candidates can be reduced up to three fold when 
isotope ratios are used (Cl, Br and ± 2 carbons).  
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 Below 1 ppm mass accuracy, molecular formulas could be unambiguously 
assigned for all compounds in AntiBase. Yet, this does not solve the problem of 
redundant molecular formulas. This problem can in part be circumvented by 
extended information gained by MS/MS.
67
 On newer MS instruments, MS/MS 
spectra can be recorded automatically in data-dependent acquisition mode and the 
accurate mass of characteristic fragments provides direct structural information.
9
 
This is particularly useful for peptides and other biopolymers where sequences 
can be derived de novo. For small molecules, the fragment ion mass spectra are 
less consistent between different spectrometers and instrumental parameters. 
Several search algorithms
68
 and commercial software packages such as the 
ACD/MS Fragmenter and Mass Frontier are available for in silico prediction of 
fragmentation patterns;
69
 however, studies by Horai et al. (2009) on a subset of 
453 metabolites in MassBank
70
 show the confidence in peak annotation to be as 
low as 3%.
69
 Thus, in order to make MS/MS data available for meaningful 
database queries, compound-specific reference spectra need to be collected at 
several different collision energies and spectra must be filtered for background 
noise before database storage.
71
 Consequently, MS/MS for dereplication purposes 
is currently restricted to those compounds included in in-house libraries.
67
  
MS in itself is not a very discriminatory method,
72
 and therefore 
secondary information need to be used for exclusion of candidates during a 
database search. Comparison of UV data can be very useful as it will give 
indications towards the composition of a potential chromophore.
5,59
 However, for 
non-chromophoric compounds this is of no value. Also, UV data is rarely 
complete in commercial databases and thus not available for comparison. 
Retention time (RT) is an additional parameter for dereplication.
73
 For certain 
compound classes there are a good correlation between RT and logD values 
(paper 2).  LogD values can be predicted, yet retention time is less suitable for a 
searchable query as even slight changes in the chromatographic conditions might 
change the RT considerably.
58
 Information on the taxonomic origin of a given 
compound is often provided in commercial databases and can thus be used to 
assess the probability of a compound being known or novel (Figure 3.7). This 
information is of little value for the dereplication of bacterial extracts due to the 
high degree of horizontal gene transfer. Overall, unless data is compared to that of 
an authentic standard, MS-based dereplication will only provide a tentative 
identification of a compound (Table 2). 
Within recent years, the combination of HPLC and NMR has 
emerged as an attractive analytical tool for dereplication of natural products aided 
by improved probe design and magnetic field strength for enhanced sensitivity 
and resolution.
42
 Unlike MS and UV, NMR provides direct structural information 
 
 
that furnishes structural elucidation (Table 2).
74
  From a set of 1D spectra, it is 
possible to get information on the qualitative (
1
H or 
13
C) and quantitative (signals 
intensities) composition of the investigated structure as well as the identity of 
functional groups (chemical shift) and bond properties (J couplings). Unlike MS 
and UV, NMR is highly non-selective, which means that it can detect compounds 
with no chromophore or with poor ionization in MS.
75
 For dereplication purposes, 
NMR detection can be obtained on-line either through direct hyphenation (on-
flow, stopped-flow, or loop-storage), through a solid-phase extraction (SPE) 
interface,
76,77
 or it can be used as an off-line detection method. 
LC-NMR has been used extensively for the dereplication of plant-
derived metabolites.
75,78
 However, there are only few examples of this method 
used for the dereplication of marine
72,79
 or microbial extracts.
80-82
 Crews’ lab has 
used NMR-based dereplication for the characterization of diphenyl ethers and 
sesterterpenes in sponge extracts.
83,84
 Likewise, Dias and Urban (2008) used a 
combination of on-line and off-line LC-NMR for the dereplication of halogenated 
monoterpenes from a marine algae, Plocamium mertensii.
85
 To the best of my 
knowledge, the only example of NMR-based dereplication of a marine bacterium 
is from the cyanobacterium, Ficherella ambigua.
86
  Here, Lin et al. (2008) applied 
off-line microdroplet NMR in order to identify novel antibacterial ambiguines in 
an extract consisting of mainly known compounds.   
The key strategy used for dereplication in the Marine Chemistry 
Group at the University of Canterbury (UoC) consists of a combination of HPLC-
UV, and off-line MS and capillary NMR (CapNMR),
87
 well integrated with their 
biological screening system.
81
 The eluate from a single HPLC run is collected in a 
96-well microtiter plate, and wells are combined to provide single-peak material 
for direct injection MS and CapNMR. The first level of dereplication is based on 
simple 1D 
1
H-NMR data that usually is acquired in 5-10 minutes (for MW < 600 
Da).
87
 The spectrum is inspected for NMR recognizable features, such as the 
number of methyl groups and their multiplicity, or coupling patterns of substituted 
benzene rings. These features can in a numerical way be used as query in 
AntiMarin to perform very powerful and discriminatory searches. Often a DQF-
COSY spectrum can be recorded in a reasonable amount of time that in some 
cases can provide a substructure that can be used as query in the various 
databases, incl. SciFinder where NMR data and accurate mass cannot be used.  
  
 During my stay at UoC, I had the chance to use this approach for the dereplication 
of an extract of Pseudoalteromonas luteoviolacea. Antibacterial activity of the 
extract was suspected to be ascribed to the dual presence of violacein and 
indolmycin (paper 1) (more details in section 3.3.2). Indolmycin had only been 
isolated from terrestrial actinomycetes,
88,89
 thus in order to validate its presence in 
Pseudoalteromonas, a pure fraction suspected to contain indolmycin was analyzed 
by CapNMR. Initial inspection of the 1D spectrum revealed the presence of two 
methyl groups, one doublet and one singlet, the latter possibly an N-methyl based 
on the chemical shift value of δH 2.8 ppm. In addition, the characteristic splitting 
pattern of a tryptophan unit was seen (Figure 3.8). Feeding this set of information 
from the 1D 
1
H-NMR spectrum to AntiMarin together with the nominal mass 257 
Da, resulted in a single candidate: Indolmycin. A full NMR dataset of pure 
indolmycin corroborated this result. The use of CapNMR for dereplication 
enabled the absolute identification of a known compound rather than just tentative 
as can be obtained by LC-UV/MS.  
NMR still trails MS in terms of the minimum sample amount 
required.
77
 From the experience at UoC, only 200-500 µg of initial extract is 
needed to provide sufficient material for the NMR analysis, usually giving 2-50 
µg of pure compound.
87
 We found this amount to be insufficient for the extract of 
P. luteoviolacea. In order to obtain sufficient amounts of pure compound, multiple 
HPLC runs were necessary, and due to the complexity of the extract manual 
fraction collection was required in order to ensure adequate purity. Like for any 
nanomole or micromole NMR technique, the purity of the peaks is of outmost 
importance as the signals are not easily deconvoluted at this scale. This means that 
the slightest impurities can hamper any interpretation of the spectra.
42,77
 In 
consequence, one has to be very careful in construction of a database query. A 
wrong input can lead to too many restrictions, and thus a false negative. Many 
other setups for NMR-based dereplication exist; however, the mentioned 
limitations (Table 2) are valid for all.  
LC-NMR dereplication can in the best case scenario completely 
obviate any large-scale purification.
86,87
 Occasionally, it is possible to identify 
novel compounds directly from a crude extract, thus condensing dereplication, 
purification, and structure elucidation into a single step.
87,90
 However, for most de 
novo structure determinations it is necessary to do large scale purification in order 
to supply sufficient material for a full dataset and determination of the absolute 
configuration of a compound by X-ray crystallography.  
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During the work with marine bacterial metabolites, we found that both the 
approach at CMB and UoC to be insufficient due to the convoluted nature of the 
samples. LC-UV/MS was not sufficiently discriminatory and could not provide 
the necessary answers of whether to pursue with purification of a given extract, 
while the CapNMR approach was too insensitive and time-consuming for 
complex extracts. In order to contribute to additional facets to the dereplication 
process, we have developed the so-called explorative solid-phase extraction 
method (paper 1).   
The intent was to construct a setup based on solid-phase extraction 
(SPE) columns that could provide essential information on functional groups 
present in an extract. Such information is suitable as query in available 
commercial databases like AntiBase. Based on statistical analysis of all 
metabolites reported in AntiBase 2008 and their theoretical pKa values, we found 
that charge is a very discriminatory factor for the dereplication of microbial 
metabolites (Figure 3.9).   
 
 
 
 
 
Some 44% of all compounds were found to have an acidic functionality, either 
represented as a carboxylic acid (18%) or as an acidic phenol or enol. In 
consequence, we decided to include two anion-exchangers, i.e. a strong anion-
exchanger (SAX) for retention of carboxylic acids and a mixed-mode anion-
exchanger (MAX) for additional retention of weak acids. Owe to the dual 
selectivity of the MAX column, information of the relative polarity of the extract 
components could also be obtained. The number of compounds with a basic 
amine functionality added up to 17%, leaving a positive charge as the most 
discriminatory for dereplication purposes. So, we decided to include a strong 
cation-exchanger (SCX) in the setup. Interestingly, there was a markedly higher 
fraction of basic functionalities in bacterial compounds (28%) compared to fungal 
(8%). Also, more compounds had an amphoteric nature (16%). This is possibly a 
reflection of different biosynthetic pathways in bacteria and fungi, with a higher 
frequency of alkaloids, non-ribosomal peptides or hybrids hereof in at least in 
certain groups of bacteria (chapter 4).
91,92
 Thus, cation-exchange for the 
dereplication and purification of bacterial metabolites is very useful.  
 
 As a fourth column, we decided to include Sephadex LH-20 for size-exclusion. In 
natural product chemistry there is a strong tradition for the use of LH-20 for 
orthogonal purification to reversed-phase C18. LH-20 is a very versatile column 
material with dual hydrophilic and hydrophobic properties that separates 
compounds on the basis of molecular size and shape. The material shows low 
irreversible absorption, giving high sample recovery, and various solvent 
interactions and hydrogen bonding result in good affinity towards phenolics and 
heteroaromatic compounds.
93
 The combination of the SAX, MAX, SCX, and LH-
20 columns provides orthogonal information of charge, polarity, and size of 
extract components to be used in dereplication and purification.  
For some extracts, we found a diol column to be an attractive 
alternative to the use of LH-20. Essentially, diol is a normal-phase column and 
will separate based on polarity like C18. However, the hydroxyl functionalized 
backbone provides excellent resolution for charged compounds,
94
 and in many 
cases we found diol be orthogonal to C18 (Figure 3.10) rather than pure silica where 
opposite elution (and thus not orthogonal) is often seen. Other polar-functionalized 
bonded silicas such as cyano- and aminopropyl were considered for the E-SPE 
setup. Bonded-phase silicas show good mass recovery and have weak ion-
exchange properties when used with aqueous solutions. These columns can be 
used with advantage for a second round of optimizations.  
The specific conditions were optimized for the individual columns, 
including loading, solvents and additives, dimensions, and number of fractions. 
Based on AntiBase 2008 statistics, we found most compounds with an ionizable 
functionality to be charged at pH 2 and 11 for anions and cations, respectively 
(paper 1). Thus, these values were used for sample load and elution on the ion-
exchangers. The strong anion- and cation-exchangers were run in a simple ‘on-
off’ mode, yielding two fractions per column with unretained (A1/C1) and 
retained (A2/C2) compounds, respectively (Figure 3.11, page 56). To avoid 
surpassing the capacity of the strong ion-exchangers, careful desalting of marine 
extracts is very important. The dual selectivity of the MAX column was exploited 
by the collection of six fractions corresponding to polar (B1), medium-polar (B2), 
and apolar (B3) neutral and basic compounds and polar (B4), medium-polar (B5), 
and apolar (B6) acidic compounds. Several gradients were attempted; however, 
the best resolution, as defined by presence of activity in a single fraction, was 
obtained with 25, 60, and 100% organic. 
 
 
 
The best resolution for LH-20 was obtained through band-based collection rather 
than time-based (D1-D5). However, this type of collection is restricted to colored 
extracts and makes it difficult to run columns on different extracts in parallel. No 
pre-packed columns with LH-20 exist, thus a certain degree of variation was 
introduced for this column due to manual packing. Different column dimensions 
were tried, but we found no significant differences between columns at this small 
scale (<100 mg dry material). We found the most important factor for good 
resolution on LH-20 to be the loading conditions. Extracts should be loaded in as 
small a volume as possible for optimal focusing on the column. Also, the presence 
of a frit in top of the column improved resolution. When diol was included in the 
setup, six fractions were collected corresponding to 100% heptane (E1), 100% 
dichlormethane (DCM) (E2), 50/50 v/v DCM/ethylacetate (EtOAc) (E3), 100% 
EtOAc (E4), 50/50 v/v EtOAc/methanol (MeOH) (E5), and 100% MeOH (E6). 
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 Based on the SAX, MAX, SCX, LH-20 setup, at total of 15 fractions was obtained 
(Figure 3.11, 16 fractions if using diol). We decided to run the four SPE columns 
in parallel as opposed to in series. Even though a sequence of SCX, followed by 
SAX and MAX would yield 13 fractions rather than 15, information about the 
stability of compounds on the individual columns would be lost.  
 
 
 
Linked to a bioassay system, the power of E-SPE for dereplication is enhanced. 
Minor constituents of an extract can exhibit exceptional potency in a given 
bioassay, and thus the sensitivity of our assays was exploited to extract chemical 
information. By comparison of LC-UV/MS traces of active and non-active 
fractions, it was possible to identify peaks as potential candidates for an observed 
bioactivity (comparative dereplication). The orthogonality of the E-SPE setup 
makes it possible to assess the number of bioactive constituents in an extract, and 
the contribution from individual compounds could be estimated by accounting 
from the titer.  
 
 
 
 
To ensure broad applicability of E-SPE, we did various tests to ensure the 
compatibility with all our bioassays. As the target organisms in most of our assays 
were sensitive to acid, it was necessary to use formic or acetic acid to regulate pH 
on the ion-exchangers as both would evaporate off more quickly than the solvent. 
For marine extracts, efficient desalting was imperative as formate and acetate ions 
formed under acidic conditions caused interference in growth inhibition assays. 
Also, components such as bile acids (originating from yeast extract) in many 
complex media were found cause interference at increased concentrations. Thus, 
in order to be able to compare the assay response, we found it imperative to 
include a blank medium sample and preferable only use simple media for 
cultivation. 
In order to validate the E-SPE method, we used several extracts of 
Pseudoalteromonas as they are known to be prolific in their production of 
bioactive natural products (paper 3).
51,92
 The E-SPE bioactivity profiles of four 
strains of P. luteoviolacea against Staphylococcus aureus revealed two distinct 
phenotypes (Figure 3.12). Type 1, representing strains S2607 and S4060, 
produced at least two antibacterial compounds, one being apolar with an amine 
and acidic phenol or enol (observed in fractions A1, B6, C2, and D5), and the 
other being medium to apolar with an acidic phenol or enol (A1, B5, C1, and D2). 
These functionalities were consistent with the presence of violacein and 
pentabromopseudilin (PL1, see section 3.2.2), and the presence of both was 
confirmed by LC-UV/MS (paper 3).  
 
 
  
 
E-SPE type 2, representing strains S4047 and S4054 (PL2, see section 3.2.2), had 
a bioactivity pattern corresponding to violacein and as well as an unknown 
antibacterial compound also with a basic functionality (A1, B2-B3, C2, and D3). 
This compound was also active against Vibrio anguillarum (paper 1). Further 
interest in this compound was fueled by activity of the E-SPE fractions in QSI 
selector assays based on lux and las/rhl QS systems (Figure 3.13),
95
 an activity 
that was undetected in the crude extract of P. luteoviolacea (unpublished results). 
As the las/rhl QS system control the expression of various virulence factors in 
Pseudomonas aeruginosa, the unknown compound has potential anti-pathogenic 
activity.
96
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Comparative dereplication by LC-UV/MS led to the tentative identification of 
indolmycin (paper 1). From the E-SPE results it was possible to design a 
purification strategy based on cation-exchange and size-exclusion for rapid, 
target-guided isolation of indolmycin. The identity of the pure compound was 
verified by NMR (section 3.3.1) and biological testing confirmed that indolmycin 
was in fact responsible for the observed activity. Re-testing of pure indolmycin at 
various concentrations revealed that the ability to down-regulate virulence gene 
expression was only valid in a very narrow concentration window. At higher 
concentrations, indolmycin was strongly inhibitory against Pseudomonas 
aeruginosa (Holm Jakobsen, unpublished results). This example demonstrates the 
power of E-SPE for mapping of multiple bioactivities in a complex extract, 
unmasking subtle bioactivities by pre-fractionation prior to biological testing, 
accelerated dereplication, and target-guided purification based on targeted 
exploitation of ionizable functionalities.  
Targeted exploitation of chemical functionalities can shortcut the 
dereplication and purification of an active compound. Yet, only 52% of the 
metabolites in AntiBase have a charged functionality. In the extract of 
Photobacterium halotolerans S2753, the active components were unretained on 
all ion-exchangers. Nonetheless, by comparison of the bioactivity profile in the 
Staphylococcus aureus growth and quorum sensing inhibition assays, it was 
evident that the antibacterial compound, holomycin (paper 4) and the QS 
inhibitors, solonamide A and B (paper 6) could easily be separated by the use of a 
diol column (Figure 3.14). This example demonstrates how E-SPE and pre-
fractionation based on orthogonal SPE columns is suitable for secondary 
screening and planning purification strategies for extracts containing active 
compounds with no charged functionalities.   
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Natural products represent an unparalleled pool of chemical diversity with 
complex biological activities that lead to competitive ecological advantage for the 
producing organism. This makes natural products an attractive resource for drug 
discovery. Today, more than 230,000 natural products are reported,
97
 and every 
year more than 1000 new structures are added only from microorganisms.
98
  That 
stresses the need for new and improved screening and dereplication methods that 
reduce the risk of structural redundancy to keep natural products as a viable 
option in drug discovery programs.  
Front line chemical evaluation of crude extracts at CMB employs 
LC-UV/MS metabolite profiling of bacteria displaying interesting biological 
activities. Chemical profiling is an efficient tool to characterize a bacterium based 
on its biosynthetic potential and makes it possible to rank extracts according to a 
criterion of novelty. We found the use of chemical profiling by LC-UV/MS very 
useful for marine bacteria such as Vibrio and Pseudoalteromonas (paper 3-6). It 
enabled the grouping of similar strains at species and sub-species level 
disregarding geographical sampling locations, thus countering the perception that 
secondary metabolites in bacteria are strictly strain-specific. Nonetheless, intra-
species variations demonstrate why metabolite profiling should be an integral part 
of an intelligent screening strategy in order to uncover the full biosynthetic 
potential of a given species.  
More detailed dereplication can be obtained after pre-fractionation. 
For simple extracts, on-line and off-line NMR-based methods can be used to 
augment the data obtained from LC-MS, providing absolute identification of 
known compounds on the expense of small amounts of extract. We found NMR-
based methods to fall short for the dereplication of complex bacterial extracts due 
to lack of sensitivity. As a complement, we developed explorative solid-phase 
extraction (E-SPE) (paper 1) that uses charged functionalities as discriminatory 
features. Orthogonal fractionation of an extract yields simpler chromatograms and 
allows comparative dereplication of active and non-active fractions, which can 
highlight potential candidates for observed biological activity and unmask 
compounds with more subtle bioactivities such as quorum sensing inhibition. 
Also, E-SPE showed that different chemotypes in Pseudoalteromonas 
luteoviolacea (paper 3) were linked to different bioactivity profiles, and 
accelerated the isolation of the key metabolites responsible for the differentiation 
(paper 1). E-SPE is an example of a new dereplication method that is well 
 integrated with other steps of the discovery process such as purification and 
structure elucidation.  
Dereplication needs to be performed at various stages of the 
discovery process, and should not be seen as a single process but rather a 
continuous critical evaluation for prioritization of extracts, fractions, and 
compounds. Based on the instruments and analytical facilities available it is 
possible to make a ‘dereplication decision tree’, like the one seen in Figure 3.15 
(page 65), to support the risk/probability assessment of the active compound(s) 
being known or novel. The strategy being pursued will depend on the compound 
classes present, the overall complexity of the extract, and biological activities 
being targeted. 
Based on the methods used during this PhD thesis and experiences 
gained, I suggest the following setup for the dereplication of microbial extracts 
(refer to decision tree in Figure 3.15): 
 LC-UV/MS is used to provide a rapid overview of the compounds in a 
bioactive extract: 
 
o The chromatogram is dominated by compounds with PKS/NRPS-
like spectral features (highly conjugated systems with 
characteristic UV spectra) or compounds with poor ionization  
Assessment of the complexity of the extract: Is the chromatogram 
dominated by few peaks with good base-line separation on a RP 
C18 column? YES/NO 
 
o The chromatogram is dominated by compounds with peptide-like 
spectral features (good ionization, no chromophore)  LC-
MS/MS: Is it possible to obtain a de novo sequence for structural 
elucidation? YES/NO 
 
 Dereplication by NMR for simple extracts (few peaks, good base-line 
separation): Scale-up to 1 L culture  Absolute identification of pure 
compound (for some compounds also in mixtures), known/novel? 
 
 Dereplication by E-SPE for complex extracts (many compounds, multiple 
biological activities, small span in polarity of extract components): Scale-
up to 1 L culture  Tentative identification based on comparative 
dereplication and ionizable functionalities, known/novel? 
 
 
 
 Assessment of the biological activity: Does the active fraction have 
activity towards a new or interesting biological target? YES/NO 
 
 Large-scale purification and full structural elucidation performed only on 
dereplicated compounds. If the active principle is a known compound, it 
might be favorable to synthesize the compound (especially for peptides 
and simple structures) or a commercial standard may be available for 
purchase. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Marine Vibrionaceae are Gram-negative, rod-shaped γ-proteobacteria that  are 
usually motile and possess a chemoheterotrophic metabolism.
1
 Members of this 
family are widespread in the marine environment, including estuaries, coastal 
waters, and sediments.
1
 The family includes eight genera (Figure 4.1): Allivibrio 
(5 species), Enterovibrio (4 species), Salinivibrio (5 species), Catenococcus (1 
species), Grimontia (1 species), Listonella (2 species), Vibrio (81 species), and 
Photobacterium (20 species).
1,2
 
 
 
 Vibrios are particularly abundant on the surface of marine macroorganisms such 
as corals, fish, seagrass, sponges, and zooplankton, where they form commensal, 
symbiotic, and pathogenic associations.
1
 Vibrio fischeri and its symbiotic host, the 
Hawaiian squid Euprymna scolopes, is the model system for studying light organ 
symbioses.
3
 V. fischeri colonizes the squid light organ and provides 
bioluminescence for the squid to use as countershading in order to evade 
predators. In return, the bacteria gain a protected nutrient environment. The 
symbiosis is highly specific. Studies have shown that even closely related bacteria 
like V. parahaemolyticus, or even V. fischeri from another niche, are not 
symbiosis-competent.
4
 Besides V. fischeri,
3
 P. leiognathi and V. logei
5
 are known 
to exist in symbiotic relationships with squid, while P. leiognathi and P. 
phosphoreum can be associated with fish.
6
  
The Vibrionaceae comprise strains being opportunistic pathogens of 
humans and marine animals. V. vulnificus, V. parahaemolyticus, and V. cholerae 
are serious human pathogens. V. cholerae probably has the greatest impact on 
human health, causing the acute diarrheal disease cholera that can result in 
epidemics.
7
 It is a very persistent bacterium that can survive on a variety of 
vectors, including zooplankton
8
 and cyanobacteria
9
. V. parahaemolyticus
10
 and V. 
vulnificus
11
 are food-borne pathogens associated with the ingestion of raw 
seafood. V. vulnificus is the more virulent of the two and causes primary 
septicaemia with high mortality via a battery of virulence factors, including 
hemolysins and proteases, siderophores, and capsular and endotoxic 
polysaccharides.
11
 V. anguillarum, V. salmonicida, and V. vulnificus are important 
fish pathogens and are widespread in aquaculture settings, where conditions seem 
to enhance their virulence.
1
 Vibrios are indigenous to healthy coral microbiomes; 
however, of nine coral infectious diseases, six are caused by members of this 
family.
12
 Increased seawater temperature can lead to a proliferation of 
opportunistic pathogens like V. coralliilyticus or V. shilonii (V. mediterranei) that 
can cause coral bleaching.
1
 Also, P. rosenbergii and Enterovibrio coralii
13
 have 
been suspected to be involved in coral disease. In V. coralliilyticus, virulence has 
been linked to enhanced levels of a zinc metalloprotease that can cause bleaching 
and coral tissue lesions.
12
  
High densities of Vibrio and Photobacterium on the surface of 
zooplankton
14
 have in part been ascribed to the ability of vibrios to utilize chitin, 
an N-acetyl D-glucosamine polymer in zooplankton exoskeletons, as carbon and 
nitrogen source.
15
 The presence of chitinases and chitinase encoding genes has 
been confirmed for several members of the family.
15-17
 Chitin has been found to 
 
 
 
control several genetic and physiological characteristics of vibrios
18
 including 
antagonistic activity (paper 5). Also, vibrios are able to degrade various other 
complex sugars such as fucoidan and laminarin found in various algal species 
(paper 5).
19
 Thus, this superior nutrient utilization might be one of the reasons for 
the ubiquitous presence of vibrios in the marine environment.
20
  
The ability to form biofilms is widespread among vibrios, playing a 
significant role in the pathogenicity of V. cholerae,
21
 V. parahaemolyticus, and V. 
vulnificus,
22
 as well as in the symbiotic colonization by V. fischeri.
23,24
 Key 
proteins include pili, lectins, exopolysaccharides, and components involved in the 
formation of flagella.
22
 Though vibrios share a high number of regulatory systems 
of biofilm formation, there are differences that could reflect different niche 
specificity or ecological roles.
25
 For example, it appears that vibrio produce 
species-specific exopolysaccharides, the major component of bacterial biofilms, 
and often have the potential to produce more than one type.
22
  
Vibrios use quorum sensing (QS) to control traits such as 
luminescence, virulence, and biofilm formation. The discovery of N-
acylhomoserine lactones as QS signals was first made in V. fischeri and V. 
harveyi, and the LuxI/R system of V. fischeri is the paradigm of Gram-negative 
quorum sensing systems even though it is not found in all vibrios.
26
 In V. fischeri, 
there are three distinct QS signals; 3-oxo-C6-HSL (1), C8-HSL (2), and AI-2 (3). 
These are used to control a regulatory cascade leading to induction of 
luminescence. The existence of multiple QS systems demonstrate the ability of 
vibrios to respond to variable marine conditions.
26
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 In contrast to most γ-proteobacteria, vibrios possess two circular 
chromosomes.
27,28
 Essential functions and housekeeping genes are usually located 
on the large chromosome ChrI, which is rather constant in size (~3 Mb), while the 
smaller ChrII is flexible in size, ranging between 0.8-2.4 Mb.
29
 ChrII contains 
accessory genes related to transcriptional regulation, for example, pathogenicity 
and antimicrobial resistance.
29,30
 Genes encoding for chitin metabolism and 
quorum sensing are split between the two chromosomes.
29
 Val and Mazel (2009) 
showed that fusing the two chromosomes
31
 yielded healthy and viable cells. 
However, generation times were markedly longer, and vibrios with only one 
chromosome were easily outcompeted by the wild-type. The ability of vibrios to 
vary the copy numbers of the two chromosomes is suspected to be involved in the 
adaptation to varying environmental conditions.
30
  Horizontal gene transfer is 
involved in the genetic flexibility of vibrios, including transduction by phages, 
plasmid conjugation
32
, and so-called ‘super-integrons’.33,34 In addition, Meibom et 
al. (2005) showed that vibrios become naturally competent when grown in the 
presence of chitin,
35
 allowing uptake of free DNA from the environment. Chitin-
induced competence has been demonstrated in V. cholerae,
35
 V. vulnificus,
36
 and 
V. fischeri.
37
 Altogether, this indicates vibrios being well-suited for rapid 
acquisition of niche-specific functions.  
The high genomic diversity of vibrios can be directly translated into 
high phenotypic variability.
28
 This makes it difficult to obtain meaningful 
groupings of vibrios at genus and species level based on isolated phenotypical 
markers.
1
 Also, the 16S rRNA gene is highly conserved among the Vibrionaceae 
and not well suited for identification to the species level.
38
 Attempts to improve 
the taxonomy include sequencing and comparison of various housekeeping genes, 
including recA, rpoA, toxR, which hold greater sequence variability than 16S.
38-41
 
Taxonomy of vibrios by genetic markers has been supplemented by chemical 
analyses, including fatty acid methyl ester (FAME) profiling, and more recently 
by whole-cell MALDI-TOF MS,
42,43
 and LC-UV/MS chemical profiling (paper 
4, 5). Chemotyping was found to be especially useful at sub-species level, 
identifying differences in antibiotic production (paper 5). Whole-cell MALDI-
TOF MS was able to distinguish closely related species like V. parahaemolyticus 
and V. alginolyticus or V. cholerae and V. mimicus scouting potential biomarkers 
within a 4,000-14,000 Da mass range.
42
  Closely related species (V. coralliilyticus 
and V. neptunius) could be distinguished based on their secondary metabolite 
production (paper 4). 
 
 
 
Considering their widespread presence in the marine environment, vibrios are 
largely underexplored for their proclivity to produce secondary metabolites. From 
Vibrionaceae, a total of 91 compounds have been reported in literature. The 
majority of these compounds have been described in only three species; V. 
parahaemolyticus, V. anguillarum, and V. vulnificus, which is likely a reflection 
of their importance as pathogens. Based on their average genome size,
29,44
 the 
vibrios are expected to be less abundant in their production of secondary 
metabolites as compared to, for example, marine actinomycetes.
45
 In the 
following, all metabolites reported from Vibrionaceae (Table 1) will be presented 
and interesting compounds highlighted in an attempt to assess the chemical 
diversity and biosynthetic potential of this group of bacteria.  
 
Marine vibrios are known producers of antibiotics in the marine environment,
46-48
 
where these compounds potentially contribute to their abundance in surface-
associated communities.
49
 Long and Azam (2001) studied antagonistic 
interactions among pelagic bacteria and found that vibrios produced broad-range 
antibacterial compounds.
50
 Similar capabilities of vibrios have been observed with 
coral-associated bacteria.
51
 The relatively widespread production of antibiotics in 
marine vibrios (paper 4) indicates that antagonistic activity may be of ecological 
importance (paper 5).  
Probably the best studied antibiotic produced by vibrios is the hybrid 
NRPS-PKS peptide antibiotic andrimid (4).
52
 The compound interferes with fatty 
acid biosynthesis
53
 and is effective against a wide range of bacteria.
54
 Structure-
activity studies by Pohlmann et al. (2005) revealed the pyrrolidinedione head was 
essential for activity, while variations in the fatty acid tail was more tolerable.
53
  
This suggested that these two structural moieties play different roles in target 
binding.  
  
Andrimid is a cosmopolitan antibiotic found in distantly related bacteria, 
including a symbiotic Enterobacter sp. from the planthopper Nilaparvata 
lugens,
55
 Pseudomonas flourescens,
56
 Pantoea agglomerans,
57
 and vibrio.
52
 The 
andrimid biosynthetic gene cluster was found to be conserved in two different 
producers.
58
 Interestingly, the cluster encodes resistance genes
59
 as well as 
specific transposases that could be responsible for the diverse occurrence of this 
antibiotic.
57,58
 From vibrios, the compound was first isolated by Oclarit et al. in 
1994,
52
 and Long et al. (2005) identified andrimid as the compound responsible 
for the growth inhibition of V. cholerae by an unidentified Vibrio strain.
48
 We 
isolated andrimid from the culture broth of a V. corallillyticus strain (paper 4) 
isolated from sediment in the tropical Indian Ocean,
60
 thus for the first time 
linking production of andrimid to a specific vibrio species. The production of 
andrimid was found to be part of different chemotypes within V. corallilyticus 
(paper 5). Two Galathea-strains, S2052 and S4053 from two distant geographical 
locations, were found to produce the antibiotic (paper 4), while the type strain 
and a close relative did not produce it. Interestingly, V. coralliilyticus S2052 
focused its production of secondary metabolites to the production of andrimid 
when grown on chitin, which mimicked natural growth conditions, at the same 
time increasing the yield of the antibiotic (paper 5). This indicated that andrimid 
potentially contributes to different niche-specificities of V. coralliilyticus. 
We isolated the highly potent pyrrothine antibiotic, holomycin (5) 
from Photobacterium halotolerans strain S2753 that originated from a mussel 
collected in the tropical Pacific (paper 4). Prior to this isolation, holomycin had 
only been isolated from actinomycetes, including Streptomyces clavuligerus,
61
 S. 
griseus,
62
 and a marine Streptomyces sp.
63
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The NRPS biosynthetic cluster encoding holomycin in S. clavuligerus was 
recently identified by Li and Walsh (2010),
64
 and this allows for the comparison 
the holomycin clusters in other producers, including Photobacterium. Holomycin 
has a broad spectrum of antibacterial activity against pathogenic bacteria such as 
Staphylococcus aureus, S. pneumoniae, S. epidermis, Enterococcus faecalis, and 
Escherichia coli.
65
 The mode-of-action in E. coli was found to include inhibition 
of RNA chain elongation, but holomycin is suspected to act as prodrug rather than 
a direct inhibitor of the RNA polymerase.
65
 We found holomycin to be strongly 
inhibitory against several marine strains from Roseobacter, Pseudoalteromonas, 
and Vibrio, including pathogens like V. harveyi, V. vulnificus, and V. 
parahaemolyticus (paper 4). This suggested that holomycin might play a role in 
antagonism in the marine environment. 
Yao and Al-Zereini recently (2010) isolated a series of 
nitrosubstrituted maleimides called aqabamycins (6-14) from a coral-associated 
Vibrio sp.
66,67
 The analogues had varying antibacterial activity against Gram-
positive bacteria, including Micrococcus luteus, Bacillus subtilis, and B. brevis as 
well as cytotoxic activity.
67
 The aqabamycins represent a unique structural group 
both due to their high degree of nitrosubstitution which is rare in nature
68
 and the 
maleimide monoxime present in aqabamycin E (10-11) and F (12).  
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The red pigment and antibiotic prodigiosin (15) has been isolated from V. 
psychroerythreus,
81
 V. gazogenes (originally termed Beneckea gazogenes but later 
revised),
82
 and V. ruber.
83
 Additional producers of this compound include 
Alteromonas rubra/Pseudoalteromonas rubra (paper 3),
111
 Hahella chejuensis,
112
 
and various Serratia
113
 and Streptomyces.
114,115
 Prodigiosin and its cyclized 
analogue (16)
71,116
 have a broad range of biological activities, including 
antimicrobial, antimalarial, immunosuppressive, and anticancer.
117-119
 
Prodiginines have clinical potential in anticancer therapy,
119
 and prodigiosin is 
currently in preclinical trials (Aida Pharmaceuticals) for pancreatic cancer.
117
 The 
clinical potential as antibiotics, however, is limited due to a low therapeutic 
window and considerable toxic effects.
120
 Starič et al. (2010) recently 
demonstrated that the production of prodiginines in a Vibrio sp. isolated from 
estuaries conferred competitiveness against a Bacillus sp. from the same 
sample,
121
 suggesting that prodigiosin might act as a antibiotic in the natural 
environment.  Interestingly, the prodigiosin producing V. gazogenes was also 
found to produce the unique magnesium containing antibiotic, magnesidin 
(17).
76,122-124
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 Shizuri and co-workers isolated two distinct groups of depsipeptides, the 
unnarmicins
84
 and ngercheumicins
78
 from a Photobacterium sp. with potent, but 
narrow-spectrum antibacterial effect against strains of Pseudovibrio. The 
unnarmicin A (18) and C (19) consist of four amino acids (L-Phe, L-Leu, D-Phe, 
L-Leu) and a 3-hydroxyoctanoic and 3-hydroxyhexanoic fatty acid, respectively. 
The ngercheumicins have a depsipeptide macrocycle and either a fatty acid (type 
I) (20) or peptide tail (type II) (21). They have been patented for treating 
infections caused by Pseudovibrio denitrificans, though no literature describes 
pathogenic traits of this bacterium.
125
 We isolated five different type II 
ngecheumicins (22-26) from cultures of the Galathea strain S2753 closely related 
to Photobacterium halotolerans (Kjærulff and Månsson, unpublished data).
126
 As 
no general nomenclature concerning the ngercheumicins exists at this writing, 
these new compounds are designated ngercheumicin A-E. Ngercheumicin A and 
B have a fully saturated tail, while C, D, and E contain a single double bond. The 
potential antibacterial effect of these compounds is yet to be determined.  
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Many vibrios produce siderophores as a strategy to sequester iron in the marine 
environment, where the iron level is extremely low.
127,128
 This is necessary to 
maintain important enzymatic processes (with iron as cofactor) and a prerequisite 
for pathogenicity for many vibrios.  
A great structural diversity has been observed among the 
siderophores produced by Vibrio species. In V. anguillarum, at least two different 
siderophore-mediated systems have been described, namely anguibactin (27)
85,129
 
and vanchrobactin (28).
130
 The non-ribosomal peptide anguibactin represents a 
unique structural class of siderophores with both a catechol and hydroxamate 
ligand and a thiazole core.
85
 The biosynthetic genes encoding this compound are 
found on a 65-kb virulence plasmid in some V. anguillarum strains. Knock-out of 
genes involved in anguibactin production was found to attenuate virulence, 
confirming that anguibactin is a prerequisite for successful host-invasion of this 
bacterium.
131
 In contrast, the catechol vanchrobactin is chromosome-encoded, and 
interestingly, the coding genes are silenced in anguibactin producing strains.
92,132
 
Recently, dimeric and trimeric versions of vanchrobactin were isolated from an 
unidentified Vibrio by Sandy et al. (2010).
86
 Also, they found anguibactin to 
possess cytotoxic activities against P388 murine leukemia cells.
86
  
Vibriobactin (30),
93
 vulnibactin (29),
95
 and fluvibactin (31)
133
 are 
unique siderophores produced by V. cholerae, V. vulnificus, and V. fluvialis, 
respectively. They are all catechol hydroxyphenyloxalone siderophores that share 
a rare norspermidine backbone, giving them a propeller-like structure. In 
vibriobactin and vulnibactin, two of the hydroxybenzoyl moieties are linked to the 
backbone through an L-threonine, forming an oxazoline ring. Fluvibactin only has 
one oxazoline ring, with one hydroxybenzoyl directly linked to the norspermidine 
terminal. Vibriobactin and vulnibactin differ only in the number of 
hydroxylations, and this high structural similarity enables cross-utilization of 
these two siderophores.
95
  
Bisucaberin (32)
90
 is a symmetric cyclic dihydroxamate produced by 
the fish pathogen V. salmonicida.
91
 Unlike most other vibrio siderophores,
131
 
bisucaberin is produced through an NRPS-independent route
134
 where alternating 
dicarboxylic acids and diamine or amino alcohols are assembled through amide or 
ester bonds.
135
  Bisucaberin was found to be useful in combinatorial anticancer 
therapy by sensitizing tumor cells to macrophage-mediated cytolysis.
90,136
 
 
 Siderophores are used as therapeutic deferration agents to treat iron overload in 
chronically transfused thalassemia patients. A stereochemically modified version 
of fluvibactin was found to efficiently remove iron without increasing microbial 
growth.
137
 It has been suggested that siderophores can be used for the 
development of a new class of ‘trojan horse’ antibiotics.138 Siderophore-antibiotic 
conjugates exploit the iron transport system of the pathogen to penetrate the 
bacterial outer membrane, increasing the antibacterial activity of the antibiotic.
139
 
Recently, Bergeron et al. (2009) made a conjugate linking antibodies to 
vulnibactin as a strategy towards a vaccine against V. vulnificus.
140
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Another interesting group of compounds produced by a member of the 
Vibrionaceae are the kahalalides. These cyclic depsipeptides were originally 
isolated from the herbivorous mollusc Elysia refescens and its diet, the green 
algae Bryopsis sp. In particular, kahalalide F (33) has an attractive spectrum of 
activities against AIDS-related opportunistic infections and various cancer cell 
lines.
141
 Kahalalide F is currently undergoing Phase II clinical trials (PharmaMar) 
for the treatment of prostate, lung, and liver cancer
141
 and in patients with severe 
psoriasis (PharmaMar/Marinomed).
142
 Interestingly, Hill and Hamann (2005) 
found kahalalide F as well as two analogues to be produced by a V. 
mediterranei/shilonii.
96
 The finding of a microbial origin for this compound 
allows for the large-scale industrial fermentation of this compound rather than 
arduous organic synthesis.  
 
Several vibrios produce the potent neurotoxin tetrodotoxin (TTX) (34), also 
known as the pufferfish poison.
105
 The true origin of TTX has been the subject of 
much debate,
143
 nonetheless V. harveyi and V. alginolyticus isolated from 
different species of pufferfish were found to produce the toxin as well as several 
analogues.
104
 Also, V. fischeri isolated from the intestines of the xanthid crab, 
Atergatis floridus produced TTX.
107
 The intestines of the pufferfish, Fugu 
vermicularis vermicularis were found to be dominated by vibrios,
104
 suggesting 
that the toxification is caused by TTX-producing bacteria accumulated through 
the food web.
105
 The role of these compounds to vibrio itself is still unclear, 
though it has been suggested to play a role in regulating sodium transport.
105
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Vibrios produce compounds that interfere with the quorum sensing system of 
Gram-positive bacteria. From a P. halotolerans strain S2753 (paper 4), we 
isolated and identified two novel depsipeptides, solonamides A and B (35-36) that 
interfered with QS regulated virulence genes in S. aureus (paper 6). In particular, 
solonamide B dramatically reduced expression of both hla encoding α-hemolysin 
and RNAIII, while increasing expression of spa encoding Protein A. This 
suggested that the depsipeptides interfere with agr, the global virulence regulator 
in S. aureus. High structural similarity of the solonamides to the natural 
autoinducers of the agr system suggested that they might be competitive 
inhibitors. Interestingly, the solonamides were found to have a pronounced effect 
on virulence gene expression in S. aureus strain USA300, which is the 
predominant community-acquired MRSA (CA-MRSA) strain in the USA.
144
 The 
solonamides strongly resemble the unnarmicins (18-19) found in an unidentified 
Photobacterium sp. (section 4.3.1).
84
 Thus, it is possible that the unnarmicins also 
possess QSI activity. In addition to the solonamides, Nielsen and Phipps 
(manuscript in preparation) isolated nigribactin (37) from V. nigripulchritudo 
S2604 as inhibitor of the same system. Nigribactin belongs to the family of 
bactins that act as siderophores in V. fluvialis and others (section 4.3.2). The 
isolation of compounds belonging to very different structural classes as inhibitors 
of agr suggests that multiple modes-of-action may be employed. Thus, the 
elucidation of the mechanism for receptor binding is in the offing.   
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 Several small molecules isolated from vibrios have been found to induce Gram-
negative quorum sensing systems. That includes various diketopiperazines (DKP). 
For example, cyclo(L-Pro, L-Leu) (38), cyclo(L-Pro, L-Val) (39), and cyclo(L-
Pro, L-Tyr) (40), DKPs commonly isolated from vibrios,
74
 were found to 
modulate LuxR-type protein activity though at higher concentrations than 
AHLs.
145
 It is speculated that these dipeptides represent a new class of naturally 
occurring QS signals potentially involved in interspecies signaling, as DKPs are 
found in most culturable marine bacteria.
146
 However, some DKPs are likely to be 
artifacts generated from media components during work-up procedures.
147
 De Nys 
et al. (2001) isolated [1-(2’-methylpropoxy)-2-hydroxy-2-methylpropoxy]-butane 
(41) from P. angustum (V. angustum) S14 with the ability to mediate expression 
in two AHL-regulated systems, inducing bioluminescence in V. harveyi and the 
AHL reporter system in Agrobacterium tumefaciens.
101
  
 
Numerous compounds have been isolated from vibrios with no biological activity 
reported so far. That includes small-molecule by-products, for example some 
nitro-substituted compounds such as 3-nitroindazole and 3-nitro-4-
hydroxycinnamic acid.
66
 From P. halotolerans S2753, we isolated a series of 
cyclic tetrapeptides; cyclo(L-Val-L-Val-L-Val-L-Val) (42), cyclo(L-Val-L-Leu-L-
Val-L-Leu) (43), cyclo(L-Val-L-Ile-L-Val-L-Ile) (44), and cyclo(L-Leu-L-Ile-L-
Leu-L-Ile) (45) (Kjærulff and Månsson, unpublished data).
126
 These types of 
peptides are often found in marine culturable bacteria,
148-151
 suggesting that they 
are storage compounds accumulated during growth under excess nutrients. We did 
not find any of these peptides to have any antibacterial effects, which is in 
concordance with the literature on similar structures.  
Many of compounds isolated from vibrios are suspected to be 
artifacts generated from media components during work-up procedures.
75,147,152
 
These include several bis- and trisindole derivatives from a V. parahaemolyticus 
strain, Bio249.
75
 An example is 1,1,1-tris(3-indolyl)methane (46) that could easily 
be formed by simple condensation of indole-3-carbaldehyde and indole, both 
having been isolated from V. parahaemolyticus.
75
 From the same V. 
parahaemolyticus strain, the cyclic terephthalic acid ester, pharacine (47)
152
 was 
isolated.
75
 This was suspected to be an artifact from plastic material contaminants; 
however, fermentation results were reproducible with no contact with plastic. 
Until biosynthetic studies have been performed, the true origin of these molecules 
remains uncertain.  
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 The versatility and widespread occurrence of vibrios can be ascribed to different 
characteristics; superior nutrient utilization, excellent biofilm formation, and their 
genetic construct. High genomic flexibility in Vibrionaceae makes this group of 
bacteria very apt to resist various environmental changes, for example through the 
acquisition of biosynthetic genes linked to the production of antibiotics or 
siderophores. So, rampant horizontal gene transfer occurs in these bacteria. As a 
reflection, most compounds isolated from vibrios have also been found in other 
types of bacteria, in many cases from distantly related taxa (paper 4). Sometimes 
the mobile genetic elements are even incorporated in the biosynthetic cluster 
itself, making it even more prone to gene-exchange. The antibiotic andrimid is an 
example of a compound encoded by such a ‘nomadic gene cluster’.153  
Production of secondary metabolites in vibrios has been linked to 
antagonism, intraspecies communication, and pathogenicity. The compounds 
produced by vibrios are mainly non-ribosomal peptides or hybrids hereof, with 
examples of N-containing compounds produced by NRPS-independent pathways. 
Despite this narrow structural span compared to metabolites produced by other 
marine bacteria, vibrios produce compounds with interesting biological activities. 
For example the solonamides, cyclic depsipeptides from P. halotolerans were 
found to attenuate virulence in a CA-MRSA strain (paper 6). 
Many vibrios have multiple lifestyles, including a planktonic (free 
swimming), sessile (attached to zooplankton or other surfaces), and a pathogenic 
form.
1
 As production of secondary metabolites often confers a selective advantage 
to the producing organism,
154
 the diverse lifestyles of these bacteria are reflected 
in their metabolic capabilities. There are intraspecies variations in the compounds 
produced, with different chemotypes potentially reflecting niche adaptation. For 
example, antagonistic strains of V. coralliilyticus isolated from seaweed or 
sediment during Galathea 3 were found to produce andrimid in high yields, while 
pathogenic related strains did not have the ability to produce the antibiotic (paper 
5). The fully sequenced genome of the V. coralliilyticus type strain is currently 
undergoing assembly (Los Alamos National Laboratory).
44
 Functional annotation 
of the genome will reveal whether the andrimid cluster is completely absent from 
the genome or the genes are merely silenced and to be expressed under 
appropriate conditions. 
 
 
 
 
 
The cosmopolitan occurrence of several vibrio metabolites raises the question 
whether there are unique Vibrionaceae metabolites. To date, only nine genomes 
from vibrios have been fully assembled,
28
 mainly pathogenic V. cholerae strains.
29
 
For the future, it will be of outmost interest to extend full-genome sequencing to 
other vibrios and investigate the prevalence of biosynthetic genes linked to 
secondary metabolism. Also, this will make it possible to compare homology of 
biosynthetic genes between diverse producers of cosmopolitan antibiotics. 
Overall, this might allow insight into the ecological roles of these bacteria and the 
conditions leading to production of their metabolites.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
So far, the marine environment has yielded thousands of bioactive metabolites, 
including antibacterial, anticancer, and antifouling activities.
1-3
 Yet, marine 
bacteria still represent an emerging source of new natural products and many taxa 
remain uncharted territory. The challenge of multi-resistant pathogens forces the 
NP chemists to look to marine bacteria as a source of new chemical diversity for 
antimicrobial therapy. 
The aim of this PhD study was to investigate the production of 
bioactive secondary metabolites from a global collection of marine 
Pseudoalteromonas and Vibrionaceae, with emphasis on the latter as it represents 
an under-explored source of natural products. Consequently, a primary goal was 
to provide a robust setup for chemical evaluation of the collected bacteria and to 
develop methods that facilitate rapid dereplication of the associated extracts. The 
results obtained have been presented in six papers and elaborated upon in the 
previous two chapters of this thesis. The broad perspectives and conclusions 
drawn from this PhD study will be discussed under the following headings.  
 
γ
Members of Pseudoalteromonas and Vibrionaceae 
are particular abundant on the surface of various marine macroorganisms, where 
they form commensal,
4,5
 symbiotic,
6
 and pathogenic associations.
5,7,8
 Several 
studies have shown that these bacteria are some of the most prolific producers of 
inhibitory compounds among marine culturable bacteria.
9-11
 Despite this high 
frequency of antagonism, only few species have been investigated for their 
proclivity to produce secondary metabolites. Especially, the vibrios are an under-
explored source of bioactive compounds. 
In our global collection of Pseudoalteromonas strains, the 
biosynthetic potential was evaluated through the overall metabolite profiles. We 
found a clear link between ecological niche and the ability to produce bioactive 
compounds (paper 3). Approximately 88% of the strains that retained 
antibacterial activity upon re-culturing came from biotic and abiotic surfaces. We 
found this to coincide with the production of pigments, thus verifying previous 
observations.
4
 In some cases, the pigments themselves had antibacterial activities 
such as violacein in P. luteoviolacea and prodigiosin in P. rubra; however, the 
production of pigments is merely an indication of the general ability to produce 
 secondary metabolites. The most antibacterial strains were found to belong to the 
purple-pigmented species, P. luteoviolacea, one of the most researched 
Pseudoalteromonas species. Nonetheless, we isolated the potent antibiotic 
indolmycin for the first time from this species (paper 1), underlining the untapped 
potential of bioactive compounds in Pseudoalteromonas. Interestingly, we found 
certain strains of P. luteoviolacea produced an ‘antibiotic cocktail’ consisting of 
either violacein/pentabromopseudilin or violacein/indolmycin. We posit that this 
coordinated expression of different antibiotics will significantly enhance the 
chance of survival for the producing organism and explain the superior 
antibacterial activity of this species in our collection.  
The biosynthetic potential of Vibrionaceae was appraised through i) 
the first complete review of metabolites reported from vibrios (chapter 4) and ii) 
metabolite profiling of strains in our global collection showing pronounced 
antibacterial activity, followed by bio-guided isolation of the active compounds 
(paper 4). We found the antibacterial activity of two Vibrio coralliilyticus strains 
(S2052 and S4053) to be ascribed to the production of the pyrrolidinedione, 
andrimid. Andrimid has previously been isolated from a Vibrio sp.;
12,13
 however, 
this is the first report linking andrimid production to a specific species (paper 4). 
From a single strain of Photobacterium halotolerans (S2753), we isolated the 
antibiotic holomycin (paper 4), two novel cyclic tetradepsipeptides called 
solonamides (paper 6), four cyclic tetrapeptides, and five different depsipeptides 
related to the ngecheumicins
14
 (Kjærulff and Månsson, unpublished data, chapter 
4).
15
 
Among compounds reported from vibrios so far, there seems to be a 
prevalence of non-ribosomal peptides or hybrids thereof, with examples of N-
containing compounds produced by NRPS-independent pathways (chapter 4). 
Though covering a limited chemical space, vibrios still produce compounds with 
attractive biological activities; for example, the cyclic depsipeptide kahalalide F 
from V. mediterranei
16
 that is undergoing Phase II clinical trials for the treatment 
of prostate, lung, and liver cancer.
17
 Few vibrios have been fully genome 
sequenced, but so far none have been functionally annotated with regard to the 
presence of biosynthetic clusters. Thus, it is still uncertain whether these bacteria 
represent a novel ‘hotspot’ of secondary metabolites or whether they are merely 
scavengers of interesting genes that facilitate their surface-associated lifestyle. 
Nonetheless, this account has highlighted the pending potential for exploring new 
bacterial sources of bioactive compounds.  
 
 
 
In 1993, one of the pioneers in marine microbial NP chemistry, Professor William 
Fenical from Scripps Institution of Oceanography wrote in a review on the 
chemical potential of marine bacteria:
18
  
This statement stems from the very early days of marine microbial NP chemistry 
and must have been based on mostly unpublished results. Nonetheless, it has 
turned out to be not far from the truth, as corroborated by results from this PhD 
study. However, the full extent of Prof. Fenical’s statement remains unexplored as 
literature is biased towards reporting novel chemistry. Only rarely are sources that 
yield no or only known chemistry described. One outlet is databases like AntiBase 
that also to some extent include results from conference proceedings. Personally, I 
think increasing the level of data sharing, ‘good’ as well as ‘bad’ results, would be 
of great value for the microbial natural products community , as it would reduce 
the risk of rediscovery and futile screening programs.  
 
 The Galathea 3 
collection has provided us with the unique opportunity to study the production of 
secondary metabolites in marine bacteria on a global scale. A major goal was to 
investigate the difference between metabolite profiles of ‘strain siblings’ collected 
from different geographical locations.  
Metabolite profiling of all 101 Pseudoalteromonas strain collected 
during the expedition (paper 3) revealed that some species were very 
homogenous in their metabolite production, regardless of sample location, while 
others showed both global and local variations. One such species was P. 
luteoviolacea, and interestingly the differences were related to production of 
antibacterial compounds. Strains S4047, S4054, and S4060 were all collected 
from the same seaweed sample near Costa Rica (Pacific Ocean), but represented 
two different chemotypes: violacein/pentabromopseudilin and violacein/-
indolmycin producers. Interestingly, strain S2607 collected from a lava rock on 
the coast of Eastern Australia also showed production of violacein/pentabromo-
pseudilin. Investigation of P. luteoviolacea strains from other culture collections 
confirmed that the chemotypes observed were present in strains outside our 
 Galathea 3 collection, covering geographical locations such as the Mexican Gulf 
and the Mediterranean. A similar trend was observed in Vibrionaceae. Vibrio 
coralliilyticus strains S2052 (sediment, west coast of Australia) and S4051 
(seaweed, Costa Rica) had nearly identical metabolite profiles despite their distant 
sample locations (paper 4). Antagonistic activities were ascribed to the 
production of andrimid; however, andrimid was neither observed in the type strain 
nor in a closely related V. coralliilyticus (paper 5). Despite a low degree of 
chemoconsistency, our studies clearly show that production of secondary 
metabolites in marine bacteria is more than a strain specific trait.  
It has been suggested that secondary metabolites represent 
functional traits with important ecological roles. Penn et al. (2009) found 
biosynthetic clusters and other niche-specific genes in Salinispora to be 
concentrated in genomic islands enriched with mobile genetic elements.
19
 They 
suggest that the evolution of secondary metabolites may act as a force driving 
bacterial diversification.
19,20
 Thus, it is reasonable to speculate that 
Pseudoalteromonas and Vibrio acquire and retain biosynthetic genes linked to 
antibiotic production as part of adapting to a specific niche. The number of strains 
included in our study is merely enough to pose interesting questions considering 
the link between biogeography and secondary metabolite production. Thus, a 
study including all 309 Vibrionaceae strains collected during the expedition, as 
well as extending our collection of Pseudoalteromonas, is of great interest. 
Nonetheless, this PhD study shows that investigation of multiple strains of the 
same species can be a valuable strategy for detection of new compounds and is 
imperative to uncovering the full biosynthetic potential of a species. 
 
Secondary metabolites are 
hypothesized to play a significant role in the population structure and dynamics of 
bacterial communities.
21
 The exigent questions in chemical ecology focus on how 
bacteria use chemical substances to interact with eukaryotic hosts and to compete 
and communicate with other microorganisms. The challenge is to link the 
chemical information with the natural ecosystem of the bacterium. Studying the 
physiological conditions, under which interesting molecules are produced, can 
provide basis for postulating their ecological roles. One approach is to use culture 
conditions that mimic the natural habitat. 
Vibrios have a versatile metabolism and are capable of degrading a 
variety of complex carbon sources. Thus, we used natural growth substrates, such 
 
 
 
as chitin and seaweed extracts, to evaluate the production of antibacterial 
compounds and other metabolites as part of our screening of Vibrionaceae. Both 
Vibrio coralliilyticus (paper 5) and Photobacterium halotolerans (paper 6) were 
able to produce their antibacterial compound, andrimid and holomycin 
respectively, when using chitin as the sole carbon source. Also, V. coralliilyticus 
was able to produce andrimid on extracts of two species of seaweed, Fucus and 
Laminaria (paper 5). As vibrios are often abundant in chitinous 
microenvironments such as on the surface of zooplankton and crustaceans, our 
studies suggests that these compounds can be produced in the natural 
environment. However, we do not know at which concentrations or how other 
environmental factors influence their production.  
The overall metabolic response to the growth conditions was 
different for the two bacteria. When grown on chitin, V. coralliilyticus produced 
only andrimid and turned down production of other metabolites (paper 5). 
Interestingly, the yield of andrimid per cell was increased two-fold compared to 
the standard laboratory medium. Conversely, P. halotolerans sustained production 
of all metabolites, and potential novel compounds were observed only on the 
chitin medium (section 3.2.2). This different phenotypic response can indicate 
different niche adaptations or different ecological roles of the compounds 
produced. Chitin has been reported to have both stimulating and inhibitory effects 
on antibiotic production in Streptomyces
22
 and Pseudoalteromonas,
23
 
corroborating that natural substrates have multiple effects. Without the 
appropriate ecological context, circumspection is required in drawing ecological 
interferences. Nonetheless, our studies show that chitin and other natural growth 
substrates can be a promising strategy for activating biosynthetic pathways in 
marine bacteria.  
 
 The selective force that is inherently linked to growth inhibition 
eventually engenders antibiotic resistance.
24
 Turning off virulence gene 
expression exogenously, and thereby quenching QS regulated virulence, may 
represent an alternative strategy for the treatment or prevention of bacterial 
infections.
25-27
 To further explore this avenue in antimicrobial therapy, we have 
included assays based on QS systems in both Gram-positive and Gram-negative 
bacteria in our Galathea 3 screening setup.  
The QSI selector assays used for identification of inhibitors of QS in 
Gram-negative bacteria is based on the two homoserine lactone-mediated systems, 
luxR from Vibrio fischeri (QSIS1) and las/rhl in Pseudomonas aeruginosa 
 (QSIS2).
28
  The latter controls the expression of various virulence factors such as 
proteases and rhamnolipids.
29
 We found indolmycin-containing E-SPE fractions 
from Pseudoalteromonas luteoviolacea to have good activity in the QSIS1 assay 
(Månsson & Holm Jacobsen, unpublished data, section 3.3.2), and the activity 
was verified by testing pure, isolate compound as well as a commercial standard. 
The effect on LasB and RhlA (QSIS2) was tested in a dose-dependent manner, 
which showed repression of lasB at low concentrations. At increased 
concentrations, indolmycin was strongly growth inhibitory of Pseudomonas 
aeruginosa and thus not a QS inhibitor in sensu stricto. These results are in 
concordance with other studies that found antibiotics at sub-inhibitory 
concentrations to affect QS-regulated gene expression.
30-32
  
The screen for inhibitors of Gram-positive QS is based on the agr 
system in Staphylococcus aureus.
33
 The assay monitors three key virulence genes, 
spa, hla, and rnaIII under the control of agr.
34
 These genes encode virulence 
factors such as extracellular toxins and cell surface adhesion factors.
35
 From a 
strain related to Photobacterium halotolerans S2753, we isolated two new cyclic 
depsipeptides, designated solonamide A and B, as potent inhibitors of this system 
(paper 6). Interestingly, the decreased expression of virulence genes was 
pronounced in the highly virulent USA300 strain, which is a predominant 
community-acquired MRSA strain in the United States.
36
 High Agr activity is 
suspected to be a main contributor to the aggressiveness of the strain.
37,38
 Thus our 
findings suggest that quorum sensing inhibition could be an option for treatment 
of S. aureus USA300 infections. The similarity in structure and size of the 
solonamides and the cognate autoinducing peptides (paper 6) imply that they 
interfere with transmission of the QS signal by competing for binding to the 
transcriptional regulator proteins. However, it will be necessary to establish their 
exact mechanism of action. Also, the ability of the solonamides to control S. 
aureus infections in appropriate animal models is of considerable interest.  
Many genes are under QS control in both Gram-positive and Gram-
negative bacteria, and thus it is not a simple drug target.
39,40
 For example, biofilm 
formation in S. aureus has been linked to low QS activity,
41
 and so there is a risk 
that the use of QS inhibitors could lead to decreased susceptibility of traditional 
antibacterial drugs. Also, it is still unknown how QS inhibition will affect the 
overall fitness of a pathogen under in vivo conditions and thus pose a selective 
pressure for the development of resistance.
42
 Studies have indicated that bacteria 
can circumvent a QS blockade by over-expressing receptor genes or by changing 
their specificity.
39
 However, as virulence interference is usually species-specific, 
the overall risk is considered to be significantly lower.
26
  
 
 
 
Many secondary metabolites appear to have crossed boundaries 
imposed by both geography and ecology.
43
 Thus, it is not uncommon to isolate 
compounds previously described from non-marine microorganisms from marine 
bacteria.
44
 Production of secondary metabolites can be seen as a functionally 
adaptive trait.
45,46
 Hence, phylogenetically unrelated species may have arrived at 
the same antibiotics independently because of the selective advantage that these 
bioactive compounds confer.
43,47
 Some antibiotics can be found widely distributed 
among distant species and even taxa, an extreme example being the 
cephalosporins that can be found in actinomycetes, γ-proteobacteria, and fungi.48  
In this PhD study, the known antibiotics indolmycin (paper 1) and 
holomycin (paper 4) have been isolated for the first time in Gram-negative 
bacteria. Both compounds have originally been isolated from terrestrial 
actinomycetes. They add to the list of violacein, pentabromopseudilin, prodigiosin 
(paper 3), and andrimid (paper 4), as examples of cosmopolitan antibiotics found 
in Pseudoalteromonas and Vibrionaceae. Horizontal gene transfer represents a 
likely mechanism for acquiring such biosynthetic gene clusters. Comparison of 
the andrimid gene cluster in Vibrio and Pantoea showed that the biosynthetic 
domains are perfectly interleaved, consistent with exchange of the whole PKS-
NRPS cluster.
49
 Also, the cluster is flanked by a transposase pseudogene 
suggesting that it has been introduced by horizontal gene transfer.
49
 This genomic 
promiscuity is not restricted to members of Pseudoalteromonas and Vibrionaceae 
in the marine environment. Five of eight isolated compounds from the 
actinobacterial genus Salinispora have been isolated from unrelated taxa.
19
 This 
underlines that bioprospecting per se is not a successful strategy for discovering 
novel chemistry.  
Bacterial NP extracts are often characterized by high 
structural complexity and diversity, the presence of multiple bioactive 
compounds, and many metabolites produced in very low yields. To make matters 
more complicated, high plasticity of bacterial genomes dissolves any taxonomic 
boundaries for secondary metabolite production. Hence, to unravel a bacterium’s 
full potential for producing novel compounds can be a daunting task.  
Statistical analysis based on data from our in-house collection of 718 
secondary metabolites from filamentous fungi showed that LC-MS is a robust 
method for front line dereplication of microbial extracts (paper 2). High 
 confidence mass spectral data can be obtained with a combination of positive and 
negative ESI-MS, using different diagnostic ions to validate the assignment of the 
molecular ion. For 93% of the compounds in the in-house database, LC-MS could 
unambiguously assign the molecular ion. In order to correctly translate the mass 
of this ion into a single molecular formula, we found that the mass accuracy needs 
to be below 1 ppm based on structures reported in AntiBase 2008. But even with 
the correct molecular formula, a search in AntiBase or other commercial 
databases will seldom produce a definitive answer. A characteristic UV spectrum 
can help narrow down the number of candidates, but for peptides containing 
mainly non-aromatic amino acids and other non-chromophoric compounds this 
information is futile. For peptides, which constitute a common compound class in 
bacteria (chapter 4),
50,51
 a primary sequence can be obtained from MS/MS which 
greatly facilitates the dereplication.  
We realized that, in most cases, a second level of dereplication is 
imperative for evaluating bacteria due to the complexity of the extracts. A large 
part of this PhD study was concerned with the development and validation of a so-
called explorative solid-phase extraction (E-SPE) protocol for dereplication of 
complex extracts (paper 1). The method is based on a set of four SPE columns 
with orthogonal selectivities that can provide valuable information about the size, 
charge, and polarity of the active components of an extract. We found especially 
the presence of ionizable functionalities to be highly discriminatory for the 
dereplication of microbial compounds. Though not as discriminatory as NMR-
based dereplication methods, we found E-SPE to be more rewarding for highly 
complex, low-output extracts such as those of marine bacteria.  
E-SPE successfully integrates the process of extract prioritization, 
dereplication, mapping of biological activities, and formulation of a purification 
strategy based on small amounts of crude extract. Since the steps of E-SPE are 
completely orthogonal, it allows access to potential new compounds and 
activities. We found that our hit rate in the QSI assays was markedly increased 
when testing E-SPE fractions rather than crude extracts. This is probably due to 
the more subtle QSI effects being camouflaged by antibacterial activity against 
the target organisms. Additional dividend to the E-SPE approach is the potential 
to design and test the optimum purification strategy before engaging in large-scale 
experiments, thus highlighting potential pitfalls and greatly improving the yield of 
purification. By having a more rational approach to the chemical screening 
process, we have saved a lot of time and effort. Moreover, the E-SPE approach 
presents a consistent setup that is transferable between different organisms.    
 
 
 
 
 
 
Dereplication needs to be performed at various stages of the discovery process, 
and should not be seen as a single process but rather a continuous critical 
evaluation for prioritization of both extracts and compounds. This is supported by 
a triad of analytical techniques each with their obvious advantages and limitations. 
The success of any dereplication will depend on choosing the right technique 
based on the difficulty and nature of the problem. The dereplication methods used 
vary with the facilities available, the type of organism, and the overall screening 
setup. Many favorable dereplication methods are available; however, a 
prerequisite for implementing a technique as part of a screening setup is that the 
equipment is available for routine analysis. Therefore, a dereplication method will 
mostly represent a compromise based on the analytical facilities of a given lab. If 
the screening setup is based on traditional growth inhibition assays, known 
candidates can often be excluded based on a tentative identification alone. 
However, when exploring new targets for antimicrobial therapy, for example, 
both novel and known compounds need to be purified and structure validated in 
order to verify the observed bioactivity if no commercial standard is available. 
Still, dereplication proactively decreases the number of fractions in a natural 
product extract that need to enter the purification process, which saves valuable 
time and resources. 
Great database resources are currently available for the dereplication 
of natural products; however, with the steady increase in isolated compounds, the 
level of data sharing in the NP community needs to be augmented. Pivotal 
information, such as 
13
C and 
1
H NMR chemical shift values, UV spectra, and 
MS/MS fragmentation patterns, is currently unavailable or incomplete in 
commercial databases. Compiling this data will enable rapid recognition of not 
only known compounds but also their analogues. Like the microbiologist share 
strains and gene sequences related to published data, the chemist should share the 
chemical data related to reported structures, which should be stored in central 
places such as Beilstein (Elsevier), Chemspider (Royal Society of Chemistry), or 
Chemical Abstracts (American Chemical Society). Though this data collection 
may be cumbersome, its benefits to the natural products community speak for 
themselves and should motivate a joint effort to complete the upgrade. 
 
 To preserve microbial natural 
products as a viable option for drug discovery, the use of a multidimensional 
screening strategy is imperative: 
 Many marine bacterial taxa remain under- or unexplored for their 
proclivity to produce bioactive compounds. While screening of 
phylogenetically novel sources does not bring a guarantee for novel 
chemistry,
43
 bioprospecting is still a simple strategy to enhance diversity 
in a screening program.
52
 Functional metagenomic libraries provide a 
means to probe the uncultured majority of marine microbial life, and 
constitute a promising tool for drug discovery.
53,54
   
 
 Culture conditions (including co-culture experiments), the use of elicitors, 
and the OSMAC approach will help accessing compounds that are not 
constitutively expressed.
52
  
 
 Traditional growth inhibition assays measure antibacterial activity with no 
distinction regarding the exact target or mode-of-action
55
 and will 
inevitably lead to a high rate of rediscovery due to the cosmopolitan 
occurrence of many antibiotics.
43
 Extending a screening program with 
target-based whole-cell assays that interrogate one target gene or a group 
of targets at a time,
56,57
 such as virulence genes,
58
 forms a rational 
approach to future drug discovery.  
 
 Testing a mixture of crude extracts, pre-fractionated samples, and pure 
compounds is necessary to obtain a realistic hit-rate, with a minimum of 
false positives and false negatives.
59-61
  
 
 Maintaining an array of analytical techniques for rapid dereplication of 
known compounds and their analogues is imperative to reducing time from 
hit to lead. Continuous reduction of the scale on which it is possible to do 
structural elucidation makes it possible to access previously overlooked 
candidates.
62
  
 
 Exponentially growing sequence information allows the discovery of 
cryptic gene clusters. In silico structure predictions combined with 
synthetic chemistry,
63
 heterologous expression, and combinatorial 
biosynthesis
64,65
 are just some of the tools for accessing and exploiting the 
biosynthetic potential of marine bacteria through genomic data.  
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Microbial natural products (NP) cover a high chemical diversity, and in consequence extracts from microorganisms are
often complex to analyze and purify. A distribution analysis of calculated pKa values from the 34390 records in
Antibase2008 revealed that within pH 2-11, 44% of all included compounds had an acidic functionality, 17% a basic
functionality, and 9% both. This showed a great potential for using ion-exchange chromatography as an integral part of
the separation procedure, orthogonal to the classic reversed-phase strategy. Thus, we investigated the use of an “explorative
solid-phase extraction” (E-SPE) protocol using SAX, Oasis MAX, SCX, and LH-20 columns for targeted exploitation
of chemical functionalities. E-SPE provides a minimum of fractions (15) for chemical and biological analyses and
implicates development into a preparative scale methodology. Overall, this allows fast extract prioritization, easier
dereplication, mapping of biological activities, and formulation of a purification strategy.
For the purification of natural products, specific chemical
information on the target compounds prior to purification is vital
for the success of the purification.1,2 If no prior knowledge about
the target compounds is available, a purification strategy is normally
developed through trial and error or by standard fractionation
procedures and often guided by one or more bioassays. Many
natural product (NP) laboratories have developed internal strategies
for standardized extract screening and purification,3-5 while in other
cases, only parts of the overall setup have been published as the
techniques have probably evolved over many years and the rationale
behind them has not been disclosed.6
For the most part, modern NP purification methods are based
on reverse-phase (RP)4,7 separations due to high capacity, recovery,
reproducibility, and chromatographic resolution compared to most
separation methods.2 However, when faced with complex extracts
containing many components, a purification strategy based solely
on RP can lead to problems. This may involve the purity of the
end products, the overall recovery from the extract, or at worst,
permanent loss of activity due to instability or degradation. This is
especially a problem with low yielding extracts typical of those
arising from marine microorganisms.8 For this type of extract,
orthogonal purification strategies are required; classically, this can
be achieved by combining RP with normal-phase chromatography
on silica gel (low cost)2 or alternatively using bonded phases such
as polyethyleneimine9,10 or diol.11,12 Ion-exchange has been used
less frequently13-16 even though many natural products contain
ionizable groups.
In contrast to preparative chemistry, matrix-dependent orthogonal
solid phase extraction (SPE) purification strategies are widely used
in trace analysis to complement the almost universal analytical
RP-LC methods used.17 This is essential to effectively remove
coeluting interferences as well as the major constituents of the
matrix. Mixed-mode sorbents,18,19 multifunctional columns,20 and
especially ion-exchange SPE21,22 are widely applied to ensure high
and consistent recoveries.
Targeted exploitation of chemical functionalities in the work with
novel compounds has not been used frequently prior to preparative
isolations. Only two papers have described methods for the
preliminary chemical characterization of NP extracts to be used as
part of the development of purification strategies. Samuelsson et
al. used Sephadex G25, anion- and cation-exchangers, and a set of
solvents for liquid-liquid partitioning to investigate the size, charge,
and polarity of the active constituents in aqueous plant extracts,13
while Cardellina et al. used a combination of Sephadex G25 and
RP resins.23 Both groups used their methods to evaluate bioactive,
aqueous extracts of high complexity. In addition, by using a
bioactivity elution matrix Cardellina et al. were also able to use
the method for dereplication and prioritization of extracts.23
In microbial NP extracts, multiple biosynthetic pathways are
often represented,21,24-28 resulting in complex extracts. To deal
with this, a standard protocol capable of exploiting the different
chemical functionalities is required. Thus, we have developed
“explorative solid-phase extraction” (E-SPE) where a set of SPE
columns with orthogonal selectivities are used to rapidly explore
the optimum purification strategy on a small scale in the exploratory
stage of the discovery process, which has the potential to be
transferred to a preparative scale. Also, by supplying information
on the presence of ionizable functional groups, the analytical (e.g.,
LC-MS) dereplication of candidates is facilitated. Here, we present
the use of E-SPE as a standard procedure that is compatible with
a broad series of bioassays and enables the use of a standardized
screening method transferable between different organisms and
bioactive NP targets. Overall, this allows a rational approach to
the purification process that is independent of the experience and
intuition of the chemist and integrates the process of extract
prioritization, dereplication leading to the mapping of biological
activities, and formulation of a purification strategy.
Results and Discussion
To determine the incidence of microbial natural products with
charged functionalities, a batch calculation using the Advanced
Chemistry Development pKa suite was conducted on all records in
AntiBase 2008,29 resulting in 34390 valid records. This revealed
(Figure 1) that 52% of all compounds reported had an ionizable
functionality (within pH range 2-11, see Figure 2). This confirmed
the potential for incorporating ion-exchange chromatography as an
integral part of the separation procedure. Three different ion-
exchangers were included in the overall setup. An approach based
on the cation exchange of amines was perceived to be the most
discriminatory prospect followed by anion exchangers for carboxylic
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acids. Thus, strong anion- and cation-exchangers (SAX and SCX)
were included to reveal the presence of carboxylic acids and amines.
A mixed-mode polymeric RP anion-exchanger (Oasis MAX) with
a poly(divinylbenzene-co-vinylpyrrolidone) backbone was included
as it has been shown not only to retain acidic compounds with a
carboxylate functionality but also weaker anions of phenols and
tautomeric enols; due to the polar polymeric backbone, it can retain
these close to the ionic groups.18,19 On the basis of observations
from analysis of fungal metabolites in food and feed samples, it
was speculated that enols, phenols, and other compounds with acidic
functionalities could be differentiated from carboxylic acids by
comparing SAX and MAX elution patterns. In addition, the MAX
column could also provide information about the relative polarity
of the compounds in the extract, thereby keeping down the number
of columns and fractions as an RP column was now not needed. A
Sephadex LH-20 column (polymeric cross-linked dextran gel for
size-exclusion) was included to give information about the relative
size of the compounds. These four orthogonal columns provided a
rational compromise to obtain the necessary information on size,
charge, and polarity of the extract components while still generating
the minimal number of fractions.
Beause the goal was to develop E-SPE as a standard operating
procedure when dealing with new microbial extracts, the procedure
was tested on both fungal and bacterial extracts, including extracts of
marine bacterial origin. Plant extracts were not included, as an existing
range of standardized prefractionation or partitioning steps are estab-
lished and targeted to separate the major compound classes present in
plants such as chlorophylls, polyphenolics, tannins, and saponins.30-32
Typically 0.5-2 mg dry extract aliquots were applied to each
column. The specific extraction procedure varied with the type of
organism and matrix. For example, media with high salt content
should be freeze-dried and redissolved in EtOH prior to ion-
exchange,33 as the ions from the media will impair the binding
(salting-out) of possible target compounds on the SAX and SCX
columns.
A total of 15 fractions were generated from each extract and
submitted for biological testing with part of the crude extract/culture
supernatant and recombined fractions from each of the columns to
reveal potential instability issues or synergy effects. To track false
positives, a blank medium sample was subjected to the same
extraction and fractionation procedures as the cultures.
The assay results were organized in a bioactivity matrix similar
to that used by Cardellina et al.23 (Figure 3). Visual interpretation
of this matrix made it possible to map the active components by
comparing the results from different assays. Active and nonactive
fractions were subjected to comparative dereplication by LC-HRMS
(Figure 4) by cross-referencing MS and UV peaks between
fractions. Peaks only appearing in active fractions and not in
nonactive fractions are potential candidates for the observed
bioactivity. Afterward, the corresponding MS and UV spectra were
extracted, adduct patterns established, and the accurate mass data
determined using reported analyses.34 The accurate mass was used
as query in a database search (AntiBase, AntiMarin, or similar).
The resulting candidates were assessed based on their: (i) mass
accuracy and isotope pattern, (ii) match between the acquired UV
spectrum and the reported UV data, (iii) observed retention time
compared to structure, LogD, molecular size etc., (iv) taxonomic
Figure 1. Distribution of microbial natural products in AntiBase
2008 with charged functionalities within pH range 2-11, perma-
nently charged groups such as sulphates, phosphates, and tertiary
amines as well as potential tautomeric forms excluded. Statistics
are based on theoretical pKa values calculated using Advanced
Chemistry Development pKa suite.
Figure 2. pKa Cumulative distribution of the ionic form of acids
and bases in Antibase 2008 at a given pH value, based on their
calculated pKa values. Theoretical pKa values calculated using
Advanced Chemistry Development pKa suite. The statistics includes
permanently charged groups such as sulphates, phosphates, and
tertiary amines but excludes potential tautomeric forms.
Figure 3. E-SPE profiles of the ethanolic extract of P. luteoViolacea
obtained in well-diffusion assays with V. anguillarum and S. aureus.
The matrix represents fractions from the four SPE columns as well
as their corresponding supernatant (SN) and crude extract (CR).
Gray ) active; white ) no activity observed. SAX fractions:
A1 ) unretained bases and neutrals, A2 ) retained acids. MAX
fractions: B1/B2/B3 ) polar/medium polar/apolar unretained bases
and neutrals, B4/B5/B6 ) polar/medium polar/apolar acidics. SCX
fractions: C1 ) unretained acids and neutrals, C2 ) retained bases.
LH-20 fractions: D1-D5 ) fractions of decreasing molecular size
(band-based). Violacein identified in fractions A1, B6, C2, and D5.
Potential new bioactive identified in fractions A1, B2, B3, C2, and
D3.
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data, (v) match between charged functionalities and ion-exchange
properties, and (vi) ESI- and ESI+ adduct patterns and the strongest
ionization mode. The final list of possible targets indicated the
likelihood of the candidates being novel structures. When the
potential targets were identified, it was possible to develop a suitable
procedure for purification, preferably based on selective ion-
exchange properties. As final validation before scaling up, the
chosen optimized combination of columns was tested in series while
following the concentration of bioactivity.
E-SPE has been introduced as a standard screening procedure
in our lab for the evaluation of new extracts. Many extracts have
been screened, and herein we present two cases, one bacterial and
one fungal, which represent some of the experience we have gained
through using this protocol. To validate our method, we applied
E-SPE with an optimized fractionation protocol to an extract of
the marine bacterium Pseudoalteromonas luteoViolacea grown in
a rich medium containing 3% sea salts. P. luteoViolacea is a known
producer of several antibacterial compounds.35-41 Under the
conditions used, it generated a highly complex extract which was
further complicated by high levels of leftover media components.
This made full dereplication on the data from the crude extract a
difficult task. The ethanolic extract was dominated by the purple
pigment, violacein, which has a broad range of antibacterial
activities, especially on Gram positive bacteria.36,42,43 E-SPE
bioactivity profiles (Figure 3) were obtained for inhibitory activity
against the Gram-negative bacterium Vibrio anguillarum and the
Gram-positive bacterium Staphyloccocus aureus.
Comparison of the three profiles showed the presence of at least
two bioactive compounds in the extract. As expected, violacein was
Figure 4. Comparative dereplication of E-SPE fractions from P. luteoViolacea active against V. anguillarum. (I) LC-MS total ion
chromatograms (ESI+) of active fractions A1, B2, B3, C2, and D3. (II) Extracted UV and ESI+ MS spectra from common peak with
retention time RT ) 5.32 min, providing an accurate mass (monoisotopic) Mm of 257.1158 Da. (III) Candidates from AntiBase 2008 that
satisfy all functional criteria elucidated by E-SPE. Total number of hits noted in parentheses.
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identified by LC-HRMS in fractions A1, B6, C2, and D5 that were
active against S. aureus. This distribution was consistent with the
functional groups present in the structure.
A second bioactive compound was observed in both assays, with
a recognizable activity pattern of fractions A1, B2, B3, C2, and
D3. On the basis of its distribution in E-SPE fractions, the
compound was expected to be nonacidic, medium to apolar, medium
sized with a basic functionality. By comparative dereplication
(Figure 4), an accurate mass of 257.1157 Da was elucidated. No
previously reported compounds from the genus Pseudoalteromonas
or related genera were found to possess these properties. However,
indolmycin,44,45 a known antibacterial from Streptomyces, was
found to be a likely candidate, as determined by a search in
AntiBase. Indolmycin has not previously been reported to be
produced by Gram negative bacteria. Therefore, for absolute
identification of the compound, a large-scale extract was made and
subjected to cation-exchange (Figure 5) followed by size-exclusion
as indicated by the E-SPE profile (Figure 3). This led to the isolation
of both violacein and indolmycin. Both structures were verified by
NMR spectroscopy and matched with previously published data.46-48
The finding of these two compounds was consistent with the original
E-SPE bioactivity matrix.
As part of the method validation, the E-SPE protocol was also
tested on a Penicillium roqueforti extract. Like the Pseudoaltero-
monas luteoViolacea, P. roqueforti yielded a complex extract with
a diverse range of metabolites.49,50 This species has been thoroughly
investigated for metabolite production because it is a very common
contaminant of food and feed as well as a starter culture for blue
cheese. As P. roqueforti is prolific in production of organic acids,
phenols, and enols, the two anion-exchangers were suitable for the
early fractionation of extracts from this fungus.51 The mixed-mode
anion exchanger (MAX) selectively retained all acids, including
acidic enols like the andrastins (pKa 4.5). Comparing the two
fractions eluted with 60% organic, unretained bases/neutrals (B2)
and acids (B5), respectively, it was clear that the MAX column as
a first step of purification markedly simplified the extract (Figure
6). The peaks across the chromatogram were essentially bisected
between B2 and B5 with no overlaps between the compounds in
the nonacidic and acidic fractions (Figure 6). The MAX separation
revealed a series of potential new compounds masked under the
peaks of the major metabolites, roquefortine C and mycophenolic
acid, which dominate the chromatogram of the crude fraction before
partitioning. These new compounds could then be purified using
an RP strategy with much improved recoveries, potentially after
an SCX step to remove alkaloids like the roquefortines. This
underlined the usefulness of employing an orthogonal purification
strategy.
The E-SPE approach offers several advantages when dealing with
complex extracts. First of all, E-SPE enables the formulation of a
purification strategy based on small amounts of crude extract. Then,
by using a four-column strategy, it is possible to design preparative
purification steps that selectively retain the target candidate (and related
compounds) or remove unwanted components. Furthermore, when
working with bioactive extracts, it is possible to test the first steps and
track the concentration of bioactivity by putting the columns in series.
This procedure can be directly translated into a larger scale purification
process with high reproducibility as was demonstrated with P.
luteoViolacea. These aspects of the E-SPE approach are considered in
more detail under the following headings.
Dereplication. Successful dereplication of natural product
extracts is imperative in the discovery process but can be time-
consuming because it requires assessment of the candidates and
retrieval of the papers describing all candidates.24,52 E-SPE
accelerates dereplication by reducing the overall number of peaks
to be identified and many of the potential candidates in a database
search can be eliminated directly based on their ion-exchange
properties. E-SPE and comparatiVe dereplication makes it, in simple
cases, possible to carry out target-guided isolation rather than
bioguided fractionation, thereby reducing the need for bioassay
support during the isolation process.53 Further advantages can be
gained by using an automatic comparison of chromatograms, e.g.,
multivariate tools based on principal component analysis (PCA)
within the software packages of the major MS vendors. By using
E-SPE, it is possible to exploit the sensitivity of biological assays
to extract information about the active components and the chemical
functionalities. This is of particular importance when working with
natural products that are poorly ionized in all MS modes and/or
for minor components present below the detection threshold.
Mapping Biological Activities. E-SPE serves as a valuable
prefractionation step before biological testing. Bugni et al.4,54 and
Appleton et al.55 demonstrated that prefractionation can extensively
reveal masked candidates in a bioassay (with up to 80% of the
candidates being masked in the original extract) and reduce false
positives.
Because the steps of E-SPE are completely orthogonal, it allows
access to potential new compounds and activities, for example, in
cases where: (i) several compounds are responsible for the observed
bioactivity, (ii) one compound is responsible for multiple bioac-
tivities, i.e. privileged structures,56,57 or (iii) if several compounds
with different activities are present in the extract.
The potential differentiation was exemplified in the case of P.
luteoViolacea (Figure 3); violacein was responsible for the anti-
staphyloccoccal effect observed, whereas indolmycin displayed
multiple types of bioactivity (antistaphyloccoccal and antivibrio).
The presence and bioactivity of indolmycin could easily have been
overlooked in the absence of any kind of prefractionation.
Scaleup and Optimization. By using E-SPE as the first step
in optimizing a small scale purification strategy, it is possible to
investigate the success or failure of individual purification steps
prior to working with a much larger extract. Because all the columns
are readily accessible for scaleup, it is possible to directly transfer
the strategy to preparative scale, as demonstrated for P. luteoVio-
lacea. Sephadex LH-20 is probably the only column that cannot
Figure 5. LC-DAD-MS chromatograms with UV (200-700 nm)
above total ion chromatogram (m/z 100-900 Da) of P. luteoVio-
lacea crude (CR) extract (top) and retained (C2) SCX fraction
(bottom). Indolmycin (RT 5.2) and violacein (RT 7.1) are selectively
retained on a strong cation-exchanger.
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be directly translated into a large-scale method as the separation is
dependent on the column dimensions, linear flow rate, loading of
the sample, etc.58 However, E-SPE still indicates whether this
solvent and time-consuming chromatographic step would be
worthwhile.
It is important to note that this protocol is only the first step to
determine the strategy being pursued. A second optimization experi-
ment could be necessary when other columns or slight variations in
the loading or elution of the compounds are to be evaluated. For
example, if highly polar compounds are encountered, redissolving the
extract in H2O then loading on Strata-X or Oasis HLB columns may
be a way to retain the bioactives. Compounds not retained under these
conditions would need to be targeted by HILIC, Sephadex G-10, or
other hydrophilic separation approaches.59
Optimization of the pH for binding acids and bases may be
another important parameter to consider before applying the E-SPE
strategy to a large-scale extract. This is of special importance when
dealing with a pH labile target, or extracts containing a large fraction
of charged compounds. Compounds such as (open lactone form)
statins and homoserine lactones are selectively retained on Oasis
MAX columns (80-100% recovery) at a 0.5 pH unit below the
pKa even though only 32% () 10pKa-pH) theoretically should be
charged. Thus, the selectivity and recovery of an ion-exchange step
can be further improved by exploiting this dynamic equilibrium
during ion-exchange.
Cost and Access. E-SPE saves time and resources when
employed on complex extracts. The method represents an inex-
Figure 6. LC-MS total ion chromatogram (m/z 100-900) of P. roqueforti E-SPE fractions from MAX column. B2 ) unretained neutrals
and bases eluting with 60% MeOH; B5 ) retained acids eluting with 60% MeOH and formic acid. Compounds with “*” are identified
through comparison with available reference standards. The rest of the compounds were tentatively identified from AntiBase 2008 through
E-SPE properties, UV spectrum, and accurate mass.
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pensive and simple type of chemical screening that can also be
used in laboratories with limited access to chemical equipment.
The cost per extract is approximately 6-8 USD plus costs for
analytical LC-DAD, LC-MS, LC-NMR, etc. When running SAX,
MAX, and SCX cartridges, it is easy to run up to 14 extracts in
parallel and these columns are readily accessible for automation in
microtiter format, as whole plates, or plates with different sorbents
that are commercially available. A lower number is recommended
for Sephadex LH-20 due to a higher variability in flow rates through
the small self-packed columns.
Even though E-SPE is fast, reproducible, and easy to use, there
are a few issues to be aware of: There should be good correlation
between the sensitivity of the assay used and the extract amounts
to avoid false negatives, but more importantly, to track false
positives, a blank medium sample should be run in parallel with
the other E-SPE samples as one will also concentrate interfering
media components.
Some knowledge of the sample matrix is necessary as high levels
of salts and fats give rise to problems in the sample run and load,
and potentially cause interference in the bioassays. This might
require adjustments to the sample pretreatment by: (i) freeze-drying
extracts and redissolving in EtOH, (ii) liquid-liquid partitioning,
(iii) Sephadex G-10 size chromatography, (iv) AgNO3 columns for
chloride precipitation, or (v) ion precipitation with acetone.
While the SPE SCX and Oasis MAX columns both consistently
retained basic and acidic compounds respectively, we found SAX
columns to be less predictable, e.g., mycophenolic acid is not well
retained on SAX (<10%) while moniliformin60 and fumonisins are
quantitatively retained.21 Also, problems with loading capacity due
to excessive amounts of organic acids in the crude extracts add to
this unpredictability. We have observed this with Aspergillus niger
extracts producing high levels of citric acid.
The original bioactivity of an extract can sometimes be lost upon
fractionation. This may be due to instability under the conditions
applied, e.g. acid/base, light, or reactive solvent, or it could be due
to strong retention of the active compound on the selected column.
For example, phosphates and sulphates will not be eluted by
lowering pH on SAX/MAX columns but need salting out or the
use of a weak anion-exchanger (WAX), while quaternary amines
on SCX columns also need salting out or the use of a weak cation
exchanger (WCX), e.g., a carboxylic acid (CBA) column.
A distribution analysis of calculated pKa’s from the 34390 records
in Antibase2008 revealed that within pH 2-11, 44% of all the
records had acidic, 17%, basic, and 9%, both functionalities. This
shows great potential for using ion-exchange chromatography as
an integral part of the separation procedure, which we pursued by
E-SPE using SAX, Oasis MAX, SCX, and Sephadex LH-20
columns in a setup giving 15 fractions for biological evaluation.
By employing orthogonal chromatographic methods, the E-SPE
approach presents a consistent setup for accelerated discovery of
novel compounds and offers faster dereplication and purification
and uses fewer, more efficient steps. The setup can readily be tailor-
made to suit individual laboratories with varying access to assays
or equipment. We trust that the E-SPE protocol will encourage other
NP groups to publish their methods and share their “tricks of the
trade” with the community.
Experimental Section
General Experimental Procedures. Solvents and buffers were all
HPLC or LC-MS grade. All aqueous solutions were prepared from H2O
obtained from a Milli-Q system from Millipore (Millerica, MA).
Samples were analyzed using an Agilent 1100 HPLC system with a
diode array detector (Waldbronn, Germany) coupled to an LCT TOF
mass spectrometer (Micromass, Manchester, UK) using a Z-spray ESI
source. A Phenomenex (Phenomenex, Torrance, CA) Luna II C18
column (50 mm ×2 mm, 3 µm) was used for separation, applying an
MeCN-H2O 0.3 mL min-1 gradient (15-100%) over 20 min at 40 °C.
Both MeCN (LC-MS grade) and H2O were buffered with 20 mM formic
acid (LC-MS grade).
Large-scale cation SPE purification of the P. luteoViolacea extract
was performed on an Isolera (Biotage, Uppsala, Sweden) automated
flash system. Details are given in the Supporting Information.
NMR spectra were recorded on a Varian INOVA AS-500 spectrom-
eter (500 MHz) equipped with a Protasis CapNMR capillary probe,
using the signals of the residual solvent protons and the solvent carbons
as internal references (δH 3.3 and δC 49.3 ppm for methanol-d4).
Bioassays were performed using standard protocols.61
Theoretical pKa calculations of Antibase2008 were made by convert-
ing a ChemFinder version of Antibase2008 to an sdf file using
ChemFinder (Cambridgesoft, Cambridge, UK) and then importing the
sdf file into ACD ChemFolder (Advanced Chemistry Development,
ACD, Toronto, Canada) and then batch calculating the pKa values using
the ACD 2008 pKa suite.
Biological Material. The marine strain included in the study,
Pseudoalteromonas luteoViolacea, was selected due to its ability to
antagonize the fish pathogenic bacteria, Vibrio anguillarum.62 P.
luteociolaceum was isolated from seaweed (latitude: 2.9817 N,
longitude: -86.6892) and identified based on phenotypic tests such as
Gram reaction, cell shape, motility, and glucose metabolism, as well
as 16S rRNA gene sequence homology. The bacterium was routinely
cultured in Marine Broth (Difco 2216). Three-day static cultures (25 °C)
were used for extractions.
The fungus used was from the IBT collection at the Center for
Microbial Biotechnology, Denmark, and authenticated by Prof. J. C.
Frisvad. Penicillium roqueforti (IBT 16404) was grown on one plate
of CYA agar for 7 days (25 °C, dark).
Sample Preparation. Bacterial cultures (25 mL) were freeze-dried
and extracted EtOH:H2O (96:4 v/v, 2 × 10 mL) for partial desalting
(no sonication; 2 × 12 h), filtered, pooled, and evaporated to dryness
with N2 flow. The agar plate containing the fungal culture was
homogenized using a stomacher and extracted directly with 20 mL
CH2Cl2:EtOAc:MeOH (3:2:1 v/v/v) and then a 50:50 (v/v) mixture of
MeCN:H2O (20 mL). Extracts were filtered, pooled, and evaporated to
dryness with N2 flow.
E-SPE Procedures. All extracts were redissolved in 400 µL of the
loading solution prior to running each column, except for Sephadex
LH-20 where 100 µL of MeOH was used.
The strong anion-exchange step was performed using Strata-SAX
columns (Phenomenex, 100 mg/1 mL), using MeOH:H2O (70%) for
extract loading and wash, and MeOH (1% formic acid or 0.5 M K3PO4)
for elution, collecting two fractions (A1 ) unretained and A2 )
retained).
Mixed-mode reverse-phase anion-exchange was performed on an
Oasis MAX column (Waters, Milford, MA, 30 mg/1 mL, 30 µm). A
MeOH:H2O solution (25%) with NH4OH (2%) was used to lock and
load the column. A series of MeOH:H2O solutions (25%, 60%, and
100%) were used for eluting nonacidic compounds, and an equal series
of MeOH:H2O solutions (25%, 60%, and 100%) acidified with formic
acid (1%) for eluting acidic compounds. For the MAX column, a total
of six fractions were collected, i.e., B1, B2, and B3 ) unretained polar/
25% MeOH, medium polar/60% MeOH, and apolar/100% MeOH; B4,
B5, and B6 ) retained polar/25% MeOH + 1% formic acid, medium
polar/60% MeOH + 1% formic acid, and apolar/100% MeOH + 1%
formic acid.
The strong cation-exchange was performed on Strata SCX (Phe-
nomenex, 100 mg/1 mL, 33 µm) using MeOH:H2O (70%) for loading
and wash, and MeOH with NH4OH (2%) for elution, collecting two
fractions (C1 ) unretained and C2 ) retained).
For size exclusion, Sephadex LH-20 (GE Healthcare, Hillerød,
Denmark) was swelled in MeOH and wet packed in syringes (1 mL)
(25 mg/1 mL, 27-163 µm) equipped with a frit, top and bottom. For
each extract (100 µL) a total of five fractions were collected, either
band-based collection for colored extracts or time-based (1:0.5:1:2:4
mL), respectively.
For all four columns, a blank medium sample corresponding to the
media used for cultivation was subjected to the same fractionation and
represented a negative control.
Detailed protocol can be found in the Supporting Information.
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Supplementary information E-SPE 
 
Purification of indolmycin and violacein. The bacterial broth (8 L) was extracted with a mixture (50/50) of 
sterile XAD 7 (Sigma-Aldrich, St. Louis, MO) and HP20 resin (Sigma-Aldrich, St. Louis, MO) (12 g of resin/L 
broth). After 24 h the resin was filtered off and washed with water (2 x 2 L), followed by extraction with 
methanol/water (50/50 v/v; 800 mL) (24h) and methanol (2 x 800 mL) (24 h). All organic extracts were pooled 
and dried completely to give a crude extract (2.0712 g). The crude was re-dissolved in methanol and water 
(90/10 v/v) and mixed with 20 g Strata-XC (Phenomenex, Torrance, CA) and dried before packing into a 25 
g SNAP column (Biotage, Uppsala, Sweden) with pure resin (5 g) in the base. The column was equilibrated (25 
mL/min) upside-down with water + formic acid (1%). The column was then turned and washed with methanol 
with formic acid (1%) (fraction 1; 782 mg).  The column was then stripped with methanol with ammonium 
hydroxide (2%) and washed until no colour remained (fraction 2; 1.0368 g). Fraction 2 was found to be enriched 
with indolmycin and violacein. These two compounds were purified on an LH20 column using methanol as 
eluent (80 g; 100 x 2 cm; 100 mg; 0.5 mL/min).   
 
 
 SOP for E-SPE: 
 
1) Prepare vials and labels. 
 
2) Prepare solvents: 
100% water (pH 7)  
25% MeOH (pH 7) 
60% MeOH (pH 7)  
70% MeOH (pH 7)  
100% MeOH (pH 7)  
 
25% MeOH (1% formic acid, pH 2)  
60% MeOH (1% formic acid, pH 2)  
100% MeOH (1% formic acid, pH 2)  
 
100% MeOH (2% ammonium hydroxide, pH 11)  
 
3) Prepare LH-20 columns: 
A 1 mL syringe (75 x 5 mm) is fitted with a frit in the bottom and wet packed (in MeOH) until 0.9 mL 
corresponding to approximately 20-30 g dry LH-20. Frit added on top as well. If dry packed, let the 
LH-20 swell in the MeOH for 30 min. before use. 
 
4) Prepare crude extracts: 
a) Bacterial extracts: 
25 mL of culture is freeze-dried (-80 °C for marine cultures) and extracted with 96% EtOH (2 x 10 mL) 
over 2 x 12 h. Centrifuge (8500 rcf/15 min) to separate cells and undissolved media components from 
extract. The extract is filtered (0.45 µm). 
b) Fungal extracts: 
One agar plate with the fungus is homogenized using a stomacher (1 min) and extracted over 2 x 12 h 
with 20 ml dichlormethane:ethyl acetate:methanol (3:2:1, v/v/v) and then a 50:50 (v/v) mixture of 
acetonitrile/water (20 mL). The extracts are pooled and filtered (0.45 µm). 
 
5) Preparation of samples: 
⅕ of the crude extract (4 mL for bacterial/8 mL for fungal) is taken directly for assay and 100 µL for 
LC-MS.  
⅕ of the crude extract (4 mL for bacterial/8 mL for fungal) is taken for each of the four SPE columns 
(≈0.5-2 mg each). 
The total of 5 vials are dried down. 
 
6) Running the SPE columns: 
a) SAX (Strata SAX, 33 µm, 100 mg/1 mL): 
Sample is dissolved in 400 µL 70% MeOH (pH 7). Unless the sample has a high salt content, increase 
sample pH with 8 µL ammonium hydroxide (2%).  
Column equilibrated with 2 x column volumes 100% MeOH followed by 70% MeOH in water (pH 7). 
Sample load and wash with 1 mL 70% MeOH (pH 7) and 1 mL 100% MeOH (pH 7) = fraction A1. 
Elute with 2 mL 100% MeOH (1% formic acid, pH 2) = fraction A2. 
100 µL of each fraction taken for LC-MS analysis.  
All fractions are dried completely. 
 
b) MAX (Oasis MAX, 30 µm, 30 mg/1 mL): 
Sample is dissolved in 400 µL 25% MeOH (pH 7). Unless the sample has a high salt content, increase 
sample pH with 8 µL ammonium hydroxide (2%).  
Column equilibrated with 2 x column volumes 100% MeOH, followed by 2 x column volumes 100% 
water (2% ammonium hydroxide, pH 11). 
Sample load and wash with 2 mL with 25% MeOH (pH 7) = fraction B1. 
Elute with 2 mL 60% MeOH (pH 7) = fraction B2. 
Elute with 2 mL 100% MeOH (pH 7) = fraction B3. 
Elute with 1 mL 100% water (pH 7) and 1 mL 25% MeOH (1% formic acid, pH 2) = fraction B4. 
Elute with 2 mL 60% MeOH (1% formic acid, pH 2) = fraction B5. 
Elute with 2 mL 100% MeOH (1% formic acid, pH 2) = fraction B6. 
100 µL of each fraction taken for LC-MS analysis. 
All fractions are dried completely. 
 
c) SCX (Strata SCX, 33 um, 100 mg/1 mL): 
Sample dissolved in 400 µL 70% MeOH (pH 7). Unless the sample has a high salt content, lower 
sample pH with 4 µL formic acid (1%). 
Column equilibrated with 2 x column volumes 100% MeOH, followed by 2 x column volumes 70% 
MeOH (pH 7). 
Sample load and wash with 1 mL 70% MeOH (pH 7) and 1 mL 100% MeOH (pH 7) = fraction C1. 
Elute with 2 mL 100% MeOH (2% ammonium hydroxide, pH 11) = fraction C2. 
100 µL of each fraction taken for MS analysis.  
All fractions are dried completely. 
 
d) LH-20 (self-packed, 20-30 mg/1 mL, 75 x 5 mm): 
Sample dissolved in 100 µL 100% MeOH. 
Column equilibrated with 100% MeOH until constant flow from column (125-150 mL/min). 
Load sample and let band focus for a short while before starting elution. 
Band-based collection is preferable if extract is coloured. 
For non-coloured extracts, collect: 
 1 : 0.5 : 1 : 2 : 4 mL = D1 : D2 : D3 : D4 : D5 
100 µL of each fraction taken for MS analysis. 
All fractions are dried completely. 
7) Prepare for assays: 
The dry samples, including blanks and crude extract, are re-dissolved in 500 µL 
50/50 (v/v) acetonitrile in water or another solvent compatible with the given 
assay. Assay-results are put into a bioactivity matrix: 
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Dereplication has become a key element of modern NP chemistry. The constant development of 20 
analytical equipment and compound databases has made it easier to determine the elemental 21 
composition, and thus tentative identification of a given compound in a sample. A major challenge 22 
remain to establish correct molecular formulas using mass spectrometry due to the diverse and 23 
complex nature of NPs such as polyketides, alkaloids, and terpenoids. Herein, we demonstrate the 24 
scope of LC-MS dereplication using data from UV/VIS DAD and ESI
+
/ESI
-
 electrospray ionization 25 
on a Time-of-Flight MS for assignment of our 718 natural product standards.  ESI
+
 proved to be the 26 
most versatile ionization method, allowing detection of 93% of the compounds including 12% that 27 
ionized poorly. Simultaneous detection of the [M+H]
+
 and [M-H]
-
 ion was observed for 60% of the 28 
compounds, but only for 37% they were both the most intense ions. From ESI
+
 alone, 56% of the 29 
compounds could be unambiguously assigned based on multiple adduct ions. From ESI
-
, this 30 
number was 37%, however with further 41% producing only [M-H]
-
. The polarity where the most 31 
intense ionization was observed was always the most trustworthy for interepretation. Poor 32 
ionization was more prevalent for small molecules (<200 Da). In ESI
-
, non-ionizing molecules were 33 
often polar basic compounds, and in ESI
+
 small aromatic acids or anthraquinones. No single ion-34 
source settings could be applied over m/z 60-2000 range, thus it was necessary to continuously 35 
switch between three settings during the chromatographic run to allow both small labile molecules 36 
and large peptides into the MS, at the same time providing pseudo MS/MS. (258 words) 37 
 38 
39 
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Microorganisms constitute an immense resource of natural product diversity that is candidates for 40 
drug development, food and feed additives, and other industrial products (1-6). Dereplication (7-9) 41 
of already known compounds and their potential analogues is a vital part of the discovery process in 42 
order to minimize time and resource consumption (1, 10-13). Several approaches to the 43 
dereplication process exist, typically based on a combination of chromatographic and spectroscopic 44 
methods and database searching. The largest and most specialized database for microbial natural 45 
products is Antibase, constructed and maintained by Laatsch and co-workers (48) and originally 46 
based on a substantial inhouse database. 47 
Over the last 10-15 years, liquid chromatography-mass spectrometry (LC-MS) has 48 
gradually replaced LC-UV/VIS diode array detection (DAD) as the preferred dereplication method 49 
for small molecules [ref]. This is largely due to the introduction of atmospheric pressure ionization 50 
(API) techniques like electrospray ionization (ESI) and atmospheric pressure chemical ionization 51 
(APCI) (9, 14-20), which allows a more gentle and versatile ionization of compounds. Also, 52 
dereplication by LC-MS has the major advantage that the accurate mass of compounds can be used 53 
as query in nearly all natural products databases. Even though dereplication by LC-NMR has had a 54 
major breakthrough within the last few years owe to the development in nano- and cryoprobes 55 
[molinski09, lang08] (21), LC-MS is still far more sensitive, providing reliable results within the 56 
nanogam range (10, 22, 23).  57 
MS instruments are continuously being improved, currently making it possible to 58 
obtain both positive and negative ionization spectra even during fast ultra-high performance liquid 59 
chromatography (UHPLC). Quadrupole-time-of-flight (QTOF) and ion-trap instruments are capable 60 
of making data-dependent MS/MS on all major peaks without the need to predefine masses, 61 
augmenting the data obtained for dereplication in a single LC run. Moreover, TOF, orbitrap, and 62 
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fourier transform ion cyclotron resonance (FT-ICR) instruments provide mass accuracies in the 0.5-63 
1 ppm range, leading to only one or very few possible elementary compositions for a given ion peak 64 
(9, 14-20). However, at this writing the best accurate mass instruments cannot make 65 
positive/negative switching fast enough for the ultra narrow peaks obtained by UHPLC.  66 
Dereplication of unknown compounds relies on accurate mass, leading to a minimum 67 
of possible elementary compositions to be used as query in a database search with only a few 68 
candidates (24). Recently, Kind et al. (25) found that compounds within a 0.5-5 ppm mass range 69 
often have very different number of carbon atoms, demonstrating that mass accuracy and isotope 70 
ratio are almost orthogonal parameters that can be used for excluding hypothetical elementary 71 
compositions. Integration of mass accuracy and isotope model fitting into one weighted parameter 72 
is consequently incorporated into most of the major MS vendors software packages, e.g. ‘SigmaFit’ 73 
(Bruker Daltonics), ‘I-fit’ (MassLynx, Waters), and ‘Score’(Mass Hunter, Agilent Technologies). 74 
For compounds classes biosynthesized from units with same elementary composition 75 
such as peptides, rhamnolipids, or polysaccharides, accurate mass compared to nominal mass 76 
determination provide limited information. Here MS/MS, or even better MS
n
, and the subsequent 77 
fragmentation patterns is more efficient, assuming that reference standards are available for 78 
modeling fragmentation  of the compounds class (26, 27). 79 
Despite many indisputable advantages, LC-MS screening with ESI or APCI faces five 80 
major problems: i) sensitivity is compound dependent with some being unable to ionize in positive 81 
and/or negative polarity, which can lead to incorrect assignment of ions to co-eluting impurities as 82 
well as ion suppresion; ii) the adduct pattern [M+H]
+
, [M+Na]
+
, [M+NH4]
+
, [M-H]
-
, [M+HCOO]
-
, 83 
etc. supporting correct assignment of the molecular ion can be difficult to interpret (21, 22, 28, 29); 84 
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iii) the adduct pattern varies substantially from system to system, and can even change during a 85 
sequence due to sodium extraction from solvent glass bottles (22, 30-33); iv) some compounds form 86 
predominant di- and trimeric ions e.g. [2M+H]
+
, [2M+Na]
+
, [3M+H]
+
, and [2M-H]
-
 , which can 87 
further complicate assignment; and finally v) some compounds fragment very easily, losing one or 88 
more H2O equivalents, formic acid, acetic acid and/or CO2 (34). Either of these problems can result 89 
in an erroneous assignment of the molecular mass (22, 29).  90 
Several studies focusing on adduct formation can be found in the literature (22, 28, 32, 91 
33), adding up to approximately 20 charged adducts and simple fragments from ESI
+
 (including 92 
[M+H]
+
 and doubly charged ions) and about 11 different from ESI
-
 (including [M-H]
-
 and doubly 93 
charged ions). All studies were performed within a single compound class such as trichothecenes 94 
(35) and sugars (36), and to the best of our knowledge, no large survey exists on adduct formation 95 
between different classes of compounds. 96 
Dereplication can be an arduous task, especially when candidates with similar masses 97 
from a databa se hit list need to be evaluated. Here UV/VIS (22) and MS/MS (31) data can be used 98 
along with taxonomic knowledge of the producing organism and its close relatives (22). Taxonomy 99 
is far more discriminatory for eukaryotes, e.g. few secondary metabolites are found across several 100 
fungal genera(41)[larsen05], than for bacteria due to less frequent horizontal gene-transfer (42). 101 
Candidates can also be differentiated based on the presence of ionizable groups by explorative 102 
solid-phase extraction (E-SPE) (43). This approach can be used to separate neutral, basic, acidic, 103 
and amphoteric compounds as well as to unmask co-eluting compounds and thereby simplify 104 
subsequent LC-MS spectra of individual fractions for analysis. Other parameters that can be used 105 
for elimination of candidates include chromatographic retention. For neutral compounds, the 106 
calculated octanol-water partition coefficient cLogP and its pH corrected LogD correlate with 107 
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retention time (44-46). This was demonstrated for acylhomoserine lactones where a convincing R
2
 108 
= 0.993 was found between RT and LogD (47).  109 
The objective of this study was to obtain a detailed understanding of adduct and 110 
fragmentation formation  in ESI
+
 and ESI
-
 for a database of 718 known compounds and to highlight 111 
compounds classes not easily detected by ESI
+
 and ESI
-
. This has not been done in a large scale for 112 
natural products, aside from our last study from 2003 (22) investigating ESI
+
 spectra of 474 113 
compounds. We also evaluate the impact of mass and isotope pattern accuracies for differentiating 114 
elementary compositions of 33,136 valid compounds in Antibase2008. Finally we have explored 115 
the accuracy of LogD calculated via ACD for predicting retention times in order to eliminate or 116 
verify candidates during dereplication. 117 
 118 
119 
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Results and Discussion 120 
[the structure of this section is not yet adjusted for Journal of Natural Products. Different topics will 121 
be discussed on the following sub-headings] 122 
Antibase and mass accuracy. To characterize the general mass distribution of microbial natural 123 
products, the accurate mass was calculated for all compounds in AntiBase2008 (48). Antibase, 124 
which is used extensively in our laboratory, contains data for secondary metabolites from 125 
microorganisms and higher fungi, including yeasts, ascomycetes, basidiomycetes, and lichens, and 126 
also algae and cyanobacteria (48). For important fungal genera such as Aspergillus, Penicillium, 127 
Alternaria, Stachybotrys, and Fusarium, we found AntiBase to contain as much as 95-98% of the 128 
compounds published in journal papers and patents. Before investigating the data in AntiBase the 129 
approximately 34,300 records were and stripped for: i) compounds with monoisotopic masses 130 
below 60 Da; ii) compounds not containing hydrogen; iii) and C24H38N12O12 (used in the database 131 
for unidentified peptides), resulting in 33,136 valid records.  132 
In table 1, the number of elementary compositions differing by less than 10, 5, 2, and 133 
1 ppm, respectively, is divided into mass intervals of 100 Da. For example, within mass range 500-134 
599 Da there are 132 compounds that cannot be differentiated with a mass difference of 5 ppm 135 
while 58 cannot at 2 ppm mass difference. The number of candidates can be reduced by 25-50% 136 
when isotope ratios are used such as the number carbon atoms (A+1 corresponding to 
12
C/
13
C ratio) 137 
and halogens or sulfur (A+2 corresponding to 
79
Br/
81
Br, 
35
Cl/
37
Cl, or 
32
S/
34
S). Sulfur can be difficult 138 
to detect due to low natural abundance of the heavier isotope, nonetheless it is found in 6.9% of the 139 
records and thus relevant for dereplication purposes. Another way to recognize sulfur containing 140 
compounds is by a low mass defect caused by the very high negative mass defect of sulfur itself 141 
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(monoisotopic mass 31.9721). The newest TOF generations from Agilent, Waters, Bruker, and 142 
Sciex are able to provide high isotope ratio accuracy of 1-5 %. The distribution found in 143 
AntiBase2008 confirms the results of Kind et al. (25) on hypothetically generated compositions 144 
within mass range 0-500 Da.  145 
The observed mass distribution of NPs within AntiBase2008 clearly stresses the 146 
importance and need for high mass accuracy in a high throughput dereplication setup: With less 147 
than 1 ppm mass accuracy, there are no overlapping candidates in AntiBase2008 (Table 1) even 148 
without information on isotopes. However, in practice the mass accuracy of the MS instrument has 149 
to be two- to four-fold better in order to compensate for fluctuations in the actual measurements to 150 
make sure two compositions are not confused (28). Such a level of accuracy can currently be 151 
achieved on FT-ICR, Orbitrap, and the newest TOF instruments if internal mass correction is used. 152 
Figure 1 presents the number of compounds with the same elemental composition as a 153 
function of the monoisotopic mass in AntiBase2008. Interestingly, the compounds with the highest 154 
redundancy in composition were all terpenes, which makes sense due to the numerous variations 155 
that exists of  e.g. non oxygenated mono- (C10H16) and sesquiterpenoids (C15H24) in fungi, due to 156 
the incorporation of repetitive isoprene units into these compounds. For most such compounds, 157 
proper isotope ratio, retention times (RT), MS/MS data, and/or prerequisite knowledge of microbial 158 
origin is imperative for successful dereplication. This is very time consuming, especially for 159 
compositions like C15H22O3 where 113 candidates exist in Antibase2008. Thus, there is a need for 160 
in-silico tools for automated fragmentation analysis of especially compounds with same molecular 161 
mass (49). 162 
 163 
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Statistical analysis based on 718 metabolites. In order to search for compounds in databases, the 164 
mass or molecular formula must be established unambiguously. Defining the molecular ion is far 165 
from evident based on ESI generated data, and knowledge of the adduct pattern is paramount. With 166 
the purpose of developing a general strategy for deducing ESI spectra, we compiled data from all 167 
718 compounds in our in-house collection and stored these in an ACD database (43). Each entry 168 
contained chemical structure, chromatographically validated (deconvoluted) monoisotopic ions 169 
from ESI
+ 
and ESI
-
, UV/VIS spectrum (pH 3-3.3), UV absorption maxima, and retention index 170 
(retention time relative to alkylphenones) (50). Also, ions corresponding to more than 5% relative to 171 
the most intense ion in ESI
+ 
and ESI
-
 ions from three different scan-functions were compiled. The 172 
data can be seen in Table 2 (and as Supporting Information, Excel format). As double charged ions 173 
were rarely observed and their formation dependent on ion-source settings (51), they were not 174 
included in Table 2. Paracelsins was the only compound class where double charged ions were 175 
observed regularly, and all are in the 1900-2000 Da range, which is in the absolute upper-range of 176 
secondary metabolites (Figure 1). Likewise, we did not include dimeric [2M+X]
+
 and trimeric ions 177 
[3M+X]
+
 (28, 33) since the intensity of these was highly irreproducible due to concentration-178 
dependent formation (51) (Figure 3).  179 
The most common adducts and fragments observed from the ESI
+
 and ESI
-
 spectral 180 
data of the 718 compounds in the database are noted in Table 3. Also, the frequency at which they 181 
occur is noted in the table (see also supplementary for further data). Adducts and fragments are 182 
recognized based on their relative mass (Δ) compared to [M+H]+ or [M-H]-, creating a characteristic 183 
pattern of ions. Figure 4 illustrates the annotation of Δ-values in ESI+ and ESI- spectra of 184 
asperphenemate to gain correct mass assignment. 185 
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In ESI
+
, the molecular ion [M+H]
+
 is in most cases the predominant ion observed in the spectrum, 186 
and the ion is formed from 88.5% of the molecules (see Table 3). 27% of the compounds produced 187 
[M+H]
+
 as the only ion. It leaves doubts to if it is [M+H]
+
, [M+H-H2O]
+
, [M+Na]
+
, or [M+NH4]
+
 188 
ion, however this can usually be revealed by careful comparison of the different scan functions. 189 
Also, most compounds making [M+Na]
+
 or [M+NH4]
+
 usually make both, causing the characteristic 190 
∆5, which results in <3% risk of assigning [M+H]+ incorrectly.  This fraction is lower than for drug 191 
molecules (52, 53) since most of these contain amines added for enhanced solubility and 192 
bioavailability. In contrast, the number of fungal and bacterial secondary metabolites with amine 193 
functionalities constitutes 8% and 28%, respectively (43). 194 
The acetonitrile adduct is the most frequently formed adduct in ESI
+
, when using 195 
acetonitrile-water as the mobile phase. Small molecules (<250 Da) like pyrones often display very 196 
prominent [M+H+MeCN]
+
 ions (m/z Δ41), often accompanied by a strong [M+Na+MeCN]+ ion 197 
(m/z Δ63) and in a few cases [M+H-H20+MeCN]
+
 (m/z Δ23). Interestingly, the same compounds 198 
did not ionize very well in negative mode. Due to its strong appearance, [M+H+MeCN]
+
 can easily 199 
be mistaken for [M+H]
+, and thus special attention should be paid to the characteristic ∆41. 200 
However, there is however a risk to confuse the pair of [M+H+MeCN]
+
 and [M+Na+MeCN]
+
 with 201 
[M+H]
+
 and [M+Na]
+
. In most cases, increasing the skimmer potential resulted in lower abundance 202 
of [M+H+MeCN]
+
, but for a few compounds it increased as if the MeCN attached to [M+H]
+
 upon 203 
collision. In a few cases fragment ion with MeCN adducts were also observed. 204 
 A strong adduct with sodium [M+Na]
+
 (m/z Δ22) was formed for 21.4% of the 205 
compounds in ESI
+
, yet only in a few cases forming the most prominent ion. [M+Na]
+
 was 206 
especially abundant for acids where it can ion-exchange on the carboxylic acid group to make 207 
[M+2Na]
+
. In alkaloids, the abundance of [M+Na]
+
 were usually very low, presumably due to a low 208 
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affinity for Na
+
 compared to H
+
 to the lone pair on the nitrogen. We speculate that the amines in 209 
many cases are protonated in the solvent state prior to leaving the droplets. 210 
An ammonium adduct [M+NH4]
+
 (m/z Δ17) is observed for 19.3% of the compounds. 211 
The affinity of ammonium is especially high for oxygenated molecules, such as polyketides, where 212 
this ion is often the most predominant in the spectrum. In contrast, this adduct is extremely rare for 213 
alkaloids. For some primary amides and amino acids, a loss of NH3 was observed [M+H-NH3]
+
, 214 
giving rise to the same mass difference of Δ17. However, as the [M+NH4]
+
 ion is often 215 
accompanied by [M+Na]
+
, this set of ions can be identified by a characteristic mass difference of 216 
Δ5.  The high abundance of [M+NH4]
+
 adducts was a surprise since ammonia was not added to any 217 
of the solvents. The intensity of [M+NH4]
+
 ion peaks usually increased during a sequence 218 
suggesting that NH3 is formed as a result of acidic hydrolysis of MeCN. This was confirmed by 219 
using pure non-acidified MeCN. Substitution of MeCN with MeOH had an even stronger effect and 220 
almost eradicated ammonium adducts.  221 
Not surprisingly, loss of water [M+H-H2O]
+
 (m/z Δ18) is the most common fragment 222 
ion formed. Inspection of the structures revealed that almost all lose H2O from an alcohol group 223 
where a β-hydrogen is available for elimination.  224 
Altogether ESI
+
 was able to detect 93% of the compounds (Table 4), however including 12.4% 225 
poorly ionizing compounds. The compounds not able to ionize were mainly small acids with the 226 
acidic carbon positioned next to a conjugated system. In part, this removes the free lone pair of the 227 
oxygen so it is unavailable for H
+
 binding. Anthraquinones are examples of such molecules where 228 
the most problems were encountered. The seven fold increase in non-ionizing compounds compared 229 
with our last study (22) was predominantly caused by an increase in this group of compounds in our 230 
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database. We found that the fraction of poorly ionizing and non-ionizing compounds could be 231 
shifted with impurity levels in the solvents and how often the solvent bottles were changed. Besides 232 
contamination of the ion-source with organic material, we observed that corrosion in the column 233 
oven (observed as corrosion at the inlet) and ions liberated here from caused a 10-100 fold drop in 234 
sensitivity for poorly ionizing compounds. Strongly ionizing compounds like alkaloids did not 235 
suffer significantly from these issues. We observed a Na
+
 efflux from the solvent bottles which 236 
lowers sensitivity and cause ion-pair effects during HILIC separations for example (54). This 237 
problem can be met by substituting glass bottles for the water with special plastic bottles (we used 238 
bottles from Dionex, Sunnyvale, CA). 239 
Based on ESI
+
 alone, only 56% of the compounds in our database could be 240 
unambiguously assigned (Table 4), meaning that at least two adducts points towards the same 241 
mass. In further 30% of the cases, only the [M+H]
+
 ion was detected. 242 
As previously observed (33), ESI
-
 produced less adducts than ESI
+
 (Table 3) and in 243 
consequence, the risk of incorrect adduct assignment is 4.5% higher (supplementary material). The 244 
most commonly formed adduct was formate adduct [M+HCOO]
-
 (m/z Δ46). Loss of 46 was 245 
fortunately rare (0.5%), thus ∆46 is therefore almost guaranteed a formate adduct. We speculate, 246 
that formate in some instances is used to deliver the charge by forming [M-HCOO]
-
, and leaving 247 
[M-H]
-
 by evaporation of formic acid. The formate adduct can often be confirmed by the presence 248 
of a chlorine adduct [M+Cl]
-, and relative mass difference of ∆10 (and a Cl isotope pattern) is 249 
therefore characteristic of this pair. In this study, [M+HCOO]
-
 and [M+Cl]
- 
were mainly formed on 250 
neutral compounds why the detection of these adducts are therefore strong indicators of molecules 251 
not containing carboxylic acids or acidic phenols.  252 
13 
 
Loss of CO2 was the most common (14%) fragment ion formed for ESI
-
. Among carboxylic acids, 253 
37% lost CO2 which was a 2½ fold higher prevalence than in the whole dataset, but still lower than 254 
expected (34, 55). Of the compounds losing CO2 in negative mode, one third lost formic acid in 255 
positive mode (5% in the whole dataset). Interestingly, loss of H2O in negative mode was very rare 256 
(Table 3) and only observed from 2% of the molecules investigated. 257 
Metal ion adducts were interestingly also observed in negative mode with [M-258 
2H+Na]
-
 and [M-H+HCOO+Na]
-
, which fitted well with ion-exchange processes. It was observed 259 
for 4.5 % of all compounds investigated, and usually for compounds containing a carboxylic acid or 260 
another acidic functionality. These adducts are also known from phospholipids (56). Thus, [M-261 
2H+Na]
-
 is a strong indication of an acidic functionality in an unknown compound being 262 
dereplicated. The positive adduct [M+2Na-H]
+
 was occasionally observed but usually below 2% 263 
abundance compared to the base peak.  264 
Notably, 17 compounds including citrinin, oosporein, and mitorubrins produced [M-265 
H+H2O]
-
 and [M+H]
+
, respectively. They were in all cases highly conjugated compounds which 266 
may be reduced and/or hydrolyzed during ESI
-
 and/or chromatography. On-column and in-source 267 
reactions can be differentiated through observation of the chromatographic peak shape as one would 268 
expect a non-Gaussian peak shape in the case of on-column reactions. 269 
For only 36.5% of the compounds, the molecular mass could be unambiguously 270 
assigned directly from ESI
-
 (Table 4). In the cases where a single ion is observed, it is most likely 271 
to be [M-H]
-
 (42.6%), and only in 7.2% of the cases could it be missassigned as [M+HCOO]
-
. This 272 
can easy be clarified by substituting the acid in the solvent to acetic acid. The lower fraction of [M-273 
H]
-
 compared to [M+H]
+
 is likely due to fundamental differences in ionization mechanism. In ESI
+
, 274 
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all charges (H
+
, Na
+
, K
+
, NH4
+
)  are added to the native molecule due to the Fe
++
 being liberated 275 
from from the steel capillary (57, 58). In negative mode, [M-H]
-
 is formed through loss of H
+
, 276 
whereas all other ions in both polarities are formed by addition of a charged adduct . 277 
One third of the compounds in our database did not ionize or ionized poorly in ESI
-
 278 
(Table 4), thus making ESI
+
 the first choice of ionization mode, unless a priori knowledge on the 279 
target compound(s) indicates ESI
-
. It has to be noted that high concentration of formic acid suppress 280 
ionization in ESI
-
 due to low pH (more difficult to deprotonate) and competition with formate ions. 281 
We have been able to obtain better ESI
-
 sensitivity by reducing the concentration; however, to 282 
obtain the best possible peak shape and consistent retentions times, we choose to maintain 20 mM 283 
formic acid during chromatography.  284 
A comparison of compounds producing [M+H]
+
 and/or [M-H]
-
 ions is shown in Table 285 
4. Both ions can be observed for 60% of the compounds investigated, yet only in 37.4% of the cases 286 
do they represent the most abundant ion. As mentioned previously, 56.4% and 36.5 % of molecular 287 
masses could be assigned unambiguously using ESI
+
 and ESI
-
, respectively. The combination the 288 
two ionization modes, resulted in 93% correctly assigned masses. The remaining 7 % consisted of 289 
poorly/non-ionizing compounds, or compounds only ionizing strongly in one mode. For example, 290 
highly polar alkaloids like roquefortines A and B, as well as simple ergots alkaloids will ionize 291 
strong as [M+H]
+
, but not at all show up in negative mode. Poorly ionization compounds were often 292 
small molecules (<200 Da)  often with a structure appearing to be volatile (few polar groups and no 293 
charge at pH 3-3.3) and we find it likely that they are lost as neutrals with the nitrogen due to the 294 
high source temperature (350 °C) and presumable requires APCI ionization. It was clear that 295 
ionization efficiency increased during the gradient run due to the higher concentration of MeCN. 296 
This phenomenon was already observed in the early days of ESI (59, 60). The sensitivity of poorly 297 
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ionizing polar compounds can therefore be enhanced by using improved columns for polar analytes 298 
such as pentafluorophenyl or HILIC columns (61, 62). Perhaps the most important observation 299 
when comparing ESI
+
 and ESI
-
  was that the polarity providing the most intense ionization always 300 
resulted in the most simple spectrum for interpretation and most reliable adduct pattern.  301 
The frequencies of ionization as well as adduct patterns in ESI
+
/ESI
-
 were compared 302 
to those of ACPI
+
/APCI
-
 on a small subset of 60 chemically diverse compounds (supplementary 303 
data), including some of the problematic compounds. This was done on an Agilent LC/MSD VL 304 
single quadrupole system using the exact the same chromatographic conditions, and after adjusting 305 
the fragmentor voltage to give comparable fragmentation to that of the Z-spray source. This ion-306 
source showed slightly better ionization of anthraquinones and apolar compounds, whereas the Z-307 
spray remained superior in ionization of small polar substances. However, the data did not indicate 308 
that the overall number of detectable compounds would be different from that of ESI.  309 
 310 
In-source fragmentation versus ion-transmission. [preliminary section] A conflict exists in the 311 
ion source, as no large m/z ions (> m/z 800) were observed at the low skimmer potential difference 312 
of 12-20 V which were needed to avoid fragmentation of small labile compounds. Part of this must 313 
originate from the higher velocity of low m/z ions between the skimmers (cones) as their velocity is 314 
higher (skimmer potential difference = ½ × m ×V
2
. Thus must an m/z 60 ion have an almost 6 time 315 
higher velocity between the skimmers than an m/z 2000 ion. The only choice is thus to use fast 316 
(compared to the chromatographic peak width) alternating skimmers potentials (illustrated in 317 
Figure 4) to obtain a broad m/z range of ions transference from the ESI source to the MS. 318 
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The use of alternating cone potentials had another advantage between adduct ions and fragment ions 319 
by enhancing fragment ions and adducts with the very stable alkali metal ions (29, 63). A third 320 
advantage is that pseudo MS/MS data can be obtained (64) as also seen in Figure 5. The overall 321 
concept is marketed as MS
E
 in QTOF instruments from Waters (65). 322 
 323 
Chromatography. [preliminary section] Due to the inherent nature of reversed phase 324 
chromatography, it is tempting to link retention and LogD which has been shown to correlate well 325 
for acylhomoserine lactones (R
2
 = 0.993) (47). As shown in Figure 5A, a similar correlation was 326 
obtained for the fumonisins (containing five ionizable groups), but for the neutral aflatoxins and 327 
sterigmatocystins (Figure 5B) the correlation was less convincing (R
2
 = 0.65) with an average 328 
predicted error of the retention index of 55 and a max error of 95. In figure 6, all 718 compounds 329 
are presented which did not prove satisfactory (R
2
 = 0.38). Several groups were analyzed 330 
individually and compounds like acylhomoserine lactones correlated excellently (R
2
 =0.99) under 331 
our conditions. In general were compounds with LogD below -1 were not retained, thus did a lower 332 
logD not impact the retention index. This shows that calculated LogD values are still of limited use 333 
for exclusion of candidates during a dereplication process unless sufficient related compounds are 334 
evaluable as reference standards to verify a given regression model. The general poor correlation 335 
seen in Figure 6, must be due to factors as inaccurate pKa calculation, ionic interactions with the 336 
underlying silica, steric effects of molecules, and ion-paring effects with  HCOO
-
 and  H3O
+
 (66-337 
70). 338 
[Major dereplication example] 339 
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Conclusion. Thorough investigation of adduct formation of 718 natural products have 340 
demonstrated that ESI
+
 was the most versatile method capable of detecting 93% of the compounds.  341 
Using the adduct pattern, 56% of the compounds could be unambiguously assigned based on ESI
+
 342 
alone, whereas 37% could be assigned be unambiguously assigned by ESI
-
 alone. Additional 41% 343 
produced [M-H]
-
 without any validating ions. No perfect ion-source settings were found to cover 344 
the full range of compounds m/z 60-2000. Consequently, it was necessary to do ultra-fast 345 
alternation between two-three settings during the chromatographic run to allow both small labile 346 
molecules and large peptides into the MS. This also provided pseudo MS/MS data. When 347 
combining data from the ESI
+
 and ESI
-
 the polarity where the most intense ionization was observed 348 
always provided both the simplest spectrum to interpret and most trustworthy adduct pattern. 349 
350 
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Experimental Section 351 
General Experimental Procedures. Solvents were HPLC grade and all other chemicals analytical 352 
grade unless otherwise stated. They were all obtained from Sigma-Aldrich (Steinheim, Germany). 353 
Specifically for the LC gradient system MeCN was Sigma 5485, and the formic acid Fluka 56302 354 
(for LC-MS). Water was purified from a Milli-Q system (Millipore, Bedford, MA). Alkylphenone 355 
standards for RI determination were diluted in MeOH in concentrations of 2-3 mM as previously 356 
described (22, 50). 357 
Theoretical pKa calculations of Antibase2008 (21, 48) were made by converting the ChemFinder 358 
version to the ACD ChemFolder (Advanced Chemistry Development, ACD, Toronto, Canada) and 359 
then batch calculating the logD values at pH 2.7, 3.0 and 3.3 using the ACD 2008 PhysChem suite 360 
(43) by Dr. Shahriar Jahanbakht (Chemacad, Obernai, France). 361 
 362 
Reference standards. Metabolite standards have been collected over the last 30 years (22, 50, 72), 363 
either from commercial sources, as gifts from different research groups, or from our own projects 364 
and therefore only available in micro to milligram quantities, some only about 50% pure. About one 365 
third of the standards have been purchased from Sigma-Aldrich, Axxora (Bingham, UK), Cayman 366 
(Ann Arbor, Mi), TebuBio (Le-Perray-en-Yvelines, France), Biopure (Tulln, Austria), Calbiochem, 367 
(San Diego, Ca), and ICN (Irvine, Ca). Reference standards were generally taken out as powder 368 
using a Pasteur pipette (1-2 mm of powder in the tip), transferred to an auto-sampler vial, and 369 
unless other stated 1.5 ml MeCN added to the vial. In case of highly polar substances not soluble in 370 
MeCN a few drops of water was added or 2-propanol was used. The standard solutions were kept at 371 
–20°C. 372 
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LC-DAD-TOFMS. Tuning and calibration in ESI
+
 was done as previously described (22). In 373 
negative mode the MS was tuned to a resolution of ca. 5000 FWHM on [M-H]
-
 of leucine 374 
enkephaline, and calibrated on a solution of PEG-di acids (average MW 200 and 600), polyalanine, 375 
1,6-dihydroxybenzoic acid, and chloramphenicol and diluted in MeCN-water (1:1 v/v). 376 
 The LockSpray connected to a custom made system equipped with 0.5 L bottle to which a 377 
positive pressure of 2-3 bar N2 was applied giving a constant flow of ca. 20 µl/min leucine 378 
enkenkephaline solution (0.1 µg/mL in MeCN-water-formic acid (50:50:0.1). The protonated and 379 
deprotonated molecular ion was used as lock mass in ESI
+
 and ESI
-
 respectively. 380 
 All analysis was done on an Agilent 1100 LC system with a diode array detector (DAD) 381 
coupled to a LCT oaTOF mass spectrometer (Micromass, Manchester, UK), with Z-spray 382 
electrospray source (ESI) and a LockSpray probe. The system was controlled by the MassLynx 4.0 383 
software. Separation was done at 40°C on a 502 mm i.d., 3 m, Luna C18 II column (Phenomenex, 384 
Torrance, CA) equipped with a Security Guard pre column, using a linear water-MeCN gradient 385 
with a constant flow of 0.3 ml/min, starting with 15% MeCN-water going to 100% MeCN in 20 386 
min, maintaining 100% MeCN for 5 min, before returning to the start conditions in 2 min and 387 
equilibrating for 5 min. Formic acid 20 mM was added to both solvents.  The UV spectra was 388 
collected by a diode array detector every 0.4 sec from 200 to 700 nm with a resolution of 2 nm. 389 
 The source was kept at 120°C and desolvation temperature was 400°C. Sample cone was 390 
continuously flipped between 18, 30 and 50 V (scan functions 1, 2 and 3 respectively), each for 0.5 391 
sec, with scan ranges of m/z 100-2000 for the last. The lock mass scan was performed every 6 s at a 392 
sample cone of 30 V. Capillary was held a 3000 V in ESI
+
 and 2000 V in ESI
-
, and the desolvation 393 
flow held at 400-450 (ESI
+
) and 675-725 L/hr (ESI
-
). 394 
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Data analysis. Data from 718 metabolites are collected in Table 2. The table lists the metabolite, 395 
formula, retention index (RI) calculated as described by Frisvad & Thrane (50), if the peak was 396 
highly asymmetrically with is marked(*) on the RI, UV data. 397 
ESI
+
 and ESI
-
 data are each separated into: i) how well the compound ionizes; ii) ions 398 
representing adducts with M (H
+
, NH4
+
, Na
+
, K
+
, Cl
-
, MeCN, H2O and formate as well as 399 
combination of these) and simple losses (H2O, NH3, acetic, CH3- and formic acid, CO2, 400 
formaldehyde); iii) and significant diagnostic fragments (usually from scan function 2 of 3). Isotope 401 
data are only included under the significant fragments in case of loss of Cl. All ions of the 402 
individual components were confirmed by manual mass de-convolution. The accurate mass 403 
measurements were calculated from spectra obtained in the front or tail of the peak to reduce 404 
influence of detector dead time by keeping the ion counts below 1000 counts.  405 
Data management. MS and UV spectra data were stored in a custom made database made in the 406 
ACD v. 12 Chemfolder. The structures of most compounds were imported from Antibase 2007 or 407 
2008 (21, 48). Table 1 in supplementary data is an Excel version of the database. Log D at pH 2.7, 408 
3.0 and 3.3 were kindly calculated as batch calculations in and added to the database. UV data were 409 
made by background subtraction and it was verified that it was not saturated. 410 
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 a
Mass difference, thus meaning that 3-4 fold better instrument mass accuracy is needed to safely 
distinguish the two.  
b
 * mass defect of -0.3 to +0.7. 
c
Assuming Cl, Br and S isotope information is  
being used 
 
Mass range (Da)Total compounds
(da) Mass difference (ppm) 10 5 5 5 5 5 2 2 2 2 2 1
Isotope constrain None ±5 C ±2 C ±2 Cc None None ±5 C ±2 C ±1 C ±1 Cc None ±5 C ±2 C ±1 C ±1 Cc None
60-99 133 45 45 38 31 0 0 0 0 0 0 0 0 0 0 0 0
100-199 2969 738 717 461 342 13 0 0 0 0 0 0 0 0 0 0 0
200-299 6167 1532 1376 811 538 104 48 43 40 32 19 0 0 0 0 0 0
300-399 6494 2119 1694 899 518 264 84 60 53 45 27 0 0 0 0 0 0
400-499 5125 2208 1636 872 567 434 195 163 138 114 92 0 0 0 0 0 0
500-599 3764 1791 1237 600 458 326 132 95 71 64 50 58 46 41 36 32 0
600-699 2065 1234 815 392 288 203 106 85 46 39 23 27 23 20 18 17 0
700-799 1590 985 669 352 273 145 69 55 26 25 23 23 20 16 16 16 0
800-899 1157 710 487 275 221 111 64 45 26 22 17 17 11 10 10 10 0
900-999 639 402 252 118 93 47 26 19 7 3 3 5 3 2 2 2 0
1000-3535 3033 1260 659 369 242 118 1 0 0 0 0 0 0 0 0 0 0
Total 33136 13024 9587 5187 3571 1775 730 1775 730 344 254 130 103 89 82 77 0
Number of compounds
Distribution of compounds in Antibase 2008 with different elementary compositions which cannot be distinguished at 
different mass-differencesa, carbon isotope ratio, and A+2 elements (S, Cl, Br) determination 
Nominalb
NAME Formula MI (amu) RI ESI+ data (m/z) ESI- data (m/z) UV_A
Oxalic acid C2H2O4 89,9953 673 No ionization 89, 135 (PO) End(100), 248(4)
Moniliformin C4H2O3 98,0004 674 No ionization 97 228(100), 260(31)
1,3-Benzendiol C6H6O2 110,0368 681 No ionization 155 (PO) End(100), 216sh, 276(40)
Histamine C5H9N3 111,0796 669 112 (PO) 156 (PO) 214
3-Nitropropionic acid C3H5NO4 119,0219 680 No ionization 118, 164, 154 204
Benzoic acid C7H6O2 122,0368 755 *164 121, 167, 189 228(60), 272(4)
Toluquinone C7H6O2 122,0368 717 No ionization No ionization 252(100), 325(7)
4-Ethylphenol C8H10O 122,0732 867 No ionization No ionization 200(100), 222(40), 278(12)
2-Phenylethanol C8H10O 122,0732 755 No ionization No ionization End(100), 208(96), 260(4)
3,5-dihydrotoluen C7H8O2 124,0524 690 125 (VPO) No ionization End(100), 220sh, 272(8)
Methyl-p-hydroquinone C7H8O2 124,0524 686 No ionization No ionization End(100), 212sh, 290(25)
5-(hydroxymethyl)-2-furaldehyde C6H6O3 126,0317 679 127, 144, 168 (PO) No ionization 234(16), 286(100)
1,2,4-Benzenetriol C6H6O3 126,0317 673 No ionization 171, 125, 161 End(100), 220sh, 290(14)
Maltol C6H6O3 126,0317 678 168, 127 No ionization 216(100), 276(86)
methyl 2-furoate C6H6O3 126,0317 778 No ionization No ionization 254
Phloroglucin C6H6O3 126,0317 673 127, 168, PO, 125, 171 204(100), 223sh, 270(4)
Pyrogallol C6H6O3 126,0317 673 No ionization 125 207(100), 224sh(85), 264(46)
Cinnamic aldehyde C9H8O 132,0575 832 174, 133 PO No ionization 224(34), 297(100)
3-Aminobenzoic acid C7H7NO2 137,0477 676 138, 179 136 (PO) End(100), 220(96), 312(5)
4-Aminobenzoic acid C7H7NO2 137,0477 683 179, 138 No ionization End(100), 220(58), 286(97)
Anthranilic acid C7H7NO2 137,0477 714 138, 179, 120 136, 182 218(100), 243(31), 330(16)
Salicylamide C7H7NO2 137,0477 705 138, 179, 121, 162 136, 182, 172, 118 204(100), 236(32), 300(18)
Tyramine C8H11NO 137,0841 663 179, 138, 121 136 (PO) End(100), 220(86), 276(23)
1,3-benzodioxol-5-ol C7H6O3 138,0317 726 No ionization No ioniation End(100), 233(15), 296(20)
2,3-dihydroxybenzaldehyde C7H6O3 138,0317 714 No ionization 137 (VPO) 216(100), 268(72), 324(12)
2,4-dihydroxybenzaldehyde C7H6O3 138,0317 725 139, 180, 275 (PO) 137 212(90), 230(65), 278(100), 312sh
2,5-dihydroxybenzaldehyde C7H6O3 138,0317 706 275 (VPO) 137 230(100), 260(55), 360(21)
3,4-dihydroxybenzaldehyde C7H6O3 138,0317 683 180 (PO) 137 214(100), 268(39), 328(12)
3,5-dihydroxybenzaldehyde C7H6O3 138,0317 685 No ionization 137, 183, 173 214(100), 268(40), 328(10)
3-Hydroxybenzoic acid C7H6O3 138,0317 697 No ionization 137 206 (100), 238(38), 296(11)
p-Hydroxybenzoic acid C7H6O3 138,0317 689 No ionization 137, 183, End(100), 208sh(85), 256(92)
Salicylic acid C7H6O3 138,0317 770 No ionization 137, 183 204(100), 234(23), 300(11)
4-Hydroxyphenylethyl alcohol C8H10O2 138,0681 687 121 (PO) No ionization End(100), 222(50), 276(11)
2,5-Dihydroxyanisol C7H8O3 140,0473 680 141, 182 (PO) 185 (PO) End(100), 254sh, 290(11)
3,5-Dihydroxyanisole C7H8O3 140,0473 690 141, 182 (PO) No ionization 205(100), 226sh, 270(5)
1,2-Dihydroxy-3-
methoxybenzene
C7H8O3 140,0473 694 141 (VPO) 185, 139, 124 End(100), 226sh, 270(3)
3,5-Dihydroxybenzyl alcohol C7H8O3 140,0473 675 141, 182, 164 PO 185, 139, 175, 113 202(100), 222sh, 278(11)
Butenolide C6H7NO3 141,0426 675 183, 142 140, 186 End
Kojic acid C6H6O4 142,0266 676 143, 184 141(VPO) 216(100), 268(78); (270, 7820)
Botryodiplodin C7H12O3 144,0781 676 No ionization 143 210
Coumarin C9H6O2 146,0368 778 188, 147 No ionization End(100), 210sh, 278(54), 310(28)
Arabenoic acid C6H10O4 146,0579 681 147, 188, 117 191, 145, 127 (PO) 240
Cinnamic acid C9H8O2 148,0524 826 190, 131, 149 147, 193, 215 204(64), 216(65), 276broad(100)
5-Hydroxy-2(3H)-benzofuranone C8H6O3 150,0317 697 No ionization 195, 149, 185, 121 End(100), 236(18), 290(11)
3-Phenylpropionic acid C9H10O2 150,0681 812 192, 174, 146 (PO) 195, 149 End(100), 2908(82), 264(4)
2,6-Dihydroxyacetophenon C8H8O3 152,0473 770 153, 194, 176 151, 197, 135, 133, 109 end(100), 222(80), 272(78), 
344(14)
2,4-Dihydroxyacetophenon C8H8O3 152,0473 756 153, 194, 135 151, 135, 109 210(100), 230(52), 276(90), 
318(48)
2,5-Dihydroxyacetophenon C8H8O3 152,0473 739 153, 194 (PO) 197, 151 236(100), 256(60), 358(29)
O-Vanilinin C8H8O3 152,0473 766 153, 194 151 (VPO) 220(100), 266(70), 346(14)
3-hydroxy-4-
methoxybenzaldehyde
C8H8O3 152,0473 711 153, 194 151, 136 208(100), 232(98), 280(82), 
312(61)
3-hydroxy-4-methylbenzoic acid C8H8O3 152,0473 703 194 (PO) 197, 151, 107 210(100), 246(44), 296(14)
3-Methylsalicylic acid C8H8O3 152,0473 864 No ionization 151, 197, 107 208(100), 240(22), 308(11)
4-Methylsalicylic acid C8H8O3 152,0473 836 No ionization 151, 107 208(100), 242(32), 300(13)
6-Methylsalicylic acid C8H8O3 152,0473 800 194, 153, 135 (PO) 151, 107, 208(100), 244(22)sh, 302(10)
Gibepyrone F C8H8O3 152,0473 701 194, 170, 153, 307, 324 No ionization 208(92), 248(18), 308(100)
p-Hydroxybenzoic acid methyl 
ester
C8H8O3 152,0473 763 194, 153, 121 (PO) 151, 197, 303, 136, 660, 631 End(100), 210sh, 258(84)
p-Hydroxyphenylacetic acid C8H8O3 152,0473 687 No ionization 151, 197 End(100), 224(43), 276(9)
p-Hydroxyphenylacetic acid C8H8O3 152,0473 689 194 151, 197, End(100), 224(43), 276(9)
4-Ethylguaiacol C9H12O2 152,0837 885 No ionization No ionization End(100), 226(19), 280(12)
2,3-dihydroxybenzoic acid C7H6O4 154,0266 696 No ionization 153, 109, 169 206(100), 244(23), 310(14)
2,4-dihydroxybenzoic acid C7H6O4 154,0266 697 196, 155, 178 (PO) 153, 109 208(100), 218sh, 254(41), 294(19)
2,5-Dihydroxybenzoic acid C7H6O4 154,0266 692 No ionization 153, 109 208(100), 232sh(30), 324(18) 
2,6-dihydroxybenzoic acid C7H6O4 154,0266 744 No ionization 153, 135, 109 208(100), 246(31), 306(18)
3,4-dihydroxybenzoic acid C7H6O4 154,0266 680 No ionization 153, 189, 109 206(100), 216(88), 260(50), 
294(24)
3,5-dihydroxybenzoic acid C7H6O4 154,0266 680 No ionization 199, 153, 109 208(100), 248(32), 306(13)
Patulin C7H6O4 154,0266 677 196 (VPO) 153, 199 276
Terrein C8H10O3 154,0630 680 No ionization No ionization 282
3-Butyl-4-methylfuran-2(5H)-one C9H14O2 154,0994 883 196, 155, No ionization 220
Nonanoic acid C9H18O2 158,1307 1059 No ionization 203, 157, 225 End
3-Indolylethanol C10H11NO 161,0841 766 162, 203, 144 No ionization 222(100), 280(20)
p-Coumaric acid C9H8O3 164,0473 714 206, 165, 147 163, 119 213(43), 227(51), 293sh, 308(100)
Phenylpyruvic acid C9H8O3 164,0473 772 No ionization No ionization 286
2,3,5,6-tetramethyl-1,4-
benzoquinone
C10H12O2 164,0837 986 No ionization No ionization 268
Gibepyrone A C10H12O2 164,0837 902 165, 206 No ionization End(89), 236(100), 332(92) 
L-Phenylalanin C9H11NO2 165,0790 673 207, 166, 120 164, 210, 232, 147 200(100), 210(98), 256(5)
α-Methoxyphenylacetic acid C9H10O3 166,0630 731 208, 184, 176, 148 211, 165, 233 End(100), 208sh, 228sh
Ethyl-p-hydroxybenzoesyre C9H10O3 166,0630 824 208, 180, 167, 162, 139, 121 165, 137 End(100), 258(80)
3-Phenyllactic acid C9H10O3 166,0630 719 No ionization 165, 211, 201, 147, 119 End(100), 210(82)
Methyl 2-methoxybenzoate C9H10O3 166,0630 829 167, 135 No ionization 206(100), 236(24), 296(18)
Methyl 4-methoxybenzoate C9H10O3 166,0630 879 208, 167, 135, 194 No ionization End(100),  210sh, 258(82)
6-Carboxypicolinic acid C7H5NO4 167,0219 680 168, 388** 386**, 122 End(100), 220sh, 272(40)
3-Hydroxymandelic acid C8H8O4 168,0423 675 No ionization 167, 133 End(100), 216sh, 278(6)
4-Hydroxymandelic acid C8H8O4 168,0423 673 192, 151, 164 167, 213, 121 End(100), 230(20), 276(4)
2,5-Dihydroxyphenylacetic acid C8H8O4 168,0423 680 210, 186, 232, 164 (PO) 167, 123, 213 End(100), 234(18), 294(12)
Orsellinic acid C8H8O4 168,0423 717 210, 169, 151, 192 167, 123 212(100), 260(44), 296(17)
Gallic acid C7H6O5 170,0215 676 No ionization 169, 125 212(100), 272(60)  
Penicillic acid C8H10O4 170,0579 702 171, 212, 188, 153 169, 215 End(48), 228(100)  
Shikimic acid C7H10O5 174,0528 672 157, 198 (VPO) 173, 219, 209, 155, 137, 111 210
Indolacetic acid C10H9NO2 175,0633 767 176, 171, 146, 130 174, 220, 130, 144, 242 220(100), 278(19), 286sh
L-Ascorbic Acid C6H8O6 176,0321 673 218, 177, 194, 175, 135 244
Fusaric acid C10H13NO2 179,0946 707 180, 152, 175, 193 No ionization End(100), 228(32), 272(45)
4-Hydroxyphenylpyruvic acid C9H8O4 180,0423 705 No ionization 179, 195, 225, 201 236(30), 304(100)
Caffeic acid C9H8O4 180,0423 691 222,  163, 181 179, 135 216(78), 240(61), 302sh, 324(100)
Stipitatic acid C8H6O5 182,0215 681 224, 183 (PO) 181, 227, 249, 266(100), 310sh, 360(20), 415sh
3-Methylorsellinic acid C9H10O4 182,0579 777 224, 183, 165 181, 137 220(100), 268(67), 304(18)
5-methyl-orselenic acid C9H10O4 182,0579 767 224, 183 181, 137 216(100), 264(44), 306(13)
Carolic acid C9H10O4 182,0579 676 183, 200, 224, 165, 155, 137 199 232(85), 264(100)
2,3-dimethoxy-5-methyl-1,4-
benzoquinone
C9H10O4 182,0579 759 183, 140, 155, 168 No ionization End(82), 268(100), 410(6)
Ethisolide C9H10O4 182,0579 728 200 (VPO) 227 (VPO) 206
Methyl 3-methoxysalicylate C9H10O4 182,0579 806 183, 246, 151, 210, No ionization 215(100), 250(25), 316(12)
Barnol C10H14O3 182,0943 812 183, 165, 224, 181,  (PO) 227, 181, 166 204(100), 222sh, 272(4)
Valine-tenuazonic acid C9H13NO3 183,0895 792 225, 185 192, 125 222(52), 278(100)
Spinulosin C8H8O5 184,0372 699 No ionization 183, 168, 140 200(81), 212(60), 296(100)
Aspyrone C9H12O4 184,0736 690 185, 167, 139, 226 (PO) 229, 219 204(100), 234sh
Asperlactone C9H12O4 184,0736 685 226, 185, 202, 141 No ionization 218
Dihydroramulosin C10H16O3 184,1099 743 185, 167, 208 No ionization Not detected
2-Acetyl-3H-quinazolin-4-one C10H8N2O2 188,0586 756 189, 147 187 206(100), 232(72), 304(38)
Aspinonene C9H16O4 188,1049 676 206, 252, 153, 127 233, 169 Not detected
Kynurenic acid C10H7NO3 189,0426 688 190, 162, 203, 188, 144 218(91), 242(100), 334(28)
Chrysogine C10H10N2O2 190,0742 686 191, 173 189, 145, 173 End(85), 228(100), 264(22), 
304(15)
3,5-Dimethyl-6-
methoxyphthalide
C11H12O3 192,0786 889 193, 210, 234, 178, 163, 149 No ionization 210(100), 244(22), 300(15)
Scytalone C10H10O4 194,0579 897 195, 236, 177, 218 193, 175, 151, 165 216(98), 230sh(78), 284(100), 
316sh(45) 
4-Hydroxymellein C10H10O4 194,0579 752 195, 177, 149, 236 (PO) 239, 229, 193, 149, 121 208(100), 244(21), 312(16)  
Dimethylphthalate C10H10O4 194,0579 843 163, 195, 135 No ionization End(100), 228(22), 276(5) 
Caffeine; Coffein C8H10N4O2 194,0804 684 195, 236 No ionization 208(100), 230sh, 272(65)
Novae-zelandin B C11H14O3 194,0943 878 195, 236, 258 No ionization 208(100), 288(21)
Galiellalactone C11H14O3 194,0943 756 195, 177 275, 239, 229,  (PO) 222
4,8-Dihydroxy-3-methyl-3,4,4a,5-
tetrahydro-1H-2-benzopyran-1-
one
C10H12O4 196,0736 745 197, 238, 260, 180 195, 241, 231 212(98), 226sh, 332(100)
L-Tenuazonic acid C10H15NO3 197,1052 826 239, 198, 144 196, 139 End(69), 222(60), 284(100) 
Tenuazonic acid C10H15NO3 197,1052 818 *239, 198 196, 139, 264 End(69), 222(60), 284(100)
Naphthalic anhydride C12H6O3 198,0317 1428 370, 329 (PO) 327, 395, 667, 181, 249 203(100), 218(94), 258(92), 298sh, 
360(62), 378sh
3,4,4a,5,6,7-Hexahydro-4,8-
dihydroxy-3-methyl-1H-2-
benzopyran-1-one
C10H14O4 198,0892 751 240, 199, 181, 182, 141 243, 233, 197 (PO) 268
Carolic acid (R) C9H12O5 200,0685 676 183, 200, 224, 165, 155, 137 199 232(85), 264(100)
Tryptophan C11H12N2O2 204,0899 678 205, 246, 188 203, 249, 239, 271, 261, 225 220(100), 280(15), 287sh
Xanthurenic acid C10H7NO4 205,0375 684 206,  178, 219, 173 204, 160 220(63), 248(100), 344(21)
5-Formylmellein C11H10O4 206,0579 846 No ionization 205 240(100), 278(50), 314sh
2-Pyruvoylaminobenzamide C10H10N2O3 206,0691 746 207, 190, 224 205, 187, 411 218(100), 245sh(28), 296(7)
3-Methyl-5,7-dimethoxypthalide C11H12O4 208,0736 794 209, 272, 191, 163 No ionization 218(100), 260(49), 292(16)
Isochromantoxin C12H16O3 208,1099 872 209, 207, 271, 191, 179, 151 207, 191, 163 204(100), 226sh, 284(12)
2,4-Dihydroxy-6-acetonyl-
benzoic acid
C10H10O5 210,0528 708 211, 193, 252 209, 123, 165 214(100), 262(50), 298(22)
Canadensolide C11H14O4 210,0892 890 211, PO 209, 255, 231, 277, 121, 137 204
Terrestric acid C11H14O4 210,0892 739 211, 200, 193, 159, 252 227***** 208(52), 231(22), 274(100)
Jasmonic acid C12H18O3 210,1256 853 211, 252 (PO) 209, 255, 419 End
Tropodithietic acid C8H4O3S2 211,9602 774 213, 236, 195, 167, 151 211, 167, 139, 107 210(100), 244(62), 306(98), 314sh, 
358(39), 450(11)
Asperline C10H12O5 212,0679 722 213, 230, 194, 153, 135 No ionization 206
Gallic acid propyl ester C10H12O5 212,0685 765 254, 213, 212, 153, 168, 171 211, 124, 169 216(100), 274(68)
9,10-Dihydrojasmonic acid C12H20O3 212,1412 908 254, 213, 194 211, 257, 279, 167 End(100), 210sh(10), 288(19)
Oxo C6 homoserine lactone C10H15NO4 213,1001 686 214, 231, 259, 277, 236, 212 Not detected
Agistatin B C11H18O4 214,1205 715 *197, 179 259, 249 PO Not detected
Hydroxy C6 homoserine lactone C10H17NO4 215,1158 680 216, 233, 238, 198, 279, 254 214 Not detected
Decarestrictine D C10H16O5 216,0998 678 217, 181 261 (VPO) Not detected
Gladiolic acid C11H10O5 222,0528 764 No ionization 221, 289, 267, 177, 147, 119 268(100), 306 (43)
Nigragillin C13H22N2O 222,1732 673 223, 264,  286, 183, 166, 129 No ionization 270
Farnesol C15H26O 222,1984 1327 *205, 149 No ionization End
Pyranonigrin A C10H9NO5 223,0481 697 224, 241 222 208(100), 262(65), 310(75)
Cerulenin C12H17NO3 223,1208 794 265, 224, 206, 196 222, 268, 204, 179 End(100), 208sh
Puberulonic acid C9H4O7 223,9957 782 225, 242 223, 241 End(60), 276(100), 318(49), 
363sh, 376(32), 412(30)
Novae-zelandin A C11H12O5 224,0685 716 225, 266 223 206(100), 286(28)
Aspergillic acid C12H20N2O2 224,1525 905 266, 225, 193, 166, 288, 197 223, 291, 269, 307, 205, 191, 151 228(80), 324(100),  HCl: (242, 
7300) (350/2, 9700)
Prephenic acid C10H10O6 226,0477 681 290, 244 (PO) 181, 163, 225, 227 End(100), 224sh
2,4-Dihydroxy-6-(1-
hydroxyacetonyl) benzoic acid
C10H10O6 226,0477 687 227, 268, 209, 250, 193, 163 225, 181, 137, 207 214(100), 260(49), 294(21)
Papyracillic acid C11H14O5 226,0841 730 227, 209 225, 271, 261, 166, 181, 193, 123 230
Terrestric acid C11H14O5 226,0841 739 211, 200, 193, 159, 252 *****227 208(52), 231(22), 274(100)
Aurantioclavine C15H18N2 226,1470 714 227, 210, 171, 154, 168, 182, 198 No ionization End(88), 224(100), 288(22)
Dihydrojasmonic acid-methyl 
ester
C13H22O3 226,1569 1077 268, 227, 194 No ionization End(100), 222(42), 292(20)
Carlosic acid C10H12O6 228,0634 684 229, 246, 211, 292 227, 139, 183, 249 232(100), 264(94), 316sh, 408(8)
Hydroxyisocanadensic acid C11H16O5 228,0998 782 270 (VPO) 227, 141, 121 230
Ergothioneine C9H15N3O2S 229,0885 674 230, 186, 127 228, 274, 125, 169 260
Hydroxypestalotin C11H18O5 230,1154 707 231, 253, 248, 294, 181, 195, 213, 167 275, 265, 203, 163, 161 242
Sorbicillin C14H16O3 232,1099 1135 233, 215, 205, 165 231, 189, 187, 213, 176 204(100), 324(83), broad to 450
Isovelleral C15H20O2 232,1463 1004 233, 215, 187, 205, 173, 274 281, 231, 263 (VPO) End(100), 210sh, 252(90)
Ascochin C12H10O5 234,0528 976 No ionization 233, 205 256(100), 289sh, 312(11)
Cyclo-L-phenylalanin-L-serin C12H14N2O3 234,1004 683 235, 207, 276, 162, 143 233, 279, 203 (PO) End
2',3'-Dihydrosorbicillin C14H18O3 234,1256 1169 235, 165, 217, 233, 178, 163, 150, 213 216(100), 232sh, 284(80), 328(30)
Visoltricin C13H18N2O2 234,1368 740 235 No ionization End(100), 282(100)
1-hydroxyeremophil-7(11),9(10)-
dien-8-one
C15H22O2 234,1620 979 235, 276, 217, 207, 189, 175, 163, No ionization 244 (100), 288(40) 
5-Methoxycarbonylmellein C12H12O5 236,0685 951 237, 278, 205 (PO) 235 230 (100), 255(sh), 312(10)
Austdiol C12H12O5 236,0685 688 237, 300, 259, 278, 177, 219, 191, 201, 163 235, 175, 174, 173, 147, 135, 161, 
163, 133
204(55), 256(70), 380(100) 
Radicinin C12H12O5 236,0685 743 237, 219, 193, 300, 254, 163 325 (PO) 208(70), 220(71), 236sh, 272(26), 
344(100)   
Walleminol C15H24O2 236,1776 910 *260, 219, 201, 145, 159 201 (VPO) End
Viridicatin C15H11NO2 237,0790 936 238, 208, 220, 192 236, 208 204(78), 222(100), 240sh(50), 
288(20), 318(27)328sh
Cyclopaldic acid C11H10O6 238,0477 822 239, 280, 221,  (PO) 237, 193, 165, 149, 135, End(35), 244(100), 274sh, 322(8)
Pachybasin C15H10O3 238,0630 1202 VPO 238 End(94), 224(61), 248sh, 
260(100), 277sh(47), 332(10), 
404(20)
Agroclavine C16H18N2 238,1470 707 239, 208, 198, 183 No ionization 228(100), 280(28)
Culmorin C15H26O2 238,1933 958 *221, 203, 262, 177, 147, 256 *283 End
Alizarin C14H8O4 240,0423 928 No ionization 239 228sh, 248(100), 280(68), 328(14), 
432(26)
Chrysazin C14H8O4 240,0423 1093 241, 282 (VPO) 239 224(100), 252(88), 284sh, 
428broad(48)
6,7-seco-Agroclavine C16H20N2 240,1626 746 241, 210, 167, 195, 154, 181 No ionization End(100), 220(84), 282(20)
Pyroclavine C16H20N2 240,1626 691 241, 210, 168, 154 No ionization 226(100), 282(25)
Costaclavin C16H20N2 240,1626 699 341, 210 No ionization 226(100), 282(25)
Festuclavine C16H20N2 240,1626 706 241, 210 No ionization 222(100), 280(20)
Oxo-C8-homoserine lactone C12H19NO4 241,1314 792 242, 259, 264, 287, 280, 305, 182, 214, 200 240 Not detected
Iodinine C12H8N2O4 244,0484 970 No ionization No ionization 288(100), 344(8), 524(8)
Verruculotoxin C15H20N2O 244,1576 681 245, 286, 217, 200 No ionization End
wpi-10-Verruculotoxin C15H20N2O 244,1576 677 245, 286, 216, 199, 133 PO End(100), 210sh
Hirsutanol-C C15H20O3 248,1412 760 249, 231, 272, 290, 203, 175, 213 293, 229 216(43), 288(100)
Diaporthin C13H14O5 250,0841 864 251, 233, 249, 295, 317 (PO) 244(100), 276(13), 286sh, 328(13)
Citrinin C13H14O5 250,0841 928 251, 314, 233, 274, 292 267, 249, 295, 205, 223, 177, 231 216(100), 242sh, 328(40)
Oxaspirodion C13H14O5 250,0841 807 268, 251, 233 PO 231, 249, 177, 159, 307 End(100), 126sh, 248(80)
Vertinolide C14H18O4 250,1205 841 201, 224, 165, 251, 273, 292 249, 499, 521 230 (40), 278(100)
Trichodermol C15H22O3 250,1569 804 292, 251, 233, 215, 274, 187 No ionization End
3-O-Methylviridicatin C16H13NO2 251,0946 930 252, 315, 236 (CH4 loss), 237 250 (PO) 294(96), 226(100), 280(20), 315sh, 
324(22), 334sh
Frequentin C14H20O4 252,1362 923 253, 235, 338, 216 251, 319, 207, 233, 179, 193 232
Walleminone C15H24O3 252,1725 900 316, 253, 235 No ionization End
Viridicatol C15H11NO3 253,0739 828 254, 208, 236 252, 224, 222(100), 240sh, 285(20), 305sh, 
318(26), 329sh
Chrysophanic acid C15H10O4 254,0579 1184 255, 296 (VPO) 253, 321, 225 (PO) 224(100), 256(65), 280sh, 288sh, 
43broad2(30)
Phomarin C15H10O4 254,0579 1048 255, 296 253, 225 220(90), 268(100), 294sh, 415(21)
Soranjidiol C15H10O4 254,0579 1076 255, 296 (VPO) 253 220(90), 268(100), 293sh(50), 
412(26)
w-Hydroxypachybasin C15H10O4 254,0579 928 255, 296 (PO) 253, 224 End(85), 222(61), 258(100), 
277sh(45), 334(10), 440(20)
Elymoclavine C16H18N2O 254,1419 676 255, 224, 212, 296, 237 No ionization End(94), 220(100), 280(21)
Epoxyagroclavine C16H18N2O 254,1419 710 255 No ioniztion 224(100), 280(20)
Lysergol C16H18N2O 254,1419 675 255 No ionization End(100), 230(86), 242(84), 
314(32)
Palitantin C14H22O4 254,1518 855 255, 237, 272, 219, 296, VPO 232
ochratoxin α C11H9ClO5 256,0139 830 257, 239 255, 211, 167 216(100), 235sh, 248sh, 336(22)
Lambertellin C14H8O5 256,0372 943 279, 257, 298 (VPO) 255, 287  (VPO) 212(100), 288(79), 432(21)
Purpurin C14H8O5 256,0372 10 257, 298 (PO) 255 204(72), 256(100), 296(30), 456sh, 
480(28), 508sh
Viridicatic acid C12H16O6 256,0947 776 257, 239 (PO) 255 233(88), 244(52), 265(100)
Chanoclavine-I C16H20N2O 256,1576 676 257, 208, 168, 193, 156, 226, 198 No ionization End(87), 224(100), 280(22)
Dihydrolysergol I C16H20N2O 256,1576 675 257 No ionization 224(100), 280(20)
Fumigaclavine B C16H20N2O 256,1576 673 257 No ionization 224(100), 280(19)
Iso-dihydrolysergol C16H20N2O 256,1576 676 259 301, 269 224(100), 282(20)
Roquefortine B C16H20N2O 256,1576 672 257, 298, 239, 197 No ionization 224(100), 280(19)
Indolmycin C14H15N3O2 257,1164 799 258, 299, 184, 156, 144 302, 256, 292, 228, 199 220(100), 282(9)
nor-Rubrofusarin C14H10O5 258,0528 934 259 257, 325, 303 226(57), 280(100), 328(4), 412(13)
Ravenelin C14H10O5 258,0528 1059 257 (VPO) strange 257, 303, 213 (PO) End(75), 236sh(60), 260(100), 
340(37), 398(10)
Alternariol C14H10O5 258,0528 869 259, 300 (PO) 257, 303, 325 204(50), 256(100), 288(20), 
300(20), 340(23)
Norlichexanthone C14H10O5 258,0528 936 259 257 204(65), 242(100), 267sh, 312(60), 
346sh
Bredinine C9H13N3O6 259,0804 671 260.169 258, 216 End(100) broad to 250, 280 (10)
2-hydroxy-1-(8-hydroxy-3-
methylisoquinolin-7-yl)-3-
methylbutan-1-one
C15H17NO3 259,1208 734 260, 242, 214, 204, 186 258, 240, 215 220 (95), 248(100), 262 (98), 364 
(49)
Maculosin C14H16N2O3 260,1161 683 302, 261, 196, 177, 136 No ionization End(100), 220sh(30), 275(5)
Cinoxacin C12H10N2O5 262,0590 743 263, 235, 326 307, 297, 261 (VPO) 250(48), 264(100), 265(53)
2,7-dimethoxy-6-ethyljuglone C14H14O5 262,0841 1086 263, 235, 220 No ionization 224(100), 260(50), 410(12)
4Z-Infectopyrone C14H16O5 264,0998 829 265, 203, 247, 223, 139, 177 263, 299, 309, 331 220(100), 269(71), 346(80)
Infectopyrone C14H16O5 264,0998 854 265, 203, 247, 139, 219, 191 309, 263, 204, 331, 143, 189 (PO) 218(100), 268(68), 328(74)
Abscisic acid C15H20O4 264,1362 800 265, 282, 247, 288, 306, 328, 229, 201, 187, 173, 219, 263, 309, 331, 219, 153, 204, 201 264
Trichothecolone C15H20O4 264,1362 712 306, 265, 247, 229, 211, 203, 187, 175 163, 161, 309, 299, 171 228
Thiamine C12H17N4OS 265,1118 672 265, 174, 154, 144, 122 233, 147, 217, 251, 263, 281 End(100), 248(63), 273sh
Diaportinol C13H14O6 266,0790 784 267, 249, 219 311, 265, 301 244(100), 276(12), 286sh, 328(12)
7α-Hydroxytrichodermol C15H22O4 266,1518 696 308, 267, 249, 284, 231, 219 311 (VPO) End
Verrucarol C15H22O4 266,1518 700 267, 308, 249, 231, 213, 185, 330 236, 207, 311, 190 (PO) End
Isoergine C16H17N3O 267,1372 675 268 No ionization End(95), 232(100), 312(312(38)
Ergine C16H17N3O 267,1372 675 268, 284, 331, 225, 223, 208 No ionization End(100), 230(86), 242(84), 
314(32)
Pachybasic acid C15H8O5 268,0372 975 No ionization 267, 241, 223, 213, 195, 167 212(80), 228(78), 260(100), 
340(10), 404(22)
Lysergic acid C16H16N2O2 268,1212 675 269 313, 267, 233 (PO) 226(100), 240sh, 310(38)
Rugulovasine B C16H16N2O2 268,1212 683 269, 251, 310, 291, 332, 328, 223, 210 313, 303, 267, 223, 179, 193 220(100), 292(15)
DihydroErgine C16H19N3O 269,1528 675 271, 311 No ionization 224(100), 282(22)
Oxo-C10-homoserine lactone C14H23NO4 269,1627 930 287, 270, 292, 333, 308, 210 268 Not detected
Islandicin C15H10O5 270,0528 1319 No ionization 269 (PO) 230(100), 252(69), 292(23), 264sh, 
492(35)
Iso-emodin C15H10O5 270,0528 941 No ionization 269, 337 (VPO) End(55), 224(100), 256(64), 
286sh, 432(30)
Emodin C15H10O5 270,0528 1087 271 (VPO), 312 269 222(100), 258sh, 268(55), 288(64), 
440(38)
Helminthosporin C15H10O5 270,0528 1276 No ionization 369, 337, 349,  (PO) 231(100), 255(49), 288(23), 
484(30), 518sh 
Dihydrolysergic Acid C16H18N2O2 270,1368 675 271 No ionization 224(100), 280(24)
Hydroxy-C10-homoserine 
lactone 
C14H25NO4 271,1784 895 272, 289, 294, 335, 310, 254 270 Not detected
Alternariol monomethylether C15H12O5 272,0685 1024 273, 314 (poor ionzation) 271, 256 204(50), 256(100), 288(20), 
300(20), 340(23)
Rubrofusarin C15H12O5 272,0685 1128 273 271 228(49), 278(100), 328(4), 408(13)
Phenicin C14H10O6 274,0477 718 275, VPO 273, 229, 245, 214, 217, 201 214(100), 270(80)
3-acethoxyeremophil-
1(2),7(11),9(10)-trien-8-one
C17H22O3 274,1569 1095 275, 316, 233, 215, 187, 173, 145 No ionization 280(100), 306sh(65) 
2,2-Dimethyl-5-amino-6-(2'E-ene-
4'-hydroxylbutyryl)-4-chromone
C15H17NO4 275,1158 872 276, 220, 238, 258, 202, 192, 174 No ionization 214(89), 252(100), 282(42), 
390(57)
Ascochitine C15H16O5 276,0998 1070 277, 259 275, 293, 321, 343, 231, 201, 202 220(81), 262sh, 280(100), 326(15), 
242(15), 416(38)
3-acethoxyeremophil-7(11),9(10)-
dien-8-one
C17H24O3 276,1725 1076 277, 318, 217, 189, 161, 147 No ionization 248 (100), 280(60) 
Sclerotigenin C16H11N3O2 277,0851 770 278, 319, 249, 233, 341, 382 No ionization 215sh(78), 230(100), 267(22), 
280(20), 310(10), 319sh
2,7-dimethoxy-5-hydroxy-6-(l-
hydroxyethyl)-1,4-
naphthoquinone
C14H14O6 278,0790 902 261, 233, 324, 302, 293, 356 No ionization 224(100), 260(50), 410(12)
Citreo isocumarin C14H14O6 278,0790 761 279, 296, 301, 219, 261 277, 323, 219 244(100), 258sh, 275(15), 286sh, 
328(13) 
Pentoxifylline C13H18N4O3 278,1379 734 279, 301, 320, 317, 342, 222, 181, 156, 138 *293, 323 214(100), 276(72)
Diaportinic acid C13H12O7 280,0583 800 281, 298, 235, 276 279, 347, 337, 325, 315, 261, 173, 
217, 205
244(100), 276(13), 286sh, 328(13)
Cyclopeptine C17H16N2O2 280,1212 854 281, 322, 561. 189, 134 279, 183, 261, 149, 175, 222 216(100), 292(5)
7-epi-Brefeldin A C16H24O4 280,1675 856 322, 281, 245, 263, 199 325, 315 (PO) End, broad to 270 nm
Cyanein C16H24O4 280,1675 857 322, 281, 263, 245, 199, 163 No ionization End, broad to 270 nm
Linoleic acid C18H32O2 280,2402 1597 322, 281, 263, 173, 325, 279, 249, 181 End
Scirpentriol C15H22O5 282,1467 683 306, 283, 265, 247, 217 327, 317 (PO) End
Fumagillol C16H26O4 282,1831 875 283, 251, 265, 233, 215 No ionization End
Oleic acid C18H34O2 282,2559 1733 324, 265, 247, 298 327, 281, 317 End
C12-homoserine lactone C16H29NO3 283,2147 1213 284, 301, 306, 143, 102 328, 318 Not detected
Macrosporin C16H12O5 284,0685 1040 285 283, 351, 268, 240 224(53), 284(100), 309sh, 280(20)
Physcion C16H12O5 284,0685 1286 285, 326 283, 269, 240 End(60), 224(100), 257sh, 
268(54),288(55), 436(36)
Questin C16H12O5 284,0685 975 285 283, 240 224(100), 250sh, 284(64), 436(27) 
Asperic acid C16H28O4 284,1982 985 253, 267, 307, 235, 285 383 222
Bostrycoidin C15H11NO5 285,0637 989 286, 327, 243 284, 352, 269, 241 (PO) 204(96), 252(100), 324(21), 472sh, 
492(29), 526sh
Piperine C17H19NO3 285,1365 1001 286, 349, 201 284, 330 250(30), 312(67), 344(100)
Catenarin C15H10O6 286,0477 1132 No ionization 285, 257 (PO) 232(100), 256(50), 276(52), 
302(32), 464sh, 492(42), 520sh
Cynodontin C15H10O6 286,0477 1349 No ionization 285, 353, 257 236(100), 284sh, 296(18), 488sh, 
516(40), 544(38), 552(39)
Flavasperone C16H14O5 286,0841 855 287 (PO) 285 End(100), 224(71), 276(67), 
325(5), 404(8)
Lichexanthone C16H14O5 286,0841 1333 287, 272, 244, 328 285, 380 (VPO) 208(71), 242(100), 308(65), 341sh
Salicin C13H18O7 286,1053 678 304, 309 331, 321 End(100), 211(sh), 268(15)
Fusoxysporone C20H30O 286,2297 1582 287, 328, 269, 175, 203 No ionization End(100), 244(85)
Pyrophen C16H17NO4 287,1158 816 288, 229, 310, 351, 286 200(100), 270(25), 323(20)
Anhydrofusarubin C15H12O6 288,0634 1125 289 (PO) 287, 272, 244, 355, 333  (PO) End(100), 236(88), 288(87),348sh, 
540(47)
Violaceic acid C15H12O6 288,0634 798 330, 289, 271 287, 309, 255, 243, 137 End(100), 228(82), 262(68), 284sh
Funalenone C15H12O6 288,0634 854 289 287 214(100), 235(sh), 265(35), 
280(sh), 368(sh), 402(40)
Violaceic acid C15H12O6 288,0634 739 No ionization 287, 243 208(100), , 274, 350
Xanthocillin-X C18H12N2O2 288,0899 1023 289, 348, 371(VPO) 287, 260, 233 End(50), 240(20), 360(100), 380sh
Citromycetin C14H10O7 290,0427 897 291, 273, 313, 354 289, 271,217, 175 212(100), 256(53), 300(35), 
368(55)
Altenusin C15H14O6 290,0790 838 291,273, 245, 239, 198, 227, 296 289, 245, 230, 271 End(100), 217sh, 258(31), 290(20)
Javanicin C15H14O6 290,0790 932 291, 249, 273 289, 357, 247, 232, 274 228(100), 304(31), 480sh, 504(28), 
538sh 
Altenuene C15H16O6 292,0947 790 293, 275, 257, 229, 201 337, 327, 291, 240(100), 280(36), 320(18)
6-Methoxy-citreoisocoumarin C15H16O6 292,0947 848 310, 293, 315, 331, 233, 275, 207 291, 337 244(100), 258sh, 278(13), 288sh, 
328(14)
Italicic acid C15H16O6 292,0947 889 310, 293, 334, 356, 275, 247, 223, 205 291,  337, 247,  219, 175 240(52), 268(48), 336(100)
Solaniol C15H16O6 292,0947 900 275, 293, 338, 257 (PO) 291, 247, 232, 273, 204, 346, 359 
(PO)
End(60), 228(100), 308(30), 
480sh, 504(28), 542sh
Curvularin C16H20O5 292,1311 891 293, 275, 310, 334, 210, 169 291, 247, 190, 203, End(100), 222(72), 272(41), 
303(30)  
Cladosporin C16H20O5 292,1311 850 293, 275, 257, 231 (PO) 291, 337 216(100), 268(65), 300(23)
Fusarochromanone C15H20N2O4 292,1423 687 293, 275, 258, 234, 315, 356 No ionization 212(80), 252(100), 280(41), 
388(56)
Trichodermin C17H24O4 292,1675 968 293, 233, 215, 274 (233 w CH3CN), 184, 187, 197, 203 No ionization End
Cyclopenin C17H14N2O3 294,1004 830 295, 336, 358, 264, 251, 236, 205 293, 208, 235, 175 End(95), 212(100), 290(6)
Dihydro-italicic acid C15H18O6 294,1103 1124 No ionization 293, 361, 249 End(60), 278(100), 330(46)
Deoxynivalenol C15H20O6 296,1260 681 297, 249, 360, 279, 231, 203 (PO) 341, 331, 357 220
Oxo-C12-homoserine lactone C16H27NO4 297,1940 1079 298, 315, 320, 336, 298, 361, 238 296, 169, 195 End
Hydroheptelidic acid C15H22O6 298,1416 740 316, 299, 281, 262, 263, 245, 221 595, 297, 279, 343, 333, 617 216
T-2 tetraol C15H22O6 298,1416 675 321, 316, 281, 263, 299 PO No ionization End
Fumigaclavine A C18H22N2O2 298,1681 690 299, 340 No ionization 224(100), 280(18)
Roquefortine A C18H22N2O2 298,1681 700 299, 340, 239 297 224(100), 280(18)
Leucyltryptophanyl-
diketopiperazine
C17H21N3O2 299,1634 778 300, 341, 130 298, 344, 334, 330, 169 220(100), 282(20), 294sh
Hydroxy-C12-homoserine 
lactone 
C16H29NO4 299,2097 1026 300, 317, 322, 363, 338, 282 298, 334, 344 End
2,8-Dihydroxy-3-methyl-9-oxo-
xanthene-1-carboxylic acid 
methyl ester
C16H12O6 300,0634 990 301, 269 299, 345, 367, 267 (PO) End(100), 236(90), 262(96), 292(36), 384(28)
Dermoglaucin C16H12O6 300,0634 1004 301 (VPO) 299, 285 (PO) 212(100), 284(99), 432(40)
Erythroglaucin C16H12O6 300,0634 1311 No ionization 299, 285 (VPO) 230(100), 256(52), 276(53), 
304(41), 370sh, 492(42), 518sh
Roseopurpurin C16H12O6 300,0634 807 301 299, 256 220(100), 252(73), 288(82), 
436(39)
3,4,5-Trihydroxy-7-methoxy-2-
methylanthraquinone
C16H12O6 300,0634 1107 301 (VPO) 299, 367 222(10), 270(46)
Questinol C16H12O6 300,0634 818 301 299, 256 224(100), 28850), 440(22)
Isodihydroauroglaucin C19H24O3 300,1725 1383 301, 283, 231, 299, 349, 218, 217, 288 230(100), 276(18), 388(14)
Aflatoxin B3 C16H14O6 302,0790 827 303, 344, 285, 257, 245, 229 301 (VPO) 206(100), 260(23), 328(28)
Aurantiamine C16H22N4O2 302,1743 788 303, 344, 235, 176 301 232(53), 320(100)
Aurantiamine C16H22N4O2 302,1743 774 303, 344 301, 347 226(100), 316(88)
Viridamine C16H22N4O2 302,1743 749 303, 260, 247, 176, 275 301, 258, 333 End(80), 222sh, 302(100), 315sh
Aspergin C19H26O3 302,1882 1521 303, 247 301, 347, 283, 273, 230(232), 276(34), 396(24)
Dehydroflavoglaucin C19H26O3 302,1882 1455 303. 285, 247 301, 273, 204, 281 End(100), 234(21), 278(24), 
388(18)
Nectriafurone C15H12O7 304,0583 902 305, 287, 303, 371, 288 End(100), 240(81), 258(80), 
324(25), 356sh, 444(57), 464sh
Griseophenone C C16H16O6 304,0947 893 305, 165, 185, 208 303, 349, 271, 265, 165 205(100), 227sh(44), 297(50), 
337sh(12)
Flavoglaucin C19H28O3 304,2038 1538 305, 249 349, 303, 275, 204, 163 End(100), 240(36), 276(36), 
388(16)
Oosporein C14H10O8 306,0376 720 No ionization 305, 249, 221, 205, 277, 233, 327 End(92), 288(100)
Canescin A C15H14O7 306,0740 865 307, 275, 229 305, 273, 261, 229, 217 248(100), 280(12), 320(11)
Fusarubin C15H14O7 306,0740 856 289, 307, 247, 330, 370 305, 373, 291, 248, 233, 262, 275 228(100), 304(30), 474sh, 500(28), 
526sh
Chromanol 1 C16H18O6 306,1103 898 289, 307, 271, 324 305, 351, 341, 163, 193, 135, 231, 
246, 261, 237
222(10), 270(46)
Chromanol 2 C16H18O6 306,1103 877 289, 307, 271, 370, 256, 343, 215 305, 351, 341, 193, 261, 163, 
135,193, 231, 246
222(10), 270(46)
Methyl italicate C16H18O6 306,1103 978 307, 324, 275, 247, 329, 370 323, 307, 305, 339, 351 240(50), 272(45), 336(100)
Expansolide A C17H22O5 306,1467 958 307, 306, 247, 265 323, 391, 263, 201 End
Circumdatin C C17H13N3O3 307,0957 795 308, 349, 271, 265, 291 306 232(100), 272(30), 302(13), 
310(12), 322SH
6,7-Dihydroxy-3-(1'-hydroxy-3'-
butanoyl)chromone-5-carboxylic 
acid
C14H12O8 308,0532 729 No ionization No ionization 219(100), 253sh, 256(100). 
352(30), 381(25)
Dihydrofusarubin A C15H16O7 308,0896 791 279, 309, 291, 320, 262, 249, 221 307, 375, 277, 262, 205, 219 208(65), 244(100), 276(36), 
300(24), 388(44)
Dihydrofusarubin B C15H16O7 308,0896 766 279, 291, 309, 262, 221, 249 307, 375, 277, 262, 205, 219 208(65), 244(100), 276(36), 
300(24), 388(44)
5'-Hydroxyasperentin C16H20O6 308,1260 785 326, 309, 331, 291, 273, 229, 173, 247, 255 307, 353, 343, 189, 263, 289 214(100), 267(68), 300(28)
Cyclopenol C17H14N2O4 310,0954 750 311, 177, 352, 146, 205, 252, 280 309, 175, 200, 224, 238, 252, 266, 
355
End(100), 214sh, 284(7)
Mollicin C14H10Cl2O4 311,9956 1079 No ionization 311, 291, 275, 240, 228, 211 208(100),262(80), 255sh, 420(18)
Aflatoxin B1 C17H12O6 312,0634 847 313, 376, 285, 335 311 (PO), 285, 200, 224(70), 264(45),336sh, 
364(68)
Nivalenol C15H20O7 312,1209 673 295, 336, 313, 247, 265, 330, 189, 175, 201 (PO) 357, 347, 313, 281 220
2-Amino-14,16-
dimethyloctadecan-3-ol
C20H43NO 313,3345 1089 355, 314, 296, 337 No ionization End
Aflatoxicol A C17H14O6 314,0790 864 297 (M+H-H2O), 378, 269, 241 313, 347, 331 (VPO) 208, 252shc, 260(30), 332(32)
Aflatoxin B2 C17H14O6 314,0790 823 315, 378, 317 313, 298, 285, 270, 257, 242 
(VPO)
200, 222(68), 
232sh,268(48),336sh, 364(90)
Heptelidic acid chlorohydrin C15H21ClO5 316,1078 879 317, 334, 299, 253, 217, 281 315, 631, 653 220(100), 266(30), 304(13)
Rosenonolactone C20H28O3 316,2038 1167 358, 317, 299, 271, 380 215, 333 (PO) End
Dichlorodiaportin C13H12Cl2O5 318,0062 1105 319, 360, 177, 246 363, 317, 245, 205 244(100), 276(12), 286sh, 328(12)
Asperthecin C15H10O8 318,0376 846 No ionization 317, 299 End(75), 236(88), 260(100), 
286(55), 316(36), 484(56), 506sh
Antibiotic Y C15H10O8 318,0376 907 319, 382, 305, 287 317, 385, 407, 285, 258 (PO) 204(78), 216(78), 244(100), 
280(95), 348(75), 364(82)
Dechlorogriseofulvin C17H18O6 318,1103 884 319, 360, 341, 382, 165, 181, 251 No ionization 212(90), 256(60), 288(100), 325sh
Zearalenone C18H22O5 318,1467 1020 319, 301, 283, 231, 187 317, 273, 175, 187, 289, 299, 149 236(100), 272(45), 318(18)
3,4-Epoxy-6-hydroxy-dolabella-
7E,12-dien-14-one
C20H30O3 318,2195 876 301, 319, 283, 360,  255 No ionization End(100), 242(70)
PR-imine C17H21NO5 319,1420 745 320, 278, 260, 232, 218, 192 318, 364, 354, 276, 258, 216 (PO) 252(100), 287sh(38)
1-Deoxybostrycin C16H16O7 320,0896 794 321, 303, 344, 285, 259 319, 301, 387, 286, 243, 258, 271 228(100), 304(28), 474sh, 500(30), 
536(18)
2,7-dimethoxy-5-hydroxy-6-(l-
acetoxyethyl)-1,4-
naphthoquinone
C16H16O7 320,0896 946 *261, 279, 302, 324, 384 No ionization 222(100), 254(49), 314(31), 
426(13)
Mycophenolic acid C17H20O6 320,1260 932 321, 343, 303, 275, 248, 207 319, 341, 275, 207, 191 216(100), 252(24), 304(12) 
PR-toxin C17H20O6 320,1260 931 321, 279, 261 319, 291, 277, 259, 231 (PO) 256
α-Zearalenol C18H24O5 320,1624 951 321, 303, 285, 267, 257, 229, 217 319, 275, 301, 291, 257, 233, 174 236(100),276(45), 316(18)
β-Zearalenol C18H24O5 320,1624 906 321, 303, 285, 267, 217 319, 365 242(100), 270(50), 312(19)
Zearalanone C18H24O5 320,1624 1011 321, 303 319, 275, 205, 301, 161 218(100), 264(56), 302(23)
Neoechinulin B C19H19N3O2 321,1477 909 322, 363, 254, 295, 266 320 End(100), 228(100), 272(78), 
282sh, 372 (47)
Chromanol 3 C17H22O6 322,1416 793 249, 231, 342, 325, 307, 388 323, 369, 359, 279, 249, 163, 193, 
188, 221
222(10), 270(46)
α-Zearalanol C18H26O5 322,1780 937 323, 305, 287 321, 361 218(100), 264(56), 302(23)
β-Zearalanol C18H26O5 322,1780 895 323, 305, 287, 277 321, 367, 277, 303 218(100), 264(56), 302(23)
Neoechinulin A C19H21N3O2 323,1634 871 324, 365, 256, 297, 268 322 226(100), 288(28), 328(33)
Sterigmatocystin C18H12O6 324,0634 1053 325, 310, 388 No ionization 204(75), 235sh, 248(100), 328(47) 
Formyl-xanthocillin X C18H16N2O4 324,1110 728 325, 282, 342, 347, 370, 388 (PO) No ionization End(70), 220(30, 278sh), 338(100)
Ergometrine C19H23N3O2 325,1790 675 326 324 End(100), 228(94), 314(36)
Ergonovinine C19H23N3O2 325,1790 675 326 370, 324 (PO) End(100), 234(100), 314(34)
Preechinulin C19H23N3O2 325,1790 837 326, 356, 370, 389, 221, 198, 258, 270, 370, 360, 324, 127 (PO) End(79), 224(100), 284(20)
Gliotoxin C13H14N2O4S2 326,0395 796 327, 263, 245, 227, 286, 217 325, 261, 243, 217 End(100), 270(39)
Dihydrosterigmatocystin C18H14O6 326,0790 1009 327, 390, 312, 299, 271 393, 325 (VPO) 206(55), 233sh,248(100), 326(44)
Trisdechloronornidulin C19H18O5 326,1154 1018 327, 368 325, 371, 281, 269 204(100), 254sh(45)
Aflatoxin G1 C17H12O7 328,0583 803 329, 392, 351 327 (VPO) 200, 220(90), 
232sh,264(40),336sh, 368(70)
Aflatoxin M1 C17H12O7 328,0583 779 329, 392, 367, 351, 346, 301, 273 327 204(100), 228(90), 264(52), 330sh, 
360(81)
Aflatoxin G2 C17H14O7 330,0740 788 331, 394, 353, 329 (VPO) 200, 216(95), 244sh, 264(40), 
372(85)
Aflatoxin M2 C17H14O7 330,0740 746 331, 348 329 , 315 End(98), 222(83), 265(53), 
360(100)
Auranthine C19H14N4O2 330,1117 820 372, 331, 348, 249 329, 276 (PO) 228(100), 268(23), 278sh, 312(10), 
322sh
Sulochrin C17H16O7 332,0896 882 333, 209, 301, 396, 237, 227, 151 331, 299, 377, 399, 181, 19, 167 208(100), 216(85), 284(40), 320sh
Byssochlamic acid C18H20O6 332,1260 1155 No ionization 331, 287, 259, 215, 207, 243, 187 
(PO)
204(100), 352(58)
Trichothecin C19H24O5 332,1624 1166 333, 374, 247, 229, 211 No ionization 216
Rugulosuvine C20H19N3O2 333,1477 819 334, 364, 375, 378, 332, 362, 408 224(100), 280(18)
Penicillin G C16H18N2O4S 334,0987 845 335, 352, 398, 160, 176, 217, 239, 307 333, 379, 401, 192, 289 End(100), 206sh(75)
Mitomycin C C15H18N4O5 334,1277 675 335, 242, 274, 357, 398 333 216(100), 242sh, 360(100)
Altersolanol A C16H16O8 336,0845 703 337, 319, 301, 273, 259, 245 335 220(100), 268(41), 430(12)
Bostrycin C16H16O8 336,0845 714 337, 400, 319, 301, 273, 259 335 (VPO) 228(100), 304(30), 482sh, 540(26), 
536sh
Cyclopiazonic acid C20H20N2O3 336,1474 1123 337, 182, 196, 400 335, 180, 140 224(100), 280(51) 
Versicolorin A C18H10O7 338,0427 1030 No ionization **** No ionization**** 222(100), 255(48), 290(84), 
454(26)
O-Methylsterigmatocystin C19H14O6 338,0790 934 339, 402, 324, 311, 306 355, 341, 369, 313, 327, 285, 271 204(85), 240(100), 312(50)
15-Acetyldeoxynivalenol C17H22O7 338,1366 726 339, 321, 356, 279, 297, 402, 386, 231, 203, 261, 380 (PO) 383, 373 220
3-Acetyldeoxynivalenol C17H22O7 338,1366 726 339, 321, 356, 279, 297, 402, 386, 231, 203, 261, 380 (PO) 383, 373 220
Aphidicolin C20H34O4 338,2457 837 *362, 344, 380, 285, 303, 267 383 (PO) End
Anacine C18H22N4O3 342,1692 786 343, 326, 198, 365, 281, 406 341, 387, 270, 212, 228, 255 202(95), 228(100), 272(29), 
308(12), 316sh
Violacein C20H13N3O3 343,0957 893 No ionization 342  (PO) 212(100), 260(52), 374(19), 
576(62)
Tensidol B C18H17NO6 343,1056 889 344, 230, 361, 407, 326 342, 228 212(100), 248(sh)
Usnic acid C18H16O7 344,0896 1345 345, 327, 303, 330, 261, 233 (PO) 343, 328, 709 232(100), 280(72), 260sh
Trypacidin C18H16O7 344,0896 934 345, 301, 313, 363, 408 345, 391, 359, 181, 313, 285 208(100), 288(55), 328sh
Gibberellic acid C19H22O6 346,1416 724 329, 388, 370, 347 (PO) 345, 391, 257, 239, 221 End
Asterric acid C17H16O8 348,0845 936 331, 349, 371, 299,287, 272 347, 393, 369, 303, 271, 256, 166, 
149
212(100), 252(30), 316(16)
Glauconic acid C18H20O7 348,1209 1030 349, 331 393, 303, 365, 347, 259 212(100), 232(88)
Clerocidin C20H28O5 348,1937 972 390, 349, 331 (VPO) 411, 347, 439 (PO) 236
pre-Paraherquamide C22H27N3O 349,2154 733 350, 322 394, 384, 358, 226(100), 282(20)
VM-55599 C22H27N3O 349,2154 727 350, 391, 322, 334 394, 384, 348, 332, 226(100), 282(18)
Penicillin V C16H18N2O5S 350,0936 880 368, 351, 160, 414, 201, 255, 233, 323 208, 349, 305, 699, 721 End(100), 210s, 268(4), 276sh
1-Hydroxybyssochlamic acid C17H18O8 350,1002 1164 368 (PO) 349, 305, 261, 217, 233 204(100), 252(58)
Cycloechinulin C20H21N3O3 351,1583 826 352, 393, 296, 188 350, 396, 335 218(100), 235(94), 268(60), 
304(72), 378(66)
Tryprostatin B C21H25N3O2 351,1947 910 352, 296, 284, 198 350, 396 (PO) End(100), 228(90), 282(22)
Griseofulvin C17H17ClO6 352,0714 934 353, 394, 319, 285, 215, 165 397, 387 VPO 212(98), 237(88), 251sh, 292(100), 
325(24)
Altertoxin I C20H16O6 352,0947 856 317, 353 (VPO) 351, 297, 263, 315, 333 (PO) 216(74), 260(100), 284(42), 
356(14)
Rubropunctamine C21H23NO4 353,1627 986 354, 376, 310, 417 352, 337, 308, 294, 253 262(70), 306(100), 416(88), 
524(96)
5-Methoxysterigmatocystin C19H14O7 354,0740 1025 355, 418, 340 No ionization 204(90), 235sh, 248(100), 275sh 
(30), 330(48)
3-hydroxy terphenylin C20H18O6 354,1103 837 355, 323, 305, 416 353, 323, 338, 399 210(100), 227sh, 276(46)
Viridiol C20H18O6 354,1103 792 355, 306, 322, 309, 281 399, 353, 279 End(62), 253(100), 320(46)
Fusarenon X C17H22O8 354,1315 693 355, 372, 418 (PO) 399 220
Rubropunctatine C21H22O5 354,1467 1255 355, 377, 414, 311, 257, 293, 241, 213 353, 327 End(100), 220(58), 244sh, 
292(28), 474(95)
Bis-dethio-bis(methylthio)-
gliotoxin
C15H20N2O4S2 356,0864 821 309, 357, 243, 420, 215, 233, 243, 251 No ionization End(100), 268(20)
Tensidol C C19H19NO6 357,1212 1035 358, 230 356, 228 212(100), 248(sh)
Monascine C21H26O5 358,1780 1249 359, 422, 261, 243, 215, 287 357, 329, 313 236(95), 296(8), 396(100)
Circumdatin-B C20H17N3O4 363,1219 859 364, 405, 427 362, 408, 347, 319, 293 End(85), 248(100), 280(28), 
340(12)
Austamide C21H21N3O3 363,1583 840 364, 427, 308, 252, 198 408, 398, 362, 430 232(100), 264sh(45), 396(8)
Monorden C18H17ClO6 364,0714 879 365, 347, 321, 303, 277, 382, 406 363, 275, 283, 319, 335, 204(100), 276(46); EtOH-HCl: 
(265, 17700)
Atpenin A5 C15H21Cl2NO5 365,0797 1156 366, 276, 348 364,328, 292, 277, 262, 313 End(100), 238(61), 272(42), 
338(58)
Brevianamide B C21H23N3O3 365,1739 822 366, 383, 429, 407, 731, 748, 383 410, 364, 400, 364, 296, 165 236(100), 258sh, 408(12) 
Brevianamide A C21H23N3O3 365,1739 822 366, 407, 338, 321, 348, 235, 310, 276 410, 364, 296 (PO) 232broad(100), 262sh, 408(13)
Candidusin C C21H18O6 366,1103 1005 367, 351, 335, 304, 411, 397, 280, 365, 349 218(100), 242sh, 282(53), 296(50), 
334(71)
Glauconic acid, open form C18H22O8 366,1315 868 367, 349 365 232 (100)
4,15-Diacetoxyscirpenol C19H26O7 366,1679 822 384, 430, 389, 307, 247, 229, 199, 211, 183, 171 No ionization End
Ferulenol C24H30O3 366,2195 1482 367, 389, 216, 243, 231, 257, 299, 311, 285, 408 365, 228 204(100), 274(28), 284(30), 
310(28), 220sh
Fumigaclavine C C23H30N2O2 366,2307 773 367 365, 214 (PO) 226(100), 280(19)
Ophiobolin G C25H34O2 366,2559 1467 430, 367, 408, 384, 349, 307, 293, 201 No ionization 236
Brevicompanine B C22H29N3O2 367,2260 1035 368, 300, 312, 341, 198, 130 412, 366 (PO) 208(100), 244(19), 300(8)
Averufin C20H16O7 368,0896 1312 No ionization 367 224(95), 292(100), 268(55), 254sh, 
322(24), 456(32)
Ochratoxin B C20H19NO6 369,1212 944 370, 324, 233, 205, 268 368, 324, 390, 280, 220 216(100), 248sh, 320(20) 
Norsolorinic acid C20H18O7 370,1053 1500 No ionization 369 236(100), 270sh, 284sh, 310(90), 
466(40)
Austocystin A C19H13ClO6 372,0401 1169 373, 436 371 248(100), 290sh, 304(30), 340(14)
Alantrypinone C21H16N4O3 372,1222 766 373, 228, 200, 436 371, 439, 226, 328, 313, 300, 212(100), 226(89), 258(27), 
267(28), 278(22), 305(12), 317sh
Equisetin C22H31NO4 373,2253 1360 374, 356, 346, 175, 188, 200, 294, 306 372, 342, 298 End(100), 236(38), 296(63)
Isomarticin C18H16O9 376,0794 878 377, 359, 313, 287 375, 443, 331, 301, 274, 313, 287, 
259
228(100), 304(30), 472sh, 500(27), 
532sh
Marticin C18H16O9 376,0794 900 377, 359 (PO) 375, 397, 331, 274, 443, 465 228(100), 304(33), 480sh, 500(29), 
532sh
Verrucine A C21H20N4O3 376,1535 774 377, 360, 332, 399, 440 375, 421, 284, 304 End(100), 230(79), 276(25), 
308(10), 316sh
Dithiosilvatin C18H22N2O3S2 378,1072 1072 379, 396, 401, 311, 251, 319, 220 377, 413, 345 End(100), 228(38), 272(22)
Hypothemycin C19H22O8 378,1315 888 379, 361, 235, 253, 343, 207, 217, 401  377, 251, 413, 179, 163, 189, 207, 
136
220 (100), 268(40), 308(19) 
Fumitremorgin C; SM-Q C22H25N3O3 379,1896 919 380, 324, 226, 412 378, 424, 803, 410, 458, 474 End(100), 224(95), 258sh, 
272(22), 296(30)
Rotiorin C23H24O5 380,1618 1371 337, 381, 444, 403 No ionization End(55), 242(49), 285(32), 
312(32), 404sh, 444sh, 47690), 
502(100), 538sh
Benzomalvin D C24H19N3O2 381,1477 1013 382, 423, 445, 249 No ionization 215(100), 232(100), 270(22), 
282sh, 312(12), 324sh
Benzomalvin A C24H19N3O2 381,1477 1078 382, 423, 351, 445, 323, 249 No ionization 215(100), 232(100), 270(22), 
282sh, 312(12), 324sh
Monascorubramine C23H27NO4 381,1940 1133 382, 445, 404, 338, 256 380, 365 262(70), 304(100), 416(88), 
528(96)
Mitorubrin C21H18O7 382,1053 1032 383, 296, 233, 215, 151 381, 399, 363, 337, 149, 123, 231, 
249, 269
216(88), 268(100), 294sh, 350(88), 
361sh
Neosolaniol C19H26O8 382,1628 703 400, 405, 365, 446, 365, 335, 305, 275, 257, 245, 215 427, 417 (PO) End 
Monascorubrin C23H26O5 382,1780 1422 383, 446, 405, 421, 339, 321 381, 337 222(30), 252(40), 290(35), 
472(100)
T-2 Triol C20H30O7 382,1992 812 383, 233, 215, 400, 281, 322 427, 417 End
Nidurufin C20H16O8 384,0840 939 385, 367 (Very poor ioonization) 383 200(100), 224(60), 294(88), 
456(30)
Stachybotrylactam C23H31NO4 385,2253 992 386, 427, 449 384, 430 220(100), 266(20), 304(12)
Pitholide B C22H26O6 386,1729 1142 387, 450, 425, 409 385 260
Ankaflavin C23H30O5 386,2093 1407 387, 450, 409, 315 385 394
Atranone E C24H34O4 386,2457 1129 387, 828 431, 421(PO) End(100), 236(79)
Cholesterol C27H46O 386,3549 2320 369 (VPO) 309, 377, 485  (VPO) End
PF-1 C22H23N5O2 389,1852 900 390, 322 388 208(100), 228(60), 308(86)
PF-3 C22H23N5O2 389,1852 900 390, 322 388 208(100), 228(60), 308(86)
Roquefortine C C22H23N5O2 389,1852 801 390, 322, 193 388, 434, 190 204(100), 236(43), 304(79) 
Sclerotiorin C21H23ClO5 390,1228 1416 303, 349, 391 No ionization End(40), 220sh, 288(23), 298sh 
260(100), 368(100), 392sh, 416sh, 
446sh, 480sh
Compactin C23H34O5 390,2406 1174 408, 391, 454, 413, 271, 185, 159, 229, 211, 253 435, 389 (PO) 228sh, 236(100), 242sh
Vermiculin C20H24O8 392,1471 812 410, 393, 375 391, 195, 437, 427 224 nm 
Asperloxin A C21H19N3O5 393,1325 878 394, 435, 457, 379 392 (VPO) 208(100), 240(49), 260(13)
Circumdatin-A C21H19N3O5 393,1325 897 394, 435, 457 392, 438, 377, 349 204(100), 236(53), 290sh, 356(16)
Ergocalciferol C28H44O 396,3392 23 397, 379 No ionization 214(100), 268(100)
Ergosterol C28H44O 396,3392 2136 395, 377, 379, 481 (VPO) 495  (VPO) End(100), 272(100), 284(100), 
290sh
Mitorubrinol C21H18O8 398,1002 862 399, 249, 151, 192, 231, 312 397, 415, 353, 229, 149, 167 212(94), 268(100), 294sh, 352(88), 
363sh
Harzianum A C23H28O6 400,1886 1044 401, 277, 233, 215, 210, 151, 399, 445, 467 202(40), 306(100)
Mycelianamide C22H28N2O5 400,1998 1146 401, 442, 265, 383 399, 200, 131 End(100), 232(32), 320(78)
Ophiobolin A C25H36O4 400,2614 1128 401, 365, 383, 464, 347, 283, 239 399 (VPO) End(60), 242(100)
Entonaemin A C21H22O8 402,1315 826 403, 466, 235, 253, 151, 316 401, 357, 233, 167, 149 (PO) 218(100), 264(47), 302(20), 
390(49)
Citreoviridin C23H30O6 402,2042 971 403, 425, 461, 441, 315, 285 447 (VPO) 204(30), 236(20), 296(50), 
388(100)
Desacetyl-fusaproliferin C25H38O4 402,2770 1044 385, 403, 466 No ionization End(100), 266(70)
Citreoviridin C23H30O6 402,2042 968 403, 315,425, 461, 420, 297, 285 447 (VPO) 204(30), 236(20), 296(50), 
388(100)
Ophiobolin B C25H38O4 402,2770 1115 403, 385, 367, 466, 349, 293 401 (VPO) End(60), 242(100)
Ochratoxin A C20H18ClNO6 403,0823 1025 404, 358, 257 402, 358, 424, 211, 254, 314 216(100), 250sh, 332(20) 
Ascochlorin C23H29ClO4 404,1754 1382 405, 387, 199, 240, 281, 403 242(100), 294(40), 240(18)
Scytalidic acid C22H28O7 404,1835 1299 387, 405, 428, 446, 465, 528 403, 359 212(100), 250(66)
Mevinolin-open lactone form C24H36O5 404,2563 1233 422, 405, 427, 443, 468, 303, 285, 199, 225, 267, 173, 249 449 (PO) 238(100), 246sh(70)
16-epi-hydroxy-roquefortine C C22H23N5O3 405,1801 795 406, 338, 320, 388 404, 540, 440, 386, 317 End(100), 246(14), 312(68)
16-hydroxy roquefortine C C22H23N5O3 405,1801 777 406, 338, 320, 388, 428 404, 440, 450, 472, 386, 317, 206, 
335
End(100), 246(14), 312(68)
Emindole DA C28H39NO 405,3032 1513 406, 438, 447, 388, 259, 171, 130 404, 434, 436, 450 End(100), 224(96), 284(18), 290sh
Nominine C28H39NO 405,3032 1601 388, 406, 271, 332, 447, 450, 434, 404, End(100), 224(94), 284(18), 291sh
Shamixanthone C25H26O5 406,1775 1844 389, 323, 470, No ionization End(100), 244(61), 276(82), 
304(22), 396(20)
3,4,15-Triacetoxyscirpenol C21H28O8 408,1784 954 426, 431, 472, 349, 307, 289, 247, 229 No ionization End
Variecoxanthone B C25H28O5 408,1931 1832 391, 323, 472, 409 No ionization End(100), 244(61), 276(82), 
304(22), 396(20)
Verrucofortine C24H31N3O3 409,2365 1007 410, 300, 304, 532 No ionization 208(100), 230(75), 264(30), 
334(48)
Verrucosine C24H31N3O3 409,2365 1012 410, 473, 342, 300, 841 408, 454, 351 204(100), 248(31), 275sh
Desertorin A C22H18O8 410,1002 876 411, 452 409 205(100), 210sh, 243sh, 297sh, 
304(52), 308sh
Orlandin C22H18O8 410,1002 839 411, 433, 474, 409, 477 212(100), 235(sh), 295(sh), 
308(45), 325(sh)
Mitorubrinic acid C21H16O9 412,0794 878 151, 192, 247, 263, 413 261, 205, 367, 411, 433 212(78), 272(100), 296sh, 448(65), 
362sh, 393sh, 418sh, 448sh
Fucosterol C29H48O 412,3705 2354 395, 454 (VPO) 235 (VPO) End
AK Toxin I C23H27NO6 413,1838 940 414, 436, 204, 222, 245, 263, 176, 134 412, 458, 480, 220, 202, 178 Edn(80), 216sh, 294(100)
TAN-1612 C21H18O9 414,0945 987 415, 397, 369, 415 (PO) 413, 435, 369, 285 230(64), 276(100), 322(24), 328sh, 
408(37)
Tentoxin C22H30N4O4 414,2267 888 415, 437, 302, 358, 312, 199, 171, 217 459, 413, 271, 369, 141, 214, 246 End(100), 218(55), 280(78)
Nimbosterol C29H50O 414,3862 2454 383, 413, 431, 442, 454 (VPO) No ionization End
Cephalosporin C C16H21N3O8S 415,1049 675 416, 438, 356, 312 414, 370, 354, 436 End
Cylindrospermopsin C15H21N5O7S 415,1162 700 416, 457, 414, 436 End
Elymoclavine-O-β-D-
fructofuranoside
C22H28N2O6 416,1947 662 417, 255, 237 461, 415 224(100), 282(21)
Atranone A C24H32O6 416,2199 1012 458, 417, 399, 381, 355, 251, 233, 355 461, 415, 371, 327, 269, 285 End(100), 224sh(65)
Asteltoxin C23H30O7 418,1992 902 419, 441, 259, 231, 277, 299 417, 463, 208 272(90), 368(100)
Citreoviridin C23H30O7 418,1992 939 275, 419, 441, 693, 837, 859 463, 453 216(25), 272(81), 372(100) 
13-Dehydroxypaxilline C27H33NO3 419,2460 1360 420, 402, 362, 330 418, 464, 360, 234(100), 250sh, 284(23)
Epicorazine A C18H16N2O6S2 420,0450 764 485, 421 483, 417, 529 End(100), 228sh(50)
Trichoverrol A C23H32O7 420,2148 813 438, 443, 421, 403, 459, 249, 290, 231, 213 465, 474, 489 (PO) 200(50), 264(100)
Trichoverrol B C23H32O7 420,2148 803 438, 443, 421, 403, 459, 249, 290, 231, 213 465, 474, 489 (PO) 200(50), 264(100)
Emindole DB C28H39NO2 421,2981 1503 404, 422, 454, 463, 130, 171 420, 450, 452, 466 End(100), 224(96), 284(18), 290sh
Paspaline C28H39NO2 421,2981 1617 422, 404, 275, 454, 438 420, 452, 144 (VPO) 207sh(48), 232(100), 280(29)
Mevinolin-open lactone form C24H38O6 422,2668 1129 405, 445, 423, 321, 303, 285, 267, 199, 173 421, 467, 489, 319 238(100), 246sh(70)
Demethylkotanin C23H20O8 424,1158 915 425, 447 423 210(100), 235(sh), 295(sh), 
308(45), 325(sh)
Desertorin B C23H20O8 424,1158 955 425, 488 423, 491 205(100), 210sh, 243sh, 297sh, 
304(52), 308sh
HT-2 toxin C22H32O8 424,2097 878 425, 442, 447, 463, 263, 245, 215 469, 459 End
Lanosterol C30H50O 426,3862 2354 409, 441, 468 (PO) No ionization End
Wortmannin C23H24O8 428,1471 750 429, 387, 446, 313, 369, 355, 295, 255 427, 399, 459, 417, 341, 385, 369, 
356 (VPO)
End(100), 260(50), 296(32)
Insulicolide A C22H25NO8 431,1580 919 414, 432, 449, 306  (VPO) 476, 166, 430, 412, 368 End(100), 212sh(75), 260(65)
Insulicolide B C22H25NO8 431,1580 871 432, 449, 495, 414, 288, 247, 299, 217 476, 430, 466, 412, 166 End(100), 212sh(75), 260(65)
Pseurotin A C22H25NO8 431,1580 817 334, 348, 432, 454, 495, 470, 316, 273 430, 270, 308, 354, 386, 476, 498 End(100), 258(69), 285sh
Fusarin C C23H29NO7 431,1944 990 414, 432, 449, 384, 396, 454, 364 430, 476 258sh, 366(100)
6-epi-Stephacidin A C26H29N3O3 431,2209 970 432, 219, 473, 387 No ionization End(83), 210sh, 246(100), 
310(22), 334sh
Stephacidin A C26H29N3O3 431,2209 973 432, 219, 260, 473 430, 448, 390, 476 End(84), 208sh, 256(100), 
310(30), 232sh
Chaetoviridin A C23H25ClO6 432,1334 1271 433, 333, 389, 455, 417, 496 431, 387, 351 220(64), 310(100), 366(72), 424sh
Psychrophilin A C23H20N4O5 432,1434 1052 450, 496. 433, 471, 304, 243, 130, 386 431, 384, 302, 255, 211 End(100), 250(30), 302 (13)
Atranone F C24H32O7 432,2148 1052 433, 474, 373, 355, 337, 327, 309 477, 467, 417, 371, 413, 389, 353, 
327
End(100), 232sh(50)
Meleagrine C23H23N5O4 433,1750 767 434, 403, 334, 318, 289 432, 363, 332 End(100), 228(71), 284sh, 328(72)
Paspalinine C27H31NO4 433,2253 1268 434, 376, 416, 466, 450 478, 432, 468, 374 End(60), 232(100), 273(27)
Notoamide E C26H31N3O3 433,2365 1031 432, 378, 366, 280, 497, 212, 497 432, 478, 496, 468, 392, 153, 278, 
240, 296
End(86), 214(78), 244(100), 
310(29), 334sh
Chaetoviridin C C23H27ClO6 434,1490 1160 417, 435, 498, 389, 433, 497 224(86), 294(54), 302sh, 288(100), 
404(98), 426sh
Paxilline C27H33NO4 435,2410 1227 436, 418, 400, 480, 434, 470, 376, 358, 330, 304 234(100), 282(20)
HC Toxin I C21H32N4O6 436,2322 750 459, 437, 475, 497, 482, 409, 240 435 (PO) End very poor UV sensitivity
16-Deoxopaxillin-16 -ol C27H35NO4 437,2566 1069 420, 402, 438, 501, 470, 476, 420, 384, 478, 472, 436 End(80), 232(100), 284(28)
α-Paxitriol C27H35NO4 437,2566 1116 438, 437, 470, 402, 420, 362, 344 478, 472, 436 230(100), 280(25)
20,25-Dihydroxyaflavinine C28H39NO3 437,2930 983 420, 402, 438, 303, 285 436 End(91), 224(100), 284(19)
Desertorin C C24H22O8 438,1315 1023 439, 480, 502 423, 355 (VPO) 205(100), 210sh, 243sh, 297sh, 
304(52), 308sh
Kotanin C24H22O8 438,1315 1012 439, 461, 477 No ionization 208(100), 235sh, 296sh, 308(47), 
316sh
Mitorubrinol acetate C23H20O9 440,1107 976 441, 291, 151, 192, 504 439, 395 216(90), 266(100), 294sh, 348(88)
Nidulin C20H17Cl3O5 442,0142 1456 443, 407, 387, 484 441 204(100), 223sh(90), 268(18)
Hypomiltin C23H22O9 442,1264 980 443, 460, 151, 192, 291, 401, 149, 167, 291 End(100), 210(92), 274(71), 
310(88)
Andrastin E C26H34O6 442,2355 1014 443, 506, 411, 383 441 End(100), 262(72)
Rugulosuvine B C27H29N3O3 443,2209 1027 444, 485, 376 442, 488, 351 200(100), 248(32), 260sh
Rubiginosin C23H24O9 444,1420 847 445, 277, 295, 235, 217, 151 443, 167, 233, 275, 123, 149, 247 220(100), 265(40), 302(18), 
388(40)
Fusaproliferin C27H40O5 444,2876 1181 427, 445, 462, 508 No ionization End(100), 264(58)
Dystanine C30H52O2 444,3967 2324 440, 381, 255 (VPO) 497,  526 (VPO) End
Alternarolide I C23H31N3O6 445,2213 910 463, 446, 468, 258, 161, 418 490, 444, 558, 400, 304 End(100), 222(54), 245sh, 275sh
Dihydrofructigenine A C27H31N3O3 445,2365 1053 446, 376, 334, 568, 487, 509 444, 490 204(100), 248(30), 280sh
Atranone B C25H34O7 446,2305 1078 447 445, 491 End(100), 230sh(65)
Oxaline C24H25N5O4 447,1907 786 448, 417, 348, 332, 386, 402, 305 446, 384, 362, 346, 330, 318 End(100), 228(70), 284sh, 328(72)
Notoamide B C26H29N3O4 447,2158 951 489, 448, 895, 466, 420 446, 464, 406 End(90), 248(100), 274sh, 314sh
Versicolamide B C26H29N3O4 447,2158 911 448, 895 446, 464, 406, 478 End(87), 248(100), 274sh, 316(4)
Marcfortine C C27H33N3O3 447,2522 771 448, 466, 420, 895, 489, 446, 464, 406 End(58), 248(100), 275sh, 318(4)
Psychrophilin D C24H24N4O5 448,1747 1106 466, 449, 249, 320, 290 447, 318, 271 End(200), 216(86), 244(70), 
304(23)
Atranone H C24H32O8 448,2097 1015 403, 431, 449, 490 447, 493 End
S14-95 C28H34O5 450,2406 1472 451, 242, 391, 201, 191 No ionization 204(100), 240(61), 324(50)
Cytochalasin J C28H37NO4 451,2723 580 452, 434, 416, 398, 475, 392 496, 486, 450, 432, 340 End
Dehydroaustinol C25H28O8 456,1779 962 498, 457 501, 455 End(100), 248(54)
Communesin A C28H32N4O2 456,2525 1072 457, 479, 385 *501, 491, 485, 469, 399 204(100), 250(18), 268(20)
DON-3-glucoside C21H30O11 458,1788 681 476, 481, 297 (PO) 503, 427, 457, 409 220
Austinol C25H30O8 458,1935 939 500, 459 503, 457 End(100), 248(54)
trans-Fumagillin C26H34O7 458,2305 1109 476, 459, 427, 522, 409, 177, 215, 233 503, 457, 525, 413 End(85), 232(100)
Aurovertin B C25H32O8 460,2097 1054 461, 261, 502, 478, 502, 183, 141, 231 505, 145  (PO) 274(98), 368(100)
Lumpidin C26H28N4O4 460,2111 880 461, 443, 239 459, 505, End(100), 250, 285sh
Echinulin C29H39N3O2 461,3042 1307 462, 479, 484, 406, 338, 525, 394, 326, 266, 334 383, 460, 423 End(98), 232(100), 280(24)
AM Toxin I- open lacone form C23H33N3O7 463,2319 897 464, 306, 486, 375, 278 462 End(100), 222(52), 250sh, 274sh
Iso-T-2 Toxin C24H34O9 466,2203 1005 484, 467, 489, 530, 215, 245, 227, 287, 305, 387 511, 501 (PO End
T-2 toxin C24H34O9 466,2203 980 484, 530, 489, 335, 215, 245, 305, 346, 368, 387 511, 501 (PO) End
Penigequinolone A C27H33NO6 467,2308 1167 450, 418, 468, 436, 310, 296, 278 466 End(199), 222&63), 230sh, 
280(33), 288sh, 326(32)
Nebramycin 6 C18H37N5O9 467,2591 670 468 No ionization Not deteceted
Communesine G C29H34N4O2 470,2682 922 471, 493, 399, 501 No ionization End(100), 272(7)
1'-O-Acetylpaxilline C29H35NO5 477,2515 1353 478, 477, 418, 462, 477, 400, 510,  346, 476, 522, 416, 234(100), 284(20)
Cytochalasin A C29H35NO5 477,2515 1085 478, 460, 442, 500, 541, 414, 394 476, 522, 458, 432 (PO) End, 230sh
Fumitremorgin B C27H33N3O5 479,2420 1158 462, 543, 507, 480, 512, 281, 394, 406 478 VPO End(100), 228(94), 278(18), 
296(21)
Cytochalasin B C29H37NO5 479,2672 945 480, 462, 444, 426, 416, 543 524, 478, 514, 460, 500 End
Distamycin A C22H27N9O4 481,2186 680 482, 291, 395, 273, 247 480 200(75), 236(80), 308(100);  HCl: 
(235, 470) (302, 565)
Dihydrocytohalasin B gamma 
lactone
C29H39NO5 481,2828 1014 482, 446, 464, 504, 428, 410, 520 526, 480, 516, 462, 280, 214, 378 End
Verrucarin J C27H32O8 484,2097 1162 502, 485, 507, 523, 231, 249, 213 501, 483, 529 (VPO) 220(100), 264(71)
Kanamycin C18H36N4O11 484,2381 670 485 No ionization Not detected
Dimerum acid C22H36N4O8 484,2533 673 485, 507 483 End
Ferri-dimerum acid C22H34FeN4O8 484,2533 672 538, 579 536 Not detecetd
Communesine H C30H36N4O2 484,2838 991 485, 515, 413, 507 No ionization End(100), 272(7)
Staplabin C28H39NO6 485,2777 1118 486, 468, 508 530, 484, 552, 530, 542 216(100), 256(21), 302(6)
Andrastin A C28H38O7 486,2618 1105 487, 427, 509, 409, 395, 377, 367 485, 453, 425 End(100), 262(53)
Pyrrocidine A C31H37NO4 487,2723 1597 488, 283, 470, 434 486, 532 End(100), 236sh, 276(3)
Terretonin C26H32O9 488,2046 994 489, 506, 471, 453 487, 255, 427, 533, 523 End(78), 280(100)
Pyrrocidine B C31H39NO4 489,2879 1423 490, 283, 472, 255 488, 534, 502 End(100), 232(21), 276(3)
Paraherquamide A C28H35N3O5 493,2577 762 494, 476, 466, 419, 352 492 228(100), 256sh, 278sh
Paspalin P1 C30H39NO5 493,2828 946 434, 476, 494, 416, 398, 557, 392 540, 538, 598 (VPO) End
Cytochalasin E C28H33NO7 495,2257 1019 513, 518, 496, 434, 534, 550, 478, 416, 336, 204, 258, 540, 494, 432, 450, 414, 360, 282, 
269 (PO)
End
Aflatrem C32H39NO4 501,2879 1498 502, 444, 198 546, 400, 442 (PO) 232(100), 284(30)
Verrucarin A C27H34O9 502,2203 975 503, 520, 525, 457, 249, 231, 290, 555, 566 547, 537, 501, 455, 389 (VPO) 260
Tryptoquialanine B C26H24N4O7 504,1645 994 505, 487, 443, 568, 543, 383, 233, 183 549, 539, 503, 443, 461, 425, 145, 
189, 225
208(100), 234(74)
AAL Toxin TB1 C25H47NO9 505,3251 804 506, 528, 488, 312, 330, 294 504, 526 Cannot be detected using UV
Asperphenamate C32H30N2O4 506,2206 1202 507, 529, 256, 238, 224 551, 268, 505 End(100), 228sh
1,1-Bis(6,8-dimethyl-8,9-epoxy-
5a,10e)ergoline
C32H34N4O2 506,2682 698 507, 254, 274, 295 No ionization 222(100), 274(33), 283sh, 295sh
Cytochalasin C C30H37NO6 507,2621 1014 525, 508, 490, 430, 412, 265 552, 506 (PO) End
Cytochalasin D C30H37NO6 507,2621 947 525, 430, 490, 530, 508, 546, 412, 402, 384, 374 No ionization End
Acetyl T-2 toxin C26H36O10 508,2308 1118 531, 547, 572, 526, 197, 287 No ionization End
Communesin B C32H36N4O2 508,2838 1060 509, 531, 437, 451 553 (VPO) 204(100), 272(90)
Territrem A C28H30O9 510,1890 1058 511, 593, 533 509, 395 (PO) 220(100), 340(48)
Alteramide A C29H38N2O6 510,2730 1065 511 509, 511  PO End
Verruculogen C27H33N3O7 511,2319 1086 494, 575, 512, 410, 392, 352, 338, 510, 556, 426, 306, 350, 157  (PO) 230(100), 276(38), 300(34)
Verrucarin H C29H36O8 512,2410 1247 530, 513, 535, 576, 551, 231, 249, 359 No ionization 226(100), 262(70)
Roridin E C29H38O8 514,2567 1120 532,  537, 515, 553, 361, 231, 249, 267 515, 559, 549 (PO) 224(100), 264(80)
Malformin A2 C22H37N5O5S2 515,2236 905 533, 538 514 (PO) End
Fusidic acid C31H48O6 516,3451 1224 457, 439, 421, 534, 580, 520 515, 561, 455, 393, 221, 473, 411 End(100), 220sh(65)
Bisdethiodi(methylthio)acetylapo
aranotin
C24H26N2O7S2 518,1181 1307 536, 541, 411, 303, 363, 381, 471 No ionization End(100), 268(28)
Rubratoxin B C26H30O11 518,1788 1013 536, 519, 501, 560, 582, 483 517, 403, 563, 473, 553, 535, 631, 
359, 243
204(100), 252(32)
Tryptoquialanine A C27H26N4O7 518,1801 1041 519, 457, 501, 582, 557, 397, 197, 213 563, 553, 517, 475, 401, 431, 457 214(100), 228(98), 280sh, 36sh
Rubratoxin A C26H32O11 520,1945 875 538, 521, 485, 503, 389, 467 519, 555, 405, 475, 361, 457, 541, 
317
204(100), 254sh(15)
AAL-Toxin TA C25H47NO10 521,3200 767 522, 544, 346, 322, 310, 292 520 ND
1-Oleoyl-sn-glycero-3-
phosphocholine 
C26H52NO7P 521,3481 1234 522, 544 566, 506 Not detected
19,20-Epoxycytochalasin C C30H37NO7 523,2570 966 524, 541, 464, 446, 428, 404, 386 568, 554, 522, 462 End
19,20-Epoxycytochalasin D C30H37NO7 523,2570 900 524, 541, 464, 428, 446, 404, 386 568, 558, 522 End
Territrem B C29H34O9 526,2203 1036 527, 509, 549 411, 525, 571, 491, 364 220(100), 332(48)
Hypocrellin B C30H24O9 528,1420 1262 529, 592, 315, 405, 471, 271 527, 513, 595, 244(100), 214sh, 262sh, 336(10), 
460(50), 548(25) 
Satratoxin H C29H36O9 528,2359 900 529, 546, 511, 592, 551, 511, 231, 249, 263 527, 573, 563, 483, 543 (PO) 200(85), 232(100), 265sh
Chaetoglobosin A C32H36N2O5 528,2624 1048 546, 529, 551, 511, 382, 400, 382, 457 573, 527, 563, 484, 509, 466 End(90), 220(100), 276(17)
Chaetoglobosin C C32H36N2O5 528,2624 1112 546, 529, 551, 567, 456, 259, 215, 346, 478 573, 527, 563, 509, 326, 380, 484, 
455
220(100), 252(25), 280sh,290sh
Malformin A1 C23H39N5O5S2 529,2393 960 547, 552, 530, 568, 593, 502, 485, 417, 441, 425 528 (PO) End, very poor sensitivity in UV
Malformin-C C23H39N5O5S2 529,2393 983 547, 530, 552, 568, 593, 502, 485, 417, 372 574, 528 End
Roridin L-2 C29H38O9 530,2516 882 548, 531, 513, 283, 249, 231 575, 529, 455, 419, 375 End(85), 260(100)
Stemphone C30H42O8 530,2880 1316 531, 513, 553, 594, 489, 471, 453, 429, 387, 529, 469, End(100), 268(50), 296(5)
Dethiosecoemestrin C27H20N2O10 532,1118 1515 406, 388, 438, 456, 479 434, 450, 468, 504 End(100), 224(91), 284(14)
Fumitremorgin D C28H28N4O7 532,1958 1072 515, 533, 471, 261, 183, 211, 411, 455 577, 531, 531 208(100), 228(90), 255sh, 274sh, 
308(8), 318sh
Roridin A C29H40O9 532,2672 965 550, 555, 403, 249, 231 577 (PO) 264
Trichoverrin A C29H40O9 532,2672 898 550, 533, 361, 515, 555, 231, 249, 571 577 (PO) 224(88), 260(100)
Trichoverrin B C29H40O9 532,2672 899 550, 555, 533, 571, 515, 361, 249, 231, 213 577 (PO) 224(88), 260(100)
Didethiobis(methylthio)acetyl-
aranotin
C24H26N2O8S2 534,1131 980 557, 552, 487, 397, 367, 319 No ionization End(100), 225(79), 258sh
Rubratoxin-B-open form C26H32O12 536,1894 884 554, 519, 537, 501, 483 535, 603, 491, 473, 403, 377, 447 208(100), 264sh
Cladofulvin C30H18O10 538,0900 1165 539 (VPO) 537, 605, 559 End(80), 232(95), 268(100), 
294sh, 448(44)
Skyrin C30H18O10 538,0900 1273 539, 521 (VPO) 537 224(100), 256(81), 296(52), 
456(40)
Rubratoxin A-open form C26H34O12 538,2050 792 556, 539, 521, 389, 485 537, 519, 559, 475, 361, 405, 431, 
317, 255
204(100), 254sh(15)
Rugulosin C30H22O10 542,1213 1077 543, 279, 273, 584 (PO) 541, 563, 269, 471 End(88), 252(100), 274sh, 
391(100)
Rubellin D C30H22O10 542,1213 995 560, 525, 566, 507, 457, 606, 479 (PO) 541, 587, 563, 577, 523, 378, 360 216(100), 236(95), 252sh, 300(23), 
498(27)
Isosatratoxin F C29H34O10 542,2152 946 560, 543, 606, 525, 231, 249 541, 577, 587, 511, 189, 219, 481, 
145, 391
200(100), 252(55)
Purpurugenone C29H20O11 544,1006 1109 545 (PO) 543, 611, 527, 285, 565, 525, 499, 
491, 581
222(100), 250(72), 276sh, 310(28), 
380(26), 496sh, 520(22), 556sh
Satratoxin G C29H36O10 544,2308 883 562, 545, 527, 608, 567, 231, 249 589, 499 200(100), 256(66)
Duclauxin C29H22O11 546,1162 1080 564, 588, 547, 515, 455, 259 (PO) 545, 613, 513, 471 204(64), 228(100), 264sh, 320(13), 
340sh
Ergosine C30H37N5O5 547,2795 771 548, 530, 268 546, 296 End(100), 224sh, 240sh, 320(26)
Ergosinine C30H37N5O5 547,2795 776 548, 530, 546, 296 End(100), 210sh, 242(52), 318(22)
Antimycin A1b C28H40N2O9 548,2734 1500 549, 571, 265, 237 547, 245, 263 228(100), 320(18)
Manzamine A C36H44N4O 548,3515 836 549, 531, 295, 275, 266, 286 593, 583, 547 216(100), 232sh, 260sh, 292(42), 
308(35), 354(21)
Dihydroergosine C30H39N5O5 549,2951 775 550, 532, 591, 270 548 224(100), 282(21)
Viomellein C30H24O11 560,1319 1135 529, 592 559, 627, 581, 527, 627 228(48), 275(100), 360(18), 
380(18), 415(17)
Ergocornine C31H39N5O5 561,2951 786 562 560, 310 End(100), 224sh, 240sh, 322(26)
Ergocorninine C31H39N5O5 561,2951 798 562, 544 560, 310 206(100), 224sh, 240(72), 318(26)
Viridicatumtoxin C30H31NO10 565,1948 1175 548, 438, 565, 566, 531, 478 564, 586, 546 240(70), 284(100), 
332(10),436(30) 
Helvolic acid C33H44O8 568,3036 1188 509, 586, 632, 572, 491, 463, 449, 439, 431, 403 567,  613, 507, 403, 525, 481, 463 End(100), 234(96)
Aurofusarin C30H18O12 570,0798 1037 571, 593 569, 615 End(82), 248(100), 272(77), 
380(20), 420(18)
Aurasperone A C32H26O10 570,1520 1245 571, 634, 569 238(25), 282(100), 330(sh), 
404(15)
Cyclochlorotine C24H31Cl2N5O7 571,1601 784 572, 554, 485, 443, 338, 251, 218 534, 606, 616, 570, 468, 281, 387, 
480, 498
End
SMTP-6 C34H40N2O6 572,2886 1205 573, 595, 527 617, 517, 607, 639, 216(100), 260(20), 
284sh,292sh,206sh
Xanthomegnin C30H22O12 574,1111 1020 No ionization 573, 595, 543, 527 232(100), 288(30), 403(20)
α -Ergocryptine C32H41N5O5 575,3108 807 576, 558, 268, 305, 348 324, 574 End(100), 220sh, 240sh, 324(24)
α-Ergocryptinine C32H41N5O5 575,3108 822 576, 558 574, 324 End(100), 210sh, 242(47), 318(23)
Destruxin A C29H47N5O7 577,3475 940 578, 600, 465, 437 576, 622, 612, 504, 191, 225, 173, 
353, 402, 424
End
Fumitremorgin A C32H41N3O7 579,2945 1355 494, 562, 580, 602, 643, 478, 352, 392, 410, 420 No ionization End(100), 228(94), 278(18), 
296(21)
Ergotaminine C33H35N5O5 581,2638 789 582 580, 330 End(100), 208sh, 240(46), 318(20)
Pyripyropene A C31H37NO10 583,2417 985 584, 625 No ionization 232(100), 264(25), 320(70) 
Dihydroergotamin C33H37N5O5 583,2795 791 584, 566, 270, 253, 322 582, 467, 423, 313, 538 End(100), 224(80), 228(17)
Janthitrem B C37H47NO5 585,3454 1075 586, 568, 510, 296 584, 630, 620, 676 End(80), 264(100), 332(60)
Baccatin III C31H38O11 586,2414 893 527, 587, 650 , 604, 509, 405, 345, 327, 527 631, 621, 585, 543 End(100), 234(38), 276(4), 284sh
Aurasperone E C32H28O11 588,1626 1100 589, 652, 453, 415 587, 655 238(30), 282(100), 330(sh), 
402(15)
Emestrin A C27H22N2O10S2 598,0716 956 599, 535, 517, 499, 489, 471, 245 597 End(100), 230sh, 260sh, 282sh
Penitremone A C37H45NO6 599,3247 1265 600, 514, 532, 582 558, 644 260(100), 286sh, 336sh
Aurasperone B C32H30O12 606,1732 1035 607, 589, 629, 670, 549, 645 605, 627, 573, 521 238(55), 282(100), 330(25), 
334(25), 408(15)
Ergocristinine C35H39N5O5 609,2951 720 610, 592, 305, 348, 223, 325, 268, 632, 648 608, 358 End(100), 210sh, 240(47), 318(20)
Lolitriol C37H49NO7 619,3509 1140  620, 510 618, 664, 654 End(38), 264(100), 288sh, 338sh
Apicidin C34H49N5O6 623,3683 1120 624, 641, 646 668, 622, 658, 462, 592 202(100), 224(92), 275sh, 292(13)
Rhizoxin C35H47NO9 625,3251 1115 626, 596, 648, 664, 232, 284 670, 660 (PO) 297(79), 312(100), 326(75)
Enniatin B2 C32H55N3O9 625,3938 1370 643, 648, 214, 196, 598, 513, 413 No ionization End
Cycloaspeptide D C35H41N5O6 627,3057 1035 628, 650, 233, 297, 352, 368, 438, 451 626 End(100), 220(61), 258(29), 
306(11)
Penitrem A C37H44ClNO6 633,2857 1261 634, 616, 558 632, 678 (PO) 236(100), 300(30) 
Secalonic acid D1 C32H30O14 638,1636 1088 639 637, 705 (PO) End(82), 216(62), 237(48), 
264(40), 337(100), 383sh
Secalonic acid D2 C32H30O14 638,1636 1164 656, 661, 639, 621, 579, 561 637, 705 (PO) End(82), 216(62), 237(48), 
264(40), 337(100), 383sh
Secalonic acid D3 C32H30O14 638,1636 1192 639, 661, 656, 677, 621, 579, 589, 561 637, 705 (PO) End(82), 216(62), 237(48), 
264(40), 337(100), 383sh
Enniatin B2 C33H57N3O9 639,4095 1418 657, 640, 662, 196, 527, 214, 427, 445 638, 610, 542, 425, 381 End
Enniatin-B1 C34H59N3O9 653,4251 1484 671, 654, 196, 210, 541, 627, 228, 441, 427 No ionization End
Viriditoxin C34H30O14 662,1636 1184 663 661 End(45), 224(40), 260(100), 
342sh, 376(23)
Enniatin A1 C35H61N3O9 667,4408 1547 685, 668, 690, 210, 541, 196, 228, 441, 555, 459 No ionization End
Neocoprogen II C27H41FeN6O11 681,2183 672 682, 704 680 Not detected
Enniatin A C36H63N3O9 681,4564 1611 699, 682, 704, 210, 555, 228, 455 No ionization End
Enniatin C C36H63N3O9 681,4564 1595 699, 682, 704, 210, 555, 228 No ionization End
Lolitrem B C42H55NO7 685,3979 1512 686, 620, 602, 584, 576 684, 730 End(38), 264(100), 288sh, 338sh
Fumonisin B4 C34H59NO13 689,3986 916 690, 712, 514, 496, 320, 338 688, 710 Not detected
Fumonisin B2 C34H59NO14 705,3936 880 706, 728, 688, 512, 336, 354 704 ND
Fumonisin B3 C34H59NO14 705,3936 857 706, 728, 788, 410, 334 704, 726, 750 Not detected
Chaetomin C31H30N6O6S4 710,1110 1050 711, 728, 647, 348, 298, 364 645, 709, 579 End(100), 218sh, 286sh(13)
Fumonisin B1 C34H59NO15 721,3885 826 722, 744, 704, 642, 546, 352, 528 720, 742, 764 ND
Fumonisin B6 C34H59NO15 721,3885 868 722, 546, 370, 352 720, 742 Not detected
Nigericin C40H68O11 724,4762 1924 742, 675 723 End
Neocoprogen I C31H47FeN6O12 751,2601 683 752 796, 750 Not detected
Ferrichrome C C28H44FeN9O12 754,2459 677 755, 772, 777 753, 799, 789 Not detected
Fusigen C33H51FeN6O12 779,2914 672 390.6 (db), 780, 802 PO End(100), 210(100), 250sh, 
430(14)
Beauvericin C45H57N3O9 783,4095 1521 801, 784, 806, 750, 685, 668, 244 782, 431 End(100), 210sh
Phalloidin C35H48N8O11S 788,3163 741 789, 753, 771, 725, 811 787. 833, 1577, 1623 End(100), 220(80), 292(30)
Cladochrome E C44H38O14 790,2262 1303 791, 813, 515, 854, 483, 637, 829, 669 789, 857, 811, 773 224(100), 268(50), 476(41), 
543(20), 584(20)
Coprogen C35H53FeN6O13 821,3020 686 822, 844 866, 820 Not detected
Rutilin A C44H40O16 824,2316 1188 825, 847, 675, 657, 507, 489 823, 655, 487, 167, 673 216(100), 268(73), 306(48), 415sh, 
464(56)
Triacetylfusarinine C C39H57N6O15 849,3898 777 906, 928 950, 904 End(100), 210(100), 250sh, 
450(12)
Taxol C47H51NO14 853,3310 1083 854, 776, 836, 876, 569, 551, 509, 387, 286, 268, 240 898, 888, 852, 792, 571, 525, 449, 
403
End(100), 232(43)
SMTP-7 C51H68N2O10 868,4874 1435 869, 891, 867, 935, 903, 841, 773 216(100), 260(22), 304(8)
SMTP-8 C52H70N2O10 882,5030 1485 884, 857, 789 881, 949, 787, 855 216(100), 256(20), 302(8)
Amphotericin B C47H73NO17 923,4879 874 924, 906, 743, 946, 761, 725, 707 922 (PO) 228(10), 340(25), 364(52), 
384(92), 408(100)
Aculeacin A C50H81N7O16 1035,5740 1119 1018, 1058, 1036, 1000, 874, 892, 762, 568 990, 1034, 946, 794, 300, 566, 
469, 539
End(100), 240sh, 276(4)
Valinomycin C54H90N6O18 1110,6312 2090 1128, 1149 1155, 1109, 1223, 956, 928, 757 End (Poor sensitivity in UV)
Cereulide C57H96N6O18 1152,6781 2172 1170, 1175 1151, 1187, 970, 984, 785 Not detected
Homocereulide C58H98N6O18 1166,6938 2269 1184,5 1165, 1201, 1228, 984, 970, 998 Not detected
Cyclosporin A C62H111N11O12 1201,8414 1400 1202, 1224, 1219 1246, 1200 End
Trichofumin-B C60H106N12O13 1202,8002 1300 1225.5, 1203.5, 989, 581, 623, 496, 409, 383 1201.6, 1247.6 End
Trichofumin-BX C60H109N13O12 1203,8319 1327 1225.5, 1203.5, 989, 581, 623, 496, 409, 383 1202.6, 1270.5 End
Cyclosporin-C C62H111N11O13 1217,8363 1420 1219, 1241, 1236, 610(db),  1262.7, 1216.7, 1330.7, 1172.7 End
Trichofumin C C69H120N16O17 1444,9017 1015 215, 1231, 936, 454, 616, 745, 1467.9, 1445.9 1489.9, 1443.9 End
Ampullosporin C77H127N19O19 1621,9556 2167 *758, 906, 503, 429, 322, 239 No ionization 220(100), 280broad(15) 
Efrapeptin F C82H141N18O16 1634,0767 1007 1633, 931, 703, 350, 1284 1631, 815(db) End
Antiamebin I C82H127N17O20 1669,9443 1066 1671, 249, 544, 787, 884, 1422, 1224, 1693 1669, 1715, 883 (db), 856(db) End
Trichotoxin A50E C78H136N20O21 1689,0189 1252 612, 851, 1078, 839, 1690, 766, 438 1687.8, 1733.8 End
Paracelsin A C88H145N23O24 1908,0833 1123 774, 1135, 908, 1001, 955, 966, 1909 1907, 960, 967, 1953 End
Paracelsin C C89H147N23O24 1922,0989 1179 774, 1149, 962, 922, 1001, 788, 1923, 1945 1921, 960, 1967 End(100), 222sh
Trichocellin A C89H147N23O24 1922,0989 1138 774, 1149, 922, 962, 1101, 973, 1923, 1945 1921, 960, 1967 End(100), 222sh
Paracelsin D C90H149N23O24 1936,1146 1182 774, 1163, 1149, 969, 1001, 936, 1937, 1959 1935, 967, 1981 End(100), 222sh
Alamethicin F C92H151N23O24 1962,1302 1275 1963, 1189, 774, 934, 982, 1029 1961, 980(db) End
Atroviridin A C92H151N23O24 1962,1302 1257 774, 1189, 934, 1963, 1029 1961 End
Atroviridin B C93H153N23O24 1976,1459 1290 788, 1189, 934, 1977, 810, 774 1975 End
Polysporin B C93H153N23O24 1976,1459 1324 774, 1203, 948, 1977, 796, 1029, 989, 1999, 1000 1975 End
Atroviridin C C94H155N23O24 1990,1615 1358 788, 1203, 810, 1991, 948, 1007, 1043 1989 End
**(2M-2H+Fe3) PO poor ionization
***(MW not to be determined) VPO very poor ionization
* cheats
db (doubly charged) MI mono isotopic mass
**** low amount of compound 
avaliable
RI Retention index 
relative to alkylphenones
***** difficult to tetermine if water 
addition happens in column or ESI-
Table 3 common "Jumps" (∆) observed in Electro spray
Positive electrospray Negative electrospray
Adducts relative to [M+H]
+
∆ (amu) 
a
Adducts relative to [M-H]
-
∆ (amu) 
a
Na
+
, very stable adduct 
b
0,0000 HCOOH 
f
46,0055
NH4
+ c
17,0265 CH3COOH 
f 60,0211
MeCN, neutral adduct 
d
41,0265 Na
+
 -H  (acids, phenols and enoles) 21,9820
Na
+ 
+ MeCN , very stable adduct 
b, d
41,0265 Cl
–
 ( A+2 isotope) 35,9767
K
+
 , very stable adduct 
b
0,0000 Opening of lactone etc. (water addition) 18,0106
K
+ 
+ MeCN , very stable adduct 
b, d
41,0265 M-2H+HCOOH+Na 67,9874
2Na
+
 - H (acids, phenols and enoles) 0,0000 Exchanging adducts
Fe
2+
 , isotope m/z 2 lower ca. 4 % 
e
0,0000 HCOOH instead of Cl
-
10,0288
Exchanging adducts Neutral losses
Na
+
 instead of NH4
+ 
-17,0265 H2O 18,0106
K
+
 instead of Na
+
0,0000 CO2 43,9898
[M - H2O + H]
+
 to [M + Na]
+
18,0106 CH3 15,0235
[M - H2O + H]
+
 to [M + MeCN + Na]
+
 
d
59,0371 CH3CHO 44,0262
[M - H2O + H]
+
 to [M + NH4]
+
35,0371 HCOOH 46,0055
[M - 2 × H2O +H ]
+
 to [M + Na]
+
36,0212 CH3COOH 60,0211
[M + NH4]
+
 to [M + H - CH3COOH]
+
 
d
77,0476
a
 mass shift
[M + Na + MeCN]
+
 to [M + H - CH3COOH]
+
 
d
101,0476
b
 increased by high in-source fragmentation settings
Neutral losses
c
 loss or addition of NH3 can usually be determined
H2O 18,0106 by looking after the [M+Na]
+
 ion
CO2 43,9898
d
 if MeCN is used as solvent.
CH3CHO 44,0262 MeCN forms NH3 upon acdic hydrolysis
HCOOH 46,0055
e
 sideophors and artefact from Fe
2+
 liberation ESI
+
CH3COOH 60,0211
f
 if added to solvent
NH3 (rare) 
c 17,0265
  
 
Table 8 Combined positive and negative ionization electrospray to determine correct molecular mass
Ionization
[M+H]+ 
& [M-H]-
[M+NH4]
+ & [M-
H+HCOOH]- ESI
+ combined with [M-H]- is unambiguous 92.9
Both poor (%) 2.7 Most intense both (%) 37.4 3.5 ESI+  alone is unambiguous 56.4
None both (%) 1.6 Observed both (%) 60.1 9.7 ESI
-  alone is unambiguous 36.5
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Abstract One hundred one antibacterial Pseudoalteromonas
strains that inhibited growth of a Vibrio anguillarum test
strain were collected on a global research cruise (Galathea 3),
and 51 of the strains repeatedly demonstrated antibacterial
activity. Here, we profile secondary metabolites of these
strains to determine if particular compounds serve as strain
or species markers and to determine if the secondary
metabolite profile of one strain represents the bioactivity of
the entire species. 16S rRNA gene similarity divided the
strains into two primary groups: One group (51 strains)
consisted of bacteria which retained antibacterial activity, 48
of which were pigmented, and another group (50 strains) of
bacteria which lost antibacterial activity upon sub-culturing,
two of which were pigmented. The group that retained
antibacterial activity consisted of six clusters in which strains
were identified as Pseudoalteromonas luteoviolacea, Pseu-
doalteromonas aurantia, Pseudoalteromonas phenolica,
Pseudoalteromonas ruthenica, Pseudoalteromonas rubra,
and Pseudoalteromonas piscicida. HPLC-UV/VIS analyses
identified key peaks, such as violacein in P. luteoviolacea.
Some compounds, such as a novel bromoalterochromide,
were detected in several species. HPLC-UV/VIS detected
systematic intra-species differences for some groups, and
testing several strains of a species was required to determine
these differences. The majority of non-antibacterial, non-
pigmented strains were identified as Pseudoalteromonas
agarivorans, and HPLC-UV/VIS did not further differentiate
this group. Pseudoalteromonas retaining antibacterial were
more likely to originate from biotic or abiotic surfaces in
contrast to planktonic strains. Hence, the pigmented, antibacte-
rial Pseudoalteromonas have a niche specificity, and sampling
from marine biofilm environments is a strategy for isolating
novel marine bacteria that produce antibacterial compounds.
Keywords Pseudoalteromonas . Antibacterial activity .
Secondary metabolites . Bioprospecting . Galathea 3
Introduction
Compounds of relevance for the pharmaceutical and
biotechnology industries are produced by marine micro-
organisms (Burgess et al. 1999), and it has been suggested
that some compounds of pharmacological interest previously
attributed to macroorganisms may in fact be of microbial
origin (Bewley and Faulkner 1998; Simmons et al. 2008;
Sudek et al. 2006). The emergence of multiresistant
pathogenic bacterial strains and the failure of combinatorial
and diversity-oriented chemistry to adequately supply the
drug discovery pipeline (Newman 2008) have re-invigorated
natural product chemistry as a path for discovery and
development of new antibiotics. With this in mind, we
isolated marine bacteria with antibacterial activity during the
Danish Galathea 3 marine research expedition (Gram et al.
2010). The antibacterial strains were tentatively identified
using 16S rRNA similarity, and one of the major groups of
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isolated bacteria was identified as Pseudoalteromonas (Gram
et al. 2010).
The genus Pseudoalteromonas consists of Gram-
negative marine bacteria belonging to the γ-proteobacteria
and is present globally in marine waters where they
constitute 0.5% to 6% of the total bacterioplankton (Wietz
et al. 2010). They are heterotrophic aerobes and non-
fermentative, and the cells are motile by one or more polar
flagella. The genus divides into two groups: pigmented and
non-pigmented species. The pigmented species are often
producers of bioactive secondary metabolites (Bowman 2007)
displaying cytotoxic (Zheng et al. 2006), antibacterial
(Gauthier 1976b; Gauthier and Flatau 1976; Isnansetyo and
Kamei 2003; Jiang et al. 2000; McCarthy et al. 1994),
antifungal (Franks et al. 2006; Kalinovskaya et al. 2004), or
antifouling (Egan et al. 2001; Holmström et al. 2002) effects.
It has been hypothesized that bioactive Pseudoalteromonas
are primarily associated with higher organisms (Holmström
and Kjelleberg 1999), suggesting an ecological role in which
some bioactive species might play an active part in host
defense against pathogens and fouling organisms (Holmström
et al. 1996; Armstrong et al. 2001; Egan et al. 2008). A link
between surface colonization and antibacterial activity has not
been experimentally verified, although several studies have
successfully isolated epiphytic bacteria with antibacterial
activity from algae and other marine organisms (Armstrong
et al. 2001; Boyd et al. 1999; James et al. 1996; Penesyan et
al. 2009). The group of non-pigmented species has highly
similar 16S rRNA gene sequences (Ivanova et al. 2004) and
is rarely inhibitory against other microorganisms, although,
Pseudoalteromonas haloplanktis strain INH produces iso-
valeric acid and 2-methylbutyric acid showing a broad
spectrum of bacterial inhibition (Hayashida-Soiza et al.
2008).
Phylogeny and differentiation of bacterial species rely
heavily on 16S rRNA gene similarity (Stackebrandt et al.
2002); however, 16S rRNA gene similarity does not
provide sufficient differentiation below species level (Fox et
al. 1992). Comparison of secondary metabolite production
has supported species delineation within the actinomycete
genus Salinispora, where strains with high 16S rRNA
similarity were shown to belong to distinct species each
with different specific metabolite profiles (Jensen et al.
2007). In mycology, comparison of chemical profiles (e.g.,
TLC, direct-infusion mass spectrometry, and HPLC with
various detectors such as UV/VIS and/or mass spectrometry)
of secondary metabolites has been widely used to identify
and differentiate filamentous fungi (chemotaxonomy) also at
sub-species level (Frisvad et al. 2008), and the chemo-
phylogeny correlates well with phylogenetic analysis of
sequences of specific housekeeping genes (e.g., chitin
synthase, β-tubulin, and calmodulin; Geiser et al. 2007).
Since several Pseudoalteromonas species produce a range of
secondary metabolites, we hypothesized that chemical
profiling and specific marker compounds could be indicative
of bioactive potential and at the same time be useful in
species identification or differentiation (Jensen et al. 2007).
The aim of the present study was to profile the
secondary metabolites of these strains to determine if
particular compounds serve as markers of strains or species
with antibacterial activity and to determine if several strains
of each species must be tested to assess the full bioactivity
potential. As part of this, we provide accurate identification
and phylogeny of these organisms by detailed 16S rRNA
gene sequence comparative analysis. Since the bacteria
were isolated from different sample types, our collection
also allows us to address aspects of Pseudoalteromonas
ecology such as the possible link between surface or
planktonic lifestyle and antibacterial activity.
Materials and Methods
Strain Isolation Approximately 500 marine bacterial strains
with antagonist activity against Vibrio anguillarum strain
90-11-287 (Skov et al. 1995) were isolated during the
Danish Galathea 3 research expedition (Gram et al. 2010).
One hundred one of these strains tentatively identified as
Pseudoalteromonas species were included in the present
study. V. anguillarum 90-11-287 was used as target strain
since the expedition ship was not equipped to handle, e.g.,
potential human pathogens, and this Vibrio strain is in our
experience very sensitive to antibacterial compounds from
other marine bacteria (Hjelm et al. 2004).
Growth Media and Culture Conditions Pseudoalteromonas
strains were grown in marine broth (MB) 2216 (Difco,
Detroit, MI, USA) and on marine agar (MA) 2216 (Difco,
Detroit, MI, USA) prepared in accordance with the
manufacturer’s instructions. Broth cultures were incubated
under stagnant conditions at 25°C. Pigment production was
determined by visual inspection of 48-h-old culture broths
(MB) and colonies grown on MA for 24 to 48 h.
Antibacterial Activity Instant Ocean (IO) bioassay agar
plates were prepared as described by Hjelm et al. (2004).
Ten grams per liter agar, 3.3 g/l casamino acids (Difco
223050, Detroit, MI, USA), and 30 g/l Instant Ocean
aquatic salts (Instant Ocean® Aquarium systems Inc.,
Sarrebourg, France) were added to distilled water and
autoclaved. Glucose (0.4%) and 10 μl/ml of V. anguillarum
overnight culture were added to the cooled (44°C) IO and
plates poured. The plates were allowed to dry for 15 min,
and if used for well diffusion agar assays (WDAA), wells
(diameter 6 mm) were punched. The inhibitory activity of
live Pseudoalteromonas bacterial cells was tested by
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spotting 48-h-old MA grown colonies on freshly prepared
IO agar plates containing V. anguillarum. Plates were
incubated at 25°C and inspected for clearing zones in the
growth of V. anguillarum after 24 h.
Cell-free supernatants were prepared to test for the
presence of water-soluble antibacterial compounds secreted
to the broth, and ethyl acetate extracts were prepared to test
for production of non-polar antibacterial compounds. Each
strain was grown in 20 ml of MB for 48 h. A 1.5-ml sample
was withdrawn for 0.2 μm filtering, and subsequently the
remainder of the culture was extracted with an equal
volume of ethyl acetate. The ethyl acetate fraction was
transferred to a new vessel, evaporated to dryness, and
redissolved in 2×0.5 ml ethyl acetate. The 1.5-ml cell-free
sterile-filtered supernatant and the ethyl acetate extracts
were stored at −20°C until tested in the WDAA (50 μl
sample per well) based on IO agar plates containing V.
anguillarum. Controls (sterile MB and pure ethyl acetate)
did not cause any inhibition zones.
The number of antibacterial Pseudoalteromonas strains
in surface samples (e.g., algae, driftwood, fish, and
sediment samples) was compared to their numbers in water
samples by the Fisher’s exact test (Fisher 1958). A 2×2
contingency table was used to test the hypothesis that
presumed antibacterial strains with stable antibacterial
activity were equally likely to be isolated from water
samples and surface samples.
16S rRNA Gene Sequence Analyses A detailed phylogenetic
analysis was performed on 16S rRNA sequences obtained in a
previous study (Gram et al. 2010). For the analysis in this
study, we conducted a BLAST (http://blast.ncbi.nlm.nih.gov)
search against a compilation of Pseudoalteromonas type
strain sequences retrieved from GenBank (list of type strains
obtained from http://www.bacterio.cict.fr), and sequences of
the type strains with a BLAST match in our strain collection
were included in 16S rRNA sequence analysis to obtain a
robust phylogenetic tree. Sequences from two additional
Pseudoalteromonas strains were included: The genus type
strain P. haloplanktis and the bioactive Pseudoalteromonas
tunicata. Salinispora arenicola CNS-205 was used as
outgroup. The sequences were aligned by the MAFFT online
software (http://www.ebi.ac.uk/Tools/mafft/; Katoh et al.
2002) and curated with the Gblocks software on its least
stringent settings (Castresana 2000; Talavera and Castresana
2007). The resulting alignment was processed using the
MEGA4 software (Tamura et al. 2007) to create neighbor-
joining and minimum evolution trees. PhyML 3.0 was used
to generate a maximum likelihood tree (Guindon and
Gascuel 2003). Phylogenetic trees were generated under
default parameters with 1,000 bootstrap replications for
neighbor-joining and minimum evolution trees and 100
bootstrap replications for the maximum likelihood tree.
GenBank accession numbers for the Pseudoalteromonas
strains used in this study are included in Supplementary
Table 1.
HPLC-UV/VIS Analysis of Secondary Metabolites The
strains were grown in static cultures in 10 ml MB for
3 days at 25°C, and for each species, one strain was
cultured in triplicate to establish extraction and growth
variation. Cultures were extracted with equal volumes of
ethyl acetate, centrifuged, and the ethyl acetate was
evaporated under N2 to dryness. Samples were redissolved
in 300 μl acetonitrile–water (1:1v/v) and filtered through a
13-mm ID PFTE syringe filter. A subsample of 2 μl was
then analyzed by reversed phase HPLC on an Agilent 1100
System equipped with a UV/VIS photo diode array detector
(scanning 200–600 nm). Separation was done on a
100 mm×2 mm i.d., 3 μm Gemini C6-phenyl column
(Phenomenex, Torrance, CA, USA), running at 40°C using
a binary linear solvent system of water (A) and acetonitrile
(B; both buffered with 50 μl/l trifluoroacetic acid) at a flow
of 300 μl/min. The gradient profile was t=0 min, 5% B;
t=22 min, 70% B; t=24.5, 100% B; t=27 min, 100% B; and
t=29 min, B=5%, holding this for 8 min prior to the next
injection. The chromatographic profiles were compared,
subtracting peaks present in media blank extracts. Samples
were analyzed in random order, and six of the first extracts
were analyzed several times during the sequence to determine
any retention time shifts. Cluster analysis was done on a
matrix of detected / non-detected peaks (1/0) using NTSYSpc
2.20q (Exeter Software, Setauket, NY, USA). SAHN clustering
was used by unweighted pair-group method (UPGMA) and
simple distance measurement. Representative extracts were
also analyzed by HPLC-UV/VIS-TOFMS in both positive and
negative electrospray (Nielsen and Smedsgaard 2003). Peaks
were tentatively identified by UV spectra and accurate mass
data by matching in Antibase 2009 (35 930 microbial
secondary metabolites; Wiley & Sons, Hoboken, NJ, USA;
Nielsen et al. 2006).
Results
Pigmentation and Antibacterial Activity The one hundred
one Pseudoalteromonas strains were originally isolated for
their ability to inhibit V. anguillarum (Gram et al. 2010).
However, on re-cultivation and re-testing for the ability to
inhibit V. anguillarum after storage at −80°C for several
months, only 51 strains retained inhibitory activity (Table 1).
These 51 strains were all inhibitory when tested as live
cultures in the “spot test” assay. Twenty of the strains
produced water-soluble, diffusible, antibacterial substances
as indicated by the ability of cell-free sterile-filtered
supernatant to inhibit growth of V. anguillarum in the
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WDAA. These 20 strains were identified as Pseudoalteromo-
nas phenolica (one strain), Pseudoalteromonas luteoviolacea
(five strains), Pseudoalteromonas rubra (nine strains), Pseu-
doalteromonas citrea (one strain), and Pseudoalteromonas
aurantia (four strains). Ethyl acetate extraction of culture
broths resulted in 19 crude extracts which inhibited growth of
V. anguillarum in the WDAA. Four of these were identified
as P. luteoviolacea and were the only strains where both cell-
free supernatant and crude ethyl acetate extracts inhibited
Vibrio growth. The remaining 15 inhibitory crude extracts all
originated from strains identified as Pseudoalteromonas
ruthenica. The crude ethyl acetate extracts of 26 strains were
intensely colored; however, only some of these extracts
inhibited growth of Vibrio indicating that the pigments were
not universally antibacterial. Cell-free culture supernatants
and ethyl acetate crude extracts of strains with no growth
inhibition of V. anguillarum in the “spot test” assay were also
tested but showed no growth inhibition.
Forty-eight of the 51 antibacterial strains were pig-
mented, while two (S3431 and S3655) of the 50 non-active
strains were pigmented (Table 1). Antibacterial activity was
significantly more likely to be produced by pigmented
strains as determined by Fisher’s exact test (two-tailed p
value of 0.0000). In total, 70 strains were isolated from
surface swabs and 31 from water samples. Of the surface-
associated strains, 45 remained active in the spot-assay in
comparison to six of the water sample strains. The Fisher’s
exact test demonstrated a significant relation between surface
association and stable antibacterial activity (two-tailed p value
of 0.0000).
Pseudoalteromonas strains were isolated on all parts of
the global cruise in both tropical and temperate waters
(Fig. 1). Our strain collection is not large enough to allow
for complete biogeographic analysis, but pigmented strains
appeared to be more frequent in coastal areas whereas the
non-pigmented strains appeared associated with open
waters (Fig. 1).
16S rRNA Gene Sequence Analyses We initially performed
a BLAST search querying the 16S rRNA gene sequence of
each strain against the GenBank database. The results of
this analysis were ambiguous, as some sequences returned
more than 40 hits all with identical scores in the BLAST
results (data not shown), frequently including the sequences
of several different Pseudoalteromonas species. Therefore,
a BLAST analysis was carried out querying the sequences
against a complete set of Pseudoalteromonas type strains,
and hence, each strain is matched with the best type strain
BLAST match (Suppl Table 1).
The 16S rRNA gene sequences were used to cluster the
strains by constructing a neighbor-joining tree, and branch
support was verified by comparison to minimum evolution
and maximum likelihood trees (Fig. 2). Nodes supported by
an 80% bootstrap cutoff were collapsed when three or more
strains were included in the cluster (Fig. 2). An exception
was made for clusters VI and VII, which are shown as
separate clusters due to obvious differences in phenotype
(pigment, bioactivity, secondary metabolite profile).
Ninety-nine of the strains fell into one of eight primary
clusters.
Clusters I and III consisted of non-pigmented non-inhibitory
strains (Table 1). Cluster I included 38 strains and the type
strains of P. haloplanktis, Pseudoalteromonas agarivorans,
Pseudoalteromonas tetraodonis, Pseudoalteromonas para-
gorgicola, Pseudoalteromonas distincta, Pseudoalteromonas
arctica, Pseudoalteromonas nigrifaciens, Pseudoalteromonas
Table 1 Identity, antibacterial activity, and pigmentation of Pseudoalteromonas strains from a global collection
16S rRNA cluster No. of strains Related type
straina
No. of strains from No. of strains
inhibiting Vibrio
Inhibition
of Vibrio
by EtAc
extractsPigmented Non-pigmented Surface samples Water samples Pigmented Non-pigmented
I 1 37 P. agarivorans 16 22 0 0 0
II 5 0 P. aurantia 2 3 5 0 0
III 0 9 P. prydzensis 8 1 0 0 0
IV 3 3 P. phenolica 3 3 3 2 0
V 4 0 P. luteoviolacea 4 0 4 0 4
VI 9 0 P. rubra 9 0 9 0 0
VII 13 0 P. flavipulchra 13 0 13 0 0
VIII 15 0 P. ruthenica 14 1 15 0 15
S1727 0 1 P. mariniglutinosa 0 1 0 0 0
S3655 1 0 P. spongiae 1 0 0 0 0
Total 51 50 70 31 49 2 19
a The type strain which the majority of the strains in the cluster were most closely related to
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elyakovii, Pseudoalteromonas carrageenovora, Pseudoalter-
omonas marina, and Pseudoalteromonas aliena. Strain
S3431—a black-pigmented strain in cluster I—did not show
more than 97% similarity even when compared to the full
GenBank database which suggests that S3431 could represent
a novel Pseudoalteromonas species. Despite the low BLAST
similarity score, phylogenetic analysis and tree construction
placed strain S3431 in the diverse cluster I (the non-collapsed
cluster I is shown in Supplementary Figure 1). Cluster III
contained no type strains which supported the BLAST
analysis where the strains in cluster III were 98% similar to
the best type strain match (Supplementary Table 1).
The remaining six of the eight clusters contained
pigmented strains. Pale yellow strains clustered with the
Fig. 1 Isolation sites of 101
Pseudoalteromonas strains with
each color code representing
one of the eight clusters as
indicated in Table 1. Each
circle represents the isolation
of one or more strains
belonging to the given cluster.
White=cluster I, yellow=cluster
II, gray=cluster III, green=
cluster IV, violet=cluster V,
red=cluster VI, orange=cluster
VII, pink=cluster VII, and
blue=non-clustered strain
 Cluster I
P mariniglutinosa AJ507251
 P prydzensis U85855
 S1727
 Cluster II
 Cluster III
 P tunicata Z25522
 P spongiae AY769918
 S3655
 Cluster IV
Cluster V
 Cluster VI
 Cluster VII
Cluster VIII
 S arenicola CNS-205
100
89
98
100
87
88
95
96
84
88
0.02
Fig. 2 Phylogenetic tree based
on 16S rRNA gene sequences of
the Galathea 3 Pseudoalteromo-
nas strains. Sequences were
aligned by MAFFT (default
options), and the resulting
alignment was used to generate
a neighbor-joining tree in the
MEGA4 software package
(default settings, 1,000
bootstraps). S. arenicola
CNS-205, GenBank accession
number CP000850, GeneID:
5705939 was used as outgroup.
Clusters containing two or more
non-type strain sequences were
collapsed. The scale bar
represents 0.02 amino acid
substitutions per nucleotide
position. Circle nodes also oc-
curred in minimum
evolution and maximum
likelihood trees
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type strains of P. citrea and P. aurantia (cluster II) and four
intensely purple strains grouped in cluster V with the type
strain of P. luteoviolacea. Cluster VI contained nine red-
pigmented strains and the type strain of P. rubra, and cluster
VII consisted of 12 intensely yellow strains, one pale yellow
strain, and the Pseudoalteromonas flavipulchra, Pseudoal-
teromonas maricaloris, and Pseudoalteromonas piscicida
type strains. Fifteen strains and their nearest BLAST match,
P. ruthenica, formed cluster VII. These strains all produced a
pale brown pigment. Cluster IV contained six strains and the
type strain of P. phenolica. Four of the strains in this cluster
had P. phenolica as their best type strain BLAST match;
however, strain S1093 had P. luteoviolacea as its best match
at 98% identity, while P. rubra and P. luteoviolacea type
strains scored identically (97%) as the best matches for
S2724. The strains in cluster IV were heterogeneous with
respect to pigmentation, some were non-pigmented and
others appeared brown.
Profiling of Secondary Metabolites The 101 strains and
select type strains were separable in discrete groups by
HPLC-UV/VIS (Fig. 3), and the triplicate profiles from an
isolate of each species were very reproducible and could be
superimposed on each other (data not shown). All of the 38
strains of the 16S rRNA cluster I fell into group A, in
which no UV/VIS peaks were unique compared to the
media blanks indicating that no secondary metabolites were
produced. This large group also included all nine strains
from 16S rRNA cluster III and strains of P. phenolica and P.
ruthenica less proficient in secondary metabolite production.
A summary of the detected compounds is shown in Table 2,
and the producer organisms are shown by 16S rRNA cluster
in Table 3.
Based on their production of specific metabolites, the
majority of pigmented bacteria formed six main groups not
including four P. rubra strains (Fig. 3). In the pigmented
bacteria, a total of 26 distinct peaks were detected and
included in the cluster analysis. We identified indolmycin,
violacein, and prodigiosin among the significant peaks
based on reference standards. Furthermore, nine peaks could
be tentatively identified based on HPLC-UV/VIS-TOFMS
results and data in Antibase2009. These nine included two
likely novel bromoalterochromides and a brominated indole
(Table 2).
Comparing the 16S rRNA gene sequence clusters with
the chemical profiling revealed several patterns. Some
compounds were exclusively produced by strains belonging
to the same cluster whereas other compounds were
produced across several strains from different clusters. All
strains in cluster II (P. aurantia/P. citrea) shared production
of compound B (retention time, RT 12.31 min) whereas the
production of four other compounds F, Q, T, and U (RT
15.47, 16.60, 17.96, and 18.28 min) were scattered in the
group. This included a novel bromoalterochromide (com-
pound Q, RT 16.60 min) that was also found in cluster VII
(P. flavipulchra/P. piscicida). Three of the other compounds
were identified as quinolines based on distinct UV spectra
and accurate mass.
P. luteoviolacea strains (cluster V) shared production of
compound D (violacein, RT 14.29) in all four strains and
the type strain but were sub-divided by compound A
(indolmycin, RT 11.21) produced by two strains and
compound Z (pentabromopseudilin, RT 22.65) produced
by the two other strains and the type strain. This division is
visible in Fig. 4, which shows chromatograms of the four
strains in cluster V. Interestingly, also two P. phenolica
strains produced compound Z.
Cluster VII (P. flavipulchra and P. piscicida) was
chemically very homogeneous. All strains except one
produced three bromoalterochromides P, Q, and R (RT
16.49, 16.60, and 17.10) of which Q and R were novel
compounds. In contrast to cluster V and compound D, the
production of P, Q, and R was not a unique marker for
strains of this cluster as P, Q, and R were also detected in
one strain from cluster II and one strain from cluster VI.
Thirteen of the 15 strains in cluster VIII, identified as P.
ruthenica, shared a unique chemical profile and produced
the compounds H, K, and O (RT 15.78, 15.98, 16.30) with
characteristic UV spectra. None of these matched com-
pounds in Antibase2009 and potentially constitute novel
antibacterials. These compounds were not detected among
strains from other clusters, yet they were not suitable as a
distinct chemical marker for cluster VIII since no secondary
metabolites were detected in the remaining two strains in
this cluster or the type strain.
The strains in cluster VI were identified as P. rubra and
were chemically very heterogeneous. Five of nine strains
produced the red pigment prodigiosin (compound M, RT
16.00) which was not detected in strains of other clusters.
Additionally, a multitude of known and non-identified
compounds were detected in one or more strains in the
cluster. In total, 16 compounds were detected within the
cluster, and 12 of these were unique for this cluster. Only
two strains shared an identical production of secondary
metabolites, further stressing the chemical diversity among
the strains in this cluster.
Discussion
We demonstrate in this study, in agreement with earlier
findings (Bowman 2007), that species within the
Pseudoalteromonas genus produce a range of secondary
metabolites, some with antibacterial activity. Several
species of the genus are intensely pigmented, and it is
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hypothesized that pigmentation co-occur with antibacterial
activity (Egan et al. 2002). In our global collection of
Pseudoalteromonas strains that demonstrated antibacterial
activity on initial isolation, strains that were pigmented
were significantly more likely to retain antibacterial
activity on re-growth than non-pigmented strains. Several
intensely colored organic extracts were not inhibitory
against V. anguillarum, and hence, we do not believe that
the pigments, in general, are the cause of the antibacterial
activity although, e.g., the purple pigment violacein is a
known antibiotic compound (Lichstein and Vandesand
1945).
Coefficient 
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Fig. 3 Dendrogram from cluster analysis of detected peaks from HPLC-UV/VIS detection of compounds in the ethyl acetate extracted broth and
biomass. Data were processed in NTSYSpc 2.20q, with SAHN clustering by UPGMA and simple distance measurement
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Nearly half of the isolated strains did not retain any
antibacterial effect after frozen storage and sub-culturing
despite being isolated on the original plates due to
antibacterial activity. The observed loss of antibacterial
activity may be due to a requirement for factors specific to
local seawater, as initial tests for antibacterial activity were
carried out using 50% local seawater (Gram et al. 2010).
Furthermore, loss of antibacterial activity may be due to
repression or inhibition of gene clusters encoding products
that are required for secondary metabolite synthesis (e.g.,
by catabolite repression). A reduction in antibiotic production
when the producer organism is grown in excess of a carbon
source is a known phenomenon (Sanchez et al. 2010), and
suppression of secondary metabolite production by excess
concentrations of other substrate components is demonstrated
in Streptomyces (Doull and Vining 1990). This could suggest
that culturing the strains under nutrient limited conditions
may reestablish production of antibacterial compounds. Also,
during the original sampling and screening procedure, the
agar plates may have harbored co-cultured microorganisms
which potentially induce antibacterial activity as has been
demonstrated by Mearns-Spragg et al. (1998). Hence, it may
be possible to re-induce the antibacterial activity if the right
conditions can be created.
Several bioactive Pseudoalteromonas have been isolated
from higher organisms, and it has been hypothesized that
antibacterial compounds may play a role in bacterial
competition or as protective agents beneficial for the host
organism (Holmström and Kjelleberg 1999). We provide
statistical evidence that surface-associated presumed antibac-
terial pseudoalteromonads are significantly more likely to
show stable production of antibacterial compounds than
Table 2 Ethyl acetate extractable secondary metabolites produced by pigmented Pseudoalteromonas strains
Compound MI (Da)c UV-max data RT (min) Code
Indolmycina 257 11.21 A
2-Pentyl-4-quinolinolb 215 12.31 B
Novel mono-brominated indole 280 13.78 C
Violaceina 343 14.29 D
Unidentified 244 212 nm (100%), 250 nm (48%) 15.21 E
2-n-Heptyl-(1H)-quinolin-4-oneb 243 15.47 F
Unidentified NI 228 nm (45%), 308 nm (100%) 15.70 G
Unidentified 386 <200 nm 15.78 H
Unidentified 316 286 nm (100%) 15.80 I
Unidentified NI <200 nm 15.81 J
Unidentified NI 228 nm (45%), 308 nm (100%) 15.98 K
Unidentified 676 <200 nm 15.99 L
Prodigiosina 323 16.00 M
Unidentified NI <200 nm 16.26 N
Unidentified NI 228 nm (45%), 308 nm (100%) 16.30 O
Bromoalterochromide Ab 843 16.49 P
Novel bromoalterochromide, 2 bromine 921 16.60 Q
Novel bromoalterochromide, 1 bromine 857 17.10 R
Unidentified 333 310 nm (100%) 17.20 S
2-n-Nonyl-(1H)-quinolin-4-oneb 271 17.96 T
Nonyl-quinolinone analogb 271 18.28 U
Unidentified 315 362 nm (100%) 18.90 V
Unidentified 244 218 nm (100%), 280 nm (82%) 19.42 W
Unidentified NI 218 nm (100%), 288 nm (82%) 19.78 X
Unidentified NI 250 nm (100), 280 nm (86) 19.92 Y
Pentabromopseudilinb 549 22.65 Z
NI no ionization or MI could not be assigned using ESI+ and ESI−
a Validated reference standard used for verification
b Accurate mass and UV data fit the data from Antibase2009
cMono-isotopic mass
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Pseudoalteromonas species isolated as planktonic cells. This
suggests that production of antibacterial compounds may
play an important role in the ability of Pseudoalteromonas
strains to colonize and persist on surfaces submerged in the
marine environment, as previously suggested for P. tunicata
strain D2 (Rao et al. 2005).
The analysis of 16S rRNA gene sequences from our global
collection of Pseudoalteromonas confirms that phylogenetic
analysis results in a number of clusters encompassing
predominantly pigmented species or non-pigmented species
(Ivanova et al. 2004). Strain S3431 was the single pigmented
strain in the so-called non-pigmented clusters. Novel
diversity might be represented in cluster III which consisted
of strains with 98% or less 16S rRNA gene sequence
similarity to Pseudoalteromonas type strains and formed a
separate cluster in the phylogenetic analysis. However, these
strains showed no antibacterial activity and no small
molecule metabolites were detected. Such novel diversity
could still represent untapped biotechnological potential,
producing, e.g., enzymes or peptides with biological activity,
as known for other non-pigmented Pseudoalteromonas
(Hoyoux et al. 2001; Violot et al. 2005).
Chemical profiling of the strains detected an array of
secondary metabolites. In addition to complementing our
analysis of 16S rRNA gene sequences, it also demonstrated
that some compounds (e.g., violacein, prodigiosin) were
characteristic of a species and other compounds were
produced by several species, and we also detected intra-
species clusters of different secondary metabolite profiles. In a
broad sense, the clustering based on 16S rRNAgene similarity
agreed with the groups resulting from the chemophylogenetic
analysis. However, some compounds were produced by
organisms of different species that then clustered together
using the secondary metabolites as basis. The chemical
analysis separated the four isolated P. luteoviolacea strains
into two distinct sub-groups, showing intra-species chemical
diversity. The P. luteoviolacea strains produced violacein and
pentabromopseudilin which are active against gram-positive
and gram-negative bacteria and the anti-staphylococcal agent
indolmycin (Hornemann et al. 1971; Hurdle et al. 2004).
Violacein and pentabromopseudilin have previously been
detected in P. luteoviolacea (Gauthier 1976a; Laatsch and
Pudleiner 1989), but to our knowledge, this is the first report
of Pseudoalteromonas strains producing indolmycin
(Månsson et al. 2010).
Within some species, all strains were consistently antibac-
terial. However, in others, such activity did not appear to be a
consistent trait of the species. For instance, strains of the 16S
cluster VI (P. phenolica) were heterogeneous in their ability
to inhibit Vibrio in our assays, while all but one strain in the
homogeneous cluster VII had identical metabolite profiles
and all were inhibitory. Even more obvious was the
heterogeneous chemical profiles within the P. rubra strains.
All except one strain shared a chemical marker prodigiosin
and/or RT 15.99 min but had major variations in 14 other
compounds. This may in part be due to loss of ability to
produce a compound. For instance, strain S2471 over time
lost ability to produce the brominated indole (RT 13.78 min).
Also, we note that the type strain DSM 6842 (ATCC 29570)
did not in our culture produce prodigiosin which has been
observed previously (Gauthier 1976b; Gauthier and Flatau
1976). The consistent bromoalterochromide production in
the two species P. piscicida and P. flavipulchra/maricaloris
(cluster VII) was expected (Speitling et al. 2007) and
supported the high DNA sequence similarity between the
two. This emphasizes the need to isolate and screen multiple
strains from each species when bioprospecting within the
genus Pseudoalteromonas, as even the homogeneous cluster
VII contains one strain with a metabolite profile that does not
share a single compound with the other strains in this cluster.
Several of the 26 detected peaks were known substances,
with a majority known as antibacterials. These included
violacein (Lichstein and Vandesand 1945), two bromop-
seudilins (Lovell 1966), two indolmycins (Werner 1980),
four quinolines (Wratten et al. 1977), and prodigiosin
(Kalesperis et al. 1975). Due to its very low aqueous
solubility, violacein probably protects against predation
rather than acts as a true antibiotic, and it has been shown to
induce cell death in grazing organisms (Matz et al. 2008).
Such compounds would be very beneficial for protection of
a biofilm, which is likely how surface-associated
Pseudoalteromonas would grow. The 14 compounds that
could not be identified were mainly not identified due to
poor ionization in ESI+ and ESI− and/or several plausible
candidates in Antibase2009. However, for chemotaxonomic
studies, identity of the compounds is not necessary as long
as they can be unambiguously identified between samples
(Frisvad et al. 2008).
Within cluster VIII (P. ruthenica) and cluster II (aurantia/
citrea), we found examples where strains with highly similar
Fig. 4 HPLC-UV/VIS profiles of the ethyl acetate extracted broth and
biomass of four P. luteoviolacea with the tailing violacein peak at 14–
15 min and in two traces pentabromopseudilin at 22-23 min in
contrast to indolmycin at 11 min in the two other traces
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16S rRNA gene sequences (>99%) and with identical
chemotaxonomy originated from geographically distinct
locations. This latter observation is in agreement with studies
on Salinispora biogeography and secondary metabolite
production in which the authors show how strains of the
marine bacterium S. arenicola isolated from worldwide
locations are highly related and produce identical patterns
of secondary metabolites (Jensen and Mafnas 2006; Jensen
et al. 2007). In contrast, the P. luteoviolacea and P. rubra
strains showed both local and global variations in their
secondary metabolite profile, which one might speculate is
due to adaptation to local specific niches.
In conclusion, we believe sampling from specific niches,
e.g., biofilms on surfaces, to be of importance in discovery of
novel secondary metabolites from the genus Pseudoaltero-
monas. While differences in metabolite patterns among
species encourage isolation and screening of novel diversity,
bioprospecting known Pseudoalteromonas species should
not be ruled out. Investigation of multiple strains of one
Pseudoalteromonas species can yield novel compounds due
to intra-species variations within secondary metabolite
profiles.
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Strain 
GenBank 
acc. # 
Latitude Longitude Water 
or 
surface 
BLAST type 
strain match 
% 
BLAST 
ident. 
Cluster 
Pigment 
Inhibition of V. anguillarum 
 +=N +=E 16S Chem. Spot-assay Sup EtAc ex 
S185 FJ457121 62.03815 -9.99592 W P. arctica 98 1 A - - - - 
S186 FJ457122 62.03815 -9.99592 W P. distinct 98 1 A - - - - 
S187 FJ457123 62.03815 -9.99592 W P. prydzensis 97 3 A - - - - 
S201 FJ457124 62.03815 -9.99592 W 
P. agarivorans 
P. distincta 
99 1 A - - - - 
S326 FJ457125 62.2603 -51.6539 S P. agarivorans 99 1 A - - - - 
S327 FJ457126 62.2603 -51.6539 S P. agarivorans 99 1 A - - - - 
S407 FJ457127 66.90525 -53.2894 W P. nigrifaciens 98 1 A - - - - 
S408 FJ457128 66.90525 -53.2894 W P. nigrifaciens 98 1 A - - - - 
S409 FJ457129 66.90525 -53.2894 W P. nigrifaciens 98 1 A - - - - 
S410 FJ457130 66.90525 -53.2894 W P. nigrifaciens 98 1 A - - - - 
S411 FJ457131 66.90525 -53.2894 W P. nigrifaciens 98 1 A - - - - 
S554 FJ457133 42.6047 -29.9597 S P. marina 99 1 A - - - - 
S558 FJ457134 42.6047 -29.9597 S P. aliena 99 1 A - - - - 
S569 FJ457136 40.67227 -28.8374 W P. tetraodonis 99 1 A - - - - 
S570 FJ457137 40.67227 -28.8374 W P. tetraodonis 99 1 A - - - - 
S815 FJ457139 23.07925 -24.0523 W P. agarivorans 99 1 A - - - - 
S816 FJ457140 23.07925 -24.0523 W P. agarivorans 99 1 A - - - - 
S979 FJ457141 23.07918 -24.0542 W P. agarivorans 99 1 A - - - - 
S980 FJ457142 23.07918 -24.0542 W P. agarivorans 99 1 A - - - - 
S981 FJ457143 23.07918 -24.0542 W P. agarivorans 99 1 A - - - - 
S983 FJ457144 4.568133 -14.7097 W P. agarivorans 99 1 A - - - - 
S1093 FJ457145 4.570467 -1.72975 W P. luteoviolacea 98 4 A - + + - 
S1189 FJ457146 4.570467 -1.72975 W P. phenolica 98 4 A Brown + + - 
S1607 FJ457149 -38.407 66.3738 S P. flavipulchra 99 7 G Yellow + - - 
S1608 FJ457150 -38.407 66.3738 S P. agarivorans 99 1 A - - - - 
S1609 FJ457151 -38.407 66.3738 S P. tetraodonis 100 1 A - - - - 
S1610 FJ457152 -38.407 66.3738 S 
P. agarivorans 
P. paragorgicola 
99 1 A - - - - 
S1612 FJ457153 -37.2168 72.7091 S 
P. agarivorans 
P. paragorgicola 
99 1 A - - - - 
S1649 FJ457154 -35.3413 79.9641 S P. prydzensis 98 3 A - - - - 
S1650 FJ457155 -35.3413 79.9641 S P. prydzensis 98 3 A - - - - 
S1688 FJ457157 -31.4061 91.17758 W P. elyakovii 99 1 A - - - - 
S1690 FJ457158 -31.4061 91.17758 W P. agarivorans 99 1 A - - - - 
S1691 FJ457159 -31.4061 91.17758 W P. agarivorans 99 1 A - - - - 
S1692 FJ457160 -31.4061 91.17758 W P. agarivorans 99 1 A - - - - 
S1727 FJ457161 -19.7461 114.8573 W P. mariniglutinosa 99 - A - - - - 
S1731 FJ457162 -19.7461 114.8573 W P. agarivorans 99 1 A - - - - 
S1845 FJ457163 -17.7746 121.8656 S P. flavipulchra 99 7 G Yellow + - - 
S1925 FJ457165 -17.0038 120.7788 S P. flavipulchra 99 7 G Yellow + - - 
S1941  FJ457166 -17.2706 121.1293 W P. agarivorans 99 1 A - - - - 
S1944 FJ457168 -17.0038 120.7788 S P. rubra 99 6 B Red + + - 
S1946 FJ457169 -17.0038 120.7788 S P. rubra 99 6 G Red + + - 
S1947 FJ457170 -17.0038 120.7788 S P. flavipulchra 99 7 G Yellow + - - 
S1948 FJ457171 -17.0038 120.7788 S P. flavipulchra 99 7 G Yellow + - - 
S2040 FJ457173 -16.0604 119.3541 S P. flavipulchra 99 7 G Yellow + - - 
S2047 FJ457174 -16.0604 119.3541 S P. flavipulchra 99 7 G Yellow + - - 
S2048 FJ457175 -16.0604 119.3541 S P. piscicida 99 7 G Yellow + - - 
S2049 FJ457176 -16.0604 119.3541 S P. piscicida 99 7 G Yellow + - - 
S2050 FJ457177 -16.0604 119.3541 S P. piscicida 99 7 G Yellow + - - 
S2053 FJ457179 -16.0604 119.3541 S P. piscicida 99 7 G Yellow + - - 
S2231 FJ457180 -33.3267 127.6573 S 
P. aurantia                  
P. citrea 
99 2 F Pale yellow + + - 
S2233 FJ457181 -33.3267 127.6573 S P. citrea 99 2 F Pale yellow + + - 
S2471 FJ457184 -22.9636 153.9486 S P. rubra 99 6 - Red + + - 
S2472 FJ457185 -22.9636 153.9486 S P. rubra 99 6 - Red + + - 
S2599 FJ457186 -10.3454 157.7956 S P. rubra 99 6 - Red + + - 
S2607 FJ457187 -10.3454 157.7956 S P. luteoviolacea 99 5 C Purple + + + 
S2676 FJ457188 -8.0692 155.8781 S P. rubra 99 6 B Red + + - 
S2678 FJ457189 -8.0692 155.8781 S P. rubra 99 6 B Red + + - 
S2717 FJ457190 -7.8244 156.0689 W P. ruthenica 99 8 A Brown + - + 
S2721 FJ457191 -8.1005 156.8451 S P. prydzensis 97 3 A - - - - 
S2722 FJ457192 -8.1005 156.8451 S P. rubra 99 6 - Red + + - 
S2724 FJ457193 -8.1005 156.8451 S 
P. rubra 
P. luteoviolacea 
97 4 G Brown + - - 
S2755 FJ457196 -9.108 156.8595 S P. flavipulchra 99 7 G Yellow + - - 
S2756 FJ457197 -15.2329 156.665 S P. ruthenica 99 8 E Brown + - + 
S2893 FJ457198 -48.915 178.1056 S P. agarivorans 99 1 A - - - - 
S2897 FJ457199 -48.915 178.1056 S P. ruthenica 99 8 E Brown + - + 
S2898 FJ457200 -48.915 178.1056 S P. ruthenica 99 8 E Brown + - + 
S2899 FJ457201 -48.915 178.1056 S P. ruthenica 99 8 E Brown + - + 
S3136 FJ457202 -66.7706 -76.4383 S P. ruthenica 99 8 E Brown + - + 
S3137 FJ457203 -66.7706 -76.4383 S P. ruthenica 99 8 E Brown + - + 
S3138 FJ457204 -66.7706 -76.4383 S P. ruthenica 99 8 E Brown + - + 
S3173  FJ457205 -67.4876 -89.1285 S P. tetraodonis 98 1 A - - - - 
S3177 FJ457206 -67.4876 -89.1285 S P. ruthenica 99 8 E Brown + - + 
S3178 FJ457207 -67.4876 -89.1285 S P. carrageenovora 99 1 A - - - - 
S3244 FJ457208 -67.4876 -89.1285 S P. ruthenica 99 8 E Brown + - + 
S3245 FJ457209 -67.4876 -89.1285 S P. ruthenica 99 8 A Brown + - + 
S3257 FJ457210 -64.0947 -62.8228 S P. ruthenica 99 8 E Brown + - + 
S3258 FJ457211 -64.0947 -62.8228 S P. ruthenica 99 8 E Brown + - + 
S3260 FJ457212 -64.0947 -62.8228 S P. agarivorans 99 1 A - - - - 
S3431 FJ457214 -50.4498 -74.8912 S P. arctica 97 1 A Black - - - 
S3655 FJ457216 -20.0568 -70.755 S P. spongiae 99 - A Orange - - - 
S3663 FJ457217 -20.0568 -70.755 S P. phenolica 97 4 C - + - - 
S3776 FJ457222 -14.2295 -76.6073 S P. agarivorans 99 1 A - - - - 
S3785 FJ457223 -14.2295 -76.6073 S P. agarivorans 99 1 A - - - - 
S3788 FJ457224 -17.0857 -72.419 W P. aurantia 98 2 F Pale yellow + + - 
S3790 FJ457225 -17.0857 -72.419 W P. aurantia 98 2 F Pale yellow + + - 
S3895 FJ457226 -14.1631 -77.4286 W P. aurantia 98 2 F Pale yellow + + - 
S3898 FJ457228 -13.818 -76.7648 W P. phenolica 97 4 A - - - - 
S3944 FJ457229 -5.3492 -81.4284 S P. mariniglutinosa 98 3 A - - - - 
S4047 FJ457230 2.9817 -86.6892 S P. luteoviolacea 98 5 D Purple + + + 
S4048 FJ457231 2.9817 -86.6892 S P. phenolica 98 4 C Brown + - - 
S4054 FJ457234 2.9817 -86.6892 S P. luteoviolacea 99 5 D Purple + + + 
S4059 FJ457237 2.9817 -86.6892 S P. rubra 99 6 B Red + + - 
S4060 FJ457238 2.9817 -86.6892 S P. luteoviolacea 98 5 C Purple + + + 
S4382 FJ457239 26.5042 -66.9964 S P. ruthenica 99 8 E Brown + - + 
S4388 FJ457240 26.5042 -66.9964 S P. ruthenica 99 8 E Brown + - + 
S4389 FJ457241 26.5042 -66.9964 S P. mariniglutinosa 97 3 A - - - - 
S4488 FJ457243 24.9963 -67.0246 S P. prydzensis 97 3 A - - - - 
S4491 FJ457244 24.9963 -67.0246 S P. prydzensis 97 3 A - - - - 
S4492 FJ457245 24.9963 -67.0246 S P. mariniglutinosa 98 3 A - - - - 
S4498 FJ457247 24.9963 -67.0246 S 
P. flavipulchra 
P. maricaloris 
99 7 F - + - - 
S4741 FJ457248 58.8041 -3.0564 S P. elyakovii 99 1 A - - - - 
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Abstract: On a global research expedition, over 500 bacterial strains inhibitory towards 
pathogenic bacteria were isolated. Three hundred of the antibacterial strains were assigned 
to the Vibrionaceae family. The purpose of the present study was to investigate the 
phylogeny and bioactivity of five Vibrionaceae strains with pronounced antibacterial 
activity. These were identified as Vibrio coralliilyticus (two strains), V. neptunius 
(two strains), and Photobacterium halotolerans (one strain) on the basis of housekeeping 
gene sequences. The two related V. coralliilyticus and V. neptunius strains were isolated 
from distant oceanic regions. Chemotyping by LC-UV/MS underlined genetic relationships 
by showing highly similar metabolite profiles for each of the two V. coralliilyticus and 
V. neptunius strains, respectively, but a unique profile for P. halotolerans. Bioassay-guided 
fractionation identified two known antibiotics as being responsible for the antibacterial 
activity; andrimid (from V. coralliilyticus) and holomycin (from P. halotolerans). Despite 
the isolation of already known antibiotics, our findings show that marine Vibrionaceae are 
a resource of antibacterial compounds and may have potential for future natural 
product discovery.  
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1. Introduction  
Bioactive secondary metabolites are believed to play a key role in microbial interactions by 
mediating antagonistic activity and intercellular communication [1]. In addition, many microbial 
natural products have biotechnological potential as antibiotics, biosurfactants, antifungal, or anticancer 
agents [2]. Sequences of microbial genomes revealed that only a small fraction of the natural product 
diversity is known, highlighting the potential for finding novel bioactive compounds in environmental 
microorganisms [3]. The need for novel antimicrobials to combat increasing antibiotic resistances in 
pathogenic bacteria has stimulated the exploration of other than the traditional sources, such as 
terrestrial actinomycetes or fungi [4]. 
The marine environment harbors bacteria with antagonistic traits [5,6], and marine microorganisms 
are a potential source of novel antimicrobials [7]. Antagonistic marine bacteria have been isolated from 
surface [8] and deep waters [9], but the majority originated from biotic surfaces such as sponges [10], 
zooplankton and macroalgae [8,11], corals [12], and bryozoans [13]. Bioactive bacterial strains 
predominantly belong to Pseudoalteromonas spp. [14], the Roseobacter clade [15], and 
Actinobacteria [16]. A number of marine-derived antimicrobials have been characterized in greater 
detail, including halogenated [17] and sulfuric [18] compounds, depsipeptides [19] and lipopeptides [20], 
glycolipids [21], as well as high molecular weight structures such as amino acid oxidases [22]. 
Also the Vibrionaceae family, Gram-negative Gammaproteobacteria ubiquitous in marine and 
brackish environments [23], harbors strains with antagonistic activity [8]. The family comprises eight 
genera, with Vibrio and Photobacterium constituting the majority of species. To date, Vibrionaceae 
have primarily been investigated due to their pathogenic potential to humans and aquatic animals, but 
they also occur in commensal or symbiotic associations with eukaryotic organisms [23]. While the 
abundance of Vibrionaceae in nutrient-rich microenvironments such as chitinous zooplankton is 
potentially related to a superior nutrient utilization based on their metabolic versatility [24], 
antagonism of competing bacteria through production of antimicrobial compounds may also contribute 
to a selective advantage. Antimicrobials from Vibrio spp. can reduce the number of other microbial 
community members and influence microscale variations in competing bacterial populations [6]. 
Antibacterial activities have been described from V. alginolyticus [25], V. parahaemolyticus [26], 
V. anguillarum [27], and several unidentified Vibrio spp. [28,29]. However, the nature and frequency 
of antagonism among vibrios is still largely unknown, and only a few antibiotic Vibrio compounds 
have been structure elucidated to date [30,31]. 
The present study describes the analysis of bioactive Vibrionaceae strains collected during a global 
marine expedition [8]. The purpose was to (i) provide phylogenetic and chemical analyses of the 
strains with strongest antibacterial activity; (ii) characterize their bioactivity depending on culture 
conditions; and (iii) isolate and elucidate the structure of bioactive metabolites. We report the 
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identification of five Vibrionaceae strains with pronounced antibacterial activity, the use of 
chemotyping to support genetic identification, and the structures of two antibacterial compounds.  
2. Results and Discussion 
2.1. Selection of Strains with Pronounced Antibacterial Activity 
Three hundred and one Vibrionaceae strains were isolated during a global marine expedition 
(http://www.galathea3.dk/uk) based on their ability to antagonize the fish pathogen Vibrio anguillarum 
strain 90-11-287 [8]. After being stored at −80 °C for between six and 12 months, all strains were 
retested for antibacterial activity against V. anguillarum strain 90-11-287 and the human pathogen 
Staphylococcus aureus strain 8325 by spotting colony mass on pathogen-seeded agar [8]. Activity was 
assessed by the formation of clearing zones around spotted colony mass. From 301 strains, only 
138 retained antibacterial activity, being a small fraction compared to other antagonistic marine 
bacteria [32,33]. One hundred strains causing pronounced inhibition (diameter of clearing zones larger 
than 10 mm) were retested using the same set-up, resulting in a subselection of 39 strains with 
reproducible strong antibacterial activity when spotted on pathogen-seeded agar. This subselection was 
inoculated in liquid cultures and extracted with ethyl acetate to determine if antibacterial compounds 
were extractable with organic solvent. Activity was seen in ethyl acetate extracts from five strains, 
which were selected for further analyses. The five bioactive strains originated from different surface 
samples collected in distant oceanic regions (Figure 1).  
Figure 1. Site of isolation, source, and species identification of five bioactive marine 
Vibrionaceae. Strains were identified to the species level by sequence analysis of several 
housekeeping genes (see below).  
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2.2. Phylogenetic Identification and Chemotyping of Strains 
All strains investigated in the present study had previously been assigned to the Vibrionaceae 
family based on 16S rRNA gene similarities [8]. However, the 16S rRNA gene is highly conserved 
among the Vibrionaceae and is not well suited for identification to the species level [34]. Therefore, 
additional sequence analyses of three housekeeping genes (recA, rpoA, and toxR) were performed. 
These genes encode constitutively expressed proteins and are suitable for phylogenetic studies of 
Vibrionaceae [34,35]. On the basis of recA and rpoA sequence similarities, strains S2052 and S4053 
were identified as Vibrio coralliilyticus, S2394 and S4051 as Vibrio neptunius, and S2753 as 
Photobacterium halotolerans (Figure 1). The toxR gene was less suited for general species 
identification due to its high variability even in closely related vibrios, as well as comparatively few 
toxR sequence data available in public gene libraries [36]. However, multiple alignments and  
neighbor-joining analyses of toxR sequences provided the best phylogenetic resolution for determining 
the relationship between the five strains (Figure 2). The usefulness of toxR for species discrimination 
was consistent with previous reports [35]. LC-UV/MS metabolite profiles underlined the close 
relationship between V. coralliilyticus S2052/4053 and V. neptunius S2394/4051, respectively. The 
evolutionary distance of P. halotolerans S2753 to the other strains was reflected by a unique 
metabolite profile (Figure 2). All five strains were consistent in their metabolite production in separate 
cultivations over a one-year interval.  
Several metabolites were produced by all V. coralliilyticus and V. neptunius strains, for instance 
those related to the peaks at retention times Rt = 11.08 and 12.03 min (Figure 2). Although they are 
different species, V. coralliilyticus and V. neptunius are closely related vibrios with only 2–3% 
sequence variation in the recA and rpoA genes (data not shown), signifying why biosynthetic pathways 
are shared between the species. Based on their molecular formulas, UV, and MS characteristics [37], 
most of the metabolites produced by both species were assigned as smaller peptides (m/z 300–500), a 
class of molecules commonly produced by marine culturable bacteria [38,39]. Despite the presence of 
shared metabolites between V. coralliilyticus and V. neptunius, clearly distinguishable peaks were seen 
as well. For instance, the major peak at retention time Rt = 10.02 min (MW 479 Da) was only seen in the 
two V. coralliilyticus, and the peak at Rt = 10.11 min (MW 493 Da) only in the two V. neptunius strains.  
The metabolites produced by P. halotolerans S2753 comprised a series of larger peptides  
(m/z 500–900) [40]. The large peak at Rt = 1.70 min (MW 213 Da) displayed a unique UV spectrum 
characteristic of that of a highly conjugated system. However, this peak could not be ascribed to any 
known compound or compound class based on LC-UV/MS data alone.  
Several metabolites (Rt = 4.70, 7.41, 8.60, 9.60, and 10.50 min) were found in all five strains and 
assigned as poly-β-hydroxybutyric acid polymers (PHB) of varying lengths (repeating unit n = 86 Da). 
This was verified by NMR for some of the compounds (data not shown). PHB are common bacterial 
storage compounds accumulated when growing on an excess carbon source [41]. 
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Figure 2. Phylogenetic and chemical relationship between five bioactive Vibrionaceae 
based on neighbor-joining analyses of aligned toxR gene sequences and LC-MS Total Ion 
Chromatograms (TIC). The scale bar relates to the number of base substitutions in toxR 
gene sequences (as displayed by branch lengths in the phylogenetic tree). 
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Chemotyping of prokaryotes has mostly been restricted to analyses of fatty acids and sugars [42], 
but we show that also the profiling of small molecules can be used for species discrimination. This 
highlights the usefulness of metabolomics for bacterial classification, adding to recent work of 
whole-cell laser desorption MALDI-TOF mass spectrometry for characterization of vibrios [43] and 
secondary metabolite profiling to assess the biosynthetic potential of marine Pseudoalteromonas [32]. 
While our study is limited to the analysis of only three species from the Vibrionaceae family, the 
isolation of two genetically and chemically closely related “strain siblings” from distant oceanic 
regions indicated that production of certain secondary metabolites is a preserved trait. Similar 
secondary metabolite profiles were also shown for marine actinomycetal Salinispora spp. [44] from 
distant habitats. Also, all Ruegeria mobilis strains from worldwide locations produced the same 
antibiotic, tropodithietic acid [33]. 
2.3. Bioassay-Guided Identification of Antibacterial Compounds 
V. coralliilyticus (strains S2052 and S4053) and P. halotolerans (S2753) inhibited both 
V. anguillarum and S. aureus, whereas V. neptunius (strains S2394 and S4051) only inhibited 
V. anguillarum (Table 1). Antibacterial activity was highest in aerated cultures and detected after one, 
three, and five days of incubation. No significant difference in activity was seen between the tested 
culture media. 
Table 1. Inhibition of V. anguillarum strain 90-11-287 and S. aureus strain 8325 by ethyl 
acetate extracts from five marine Vibrionaceae. Antibacterial activity is displayed by the 
diameter of clearing zones (−: no activity; +: between 0 and 15 mm; ++: between 15 and 
30 mm; +++: over 30 mm). 
  Inhibition of  
Strain Species V. anguillarum S. aureus 
S2052 V. coralliilyticus +++ ++ 
S2394 V. neptunius ++ − 
S2753 P. halotolerans +++ ++ 
S4051 V. neptunius ++ − 
S4053 V. coralliilyticus ++ + 
The finding of bioactivity among marine Vibrionaceae underlined marine microorganisms being a 
source of antimicrobials. To our knowledge, none of the species investigated here have previously 
been studied with respect to their secondary metabolome including antibacterial compounds.  
To identify the compounds responsible for the observed activity, large-scale cultivations and 
fractionations were undertaken for V. coralliilyticus S2052 and P. halotolerans S2753, representing 
two distant Vibrionaceae species with different metabolite profiles. All fractionation steps were guided 
by activity testing against V. anguillarum strain 90-11-287. 
Initial dereplication of S2052 by LC-UV/MS [37] and explorative solid-phase extraction (E-SPE) [45] 
indicated that andrimid (Rt = 10.02 min; Figure 2) could be responsible for the antibacterial activity. 
This compound (Figure 3a), a hybrid nonribosomal peptide-polyketide antibiotic, was first described 
from an insect endosymbiont [46] and later found in other microbial species [47,48] including marine 
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vibrios [29,31]. Pure andrimid was isolated for NMR analysis, and our data was in accordance with 
literature data [47]. Andrimid acts as an acetyl-CoA carboxylase inhibitor [49], and we extended its 
broad antibiotic spectrum [50] by showing inhibition of the bacterial pathogens Salmonella Enteritidis, 
Bacillus cereus, Yersinia enterolitica, Yersinia ruckeri, Vibrio harveyi, and Vibrio vulnificus (data not 
shown). Production of andrimid was also confirmed for the other isolated V. coralliilyticus strain, 
S4053. We furthermore speculate whether a recent report of antagonism in the V. coralliilyticus type 
strain [12] was also attributed to this compound. Previous studies have revealed almost identical 
andrimid gene clusters and a transposase pseudogene in two producer species, suggesting horizontal 
gene transfer as the most likely explanation behind the cosmopolitanism of the antibiotic [51]. We 
hypothesize that such transfer is also the reason for its presence in V. coralliilyticus S2052 and S4053. 
Our study is the first linking andrimid production to a specific Vibrio species, with production 
occurring in two strains isolated from very different geographical regions and sources.  
The antibacterial compound of P. halotolerans S2753 was identified as holomycin (Rt = 1.70 min; 
Figure 2), a compound belonging to the pyrrothine class of antibiotics acting by interference with RNA 
synthesis [52]. Our NMR data (Figure 3b) was consistent with previous reports [53]. Holomycin has 
until now only been found in Gram-positive Streptomyces [54,55], and the present study is the first 
demonstrating production of this antibiotic in a Gram-negative heterotrophic bacterium. While parallel 
evolution of this trait is possible, horizontal gene transfer is the more likely explanation for its 
occurrence in both Vibrionaceae and actinomycetes. We extended the broad-spectrum activity of 
holomycin [52] by showing inhibition of the bacterial pathogens Listeria monocytogenes, 
Serratia marcescens, S. Enteritidis, B. cereus, Y. enterolitica, Y. ruckeri, V. harveyi, V. vulnificus and 
V. parahaemolyticus, as well as of several marine strains from the Roseobacter and 
Pseudoalteromonas groups (data not shown). 
Figure 3. Structures of andrimid (a) and holomycin (b) isolated from marine Vibrionaceae. 
 
Neither andrimid nor holomycin were produced by V. neptunius S2394 and S4051, and further 
fractionation and purification is needed to identify the compound(s) responsible for their antibacterial 
activity. Interestingly, V. neptunius S4051 and V. coralliilyticus S4053 were isolated from the same 
seaweed sample, showing that two antagonistic Vibrio species whose antibacterial activity is based on 
different compounds co-occur in the same microenvironment. Moreover, the same sample also 
contained an antibiotic-producing Pseudoalteromonas strain [8]. 
Two of the antagonistic Vibrionaceae species harbor pathogenic strains, with V. coralliilyticus 
being pathogenic to corals [56] and V. neptunius being pathogenic to oysters [57]. While we do not 
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dual physiology, being antagonistic against other prokaryotes but pathogenic towards higher 
organisms. Moreover, the production of antibiotics in several species suggests that these compounds 
may be of ecological importance [1]. 
This study highlights one of the challenges in natural product discovery. Despite major screening 
efforts for novel antimicrobials to be used in pharmaceutical, food, and aquaculture industries, only a 
limited amount of compounds have been discovered in recent years [58]. While the isolation of 
culturable bacteria remains a promising approach [42] and the secondary metabolome of marine 
vibrios has not been extensively studied, we only isolated known compounds despite careful 
dereplication prior to any compound purification. Dereplication is apparently troubled by the high 
degree of gene transfer between distantly related bacteria such as Gram-positive actinomycetes and 
Gram-negative Proteobacteria [3]. Many compounds in natural product databases such as AntiBase [59] 
have similar masses (<5 ppm difference), so even the combination of UV/VIS spectra, accurate mass 
data (<5 ppm), and E-SPE [45] is not sufficiently discriminatory for these organisms. To avoid 
isolation of redundant chemistry, dereplication by NMR [60] or ultra high-resolution mass 
spectrometry (<1 ppm) with high isotope accuracy ratios for correct elementary composition 
determination [61] is imperative to exclude previously isolated compounds.  
3. Experimental Section  
3.1. Isolation of Bioactive Marine Vibrionaceae 
During a global research expedition (http://www.galathea3.dk/uk), marine bacterial strains were 
isolated from environmental samples and screened for antagonistic activity against a pathogenic 
Vibrio anguillarum, strain 90-11-287. Three hundred and one bioactive strains were identified as 
Vibrionaceae based on 16S rRNA gene similarities [8]. Pure cultures of strains were stored in 
cryoprotectant solution at −80 °C until being analyzed in the present study. 
3.2. Selection of Strains with Pronounced Antibacterial Activity 
All 301 strains were retested for antibacterial activity by spotting colony mass on agar seeded with 
either V. anguillarum strain 90-11-287 or S. aureus strain 8325. Activity was assessed by the 
formation of clearing zones around spotted colony mass. Selected active strains were grown both 
stagnant and aerated (200 rpm) in 30 mL Marine Broth 2216 (Difco 279110) for 3 days at 25 °C in 
250 mL glass bottles. Cultures were extracted with an equal volume of HPLC-grade ethyl acetate 
(EtOAc) for 30 min. The organic phase was transferred to fresh sample vials and evaporated under 
nitrogen until dryness. Extracts were redissolved in 1 mL of EtOAc and stored at −20 °C until further 
analysis. EtOAc extracts were tested in a well diffusion agar assay [62] for activity against 
V. anguillarum strain 90-11-287 and S. aureus strain 8325.  
3.3. Phylogenetic Analysis 
Genomic DNA was extracted from 1-day cultures using the NucleoSpin Tissue Kit (Macherey-Nagel, 
Düren, Germany) according to the manufacturer's instructions. PCR for recA and toxR gene fragments 
was performed according to [35], and PCR for rpoA gene fragments according to [34]. PCR products 
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were checked by agarose gel electrophoresis and purified using the Wizard PCR Preps DNA Direct 
Purification System (Promega, Madison, USA) according to the manufacturer’s instructions. Obtained 
nucleotide sequences were edited using Chromas Lite (Technelysium, Australia) and aligned to its 
closest sequence relative [36]. The phylogenetic relationship between the five isolates was determined 
by neighbor-joining analyses (1000 bootstrap replicates) of nucleotide and amino acid alignments 
(translated using EMBOSS Transeq, http://www.ebi.ac.uk/Tools/emboss/transeq/) done in ClustalX. 
Gene sequences have been deposited at GenBank under the accession numbers HQ452614–452618 
(toxR), HQ452619–452623 (recA), and HQ452624–452628 (rpoA). 
3.4. Influence of Culture Conditions on Bioactivity 
The five strains with strongest antibacterial activity (S2052, S2394, S2753, S4051, and S4053) were 
grown both stagnant and aerated (200 rpm) at 25 °C in either Marine Broth (MB) or Marine Minimal 
Medium [63] containing 0.4% glucose and 0.3% casamino acids (MMM). Per strain and culture 
condition, three bottles were inoculated with 30 mL of medium each, of which each one was sampled 
after 1, 3, and 5 days of incubation. In addition, strains were grown in 30 mL sea salt solution (Sigma 
S9883; 40 g L
−1
) with 0.4% glucose and 0.3% casamino acids for 3 days (200 rpm) at 25 °C. EtOAc 
extracts were prepared as described above, and tested in a well diffusion agar assay [62] for activity 
against V. anguillarum strain 90-11-287 and S. aureus strain 8325. 
3.5. Chemotyping 
Liquid chromatography-diode array/mass spectrometry (LC-UV/MS) analyses were performed on 
dried EtOAc extracts redissolved in methanol (MeOH) from all tested culture conditions to visualize 
the array of produced molecules. In addition, 3-day MMM cultures were extracted and analyzed in 
biological triplicate. LC-UV/MS was performed on an Agilent 1100 liquid chromatograph with a diode 
array detector (Agilent, Waldbronn, Germany) coupled to an LCT TOF mass spectrometer 
(Micromass, Manchester, UK) using a Z-spray ESI source. The separation was done on a Luna II C18 
column (50 mm × 2 mm, 3 µm) (Phenomenex, Torrance, CA) fitted with a security guard system using 
a linear gradient starting from 15% acetonitrile (MeCN) in water (H2O) to 100% MeCN over 20 min at 
a flow rate of 300 µL min
−1
. Both MeCN (HPLC grade) and H2O were buffered with 20 mM 
HPLC-grade formic acid (FA). 
3.6. Isolation and Structural Elucidation of Antibacterial Compounds 
Strains S2052 and S2753 were grown in 20 L sea salt solution (Sigma S9883; 40 g L
−1
) with 
0.4% glucose and 0.3% casamino acids for 3 days (100 rpm) at 25 °C. On day 3, sterile Dianion 
HP20SS resin (Sigma-Aldrich, St. Louis, MO) was added to the broth (12 g of resin L
−1
). After 24 h, 
the resin was filtered off and washed with H2O (2 × 1 L), followed by extraction with MeCN/H2O 
(80/20 v/v; 2 × 1500 mL).  
For S2052, all organic extracts were pooled, absorbed onto 90 g Sepra ZT C18 (Phenomenex), and 
dried before packing into a 100 g SNAP column (Biotage, Uppsala, Sweden) with pure resin (10 g) in 
the base. Using an Isolera flash purification system (Biotage), the extract was subjected to a crude 
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fractionation using a MeCN/H2O gradient (flow rate 30 mL min
−1
) starting with 10% MeCN (10 min, 
isocratic), increasing to 100% MeCN (25 min) before washing with 100% MeCN (15 min). Fractions 
were automatically collected using UV detection (210 and 320 nm). The fraction with antibacterial 
activity (185 mg) was subjected to further purification on a Luna II C18 column (250 × 10 mm, 5 μm) 
(Phenomenex) using a 45–70% MeCN/H2O gradient (buffered with 20 mM FA, flow rate 5 mL min
−1
) 
over 20 minutes on a Gilson 322 liquid chromatograph with a 215 liquid handler/injector (BioLab, 
Risskov, Denmark). This yielded 7.6 mg of pure andrimid.  
For S2753, the MeCN/H2O extract from Dianion HP20SS extraction was evaporated until dryness 
on a rotary evaporator. The extract was redissolved in EtOAc, absorbed onto 5 g Isolute diol (Biotage), 
and added to a glass column with pure diol (95 g). A total of 12 fractions were collected from the diol 
column (100 g, 20 × 350 mm) ranging from heptane, dichloromethane, EtOAc to pure MeOH, running 
under gravity. The fraction with antibacterial activity (172 mg, 100% EtOAc) was further separated on 
the Isolera flash purification system, on Sepra ZT C18 (10 g SNAP) using a MeCN/H2O gradient (flow 
rate 12 mL min
−1
) starting with 5% MeCN increasing to 30% MeCN (12 min), quickly increasing to 
100% MeCN (10 min). Fractions were automatically collected using UV detection (210 and 380 nm). 
Pure holomycin (4.3 mg) was obtained after final purification on a Luna II C18 column (250 × 10 mm, 
5 μm) (Phenomenex) using a MeCN/H2O (buffered with 20 mM FA) gradient from 7–37% MeCN 
over 17 min.  
NMR spectra were recorded on a Bruker Avance 800 MHz spectrometer with a 5 mm TCI 
Cryoprobe at the Danish Instrument Center for NMR Spectroscopy of Biological Macromolecules, 
using standard pulse sequences. The NMR data used for the structural assignment of andrimid and 
holomycin were acquired in DMSO-d6 (δH 2.49 and δC 39.5 ppm). 
Optical rotation was measured on a Perkin Elmer Model 341 polarimeter (Perkin Elmer, Waltham, 
MA) (αD at 589 nm). 
Andrimid: orange-yellow amorphous solid; UV (MeCN/H2O) λmax 200 (100%), 280 (40%) nm; 
[α]D
20
 −62.9° (c 0.24, MeOH); 1H NMR δH ppm: 0.75 (3H, d, 6.7 Hz, H-4’), 0.80 (3H, d, 6.7 Hz, H-5’), 
1.07 (d, 7.2 Hz, 1H, H-6), 1.78 (3H, d, 6.7 Hz, H-8’’’), 2.30 (m, 1H, H-3’), 2.65 (1H, dd, 14.6, 6.2 Hz, 
H-2a’’), 2.77 (1H, dd, 14.6, 8.2 Hz, H-2b’’), 2.91 (m, 1H, H-4), 3.92 (d, 5.6 Hz, 1H, H-3), 4.62 (dd, 8.4, 
5.4 Hz, 1H, H-2’), 5.28 (1H, m, H-3’’), 5.90 (1H, m, H-7’’’), 6.01 (1H, d, 15.2 Hz, H-2’’’), 6.18 (1H, m, 
H-6’’’), 6.26 (1H, dd, 14.5, 11.4 Hz, H-4’’’), 6.53 (1H, dd, 14.5, 10.0 Hz, H-5’’’), 7.00 (1H, dd, 15.2, 
11.4 Hz, H-3’’’), 7.20 (1H, m, H-7’’), 7.29-7.31 (4H, m, H-5’’/H-6’’), 8.11 (1H, d, 8.4 Hz, NH-2’), 
8.42 (1H, d, 8.5 Hz, NH-3’’), 11.36 ( s, 1H, NH-1); 13C NMR δC ppm: 14.5 (C-6), 17.2 (C-4’),  
18.3 (C-8’’’), 19.4 (C-5’), 28.1 (C-3’), 39.0 (C-4), 41.9 (C-2’’), 57.8 (C-3), 63.1 (C-2’), 124.2 (C-2’’’), 
126.4 (C-5’’), 126.9 (C-7’’), 128.1 (C-4’’’), 128.2 (C-6’’), 131.5 (C-6’’’), 133.4 (C-7’’’), 139.0 (C-5’’’), 
139.4 (C-3’’’), 142.9 (C-4’’), 164.3 (C-1’’’), 169.9 (C-1’’), 173.8 (C-2), 180.0 (C-5), 203.9 (C-1’); 
HRESIMS m/z 479.2435 (calcd for C27H33N3O5, 479.2420). 
Holomycin: orange-yellow prisms; UV (MeCN/H2O) λmax 200 (100%), 280 (40%) nm; 
1
H NMR 
δH ppm: 2.01 (s, 1H, H-9), 7.04 (s, 1H, H-1), 9.86 (s, 1H, NH-7), 10.69 (s, 1H, NH-3); 
13
C NMR 
δC ppm: 22.4 (C9), 110.6 (C-1), 115.4 (C-5), 133.7 (C-2), 133.9 (C-6), 167.9 (C-4), 168.8 (C-8); 
HRESIMS m/z 213.9860 (calcd for C7H6N2O2S2, 213.9871). 
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4. Conclusions 
The present study adds to the knowledge of Vibrionaceae bioactivity and physiology by showing a 
worldwide occurrence of marine strains producing antibacterial compounds. In addition, we underlined 
that chemotyping can support gene-based species identification and help resolving phylogenetic 
relationships within a genetically homogenous family such as the Vibrionaceae. The discovery of 
known antibiotics that are also produced by evolutionary distant microbes suggests an involvement of 
horizontal gene transfer, and indicates that these compounds are fundamental to compete and 
communicate in the natural habitat. The cosmopolitanism of identical antibiotics has major 
implications for natural product discovery strategies and stresses the need for careful dereplication in 
the initial stages of screening. An alternative approach could be the screening for largely untested 
bioactivities, for instance, interference with quorum sensing or modulation of gene expression. 
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Summary  25 
Vibrio coralliilyticus is a putative coral pathogen in tropical oceans, but also possesses 26 
antagonistic traits. We previously reported antibacterial activity in Vibrio coralliilyticus strain 27 
S2052 based upon the antibiotic andrimid. The purpose of the present study was to determine 28 
whether the antibiotic is produced under conditions mimicking natural habitats of vibrios. V. 29 
coralliilyticus S2052 synthesized andrimid with both chitin and seaweed extracts as sole nutrient 30 
source. In laboratory medium, S2052 produced a range of secondary metabolites, including 31 
andrimid. With chitin, the biosynthesis of metabolites other than andrimid was largely abolished, 32 
and the yield of the antibiotic was two-fold higher. The metabolic focus on andrimid production 33 
with chitin indicates that the antibiotic serves an ecophysiological function. Comparison of S2052 34 
with two related V. coralliilyticus strains (LMG20984
T
 and LMG10953) revealed physiological 35 
differences between these close relatives. Despite overall similar secondary metabolomes, 36 
LMG20984
T
 and LMG10953 did not produce andrimid, and their optimum biosynthetic 37 
temperature was 30 as compared to 25 °C for S2052. Although the true pathogenic potential of 38 
S2052 is unknown, we showed that it contains a zinc metalloprotease gene linked to coral disease. 39 
Different physiologies of S2052 and closely related strains indicated that V. coralliilyticus 40 
subspecies may be adapted to different niches.  41 
 42 
(195 words) 43 
 44 
 45 
 46 
 47 
 48 
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Introduction 49 
The Vibrionaceae are a diverse family of Gram-negative heterotrophic bacteria 50 
commonly found in marine and brackish environments. Vibrios contain several commensal and 51 
symbiotic species, but are primarily researched due to their pathogenic potential towards man and 52 
marine eukaryotes (Thompson et al., 2004). Vibrio coralliilyticus is a model organism for the study 53 
of coral disease, being responsible for bleaching and tissue lesions in Pocillipora damicornis (Ben-54 
Haim et al., 2003b) and the potential aetiological agent of White Syndrome throughout the Indo-55 
Pacific (Sussman et al., 2008). The physiological and genetic background of its virulence (Sussman 56 
et al., 2009; Meron et al., 2009) includes a characteristic temperature-dependent pathogenicity 57 
which only occurs above 25 °C (Ben-Haim et al., 2003a). Increasing seawater temperatures due to 58 
global warming may therefore facilitate outbreaks of coral disease by V. coralliilyticus and other 59 
pathogens (Rosenberg and Ben-Haim, 2002). The species is also able to infect crustaceans, rainbow 60 
trout (Austin et al., 2005), and bivalve larvae (Ben-Haim et al., 2003a). There is substantial genetic 61 
variation between V. coralliilyticus strains, indicating the existence of endemic populations in 62 
different oceanic regions (Pollock et al., 2010a). Potentially, this could also be reflected in a 63 
presence of strains with different niches based on physiological variation, for instance their 64 
pathogenicity or metabolic activity.  65 
The Vibrionaceae also harbour strains with antibacterial activity (Long and Azam, 66 
2001), and several antagonistic vibrios, including V. coralliilyticus, were recently isolated from the 67 
marine environment (Gram et al., 2010). V. coralliilyticus strain S2052 was isolated from sediment 68 
in the tropical Indian Ocean, and antagonized bacterial pathogens by production of the antibiotic 69 
andrimid (Wietz et al., 2010). Also the V. coralliilyticus type strain has antibacterial activity 70 
(Rypien et al., 2010), but it has not been determined whether this was related to the same 71 
compound. Andrimid is a hybrid nonribosomal polyketide-peptide antibiotic and effective against a 72 
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wide range of bacteria (Singh et al., 1997) by interference with fatty acid synthesis (Freiberg et al., 73 
2004). The antibiotic is also produced by other microbes, including an insect endosymbiont 74 
(Fredenhagen et al., 1987), an enterobacterium (Jin et al., 2006), as well as marine pseudomonads 75 
(Needham et al., 1994) and vibrios (Oclarit et al., 1994; Long et al., 2005). The cosmopolitan 76 
occurrence of andrimid is likely related to horizontal gene transfer (Fischbach, 2009).  77 
 Many studies of bacterial physiology are conducted using laboratory substrates that do 78 
not reflect conditions in the natural habitat. However, laboratory growth conditions can shift the 79 
phenotype towards a metabolic state that is potentially unlike the environmental ecology of a 80 
microorganism (Palkova, 2004). The source of carbon (Sanchez et al., 2010) and nutrient 81 
availability (Demain et al., 1983) can have a substantial influence on secondary metabolism. An 82 
excess of nutrients – typically not encountered in the oligotrophic marine environment – can 83 
increase the synthesis of storage compounds, for example polyhydroxybutyrates (Chien et al., 84 
2007), but suppress antibiotic production (Doull and Vining, 1990).  85 
Also the presence of a natural growth substrate, such as chitin, can influence bacterial 86 
physiology. Chitin is the most abundant biopolymer in the marine environment, particularly found 87 
in the exoskeletons of crustaceans and zooplankton (Gooday, 1990), and profoundly linked to the 88 
ecology of vibrios. In the human pathogen V. cholerae, chitin influences bacterial ecophysiology at 89 
multiple hierarchical levels including chemotaxis, biofilm formation, nutrient cycling, 90 
pathogenicity, as well as commensal and symbiotic relationships with higher organisms (Pruzzo et 91 
al., 2008). Vibrios are often abundant in chitinous microenvironments (Thompson et al., 2004) due 92 
to their ability to utilize chitin as carbon and nitrogen source by secretion of chitinases (Hunt et al., 93 
2008). Vibrios also occur in epiphytic communities of macroalgae, including the brown seaweed 94 
Laminaria (Laycock, 1974), which is potentially linked to the degradation of algal-derived 95 
carbohydrates (Goecke et al., 2010). The utilization of chitinous and algal substrates, possibly 96 
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combined with the production of antagonistic compounds, could provide vibrios with a selective 97 
advantage to colonize biotic surfaces.  98 
The purpose of the present study was to determine whether V. coralliilyticus S2052 99 
produces the antibiotic andrimid under conditions mimicking natural habitats of vibrios. Production 100 
of andrimid with seaweed extracts and stimulated biosynthesis with chitin suggested an ecological 101 
role of the antibiotic. Furthermore, comparison of antibiosis, secondary metabolism and potential 102 
pathogenicity traits (Sussman et al., 2008; 2009) in S2052 and two related strains suggested that V. 103 
coralliilyticus harbours several subspecies with different antagonistic potential and 104 
ecophysiological characteristics.  105 
  106 
 107 
Results 108 
 109 
Andrimid production under natural growth conditions 110 
 V. coralliilyticus S2052 inhibited pathogenic bacteria by production of the antibiotic 111 
andrimid when grown in laboratory medium (Wietz et al., 2010). Here, we investigated growth and 112 
andrimid production under natural conditions with chitin, seaweed extracts, or pure algal 113 
carbohydrates as sole nutrient source. S2052 grew well in chitin medium, and chitinolytic activity 114 
was visually detected as disappearance of the colloidal chitin precipitate. Antibacterial activity and 115 
production of andrimid was confirmed by bioassay testing against V. anguillarum strain 90-11-287 116 
and LC-UV/MS analyses with comparison to an NMR validated standard. With chitin, S2052 117 
abolished the production of an array of metabolites produced in laboratory medium (Fig. 1) that had 118 
been assigned as polyhydroxybutyrates and smaller peptides by NMR spectroscopy (Wietz et al., 119 
2010).  120 
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 In seaweed media, the type and concentration of seaweed extract influenced growth 121 
characteristics and andrimid production. With Fucus, only 50 and 100% extract concentration 122 
yielded distinct growth. Bioactivity and considerable production of andrimid was detected with 50, 123 
but hardly any with 100% extract concentration. With Laminaria, high cell densities were reached 124 
at 25, 50, and 100%. Bioactivity and production of andrimid was confirmed for all extract 125 
concentrations. We tested whether the observed bioactivities reflected an ability to degrade known 126 
components from Fucus and Laminaria likely present in the crude extracts. Therefore, the 127 
polysaccharide fucoidan and its main monomer fucose (mainly present in Fucus), the 128 
polysaccharide laminarin (mainly present in Laminaria), as well as the polysaccharide alginate and 129 
the monosaccharide mannitol (present in both), were tested as sole carbon source. Distinct growth 130 
was only seen with 1% alginate; however, no andrimid was produced as confirmed by bioactivity 131 
testing and LC-UV/MS.  132 
 133 
Growth and quantification of andrimid in chitin versus laboratory media 134 
 In laboratory medium, there was no lag phase and exponential growth started 135 
immediately. Andrimid was detected after 10 hours at an approximate culture density of 5×10
8
 cells 136 
mL
-1
. The yield of andrimid (production per cell) peaked after 10 h, reaching approx. 10 pmol per 137 
cell. Despite continuing growth between 12 and 24 h, the first decreasing and then stagnant yield 138 
illustrated that no additional andrimid was produced (Fig. 2). With chitin, there was a three-hour lag 139 
phase before exponential growth started, and the generation time was longer than in laboratory 140 
medium. Andrimid production was detected after 18 h and at a slightly lower culture density (10
7
 141 
cells mL
-1
). The yield peaked after 24 h at over 20 pmol per cell, being two-fold higher than with 142 
laboratory medium. Production stopped along with an increase in growth between 24 and 30 h. The 143 
slightly decreasing yield towards the end of the incubation period indicated that the antibiotic was 144 
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partially degraded with time. UPLC-UV analyses of ethyl acetate extracts obtained at every 145 
sampling point underlined earlier observations (Fig. 1) in a time-dependent manner, showing that 146 
over 72 h very few metabolites other than andrimid were produced when grown with chitin. 147 
  148 
Influence of temperature on metabolite production in S2052 and related strains 149 
 We compared the production of andrimid and metabolite profiles of S2052 with two 150 
related V. coralliilyticus strains, LMG20984
T
 and LMG10953. Since the pathogenic potential (Ben-151 
Haim et al., 2003a) and intercellular chemistry (Boroujerdi et al., 2009) of V. coralliilyticus is 152 
temperature-regulated, we tested growth at 15, 20, 25, 30, and 35 °C to see whether temperature 153 
also influences secondary metabolite and antibiotic production. 154 
 All strains grew from 15 to 35 °C, with fast doubling times (estimated 20-30 minutes) 155 
above 30 °C. The three strains had almost identical secondary metabolite profiles, but andrimid 156 
(peak at 10.01 min) was only produced by S2052. In contrast, another metabolite (peak at 9.87 min) 157 
was mainly produced by LMG20984
T
 and LMG10953 (Fig. 3). S2052 produced andrimid at 15, 20 158 
and 25 °C, but only limited amounts at 30 and not at all at 35 °C. We tested whether the lack of 159 
production above 30 °C was related to compound degradation over the 3-day incubation period, yet 160 
andrimid was neither detected in cultures incubated for only 12 h. Temperature optima for 161 
secondary metabolite production differed between the strains. Higher relative abundances of 162 
metabolites revealed that S2052 had highest biosynthetic capacity at 25 °C, while only limited 163 
amounts were produced at 30 °C. In contrast, LMG20984
T
 and LMG10953 had the maximum 164 
biosynthetic capacity at 30 °C (Fig. 3). These physiological distinctions questioned the 165 
identification of S2052 as V. coralliilyticus, however, we verified the species affiliation by 166 
successful amplification of a dnaJ gene fragment using V. coralliilyticus specific primers (Pollock 167 
et al., 2010b). The relationship of S2052 to the demonstrated coral pathogens LMG20984
T
 and 168 
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LMG10953 was furthermore underlined by amplification of a zinc metalloprotease gene fragment 169 
linked to pathogenicity (Sussman et al., 2008; 2009).  170 
 171 
 172 
Discussion  173 
 The Vibrionaceae family comprises symbiotic, commensal, pathogenic (Thompson et 174 
al., 2004), as well as antagonistic strains (Long and Azam, 2001; Gram et al., 2010). The relatively 175 
widespread production of antibiotics in marine vibrios including V. coralliilyticus (Wietz et al., 176 
2010) indicated that antagonistic activity may be of ecological importance. To further test this 177 
hypothesis, the present study investigated andrimid production in V. coralliilyticus S2052 under 178 
conditions mimicking natural habitats of vibrios. Antagonism based upon the utilization of natural 179 
substrates could facilitate the colonization of biotic surfaces, and contribute to the association of 180 
vibrios with zooplankton (Thompson et al., 2004) and macroalgae (Laycock 1974). 181 
Chitinolytic activity is a core function of the Vibrionaceae (Hunt et al., 2008), making 182 
it a potential reason for their ubiquitous occurrence (Riemann and Azam, 2002). Chitin controls 183 
several genetic and physiological characteristics of vibrios (Pruzzo et al., 2008), and the present 184 
study showed that it also influences antagonistic activity. The stimulation of antibiotic production 185 
by chitin was potentially related to observations in streptomycetes (Rigali et al., 2008), the 186 
paradigm of antibiotic-producing bacteria (Hopwood, 1999). The almost complete shut-down of 187 
metabolite production except for andrimid indicated that all available carbon was used for its 188 
biosynthesis, suggesting that a competitive phenotype was formed that could be of advantage in the 189 
natural habitat. We can, however, only speculate about the ecological role of andrimid. The 190 
combination of chitinolytism and antibiosis could provide a selective advantage in the colonization 191 
of chitinous microenvironments by using andrimid to antagonize competing bacteria. Andrimid 192 
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could also represent a chemical mean to provide grazing resistance. Such a scenario has been shown 193 
for the bioactive bacterial compound violacein, which has both antibacterial and antiprotozoan 194 
activity (Matz et al., 2004). The link between chitin and andrimid could also play a role in 195 
pathogenicity, comparable to the importance of chitinase activity in V. cholerae infections (Kirn et 196 
al., 2005). Considering the ubiquity of quorum sensing in vibrios including V. coralliilyticus (Tait et 197 
al., 2010) we hypothesized that andrimid production and/or chitinolytism would be controlled by 198 
such mechanisms. Although quorum sensing can be linked to chitinase activity (Chernin et al., 199 
1998; Defoirdt et al., 2010) we did not detect any signalling molecules using two different 200 
microbiological AHL monitors (McClean et al., 1997; Cha et al., 1998) (data not shown).   201 
We hypothesized that variations in growth and andrimid production between Fucus 202 
and Laminaria extracts reflected differing abilities of S2052 to utilize species-specific algal 203 
compounds. Degradation of fucoidan (Furukawa et al., 1992) and laminarin (Alderkamp et al., 204 
2007) has been shown in vibrios, but S2052 was unable to utilize these as sole nutrient source. In 205 
contrast, S2052 could utilize alginate, but no andrimid was produced. In combination with missing 206 
antibiosis in undiluted compared to diluted Fucus extract, this suggested that biosynthesis of the 207 
antibiotic is not a constitutive trait, requires a mixture of algal nutrients, and can be influenced by 208 
substrate type or concentration. 209 
 The almost identical metabolite profiles of S2052, LMG20984
T
 and LMG10953, 210 
together with the presence of a conserved dnaJ gene fragment, confirmed that all three strains 211 
belong to V. coralliilyticus. However, the production of andrimid in S2052 but its absence in 212 
LMG20984
T
 and LMG10953 showed that even such closely related strains can possess 213 
considerable physiological variation. Missing production in LMG20984
T 
furthermore implied that 214 
its antagonism against coral-associated bacteria (Rypien et al., 2010) is caused by a compound that 215 
is untraceable in our approach. Nevertheless, the increased antibiosis of LMG20984
T
 at 25 216 
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compared to 30°C was potentially related to the observation in S2052. In combination, these results 217 
suggest that antagonistic interactions involving vibrios play a greater role at lower temperatures. 218 
Stopping andrimid production above 30 °C was consistent with another andrimid-producing Vibrio 219 
(Long et al., 2005), and potentially related to the fact that the synthesis of polyketides and 220 
nonribosomal peptides can be thermoregulated (Rohde et al., 1998).  221 
The increased biosynthetic capacity of the known pathogens LMG20984
T
 and 222 
LMG10953 at higher temperatures was consistent with a previous report using metabolomics 223 
(Boroujerdi et al., 2009), and probably reflected that pathogenicity only occurs above 25 °C (Ben-224 
Haim et al., 2003a). The higher metabolite production of S2052 at lower temperatures implied that 225 
its pathogenic potential may differ from LMG20984
T
 and LMG10953. However, the presence of a 226 
zinc metalloprotease gene linked to disease signs in corals (Sussman et al., 2008; 2009) contradicted 227 
this hypothesis. It has to be noted, though, that the presence of the gene does not necessarily imply 228 
pathogenicity, since coral disease such as White Syndrome is likely multifactorial (Sussman et al., 229 
2008). The observation of two different phenotypes – one pathogenic, non-andrimid producing with 230 
a temperature optimum of 30 °C (LMG20984
T
 and LMG10953) and one andrimid-producing with 231 
potential pathogenicity and a temperature optimum of 25 °C (S2052) – possibly reflects genetic 232 
variability (Pollock et al., 2010a) and differing enzymatic capacities (Ben-Haim et al., 2003a) 233 
among V. coralliilyticus. Differing physiologies could even relate to geographically separated, 234 
endemic populations within the species (Pollock et al., 2010a). Our results suggest that bacterial 235 
taxonomy could benefit from complementation by metabolite analyses (Gevers et al., 2005). The 236 
potential of metabolomics for bacterial typing has been exemplified with 12 strains of E. coli, 237 
showing that all had a different metabolic fingerprint and only shared a core set of compounds 238 
(Maharjan and Ferenci, 2005). Also strains from the marine bacterium Pseudoalteromonas 239 
11 
 
luteoviolacea could be grouped into subspecies according to their secondary metabolome (Vynne et 240 
al., under revision).  241 
In conclusion, production of andrimid with seaweed extracts and stimulated 242 
biosynthesis with chitin implied that antagonistic traits in V. coralliilyticus serve an ecological 243 
function. Antagonism based upon the utilization of natural substrates could provide a competitive 244 
advantage, facilitate the colonization of biotic surfaces, or play a role in pathogenicity. The 245 
presence of different phenotypes among V. coralliilyticus indicated the existence of several 246 
subspecies with different ecophysiogical characteristics. The variations in antibiosis and 247 
biosynthetic temperature optima suggested that closely related V. coralliilyticus strains may occupy 248 
different niches and respond differently to environmental variation.  249 
 250 
 251 
Experimental procedures 252 
 253 
Preparation of natural growth substrates. Colloidal chitin was prepared from practical grade 254 
chitin (Sigma P7170) as follows: 10 g chitin were hydrolyzed in 400 mL ice-cold 37% HCl for 20 255 
min and stirred at 37 °C until clear. The solution was poured into 4 L of dH2O and placed at 4 °C 256 
overnight for settlement of chitin. The supernatant was aspirated and chitin resuspended in 2 L of 257 
dH2O. Chitin was collected by centrifugation (4000 g for 12 min) and resuspended in 1 L dH2O. 258 
The pH was adjusted to 7 using KOH pellets. The solution was homogenized for 5 min using an 259 
Ultra-Turrax (IKA, Staufen, Germany) and autoclaved. The final concentration of colloidal chitin 260 
was determined from a dried (70 °C overnight) subsample. Aqueous seaweed extracts were 261 
prepared from the brown macroalgae Fucus vesiculolus and Laminaria saccharina freshly collected 262 
from Danish coastal waters. Algae were cut in strips and homogenized in 8 mL sea salt solution 263 
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(Sigma S9883, 40 g L
-1
) per 1 g algae using an Ultra-Turrax (IKA). Extracts were centrifuged (15 264 
min at 2000 g) to precipitate larger pieces, filtered through Whatman No 1, and centrifuged again 265 
(10 min at 6000 g) to remove remaining particles. Extracts were sterilized by filtration (0.2 µm) and 266 
stored at 4 °C. The pure algal carbohydrates fucoidan (Sigma F5631; 1% w/v), fucose (Sigma 267 
F8150; 10% w/v), laminarin (Sigma L9634; 2% w/v), and mannitol (Sigma M4125; 10% w/v) were 268 
readily dissolved in dH2O. A 1% alginate solution was prepared by slow addition of alginate 269 
(Sigma 05550) and sea salts (40 g L
-1
) to dH2O to prevent gelling. All solutions were sterilized by 270 
filtration (0.2 µm).  271 
 272 
Bacterial strains and growth conditions. V. coralliilyticus S2052 (Gram et al., 2010) was 273 
inoculated in marine minimal medium (MMM) (Östling et al., 1991) containing (i) 0.2% colloidal 274 
chitin, (ii) 10, 25 and 50% of seaweed extracts, and (iii) 0.05, 0.2 and 0.4% of algal carbohydrates. 275 
In addition, undiluted (100%) seaweed extracts, as well as stock solutions of fucoidan/alginate (1%) 276 
and laminarin (2%) amended with sea salts (40 g L
-1
), were tested as growth substrate. Furthermore, 277 
S2052 was inoculated in MMM containing 0.4% glucose and 0.3% casamino acids, representing 278 
laboratory medium. Cultures were grown aerated (200 rpm) at 25 °C for 3 (laboratory medium, 279 
chitin, 1% alginate and 50/100% seaweed extract) or 7 days (10/25% seaweed extract). Metabolite 280 
production in S2052 was compared to two related strains (LMG20984
T
 and LMG10953). Cultures 281 
were grown aerated (200 rpm) in each 30 mL MMM with 0.4% glucose and 0.3% casamino acids at 282 
15, 20, 25, 30, and 35 °C for 3 days. All strains were furthermore screened by PCR for a dnaJ gene 283 
fragment conserved in V. coralliilyticus (Pollock et al., 2010b) and the presence of a Vibrio zinc 284 
metalloprotease gene (Sussman et al., 2008). 285 
Andrimid detection. All cultures were extracted with an equal amount of HPLC-grade ethyl 286 
acetate for 30 min. The organic phase was transferred to fresh sample vials and evaporated under 287 
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nitrogen until dryness. The residue was redissolved in 1 mL of ethyl acetate and tested for activity 288 
against V. anguillarum strain 90-11-287 using a well diffusion agar assay (Hjelm et al., 2004). 289 
Blank samples representing all tested culture conditions were analyzed to exclude antibacterial 290 
activity by any components of the growth substrates. All active samples were analyzed for the 291 
presence of andrimid by liquid chromatography-diode array/mass spectrometry (LC-UV/MS). 292 
Extracts were redissolved in methanol and analyzed on an Agilent 1100 liquid chromatograph with 293 
a diode array detector (Agilent, Waldbronn, Germany) coupled to an LCT TOF mass spectrometer 294 
(Micromass, Manchester, UK) using a Z-spray ESI source. Separation was obtained on a Luna II 295 
C18 column (50 × 2 mm, 3 μm; Phenomenex, Torrance, CA) fitted with a security guard system 296 
using a linear gradient starting from 15% acetonitrile (MeCN) in water (both buffered with 20 mM 297 
formic acid) increasing to 100% MeCN over 20 minutes at a flow rate of 0.3 mL min
-1
. In LC-298 
UV/MS profiles of seaweed cultures, the bacterial metabolites were camouflaged by a large number 299 
of co-extracted algal compounds, but andrimid could be detected by its high-resolution molecular 300 
mass using the selective ion-trace (m/z 480.25, ESI
+
). 301 
 302 
Growth kinetics of S2052. S2052 was inoculated at approx. 10
3
 cells mL
-1 
in 300 mL MMM with 303 
(i) 0.4% glucose and 0.3% casamino acids and (ii) 0.2% colloidal chitin (each in duplicate). 304 
Cultures were grown aerated (200 rpm) at 25 °C. Sampling points were set according to growth 305 
characteristics in a preliminary test (data not shown). Glucose/casamino acid cultures were sampled 306 
after 0, 2, 4, 6, 8, 10, 12, 15, 24, 48 and 72 h, and chitin cultures after 0, 3, 6, 9, 12, 15, 18, 21, 24, 307 
27, 30, 33, 48 and 72 h. At each time point, 12 mL of culture were sampled. A serial dilution series 308 
was plated on Marine Agar 2216 (Difco 212185) and determination of colony forming units (CFU 309 
mL
-1
) performed after 2 days of incubation at 25 °C.  310 
 311 
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Andrimid quantification. At each sampling point, the amount of andrimid was quantified directly 312 
from sterile-filtered (0.2 µm) culture using ultra-high liquid chromatography-diode array (UPLC-313 
UV) analyses on a Dionex RSLC Ultimate 3000 (Dionex, Sunnyvale, CA) equipped with a diode-314 
array detector. Separation was obtained on a Kinetex C18 column (150 × 2.1 mm, 2.6 μm; 315 
Phenomenex) maintained at 60 ºC using a linear gradient starting from 15% MeCN in water (both 316 
buffered with 50 ppm trifluoroacetic acid) increasing to 100% MeCN over 7 minutes at a flow rate 317 
of 0.8 mL min
-1. Injection volume was 20 μL. Andrimid (Rt = 4.44 min) was detected from the 302 318 
± 2 nm chromatogram using quantification by external standard calibration with an NMR validated 319 
standard of pure andrimid (Wietz et al., 2010). A standard curve from six different andrimid 320 
concentrations (0.06, 0.2, 0.3, 0.45, 0.65, and 2.5 mM) resulted in a linear calibration curve with R
2
 321 
= 0.9991. In addition, 5 mL culture from each time point were extracted twice with ethyl acetate 322 
(with and without 1% formic acid) to investigate the overall production of secondary metabolites 323 
over time. The extracts were pooled and evaporated under nitrogen until dryness. The residue was 324 
redissolved in 1 mL methanol and filtered (0.45 μm) before subjected to UPLC-UV analyses as 325 
described above using a 3 μL injection volume.  326 
 327 
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Figure legends 479 
 480 
Fig. 1 LC-MS metabolite profiles (total ion chromatogram ESI
+
) of V. coralliilyticus S2052 in 481 
laboratory (A) and chitin (B) medium. The peak with retention time Rt = 10.01 relates to andrimid 482 
(Wietz et al., 2010). 483 
 484 
Fig. 2 Growth and production of andrimid in V. coralliilyticus S2052 over 72 h in laboratory versus 485 
chitin medium. Closed lines: cell density (CFU mL
-1
), dotted lines: yield of andrimid (pmol per 486 
cell) in laboratory (■) and chitin (▲) medium. 487 
 488 
Fig. 3 LC-MS metabolite profiles (total ion chromatogram ESI
+
) of V. coralliilyticus S2052, 489 
LMG20984
T
 and LMG10953 grown at 25 and 30 °C. 490 
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Abstract  20 
During a global research cruise, more than five hundred marine bacterial strains capable of 21 
inhibiting the growth of pathogenic bacteria were collected. The purpose of the present study was to 22 
determine if these marine bacteria are also a source of compounds that interfere with bacterial 23 
quorum sensing (QS) systems. In the human pathogen S. aureus, the Agr QS system controls a 24 
diverse set of virulence factors. Using a gene reporter fusion bioassay, we searched for compounds 25 
that interfere with Agr as characterized by enhanced expression of spa, encoding Protein A, and 26 
reduced expression of hla, encoding α-hemolysin, and RNAIII, the effector molecule of Agr. 27 
Bioassay-guided fractionation of crude extracts from a marine Photobacterium led to the isolation 28 
of two novel cyclodepsipeptides, designated solonamide A and B, that repress Agr in S. aureus 29 
strain 8325-4. Northern blot analysis confirmed the Agr interfering activity of pure solonamides in 30 
both S. aureus strain 8325-4 and the highly virulent, community-acquired strain USA300 (CA-31 
MRSA). To our knowledge, this is the first report of inhibitors of the Agr system produced by a 32 
marine bacterium. (178 words) 33 
 34 
Key words: Photobacterium, Vibrionaceae, antivirulence, quorum sensing inhibition, agr, 35 
solonamide36 
 3 
Introduction 37 
Microorganisms are an attractive source of new natural products with antimicrobial properties (2,8), 38 
and the marine environment constitutes a prolific resource for the isolation of less exploited 39 
microorganisms (11,19,51). Many marine microenvironments stimulate the production of specific 40 
metabolites as a response to environmental factors (12). It is likely that some of these compounds 41 
mediate both intra- and interspecies microbial interactions, including antagonism, and they can 42 
therefore be seen as potential new scaffolds for development of drug lead candidates (12,28). The 43 
increasing problem of antibiotic resistance among human pathogens highlights the need for novel  44 
therapeutic strategies (65). The search for new avenues in microbial control has therefore been 45 
extended from traditional growth inhibiting compounds to compounds that target, for example, 46 
quorum sensing (QS) pathways (9,52,54).  Quorum sensing inhibitors (QSI) do not necessarily kill 47 
or inhibit the growth of a pathogen but rather modulate microbial phenotypes, for example by 48 
attenuating virulence (3,6).  49 
Staphylococcus aureus is one of the main causes of nosocomical infections, and 50 
methicillin-resistant S. aureus (MRSA) are emerging at an alarming rate (18,21). The virulence of 51 
S. aureus is ascribed to a number of virulence factors, including extracellular toxins such as α-52 
hemolysin encoded by hla, and cell surface adhesion factors such as Protein A encoded by spa  (7). 53 
Their expression is coordinated through several key regulators, of which the Agr (accessory gene 54 
regulator) quorum sensing system is central (44). Agr is encoded by the agr locus and is composed 55 
of a classical two component system with a sensor histidine kinase, AgrC, and a response regulator, 56 
AgrA, in addition to AgrB and AgrD which are responsible for the production of the quorum 57 
sensing signal (36,43). Agr-dependent quorum sensing is mediated via cyclic thiolactone 58 
octapeptides, termed autoinducing peptides (AIP), that control virulence gene expression through 59 
 4 
the effector molecule, RNAIII (24,25). Structure-activity studies (SAR) of the AIPs have led to the 60 
construction of synthetic inhibitors of the Agr system (30,36); however, there are only few reports 61 
of natural antagonists of this system (26,38,50). Nielsen et al (40) recently developed a screening 62 
assay based on S. aureus lacZ reporter fusion strains, where the effect of compounds or extracts on 63 
expression of three key virulence genes (spa, hla, and rnaIII) and hence potential interference with 64 
the Agr locus can be assessed. Subsequently, the assay was used to identify two xanthones as novel 65 
quorum sensing interfering compounds in S. aureus (40).  66 
We recently established a global collection of marine bacteria that display 67 
antibacterial activity (17). The purpose of the present study was to screen pure cultures, crude 68 
bacterial extracts, and purified secondary metabolites from this collection of marine bacteria for 69 
potential inhibitors of the Agr system. One of the bacterial families investigated was the 70 
Vibrionaceae. These bacteria are ubiquitous in marine and brackish environments and often 71 
associated with marine organisms (61). The Vibrionaceae consist of eight genera, with Vibrio and 72 
Photobacterium constituting the majority of species. Vibrio spp. can be pathogenic to humans 73 
(9,16,34) or marine animals (36), but also occur in the commensal microflora of zooplankton (61) 74 
or live as bioluminescent symbionts with squid or fish (15,20,53). The Photobacterium genus 75 
similarly comprises symbiotic (1,4) and fish pathogenic species (32,62) but does not, to our 76 
knowledge, contain any human pathogens. Members of the Vibrionaceae have been found to 77 
produce broad range inhibitory compounds (17,28), however only few of the antibacterial 78 
compounds have been isolated to date. Antimicrobial compounds  from Vibrio species include the 79 
pyrrolidinediones andrimid (29,46,63) and moiramide B (39) that inhibit fatty acid synthesis (49). 80 
In addition, we recently reported the production of the potent pyrrothine antibiotic holomycin by a 81 
marine Photobacterium (63).  82 
 5 
Herein, we report the isolation and chemical investigation of two novel depsipeptides 83 
produced by that same Photobacterium strain. The compounds, designated solonamides A and B, 84 
inhibit the Agr quorum sensing system of S. aureus and therefore interfere with its virulence gene 85 
expression. This indicates that the Vibrionaceae and other marine bacteria could be a promising 86 
source of novel chemistry with potential use in antibacterial therapy.  87 
 88 
89 
 6 
Materials and Methods 90 
Isolation and identification of strain S2753. Bacterial strain S2753 was isolated from a mussel 91 
surface collected in the tropical Pacific (9.1° S 156.8° E) during the Danish Galathea 3 expedition 92 
(17). S2753 was assigned to the Vibrionaceae by 16S rRNA gene sequence similarity (17) and 93 
identified as being closely related to Photobacterium halotolerans based on recA and rpoA gene 94 
sequences, with homologies of 87% (recA) and 94% (rpoA) (63). BLAST analyses showed that 95 
other closely related species were Photobacterium rosenbergii and Photobacterium angustum S14 96 
(13).  97 
 98 
Initial screening for anti-virulence compounds. S2753 was cultured in each 30 mL of (i) marine 99 
minimal medium (MMM) (48) containing 0.4% glucose and 0.3% casamino acids, (ii) Marine 100 
Broth 2216 (MB; Difco 2216), (iii) Sigma Sea Salts (SSS; Sigma S9883; 40 g L
-1
) containing 0.4% 101 
glucose and 0.3% casamino acids, and (iv) MMM containing 0.2% colloidal chitin prepared 102 
according to Wietz et al. (submitted) (64). All cultures were incubated aerated (200 rpm) for 72 103 
hours at 25 °C.  All cultures were extracted with an equal volume of ethyl acetate (EtOAc). The 104 
extract was evaporated under nitrogen until dryness and redissolved in 300 μL 80% v/v ethanol 105 
(EtOH) in water. 20 μL of the extract was tested in an agar-diffusion assay where expression from 106 
promoters of hla, rnaIII, and spa is monitored (41).  107 
 For further screening, the culture broth of S2753 grown in MMM (1 L, 72 h, 25 °C, 108 
100 rpm) was extracted directly with sterile Diaion HP20SS (12 g L
-1
, 24 h) (Sigma-Aldrich, St. 109 
Louis, MO). The resin was filtered off and washed with 80% (v/v) acetonitrile (MeCN)/water (300 110 
mL) and the extract evaporated until dryness on a rotary evaporator. From this extract, 10 mg dry 111 
material was subjected to an explorative solid-phase extraction (E-SPE) protocol by Månsson et al 112 
 7 
(33). This yielded 15 fractions for re-testing in the agar-diffusion assay as described above.  The E-113 
SPE fractions were also tested for antibacterial activity against Vibrio anguillarum strain 90-11-287 114 
and S. aureus 8325 in a well diffusion agar assay (22).  115 
 116 
Extraction and purification of solonamides A and B. Using 10 L glass fermentors, S2753 was 117 
cultured in 5 x 4 L SSS containing 0.4% glucose and 0.3% casamino acids in (25 °C, 72 h, 100 118 
rpm). The broth was extracted directly with Diaion HP20SS (12 g L
-1
) as described above. The 119 
extract (3.4 g) was redissolved in EtOAc, absorbed onto 5 g Isolute diol (Biotage, Uppsala, 120 
Sweden) and added to a glass column with pure diol (95 g). A total of 12 fractions were collected 121 
from the diol column (100 g, 20 x 350 mm) ranging from heptane, dichlormethane (DCM), EtOAc, 122 
to pure methanol (MeOH), running under gravity. The fractions containing the QSI compounds 123 
(fraction 5, 20:80 (v/v) EtOAc/DCM and fraction 6, 40:60 (v/v) EtOAc/DCM) were separated on 124 
Sepra ZT C18 (Phenomenex, Torrance, CA)(10 g SNAP) on an Isolera automated flash system 125 
(Biotage) using a MeCN/water gradient 25-75% over 20 min (12 mL min
-1
). Pure compounds were 126 
obtained directly: Solonamide A (17 mg) and B (201 mg). Activity of pure compounds was tested 127 
in the agar-diffusion assay as described above (20 μL per well), with a final concentration of 128 
compounds of 5 mg mL
-1
 in dimethyl sulfoxide (DMSO).   129 
 130 
Structural characterization of the solonamides.  NMR spectra were recorded on a Varian Unity 131 
Inova 500 MHz spectrometer equipped with a 5 mm probe using standard pulse sequences. The 132 
signals of the residual solvent protons and solvent carbons were used as internal references (δH 2.49 133 
and δC 39.5 ppm for DMSO).  134 
 8 
LC-MS and LC-MS/MS analyses were performed on a maXis quadrupole time of 135 
flight mass spectrometer (Bruker Daltonics, Bremen, Germany) equipped with an electrospray 136 
(ESI) ion source. The MS was connected to an Ultimate 3000 UHPLC system (Dionex, Sunnyvale, 137 
CA) equipped with a diode-array detector. Separation was performed at 40 ºC on a 150 mm × 2.1 138 
mm ID, 2,6 µm Kinetex C18 column (Phenomenex) using a linear water/MeCN (both buffered with 139 
20 mM formic acid) gradient starting from 15% MeCN and increased to 100% in 13 minutes at a 140 
flow of 0.4 mL min
-1
. The MS and MS/MS experiments were performed in ESI
+
 with a data 141 
acquisition range of m/z 100-1200 with collision energy of 27 V. The MS was calibrated using 142 
sodium formate automatically infused prior to each analytical run, providing a mass accuracy of 143 
less than 1 ppm in MS mode and 2 ppm in MS/MS mode.  144 
The absolute configuration of the amino acids were found using acid hydrolysis (6 M 145 
HCl, 110 °C, 20 h) (16) and derivatisation with Marfey’s reagent (1-fluoro-2,4-dinitrophenyl-5-L-146 
alanine amide, FDAA, Sigma-Aldrich) following the protocol described by Bonnard et al. (5). 147 
Ultra-high liquid chromatography-diode array (UHPLC-UV) analyses of the amino acids were done 148 
on a Dionex RSLC Ultimate 3000 (Dionex) equipped with a diode-array detector. Separation was 149 
obtained on a Kinetex C18 column (150 x 2.10 mm, 2.6 μm, Phenomenex) maintained at 60 ºC using 150 
a linear gradient starting from 25% MeCN in water (both buffered with 50 ppm TFA) increasing to 151 
27% MeCN over 6 minutes at a flow rate of 0.8 mL min
-1
. Retention times of the FDAA amino acid 152 
derivatives  used as standards were as follow (maximum standard deviation ± 0.002 min): FDAA 153 
(1.50 min), L-Ala (1.14 min), D-Ala (1.61 min), L-Phe (3.58 min), D-Phe (5.04 min), L-Leu (3.77 154 
min), D-Leu (5.49 min), comparable to the observed retention times from the solonamide-derived 155 
amino acids.  156 
 9 
To specify the stereochemistry of enantiomeric amino acids, the depsipeptides were 157 
reduced by LiBH4. The resulting linear peptides were subjected to the above mentioned acid 158 
hydrolysis and Marfey’s derivatisation. Details are given in the Supplemental Material.  159 
 For the absolute configuration of the fatty acid residues, the (R)- and (S)-Mosher’s 160 
esters were prepared for both depsipeptides, and the stereocenters were assigned based on their 
1
H 161 
and 
19
F chemical shift differences (ΔδSR) (10,56). Details are given in the Supplemental Material.  162 
Solonamide A: white amorphous solids; UV (MeCN/H2O) λmax 200 nm (100%); for 163 
NMR data refer to table 1 in Supplemental Material; HRESIMS m/z 558.3416 (calcd for 164 
C30H46N4O6, 558.3496).  165 
Solonamide B: white amorphous solids; [UV (MeCN/H2O) λmax 200 nm (100%); for 166 
NMR data refer to table 2 in Supplemental Material; HRESIMS m/z 586.3725 (calcd for 167 
C32H50N4O6, 586.3730).  168 
 169 
LC-UV/MS analyses of related Photobacterium strains.  To investigate the potential production 170 
of Agr inhibitors in related Photobacterium strains, the metabolite profile of S2753 was compared 171 
by liquid chromatography-diode array/mass spectrometry (LC-UV/MS) to P. halotolerans (LMG 172 
22194
T
), P. rosenbergii (LMG 22223
T
), and P. angustum (S14) described by de Nys et al. (13). All 173 
strains were grown in 30 mL MMM containing 0.4% glucose and 0.3% casamino acids for 72 h at 174 
25 C and 200 rpm. Cultures were extracted with an equal volume of EtOAc and evaporated under 175 
nitrogen.  Residues were redissolved in MeOH for LC-UV/MS analyses and in 80% EtOH for 176 
biotesting. Inhibition of Agr was tested as described above. Extracts were also tested against V. 177 
anguillarum strain 90-11-287 for inhibition of growth. LC-UV/MS analyses were performed on an 178 
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Agilent 1100 liquid chromatograph with a diode array detector (Agilent, Waldbronn, Germany) 179 
coupled to an LCT TOF mass spectrometer (Micromass, Manchester, UK) using a Z-spray ESI 180 
source. Separation was obtained on a Luna II C18 column (50 x 2 mm, 3 μm, Phenomenex) fitted 181 
with a security guard system using a linear gradient starting from 15% acetonitrile (MeCN) in water 182 
(both buffered with 20 mM formic acid) increasing to 100% MeCN over 20 minutes at a flow rate 183 
of 0.3 mL min
-1
. 184 
 185 
Northern blot analysis. Northern blot analysis was performed as described previously (23). The 186 
strains used were S. aureus FPR 3757 (14), CA-MRSA USA300 obtained from ATCC (Boras, 187 
Sweden), and 8325-4 (44). Samples for RNA purification were taken from cultures in Tryptone 188 
Soya Broth (TSB, Oxoid, Greve, Denmark) shaking at 185 rpm at 37˚C in a water bath (10 mL 189 
culture in 100 mL Erlenmeyer flask). Growth was monitored by measuring optical density at OD600. 190 
Start inoculum was OD600=0.03. Solonamides were added at OD600=0.4. Samples for RNA 191 
purification were taken at OD600=0.7 and 1.7. Probes targeting rnaIII, spa, and hla transcripts were 192 
amplified by PCR using the primers: hla forward (5’- GGG TTA GCC TGG CCT TCA GCC-3’), 193 
hla reverse (5’- GGG TGC CAT ATA CCG GGT TC-3’), spa forward (5’- GGG GGT GTA GGT 194 
ATT GCA TCT G-3’), spa reverse (5’- GGG GCT CCT GAA GGA TCG TC-3’), rnaIII forward 195 
(5’- GGG GAT CAC AGA GAT GTG ATG-3’), and rnaIII reverse (5’- GGG CAT AGC ACT 196 
GAG TCC AAG G-3’) (TAG Copenhagen A/S, Denmark). The resulting PCR fragments were 197 
311bp (hla), 719bp (spa), and 316bp (rnaIII), respectively.  198 
 199 
200 
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Results 201 
Identification of QS inhibitors from Photobacterium halotolerans. In an initial search for 202 
antimicrobial compounds that inhibit the growth of Staphylococcus aureus and Vibrio anguillarum, 203 
we isolated strain S2753 related to Photobacterium halotolerans (17). Subsequently, the known 204 
antibiotic, holomycin, was identified as responsible for the antibacterial activity (63). When 205 
investigating ethyl actetate extracts of S2753 in an agar-diffusion assay monitoring expression of 206 
the S. aureus virulence genes hla, rnaIII, and spa (40), we observed an increased expression of spa 207 
and decreased expression of hla and rnaIII.  The inverse effect of the extracts on spa and hla/rnaIII 208 
expression, respectively, indicated the presence of at least one compound that interferes with the S. 209 
aureus QS system (44). Secondary screening of the extract by explorative solid-phase extraction (E-210 
SPE) (33) detected the potential QSI activity in a fraction that did not inhibit growth of S. aureus 211 
(data not shown). In the E-SPE separation, we found that diol was a useful column material for the 212 
initial separation of the active components. A large-scale culture (20 L) of S2753 was extracted by 213 
Diaion HP20SS. Due to poor solubility, the crude extract was absorbed directly onto the diol and 214 
fractionated. Final purification was accomplished by C18 reversed-phase separation, resulting in the 215 
isolation of two compounds active in the S. aureus agar-diffusion assay (Figure 1). The activity of 216 
these pure (NMR purity) compounds was comparable to the initial activity of the extract, 217 
confirming that these compounds are responsible for the changes in gene expression. The 218 
compounds did not inhibit growth of S. aureus or V. anguillarum (data not shown). The active 219 
compounds were produced by S2753 under all tested culture conditions, including laboratory media 220 
(MB, MMM, and SSS) as well as under conditions mimicking the natural environment, using chitin 221 
as sole nutrient source (data shown in Supplemental Material). 222 
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Structure elucidation of the solonamides. The solonamides were isolated as white powder with 223 
respective molecular formulas C30H46N4O6 (A) and C32H50N4O6 (B) as determined by HRMS (1 224 
ppm mass accuracy). Analysis of NMR data characterized the structure of the solonamides as 225 
cyclodepsipeptides consisting of four amino acids and a 3-hydroxy fatty acid (Figure 2) (for details 226 
refer to Supplemental Material). The amino acid composition was elucidated as alanine, 227 
phenylalanine, and two leucines for both peptides based on DQF-COSY and HSQC NMR 228 
experiments. The spin systems of the amino acids were confirmed through strong and unambiguous 229 
H2BC correlations (45) and the carbonyl signals assigned by HMBC correlations. Through careful 230 
inspection of the DQF-COSY and H2BC data, solonamide A was found to contain a 3-231 
hydroxyhexanoic acid, while B contains a 3-hydroxyoctanoic acid. Long-range HMBC and NOESY 232 
correlation data allowed the sequence of amino acids to be established as fatty acid-Phe-Leu-Ala-233 
Leu. This was corroborated by MS-MS experiments giving the exact molecular formula of the 234 
fragments (2 ppm mass accuracy). The signal from one oxygen-bearing carbon with a high carbon 235 
shift indicated an ester linkage. Lastly, the ring closure linkage was secured by HMBC correlations 236 
from H-3 in the fatty acid moiety to the carbonyl in Leu and a weak NOESY correlation from H-3 237 
to the Leu amide and Hα proton. In total, this accounted for the ten degrees of unsaturation resulting 238 
from the ring, five carbonyls, and the Phe aromatic ring. 239 
Absolute configurations of the individual amino acid units were established by acid 240 
hydrolysis, Marfey’s, and UHPLC-UV analysis. Both peptides were found to contain L-Phe, D-Ala, 241 
and an enantiomeric pair of L-Leu and D-Leu. Acid hydrolysis of the reduced, linear peptides and 242 
subsequent Marfey’s derivatisation specified the stereochemistry of the two Leu, exchanging the L-243 
Leu peak (RT 3.77 min) with a new peak (RT 3.73 min), attributable to the corresponding alcohol. 244 
Thus, L- and D-stereochemistry was assigned as fatty acid-L-Phe-D-Leu-D-Ala-L-Leu in both 245 
solonamide A and B.      246 
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The absolute configuration of the fatty acid was found by NMR spectroscopic analysis 247 
of the 
1
H and 
19F chemical shift differences (ΔδSR) in the (R)- and (S)- Mosher’s esters analysis of 248 
solonamide A and B. The absolute stereochemistry of C-3 in the 3-hydroxy fatty acids was 249 
established as (R) in both depsipeptides (Figure 2). 250 
 251 
Solonamides interfere with Agr. Northern Blot analysis was used to verify that the purified 252 
solonamides did in fact cause changes in gene expression as observed in the agar-diffusion assay. 253 
To this end we isolated mRNA from S. aureus 8325-4 and the community acquired strain, USA300, 254 
at different stages of growth following solonamide exposure. Solonamide B reduced dramatically 255 
the expression of both hla and RNAIII while increasing expression of spa, suggesting that the 256 
compound interfere with Agr regulation (Figure 3). Intriguingly, the decreased expression of the 257 
RNAIII effector molecule was even more pronounced in the highly virulent USA300 strain, 258 
FPR3757, where high Agr activity is suspected to be a main contributor to the aggressiveness of the 259 
strain (14,27). Solonamide A was able to increase spa expression, but caused only a marginal 260 
reduction of hla and RNAIII expression in both 8325-4 and USA300. The discrepancy between 261 
results from the Northern blot and the agar-diffusion assay may be rooted in the much higher 262 
concentrations of solonamides that are used in the agar-diffusion assay as compared to the Northern 263 
blot analysis. Also, the Northern blot analysis requires inspection after ½ and 2 hours, whereas the 264 
agar-diffusion assay has a longer time-line for inspection at 15 and 35 hours, which could be of 265 
significance for the results.  266 
 267 
Production of solonamides by related Photobacterium  strains. To test whether the solonamides 268 
are also produced by related Photobacterium strains, we compared S2753 with P. halotolerans 269 
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LMG 22194
T
, P. rosenbergii LMG 22223
T
, and P. angustum S14 (13). None of these strains 270 
produced solonamides (as confirmed by LC-UV/MS), and none affected virulence gene expression 271 
in the gene-reporter agar-diffusion assay. None of the three strains inhibited growth of V. 272 
anguillarum, and holomycin, the antibiotic of S2753 (63), was not detected.  273 
 274 
 275 
276 
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Discussion  277 
The rapid, worldwide increase in antibiotic resistant Staphylococcus aureus strains (18) has led to 278 
an intense search for compounds with potential use in alternative therapeutic strategies (9). 279 
Virulence of S. aureus involves a complex set of proteins, with the Agr quorum sensing system 280 
controlling expression of several of the virulence genes. The investigation of crude extracts and 281 
fractions from a marine Photobacterium led to the identification of two novel depsipeptides, 282 
solonamides A and B, as potent inhibitors of this system. The natural inducers of Agr are 16-283 
membered thiolactone macrocycles carrying a peptide tail necessary for full Agr activation through 284 
binding to the membrane bound sensor histidine kinase (31,36). Structure-activity studies 285 
demonstrated that the macrocyclic ring is required for antagonistic activity (31), and synthetic 286 
studies have led to the construction of global inhibitors based on truncated AIPs (31,37). The 287 
similar structures and sizes of the solonamides and the truncated AIPs (Figure 4) suggest that they 288 
may be competitive inhibitors of the Agr system. Unlike the AIPs, the solonamides are cyclized 289 
through a 3-hydroxy fatty acid forming a lactone rather than a thiolactone. However, synthetic 290 
lactone and lactam variations of natural AIPs have been found to have antagonistic activity 291 
(31,35,36), which our study corroborates. While cross-inhibition of Agr by AIPs is more tolerant of 292 
sequence and structural diversity than is activation (31), Mayville et al (35) found that the presence 293 
of the hydrophobic leucine and phenylalanine residues is important for the inhibition of the Agr 294 
response. Both solonamides contain a leucine and phenylalanine; however, the reduced activity of 295 
solonamide A suggests that the overall hydrophobicity of the depsipeptides affected by the varying 296 
length of the fatty acid moiety is an important factor influencing activity.   297 
Interestingly, we found solonamide B interefered with Agr not only in S. aureus 8325-298 
4 but also in strain USA300, which is a predominant community-acquired MRSA (CA-MRSA) 299 
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strain in the US (60). This finding suggests that quorum sensing inhibition could be an option for 300 
treatment of S. aureus USA300 infections. The solonamides are the first report of antagonists 301 
produced by a natural source mimicking the structure of natural AIPs. There are few other examples 302 
of natural antagonists of the Agr system. Kiran et al (2008) identified hamamelitannin from 303 
Hamamelis virginiana (witch hazel) as an inhibitor of RNAIII and δ-hemolysin expression in S. 304 
aureus 8325-4, USA300, and clinical S. epidermidis isolate MH (26). Also, ambuic acid from an 305 
unidentified fungal strain was found to attenuate Agr (38).   306 
To the best of our knowledge, only two species of Photobacterium have been 307 
investigated for their chemistry so far (34,47,57). Oku et al (47) isolated the unnarmicins A and C 308 
(Figure 5) from a marine Photobacterium strain MBIC06485 related to P. leiognathi. Like the 309 
solonamides, unnarmicin A and C consist of four amino acids (L-Phe, L-Leu, D-Phe, L-Leu) and a 310 
3-hydroxyoctanoic and 3-hydroxyhexanoic fatty acid, respectively. The unnarmicins were found to 311 
have selective antibacterial activity against two strains of Pseudovibrio (47) and inhibit the fungal 312 
ABC transporter (47,58). Due to the high structural similarity, it can be hypothesized that the 313 
unnarmicins are also capable of attenuating Agr. The finding of the unnarmicin in another marine 314 
Photobacterium sp. suggests that production of such peptides could be a common feature in this 315 
group of bacteria. Yet, we did not detect solonamide A or B in any of the related strains that we 316 
investigated.  317 
The yield of solonamides was up to 5 mg L
-1
, which is high, compared to other γ-318 
proteobacteria. For example, the yield of unnarmicins from a Photobacterium sp. was ten times 319 
lower (47). The solonamides were produced on a chitin based medium, mimicking natural 320 
conditions, which indicates that these compounds are produced in the natural environment. Also, 321 
the solonamides have D-alanine and D-leucine incorporated; amino acids that are not present in the 322 
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laboratory medium. Thus, the Photobacterium seems to produce these specific stereoforms rather 323 
than incorporating available amino acids. Altogether, this suggests that the solonamides are more 324 
than mere metabolic bi-products or storage compounds produced under laboratory conditions. 325 
Given the relatively low abundance of staphylococci in the marine environment, it 326 
seems unlikely that the P. halotolerans S2753 produce solonamides as part of a deliberate strategy 327 
to interfere with this specific type of bacteria. However, the solonamides might be targeted at other 328 
gram-positive bacteria in the marine environment, such as bacilli and actinobacteria, though little is 329 
known about quorum sensing pathways in marine Gram-positive bacteria. Acylated homoserine 330 
lactones, the most widely researched type of QS molecules in Gram-negatives, can serve as both 331 
agonists and antagonists in different systems (50), and thus the solonamides may also serve as 332 
quorum sensing signals for the Photobacterium itself. However, we did not detect solonamides or 333 
compounds with similar QSI activity in any of the related strains.  334 
QS inhibitors have been found from other marine bacteria. Teasdale et al (2009) 335 
identified two phenylethylamides from a Halobacillus salinus capable of inhibiting QS-controlled 336 
behaviors in gram-negative bacteria (59). In addition, extracts from coral-associated Bacillus 337 
horikoshij inhibits biofilm formation in Streptococcus pyogenes through suspected QS inhibition 338 
(42).  Blockage of accessory gene functions with such natural inhibitors might promote colonization 339 
of surfaces or accession of nutrients (24,36,55). The full extent of the combination of QSI and 340 
antibiosis for bacterial competition in the marine environment is still unknown.  341 
Considering their ubiquitous presence in the marine environment, the Vibrionaceae 342 
are chemically under-explored. However, this study as well as other recent work from our lab 343 
(63,64) demonstrate that species within the Vibrionaceae are capable of producing secondary 344 
metabolites with antibacterial activities. Here we have demonstrated that members of Vibrionaceae 345 
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could be a promising source of new bioactive compounds with nontoxic effects against pathogenic 346 
bacteria by the report of three novel cyclic depsipeptides with selective inhibition of the Agr system 347 
in S. aureus.  348 
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List of figures:  356 
Figure 1: Effect of solonamides (A and B) on hla, rnaIII and spa expression. Solonamides (5 mg 357 
mL
-1
) were added to wells in TSA plates containing the 8325-4 derived lacZ reporter strains PC322 358 
(hla::lacZ), SH101F7 (rnaIII::lacZ), or PC203 (spa::lacZ). Incubation time was 15 h for plate I and 359 
II, and 35 h for plate III (plate numbering indicated with white letters).  360 
Figure 2: Structures of solonamides A and B produced by Photobacterium halotolerans strain 361 
S2753.  362 
Figure 3. Effect of solonomides A and B on virulence gene expression in S. aureus strain 8325-4 363 
(44) and USA300 (14) examined by Northern blot analysis. Solonamides were added to 364 
exponentially growing cultures at OD600=0.4, and RNA was purified at OD600=0.7 and 1.7. The 365 
RNA was reacted with probes recognizing hla, rnaIII, and spa, respectively. DMSO was used as 366 
negative control.  367 
Figure 4. (I) Structure of natural group I AIP (R = Thr-Ser-Tyr-H), (II) Synthetic Agr inhibitor 368 
based on a truncated AIP-I analogue (37).  369 
Figure 5. Structure of unnarmicin A (R = Et) and C (R = H) (47).  370 
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Supplemental Materials 
 
A1: LC-MS selective ion-trace of solonamide A (m/z 558, RT = 11.43 min) and solonamide B (m/z 
586, RT = 13.25 min) production on different growth media, including marine minimal media with 
glucose (MMM), marine broth (MB), sigma sea salts (SSS), and marine minimal media with chitin 
(Chitin). Slight shift in retention times due to inter-batch variations on the LC-MS system. 
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Assignments of the depsipeptides were performed using a conventional assignment approach.  
HMBC correlations between  3-H/1-CO, 3-H/36-CO and NOEs between 3-H/31-Hα-Leu confirms 
the lactone closure of the structure. The figure (A3) below shows key correlation for the lactone 
ring closure. 
 
 
 
 
 
 
 
 
 
A4. Numbering scheme used for the assignment of solonamid A (left) and B (right) 
  
Table 1. Solonamide A 
Atom 
assignment 
1
H-chemical shift/ppm 
#H, multiplicity, J/Hz 
13
C-chemical shift/ppm HMBC connectivities 
Hha    
1 - 170.6 - 
2 2.67, 1H, dd, 13.5, 3.8 
2.11, 1H, dd, 13.5, 10.1 
40.7 1, 3, 4 
3 5.14, 1H, m 72.1 1, 5 
4 1.62, 1H, m 
1.45, 1H, m 
36.2 2, 3, 6 
5 ~1.22, 1H, m 17.7 3, 4  
6 0.85, 3H, t, 7 13.8 4, 5 
Phe    
7 - NH  8.61, 1H, d, 3.2 - 1 
8 - CHα 4.26, 1H, ddd, 10, 6.1, 3.2 55.9 9, 10, 14 
9 - CHβ,1 2.94, 1H, dd, 13.3; 6.1 
2.72, 1H, dd, 13.3; 10 
36.4 8, 10, 11/15, 14 
10 - 135.8 - 
11,15 7.18, 2H, m 129.1 9, 13 
12,14 7.25, 2H, m 128.4 10 
13 7.18, 1H, m 126.5 11 
16 - CO - 174.4 - 
Leu
1 
   
17 - NH 8.63, 1H, d, 5.6 - 16, 18, 19 
18 - CHα 3.56, 1H, m 53.1  
19 - CHβ,1 1.36, 1H, m 
1.29, 1H, m 
38.9 18, 21, 22 
20 - CHγ 0.97, 1H, m 23.5 21 
21 - CHδ,1 0.69, 3H, d, 6.6 23.2 19, 20 
22 - CHδ,1 0.52, 3H, d, 6.5 20.7 19, 20 
23 - CO - 171.8 - 
Ala    
24 - NH 7.53, 1H, d, 8.9 - 23,25 
25 - CHα 4.18, 1H, m 48.2 26, 27 
26 - CHβ,1 1.32, 3H, d, 7.4 16.6 27 
27 - CO - 171.3 - 
Leu
2 
   
28 - NH 7.08, 1H, d, 10 - 27, 29 
29 - CHα 4.46, 1H, dt, 10; 4.4 49.0 30, 31, 34 
30 - CHβ,1 1.63, 1H, m 
1,53, 1H, m 
39.3 29, 31, 33, 27/34 
 
31 - CHγ 1.50, 1H, m 23.9 29, 30, 33 
32 - CHδ,1 0.86, 3H, d, 6.5 23.2 30, 31, 33 
33 - CHδ,1 0.81, 3H, d, 6.5 21.3 30 
34 - CO - 171.2 - 
  
Table 2. Solonamide B 
Atom 
assignment 
1
H-chemical shift/ppm 
#H, multiplicity, J/Hz 
13
C-chemical shift/ppm HMBC connectivities 
Hoa    
1 - 170.4 - 
2 2.69, 1H, dd, 13.5; 3.7 
2.11, 1H, dd, 13.5; 10.3 
40.5 1,3,4 
3 5.13, 1H, m 72.0 1, 4, 5, 36 
4 1.65, 1H, m 
1.45, 1H, m 
33.8 5, 6 
5 ~1.20, 2H, m 23.8 6,7 
6 ~1.22, 2H, m 30.8  
7 1.25, 2H, m 21.8  
8 0.84, 3H, m 13.6 6 
Phe    
9 - NH 8.59, 1H, d, 3.0 - 1, 10, 11, 18 
10 - CHα 4.26, 1H, ddd, 10;6.1; 3.3 55.6 11,18 
11 - CHβ 2.95, 1H, dd, 13.3; 6.1 
2.73, 1H, dd, 13.3; 10 
36.1 10,12, 13/17,18 
 
12 - 136.0 - 
13,17 7.20, 2H, m 128.7 11, 15 
14,16 7.26, 2H, m 128.0 12, 14/16 
15 7.20, 1H, m 126.2 13/17 
18 - CO - 174.2 - 
Leu
1 
   
19 - NH 8.64, 1H, d, 5.6 - 18, 20, 21 
20 - CHα 3.57, 1H, m, 9; 5.6; 3.5 52.7 21, 22, 25 
21 - CHβ 1.31-1.37, 2H, m 38.6 20, 22, 24 
22 - CHγ 0.99, 1H, m 23.3  
23 - CHδ,1 0.70, 3H, d, 6.6 22.9 21, 22, 24 
24 - CHδ,2 0.53, 3H, d, 6.4 20.4 21, 23 
25 - CO - 171.6 - 
Ala    
26 - NH 7.48, 1H, d, 8.9 - 25, 27, 28 
27 - CHα 4.18, 1H, m 47.8 28, 29 
28 - CHβ 1.33, 3H, d, 7.3 16.4 27, 29 
29 - CO - 170.9 - 
Leu
2 
   
30 - NH 7.05, 1H, d, 10 - 29, 31 
31 - CHα 4.47, 1H, dt, 10; 4.3 48.6 32, 33, 29/36 
32 - CHβ,1 1.64, 1H, m 
1.52, 1H, m 
39.0  31, 33, 35, 29/36  
33 - CHγ 1.50, 1H, m 23.8 32, 34,35 
34 - CHδ,1 0.86, 3H, d, 6.6 23.0 32, 33, 35 
35 - CHδ,1 0.82, 3H, d, 6.4 21.1 32, 33 
36 - CO - 170.8 - 
 A5. 1D 
1
H spectrum of Solonamide A 
 
A6. 1D 
1
H spectrum of Solonamide B 
  
MS/MS data  
A7: MS and MS/MS spectrum of solonamide A (C30H46N4O6, calcd. 558.3496, Δ m/z 0.8 ppm) with 
characteristic fragments and their molecular formulas (Δ m/z 0.2-0.6 ppm): 
 
A8: MS and MS/MS spectrum of solonamides B (C32H50N4O6, calcd. 586.3730, Δ m/z 0.0 ppm) 
with characteristic fragments and their molecular formulas (Δ m/z 0.2-0.6 ppm): 
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A9: Characteristic fragments for solonamide A (left) and B (right): 
  
 
Establishment of absolute configuration 
The absolute configuration of C3 at 3-hydroxyhexanoic acid (Hha) and 3-hydroxyoctanoic acid 
(Hoa) was determined using the Mosher’s method. Here with the Mosher’s method two enantiomers 
of an acid chloride (α-methoxy-α-trifluoromethylphenylacetic acid chloride, MTPA-Cl) are reacted 
with the secondary alcohol at the stereogenic center in order to reveal the configuration of this 
center. The reaction yields two diastereoisomers with known configuration around one of the 
stereogenic centers enabling the determination of the other stereogenic center.  
The sign of the ∆δ values can be seen in the figures below, all pointing toward the same 
configuration at the C3 stereocenter in Hha and Hoa. The values for ∆δ are positive for the alkane 
end of Hha/Hoa and negative towards the carbonyl end, which points towards an R-configration of 
the C3 stereocenter. The difference seen in the flourine NMR data supports this conclusion when 
the alkane chain of the molecule is regarded as least bulky compared to the remaining part of the 
molecule with a ∆δ(SR) ~ -0.68 ppm . 
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A10. Distribution of the ∆δ values calculated for the 3-hydroxyhexanoic acid (Hha) of solonamide 
A 
 
 
 
 
 
 
 
A11. Distribution of the ∆δ values calculated for the 3-hydroxyoctanoic acid (Hoa) of solonamide B 
 
Experimental procedure used for Mosher’s:  
Methanolysis of solonamide A (and B) 
5 mg (8.52 μmol) of the depsipeptide (solonamide A) is dissolved in 1.5 mL of 0.5 M NaOMe in 
MeOH and stirred at room temperature for 1 h. The reaction mixture is neutralised by careful 
addition of 1M HCl (aq) and the pH is monitored with universal indicator paper. The reaction 
mixture is concentrated to dryness on a rotary evaporator, and partitioned in EtOAc and H2O. 
Methanolysis of solonamide B was performed using the same procedure. The organic phase is 
concentrated to dryness on a rotary evaporator and the methyl ester product verified by LC-MS 
([M+H]
+
 A: 591.3803 Da, B: 619.4053 Da) and purified by RP-HPLC on a Waters HPLC with a 
600 controller and a 996 photodiode array detector using a water/MeCN gradient elution from 40 to 
60 % MeCN over 20 min (5 mL/min) with a Luna C18 column (5 µm, 250x10 mm, Phenomenex). 
Pure methyl esters of solonamide A (1.1 mg) and B (2.7 mg). 
 
Preparation of the R-MTPA ester of solonamide A (and B) 
To a stirred solution of the purified methanolysis product (0.55 mg, 0.889 μmol) in dry pyridine 
(150 µL) is added 5 µL (catalytic amount, 0.1 eq) of a solution of dimethylaminopyridine (DMAP) 
in dry pyridine (0.4 mg, 50 µL). After 10 min 9.1 µL S-(+)-MTPA-Cl (48.6 μmol) is added and the 
reaction is left overnight at room temperature. The reaction mixture is dried on a speedvac, 
redissolved in MeOH and purified on a Waters HPLC with a 600 controller and a 996 photodiode 
array detector using a water/MeCN gradient elution from 45 to 100 % MeCN over 20 min (5 
mL/min) with a Luna C18 (5 µm, 250x10 mm, Phenomenex) column to give pure R-MTPA ester (A: 
0.5 mg, B: ~1.2 mg). 
 
Preparation of the S-MTPA ester of solonamide A (and B) 
Using the same procedure as for the R-MTPA ester, the S-MTPA ester is produced by reaction with 
R-(–)-MTPA-Cl. Pure R-MTPA esters (A: 0.4 mg, B: ~1.1 mg). 
 
 
 
 
 
 
Establishing stereochemistry of enantiomeric Leu by reduction and Marfey’s 
2 mg of solonamide B is reduced in 2 M LiBH4 in THF at 0°C for 30 min, then at rt overnight and 
lastly heated to 50˚C for 30 min. EtOAc is added and the reaction is quenched with sat. NH4Cl (aq) 
before the product is extracted with EtOAc, CH2Cl2  and Et2O concentrated and purified by RP-
HPLC on a Waters HPLC with a 600 controller and a 996 photodiode array detector using a 
water/MeCN gradient elution from 25 to 80% MeCN over 20 min (5 mL/min) with a Luna C18 
column (5 µm, 250x10 mm, Phenomenex). Yields 0.7 mg of reduced open-chain solonamide B. The 
same procedure is used for solonamide A, only with a gradient of 35-70 %, yielding 0.8 mg. 
300 µg of each peptide is hydrolysed with 300 µL 6 M HCl at 110°C for 20 h. To the hydrolysis 
products is added 75 µL water, 20 µL 1 M NaHCO3 solution and 100 µL 1% FDAA in acetone, 
followed by reaction at 40°C in 1 h. The vial is removed from the heat, neutralised with 10 µL 2 M 
HCl and the solution is diluted with 395 µL MeOH to a total volume of 0.5 mL. The FDAA 
derivatives are analysed by UPLC on a Dionex Ultimate 3000 with a diode array detector and a 
Kinetex C18 column (2.6 µm, 150x2.10 mm, Phenomenex). The analyses are run with a gradient 
elution of water/MeCN from 25 to 37 % MeCN over 6 min (60°C, 0.8 mL/min) and the FDAA 
derivatives of the hydrolysates are compared to retention times of the standard amino acid 
derivatives: D-Ala (1.61 min), L-Ala (1.14 min), D-Leu (5.49 min), L-Leu (3.77 min), D-Phe (5.04 
min), L-Phe (3.585 min). FDAA elutes at 1.50 min. 
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